[
  {
    "id": "41511787",
    "title_en": "Sulforaphane attenuates DSS-induced ulcerative colitis <i>via</i> the Nrf2/STAT3 signaling pathway and gut microbiota modulation.",
    "pub_date": "2026 Jan",
    "journal": "Food & function",
    "abstract_en": "Sulforaphane (SFN) is an isothiocyanate derived from cruciferous vegetables. Our previous studies have shown that nuclear factor (erythroid-derived 2)-like 2 (Nrf2) and signal transducer and activator of transcription 3 (STAT3) may play roles in the protective effects of SFN against dextran sulfate sodium (DSS)-induced ulcerative colitis (UC) in mice. This study aims to elucidate the underlying mechanisms. GEO database analysis revealed that <i>Nrf2</i> expression was reduced, while <i>STAT3</i> expression was elevated in the colonic mucosa of UC patients compared to healthy controls (<i>P</i> < 0.01). In the DSS-induced Caco-2 cell model, <i>Nrf2</i> siRNA transfection abolished the effects of SFN on enhancing Nrf2 and tight junction protein expression, suppressing inflammatory factors and reducing the phosphorylated-STAT3/STAT3 ratio. In DSS-induced UC mice, SFN alleviated colitic symptoms in wide-type mice, including weight loss, colon edema and shortening, and inflammatory cell infiltration. SFN also reduced the levels of inflammatory cytokines and enhanced tight junction protein expression in wide-type mice with colitis. However, these protective effects were largely abolished in Nrf2 knockout mice. Moreover, in Nrf2 knockout colitis mice, SFN reduced the gut microbial diversity and decreased the relative abundance of <i>Firmicutes</i> at the phylum level, as well as <i>Muribaculaceae</i> and <i>Lachnospiraceae</i>_NK4A136 at the genus level. In conclusion, the protective effects of SFN against UC may involve the regulation of the Nrf2/STAT3 signaling pathway and modulation of the gut microbiota, highlighting Nrf2 as a key mediator of SFN's action.",
    "para1": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°æ–¼é é˜²å’Œç·©è§£æ½°ç˜æ€§çµè…¸ç‚ï¼ˆUCï¼‰æœ‰æ½›åœ¨çš„å¥½è™•ã€‚æ½°ç˜æ€§çµè…¸ç‚æ˜¯ä¸€ç¨®å½±éŸ¿è…¸é“çš„æ…¢æ€§ç–¾ç—…ï¼Œæœƒå°è‡´è…¸é“ç™¼ç‚å’Œä¸é©ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é€éèª¿ç¯€ç‰¹å®šçš„ä¿¡è™Ÿå‚³å°è·¯å¾‘ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„è…¸é“å¥åº·ï¼Œæ¸›å°‘ç™¼ç‚åæ‡‰ï¼Œé€™å°æ–¼æœ‰æ½°ç˜æ€§çµè…¸ç‚é¢¨éšªçš„äººä¾†èªªï¼Œå¯èƒ½æ˜¯ä¸€å€‹æœ‰ç›Šçš„é£²é£Ÿè£œå……é¸æ“‡ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨æ½°ç˜æ€§çµè…¸ç‚ä¸­çš„ä½œç”¨æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œè˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿è…¸é“ä¸­çš„ç‰¹å®šä¿¡è™Ÿå‚³å°è·¯å¾‘ï¼Œå°¤å…¶æ˜¯Nrf2å’ŒSTAT3é€™å…©å€‹é—œéµå› å­ï¼Œä¸¦ä¸”é€™äº›å› å­åœ¨æ½°ç˜æ€§çµè…¸ç‚æ‚£è€…çš„è…¸é“çµ„ç¹”ä¸­è¡¨ç¾å¦‚ä½•ã€‚é€éé€™äº›ç ”ç©¶ï¼Œç§‘å­¸å®¶å¸Œæœ›èƒ½æ›´æ·±å…¥äº†è§£è˜¿è””ç¡«ç´ çš„æ½›åœ¨å¥åº·ç›Šè™•åŠå…¶ä½œç”¨æ©Ÿåˆ¶ã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†å°é¼ æ¨¡å‹å’Œç´°èƒå¯¦é©—ä¾†é€²è¡Œç ”ç©¶ã€‚åœ¨å°é¼ å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†DSSèª˜å°çš„æ½°ç˜æ€§çµè…¸ç‚æ¨¡å‹ï¼Œè§€å¯Ÿè˜¿è””ç¡«ç´ å°å°é¼ çš„å½±éŸ¿ï¼ŒåŒ…æ‹¬é«”é‡è®ŠåŒ–ã€è…¸é“è…«è„¹å’Œç™¼ç‚ç´°èƒçš„æµ¸æ½¤æƒ…æ³ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„åˆ©ç”¨Caco-2ç´°èƒæ¨¡å‹ä¾†æ¢è¨è˜¿è””ç¡«ç´ å°ç´°èƒå…§Nrf2å’ŒSTAT3çš„å½±éŸ¿ï¼Œä¸¦ä½¿ç”¨siRNAæŠ€è¡“ä¾†å¹²æ“¾Nrf2çš„è¡¨é”ï¼Œä»¥è©•ä¼°å…¶å°è˜¿è””ç¡«ç´ æ•ˆæœçš„å½±éŸ¿ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æ”¹å–„æ½°ç˜æ€§çµè…¸ç‚å°é¼ çš„ç—‡ç‹€ï¼Œæ¸›å°‘é«”é‡æå¤±ã€è…¸é“è…«è„¹å’Œç™¼ç‚ç´°èƒçš„æµ¸æ½¤ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½é™ä½ç™¼ç‚ç´°èƒå› å­çš„æ°´å¹³ï¼Œä¸¦å¢å¼·è…¸é“ç·Šå¯†é€£æ¥è›‹ç™½çš„è¡¨é”ã€‚ç„¶è€Œï¼Œé€™äº›ä¿è­·ä½œç”¨åœ¨ç¼ºä¹Nrf2çš„å°é¼ ä¸­å¤§å¹…æ¸›å¼±ï¼Œé¡¯ç¤ºNrf2åœ¨è˜¿è””ç¡«ç´ çš„ä½œç”¨ä¸­æ‰®æ¼”äº†é‡è¦è§’è‰²ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ æœƒæ”¹è®Šè…¸é“å¾®ç”Ÿç‰©çš„å¤šæ¨£æ€§ï¼Œé€™äº›çµæœæç¤ºè˜¿è””ç¡«ç´ å¯èƒ½é€éèª¿ç¯€Nrf2/STAT3ä¿¡è™Ÿé€šè·¯å’Œè…¸é“å¾®ç”Ÿç‰©ä¾†ç™¼æ®ä½œç”¨ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°æ–¼é é˜²å’Œç·©è§£æ½°ç˜æ€§çµè…¸ç‚ï¼ˆUCï¼‰æœ‰æ½›åœ¨çš„å¥½è™•ã€‚æ½°ç˜æ€§çµè…¸ç‚æ˜¯ä¸€ç¨®å½±éŸ¿è…¸é“çš„æ…¢æ€§ç–¾ç—…ï¼Œæœƒå°è‡´è…¸é“ç™¼ç‚å’Œä¸é©ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é€éèª¿ç¯€ç‰¹å®šçš„ä¿¡è™Ÿå‚³å°è·¯å¾‘ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„è…¸é“å¥åº·ï¼Œæ¸›å°‘ç™¼ç‚åæ‡‰ï¼Œé€™å°æ–¼æœ‰æ½°ç˜æ€§çµè…¸ç‚é¢¨éšªçš„äººä¾†èªªï¼Œå¯èƒ½æ˜¯ä¸€å€‹æœ‰ç›Šçš„é£²é£Ÿè£œå……é¸æ“‡ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨æ½°ç˜æ€§çµè…¸ç‚ä¸­çš„ä½œç”¨æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œè˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿è…¸é“ä¸­çš„ç‰¹å®šä¿¡è™Ÿå‚³å°è·¯å¾‘ï¼Œå°¤å…¶æ˜¯Nrf2å’ŒSTAT3é€™å…©å€‹é—œéµå› å­ï¼Œä¸¦ä¸”é€™äº›å› å­åœ¨æ½°ç˜æ€§çµè…¸ç‚æ‚£è€…çš„è…¸é“çµ„ç¹”ä¸­è¡¨ç¾å¦‚ä½•ã€‚é€éé€™äº›ç ”ç©¶ï¼Œç§‘å­¸å®¶å¸Œæœ›èƒ½æ›´æ·±å…¥äº†è§£è˜¿è””ç¡«ç´ çš„æ½›åœ¨å¥åº·ç›Šè™•åŠå…¶ä½œç”¨æ©Ÿåˆ¶ã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†å°é¼ æ¨¡å‹å’Œç´°èƒå¯¦é©—ä¾†é€²è¡Œç ”ç©¶ã€‚åœ¨å°é¼ å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†DSSèª˜å°çš„æ½°ç˜æ€§çµè…¸ç‚æ¨¡å‹ï¼Œè§€å¯Ÿè˜¿è””ç¡«ç´ å°å°é¼ çš„å½±éŸ¿ï¼ŒåŒ…æ‹¬é«”é‡è®ŠåŒ–ã€è…¸é“è…«è„¹å’Œç™¼ç‚ç´°èƒçš„æµ¸æ½¤æƒ…æ³ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„åˆ©ç”¨Caco-2ç´°èƒæ¨¡å‹ä¾†æ¢è¨è˜¿è””ç¡«ç´ å°ç´°èƒå…§Nrf2å’ŒSTAT3çš„å½±éŸ¿ï¼Œä¸¦ä½¿ç”¨siRNAæŠ€è¡“ä¾†å¹²æ“¾Nrf2çš„è¡¨é”ï¼Œä»¥è©•ä¼°å…¶å°è˜¿è””ç¡«ç´ æ•ˆæœçš„å½±éŸ¿ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æ”¹å–„æ½°ç˜æ€§çµè…¸ç‚å°é¼ çš„ç—‡ç‹€ï¼Œæ¸›å°‘é«”é‡æå¤±ã€è…¸é“è…«è„¹å’Œç™¼ç‚ç´°èƒçš„æµ¸æ½¤ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½é™ä½ç™¼ç‚ç´°èƒå› å­çš„æ°´å¹³ï¼Œä¸¦å¢å¼·è…¸é“ç·Šå¯†é€£æ¥è›‹ç™½çš„è¡¨é”ã€‚ç„¶è€Œï¼Œé€™äº›ä¿è­·ä½œç”¨åœ¨ç¼ºä¹Nrf2çš„å°é¼ ä¸­å¤§å¹…æ¸›å¼±ï¼Œé¡¯ç¤ºNrf2åœ¨è˜¿è””ç¡«ç´ çš„ä½œç”¨ä¸­æ‰®æ¼”äº†é‡è¦è§’è‰²ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ æœƒæ”¹è®Šè…¸é“å¾®ç”Ÿç‰©çš„å¤šæ¨£æ€§ï¼Œé€™äº›çµæœæç¤ºè˜¿è””ç¡«ç´ å¯èƒ½é€éèª¿ç¯€Nrf2/STAT3ä¿¡è™Ÿé€šè·¯å’Œè…¸é“å¾®ç”Ÿç‰©ä¾†ç™¼æ®ä½œç”¨ã€‚",
    "fb_post": "æ ¹æ“šã€ŠFood & functionã€‹æ–¼ 2026 å¹´ 1 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± è½èªªéè˜¿è””ç¡«ç´ å—ï¼Ÿé€™ç¨®ä¾†è‡ªé’èŠ±æ¤°èœçš„æˆåˆ†ï¼Œæœ€è¿‘åœ¨æ½°ç˜æ€§çµè…¸ç‚çš„ç ”ç©¶ä¸­å¼•èµ·äº†å¤§å®¶çš„æ³¨æ„ï¼\n\næ½°ç˜æ€§çµè…¸ç‚æ˜¯ä¸€ç¨®è®“è…¸é“ç™¼ç‚çš„æ…¢æ€§ç–¾ç—…ï¼Œæœƒè®“äººæ„Ÿåˆ°ä¸é©ã€‚ç§‘å­¸å®¶å€‘æƒ³çŸ¥é“ï¼Œè˜¿è””ç¡«ç´ åˆ°åº•èƒ½ä¸èƒ½å¹«åŠ©æ”¹å–„é€™ç¨®æƒ…æ³ã€‚æ–¼æ˜¯ï¼Œä»–å€‘é€²è¡Œäº†ä¸€ç³»åˆ—å¯¦é©—ï¼Œçœ‹çœ‹è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿è…¸é“è£¡çš„é—œéµä¿¡è™Ÿé€šè·¯ï¼Œå°¤å…¶æ˜¯Nrf2å’ŒSTAT3é€™å…©å€‹é‡è¦å› å­ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨å°é¼ æ¨¡å‹ï¼Œè§€å¯Ÿè˜¿è””ç¡«ç´ å°å°é¼ çš„å½±éŸ¿ï¼ŒåŒ…æ‹¬é«”é‡è®ŠåŒ–å’Œè…¸é“çš„ç™¼ç‚æƒ…æ³ã€‚çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æ¸›å°‘å°é¼ çš„é«”é‡æå¤±ã€è…¸é“è…«è„¹ï¼Œä¸¦é™ä½ç™¼ç‚ç´°èƒçš„æ•¸é‡ï¼æ›´æœ‰è¶£çš„æ˜¯ï¼Œé€™äº›æ•ˆæœåœ¨ç¼ºä¹Nrf2çš„å°é¼ ä¸­å¤§å¹…æ¸›å¼±ï¼Œé¡¯ç¤ºNrf2åœ¨é€™å€‹éç¨‹ä¸­æ‰®æ¼”äº†é‡è¦è§’è‰²ã€‚\n\nâœ¨ ç¸½çµä¾†èªªï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„æ½°ç˜æ€§çµè…¸ç‚çš„ç—‡ç‹€ã€‚\n2. Nrf2æ˜¯è˜¿è””ç¡«ç´ ç™¼æ®ä¿è­·ä½œç”¨çš„é—œéµå› å­ã€‚\n3. è˜¿è””ç¡«ç´ é‚„å¯èƒ½å½±éŸ¿è…¸é“å¾®ç”Ÿç‰©çš„å¤šæ¨£æ€§ã€‚\n\né›–ç„¶é€™äº›ç™¼ç¾å¾ˆæœ‰å¸Œæœ›ï¼Œä½†æˆ‘å€‘é‚„éœ€è¦æ›´å¤šç ”ç©¶ä¾†äº†è§£è˜¿è””ç¡«ç´ çš„å…¨é¢æ•ˆæœï¼",
    "image_prompt": "Create an infographic that explains the experimental methods and main findings of a study on sulforaphane, a compound from broccoli, and its effects on ulcerative colitis. Use a flat design style with a white or light-colored background and soft colors. Include simple icons representing broccoli or sulforaphane, experimental subjects like simplified mice or cells, arrows or flow lines indicating the experimental steps, and a section labeled 'Main Findings' that highlights protective effects and changes observed.",
    "is_human_study": true,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "æ½°ç˜æ€§çµè…¸ç‚ Ulcerative Colitis",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41511787/"
  },
  {
    "id": "41438577",
    "title_en": "Sulforaphane-cysteine elicits apoptosis through JNK-mediated caspase activation in oral squamous cell carcinoma cells.",
    "pub_date": "2026",
    "journal": "Journal of Cancer",
    "abstract_en": "Sulforaphane-cysteine (SFN-Cys) is a naturally-occurring form of plant-derived isothiocyanate metabolites that displays several tumor-suppressive properties. However, the oncostatic potential of SFN-Cys on oral squamous cell carcinoma (OSCC) is mostly elusive. In this study, we tried to test whether SFN-Cys affects OSCC to progress and further explored the underlying array of molecular cues that SFN-Cys mediates. Our results demonstrate that SFN-Cys was an effective inducer of cytotoxicity to OSCC cells, accompanied with blockage of cell cycling and promotion of apoptotic events. Moreover, treatment of OSCC cells with SFN-Cys attuned an apoptosis-associated protein regulatory program, underlined by downregulation of apoptosis suppressors (cIAP-1 and XIAP) and activation of caspase cascades. Furthermore, caspase activations in SFN-Cys-treated OSCC cells were affected by the pre-incubation with a specific c-Jun N-terminal kinase (JNK) inhibitor, suggesting a functional link of JNK pathway to SFN-Cys's actions in OSCC cells. Collectively, our data revealed that SFN-Cys hampered cell cycle progression and elicited apoptotic responses in OSCC via a JNK-mediated activation of caspase pathways. These findings provide possible avenues for the application of a natural compound in the management of oral malignancies.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›æœ‰é—œå¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨å£è…”ç™Œçš„ç®¡ç†ä¸Šã€‚è˜¿è””ç¡«ç´ é€™ç¨®å¤©ç„¶åŒ–åˆç‰©é¡¯ç¤ºå‡ºå°è…«ç˜¤çš„æŠ‘åˆ¶æ½›åŠ›ï¼Œé€™å¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚æ–¹æ³•æä¾›æ–°çš„æ€è·¯ã€‚éš¨è‘—å£è…”ç™Œçš„ç™¼ç—…ç‡é€æ¼¸ä¸Šå‡ï¼Œå°‹æ‰¾æœ‰æ•ˆçš„é é˜²å’Œæ²»ç™‚æ‰‹æ®µè®Šå¾—è¶Šä¾†è¶Šé‡è¦ã€‚é€™é …ç ”ç©¶çš„çµæœå¯èƒ½æœ‰åŠ©æ–¼é–‹ç™¼æ–°çš„æ²»ç™‚ç­–ç•¥ï¼Œåˆ©ç”¨å¤©ç„¶æˆåˆ†ä¾†å°æŠ—é€™ç¨®ç–¾ç—…ï¼Œå¾è€Œæ”¹å–„æ‚£è€…çš„ç”Ÿæ´»å“è³ªå’Œé å¾Œã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ -åŠèƒ±æ°¨é…¸ï¼ˆSFN-Cysï¼‰å°å£è…”é±—ç‹€ç´°èƒç™Œï¼ˆOSCCï¼‰çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™ç¨®å¤©ç„¶åŒ–åˆç‰©æ˜¯å¦èƒ½å¤ æŠ‘åˆ¶å£è…”ç™Œç´°èƒçš„é€²å±•ï¼Œä¸¦é€²ä¸€æ­¥æ¢ç´¢å…¶ä½œç”¨çš„åˆ†å­æ©Ÿåˆ¶ã€‚å£è…”é±—ç‹€ç´°èƒç™Œæ˜¯ä¸€ç¨®å¸¸è¦‹çš„å£è…”æƒ¡æ€§è…«ç˜¤ï¼Œå°æ–¼å…¶æ²»ç™‚æ–¹æ³•çš„ç ”ç©¶ä»ç„¶ç›¸å°æœ‰é™ï¼Œå› æ­¤æœ¬ç ”ç©¶çš„çµæœå°‡å°ç›¸é—œé ˜åŸŸçš„ç ”ç©¶å…·æœ‰é‡è¦æ„ç¾©ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†å£è…”é±—ç‹€ç´°èƒç™Œç´°èƒä½œç‚ºç ”ç©¶å°è±¡ï¼Œä¸¦æ¸¬è©¦äº†ä¸åŒæ¿ƒåº¦çš„è˜¿è””ç¡«ç´ -åŠèƒ±æ°¨é…¸å°é€™äº›ç´°èƒçš„å½±éŸ¿ã€‚ç ”ç©¶æ–¹æ³•åŒ…æ‹¬è©•ä¼°ç´°èƒçš„ç´°èƒæ¯’æ€§ã€ç´°èƒé€±æœŸçš„è®ŠåŒ–ä»¥åŠå‡‹äº¡çš„ç›¸é—œäº‹ä»¶ã€‚é€éé€™äº›å¯¦é©—ï¼Œç ”ç©¶è€…å¸Œæœ›èƒ½å¤ æ­ç¤ºè˜¿è””ç¡«ç´ -åŠèƒ±æ°¨é…¸åœ¨å£è…”ç™Œç´°èƒä¸­çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œä¸¦äº†è§£å…¶å¦‚ä½•å½±éŸ¿ç´°èƒçš„ç”Ÿå­˜å’Œæ­»äº¡ã€‚",
    "para4": "ä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ -åŠèƒ±æ°¨é…¸èƒ½æœ‰æ•ˆèª˜å°å£è…”é±—ç‹€ç´°èƒç™Œç´°èƒçš„ç´°èƒæ¯’æ€§ï¼Œä¸¦ä¸”é˜»ç¤™ç´°èƒé€±æœŸçš„é€²å±•ï¼Œä¿ƒé€²å‡‹äº¡äº‹ä»¶çš„ç™¼ç”Ÿã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ -åŠèƒ±æ°¨é…¸çš„ä½œç”¨èˆ‡ä¸€ç¨®ç‰¹å®šçš„JNKé€šè·¯æœ‰é—œï¼Œé€™è¡¨æ˜è©²é€šè·¯åœ¨å…¶ä½œç”¨æ©Ÿåˆ¶ä¸­æ‰®æ¼”äº†é‡è¦è§’è‰²ã€‚é€™äº›çµæœç‚ºåˆ©ç”¨å¤©ç„¶åŒ–åˆç‰©ä¾†ç®¡ç†å£è…”æƒ¡æ€§è…«ç˜¤æä¾›äº†æ–°çš„å¯èƒ½æ€§ï¼Œå„˜ç®¡å°šéœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶è‡¨åºŠæ‡‰ç”¨çš„æ½›åŠ›ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›æœ‰é—œå¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨å£è…”ç™Œçš„ç®¡ç†ä¸Šã€‚è˜¿è””ç¡«ç´ é€™ç¨®å¤©ç„¶åŒ–åˆç‰©é¡¯ç¤ºå‡ºå°è…«ç˜¤çš„æŠ‘åˆ¶æ½›åŠ›ï¼Œé€™å¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚æ–¹æ³•æä¾›æ–°çš„æ€è·¯ã€‚éš¨è‘—å£è…”ç™Œçš„ç™¼ç—…ç‡é€æ¼¸ä¸Šå‡ï¼Œå°‹æ‰¾æœ‰æ•ˆçš„é é˜²å’Œæ²»ç™‚æ‰‹æ®µè®Šå¾—è¶Šä¾†è¶Šé‡è¦ã€‚é€™é …ç ”ç©¶çš„çµæœå¯èƒ½æœ‰åŠ©æ–¼é–‹ç™¼æ–°çš„æ²»ç™‚ç­–ç•¥ï¼Œåˆ©ç”¨å¤©ç„¶æˆåˆ†ä¾†å°æŠ—é€™ç¨®ç–¾ç—…ï¼Œå¾è€Œæ”¹å–„æ‚£è€…çš„ç”Ÿæ´»å“è³ªå’Œé å¾Œã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ -åŠèƒ±æ°¨é…¸ï¼ˆSFN-Cysï¼‰å°å£è…”é±—ç‹€ç´°èƒç™Œï¼ˆOSCCï¼‰çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™ç¨®å¤©ç„¶åŒ–åˆç‰©æ˜¯å¦èƒ½å¤ æŠ‘åˆ¶å£è…”ç™Œç´°èƒçš„é€²å±•ï¼Œä¸¦é€²ä¸€æ­¥æ¢ç´¢å…¶ä½œç”¨çš„åˆ†å­æ©Ÿåˆ¶ã€‚å£è…”é±—ç‹€ç´°èƒç™Œæ˜¯ä¸€ç¨®å¸¸è¦‹çš„å£è…”æƒ¡æ€§è…«ç˜¤ï¼Œå°æ–¼å…¶æ²»ç™‚æ–¹æ³•çš„ç ”ç©¶ä»ç„¶ç›¸å°æœ‰é™ï¼Œå› æ­¤æœ¬ç ”ç©¶çš„çµæœå°‡å°ç›¸é—œé ˜åŸŸçš„ç ”ç©¶å…·æœ‰é‡è¦æ„ç¾©ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†å£è…”é±—ç‹€ç´°èƒç™Œç´°èƒä½œç‚ºç ”ç©¶å°è±¡ï¼Œä¸¦æ¸¬è©¦äº†ä¸åŒæ¿ƒåº¦çš„è˜¿è””ç¡«ç´ -åŠèƒ±æ°¨é…¸å°é€™äº›ç´°èƒçš„å½±éŸ¿ã€‚ç ”ç©¶æ–¹æ³•åŒ…æ‹¬è©•ä¼°ç´°èƒçš„ç´°èƒæ¯’æ€§ã€ç´°èƒé€±æœŸçš„è®ŠåŒ–ä»¥åŠå‡‹äº¡çš„ç›¸é—œäº‹ä»¶ã€‚é€éé€™äº›å¯¦é©—ï¼Œç ”ç©¶è€…å¸Œæœ›èƒ½å¤ æ­ç¤ºè˜¿è””ç¡«ç´ -åŠèƒ±æ°¨é…¸åœ¨å£è…”ç™Œç´°èƒä¸­çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œä¸¦äº†è§£å…¶å¦‚ä½•å½±éŸ¿ç´°èƒçš„ç”Ÿå­˜å’Œæ­»äº¡ã€‚\n\nä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ -åŠèƒ±æ°¨é…¸èƒ½æœ‰æ•ˆèª˜å°å£è…”é±—ç‹€ç´°èƒç™Œç´°èƒçš„ç´°èƒæ¯’æ€§ï¼Œä¸¦ä¸”é˜»ç¤™ç´°èƒé€±æœŸçš„é€²å±•ï¼Œä¿ƒé€²å‡‹äº¡äº‹ä»¶çš„ç™¼ç”Ÿã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ -åŠèƒ±æ°¨é…¸çš„ä½œç”¨èˆ‡ä¸€ç¨®ç‰¹å®šçš„JNKé€šè·¯æœ‰é—œï¼Œé€™è¡¨æ˜è©²é€šè·¯åœ¨å…¶ä½œç”¨æ©Ÿåˆ¶ä¸­æ‰®æ¼”äº†é‡è¦è§’è‰²ã€‚é€™äº›çµæœç‚ºåˆ©ç”¨å¤©ç„¶åŒ–åˆç‰©ä¾†ç®¡ç†å£è…”æƒ¡æ€§è…«ç˜¤æä¾›äº†æ–°çš„å¯èƒ½æ€§ï¼Œå„˜ç®¡å°šéœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶è‡¨åºŠæ‡‰ç”¨çš„æ½›åŠ›ã€‚",
    "fb_post": "æ ¹æ“šã€ŠJournal of Cancerã€‹æ–¼ 2026 å¹´ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„æ—¥å¸¸é£²é£Ÿä¸­ç«Ÿç„¶å¯èƒ½è—è‘—å°æŠ—å£è…”ç™Œçš„ç§˜å¯†æ­¦å™¨ï¼æœ€è¿‘ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ é€™ç¨®å¤©ç„¶åŒ–åˆç‰©ï¼Œæˆ–è¨±èƒ½å¹«åŠ©æˆ‘å€‘æŠµæŠ—å£è…”ç™Œçš„å¨è„…ã€‚é€™é …ç ”ç©¶å°ˆæ³¨æ–¼è˜¿è””ç¡«ç´ -åŠèƒ±æ°¨é…¸ï¼ˆSFN-Cysï¼‰ï¼Œç§‘å­¸å®¶å€‘æƒ³çŸ¥é“å®ƒå¦‚ä½•å½±éŸ¿å£è…”é±—ç‹€ç´°èƒç™Œï¼ˆOSCCï¼‰ï¼Œé€™æ˜¯ä¸€ç¨®å¸¸è¦‹çš„å£è…”æƒ¡æ€§è…«ç˜¤ã€‚ ç ”ç©¶åœ˜éšŠä½¿ç”¨äº†å£è…”ç™Œç´°èƒï¼Œæ¸¬è©¦ä¸åŒæ¿ƒåº¦çš„è˜¿è””ç¡«ç´ -åŠèƒ±æ°¨é…¸ï¼Œè§€å¯Ÿç´°èƒçš„åæ‡‰ã€‚çµæœé¡¯ç¤ºï¼Œé€™ç¨®åŒ–åˆç‰©ä¸åƒ…èƒ½æœ‰æ•ˆèª˜å°ç™Œç´°èƒæ­»äº¡ï¼Œé‚„èƒ½é˜»æ­¢ç™Œç´°èƒçš„å¢é•·ï¼æ›´æœ‰è¶£çš„æ˜¯ï¼Œå®ƒçš„ä½œç”¨èˆ‡ä¸€æ¢ç‰¹æ®Šçš„JNKé€šè·¯æœ‰é—œï¼Œé€™æ„å‘³è‘—æˆ‘å€‘å¯èƒ½æ‰¾åˆ°äº†ä¸€å€‹æ–°çš„ç ”ç©¶æ–¹å‘ã€‚ è®“æˆ‘å€‘ä¾†ç¸½çµä¸€ä¸‹é€™é …ç ”ç©¶çš„é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼å°æŠ—å£è…”ç™Œã€‚\n2. å®ƒèƒ½ä¿ƒé€²ç™Œç´°èƒçš„æ­»äº¡ï¼Œä¸¦æŠ‘åˆ¶ç´°èƒå¢é•·ã€‚\n3. é€™é …ç ”ç©¶ç‚ºæœªä¾†çš„æ²»ç™‚æ–¹æ³•æä¾›äº†æ–°çš„æ€è·¯ï¼",
    "image_prompt": "Create a flat design infographic that explains the experimental method and main results of a study on sulforaphane-cysteine (SFN-Cys) and its effects on oral squamous cell carcinoma (OSCC). Include simple icons representing broccoli or sulforaphane, simplified human or cell figures as experimental subjects, arrows or flow lines to show the experimental steps, and a section highlighting the main results such as protective effects and changes observed. Use a light background with soft colors for a scientific and informative style.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "å£è…”é±—ç‹€ç´°èƒç™Œ Oral Squamous Cell Carcinoma",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41438577/"
  },
  {
    "id": "41265122",
    "title_en": "Synergistic strategies of sulforaphane biosynthesis and functional properties in broccoli sprouts powder obtained from sucrose stress modulation coupled with vacuum freeze-drying.",
    "pub_date": "2026 Jan",
    "journal": "Food chemistry",
    "abstract_en": "This study investigated methionine-sucrose stress treatments on glucoraphanin biosynthesis in broccoli sprouts and the impact of vacuum freeze-drying (VFD) on sprout powder quality. Results showed that sucrose treatment elevated glucoraphanin content by 316.30Â % in 4-day sprouts compared to the control (9.72Â mg/g), accompanied by increases of 42.65Â % in total isothiocyanates (ITCs) and 70.00Â % in anthocyanins. The treatment enhanced myrosinase activity and upregulated osmotic regulators. PCA confirmed that sucrose stress optimized the nutritional quality of broccoli sprouts and exhibited potential in sulforaphane enrichment. The VFD broccoli sprout powder exhibited high retention of sulforaphane (6.00Â mg/g dw) and total ITCs (7.00Â mg/g dw), with optimal water-holding capacity, oil-holding capacity, and swelling capacity. The sulforaphane extract exhibited significant antimicrobial activity against E. coli (16.00Â mm inhibition zone) and Staphylococcus aureus (10.02Â mm). The synergistic application of sucrose stress and VFD presents a promising approach for developing functional foods.",
    "para1": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›æœ‰è¶£çš„å•Ÿç¤ºã€‚ç ”ç©¶é¡¯ç¤ºï¼Œé€éç‰¹å®šçš„è™•ç†æ–¹æ³•ï¼Œå¯ä»¥æå‡é’èŠ±æ¤°èœèŠ½ä¸­çš„ç‡Ÿé¤Šæˆåˆ†ï¼Œç‰¹åˆ¥æ˜¯è˜¿è””ç¡«ç´ çš„å«é‡ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®è¢«èªç‚ºæœ‰åŠ©æ–¼æŠ—æ°§åŒ–å’ŒæŠ—èŒçš„åŒ–åˆç‰©ï¼Œå¯èƒ½å°æ–¼å¢å¼·å…ç–«ç³»çµ±å’Œé é˜²æŸäº›ç–¾ç—…æœ‰æ­£é¢å½±éŸ¿ã€‚å› æ­¤ï¼Œé€™é …ç ”ç©¶çš„çµæœå¯èƒ½ç‚ºæœªä¾†çš„å¥åº·é£²é£Ÿå’ŒåŠŸèƒ½æ€§é£Ÿå“çš„é–‹ç™¼æä¾›æ–°çš„æ–¹å‘ï¼Œå°¤å…¶æ˜¯åœ¨æå‡é’èŠ±æ¤°èœç­‰è”¬èœçš„ç‡Ÿé¤Šåƒ¹å€¼æ–¹é¢ã€‚",
    "para2": "æœ¬ç ”ç©¶ä¸»è¦é—œæ³¨çš„æ˜¯é’èŠ±æ¤°èœèŠ½åœ¨ç‰¹å®šè™•ç†ä¸‹çš„ç‡Ÿé¤Šæˆåˆ†è®ŠåŒ–ï¼Œå°¤å…¶æ˜¯è˜¿è””ç¡«ç´ çš„åˆæˆã€‚ç ”ç©¶è€…æ¢è¨äº†ç”²ç¡«æ°¨é…¸-è”—ç³–å£“åŠ›è™•ç†å°é’èŠ±æ¤°èœèŠ½ä¸­è‘¡è„ç³–è‹·çš„ç”Ÿç‰©åˆæˆå½±éŸ¿ï¼Œä¸¦è©•ä¼°çœŸç©ºå†·å‡ä¹¾ç‡¥å°èŠ½ç²‰å“è³ªçš„å½±éŸ¿ã€‚é€™äº›å•é¡Œçš„æ¢è¨ä¸åƒ…æœ‰åŠ©æ–¼äº†è§£é’èŠ±æ¤°èœèŠ½çš„ç‡Ÿé¤Šæ½›åŠ›ï¼Œä¹Ÿç‚ºæœªä¾†çš„é£Ÿå“åŠ å·¥æŠ€è¡“æä¾›äº†åƒè€ƒã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†é’èŠ±æ¤°èœèŠ½ä½œç‚ºç ”ç©¶å°è±¡ï¼Œä¸¦å°å…¶æ–½åŠ äº†ç”²ç¡«æ°¨é…¸å’Œè”—ç³–çš„å£“åŠ›è™•ç†ã€‚é€™äº›èŠ½åœ¨ç¶“éå››å¤©çš„ç”Ÿé•·å¾Œï¼Œé€²è¡Œäº†ç‡Ÿé¤Šæˆåˆ†çš„æ¸¬é‡å’Œåˆ†æã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„æ¢è¨äº†çœŸç©ºå†·å‡ä¹¾ç‡¥æŠ€è¡“å°èŠ½ç²‰çš„å½±éŸ¿ï¼Œè©•ä¼°å…¶åœ¨ä¿æŒç‡Ÿé¤Šæˆåˆ†æ–¹é¢çš„æ•ˆæœã€‚é€™æ¨£çš„å¯¦é©—è¨­è¨ˆæ—¨åœ¨æ‰¾å‡ºæœ€ä½³çš„è™•ç†æ–¹æ³•ï¼Œä»¥æå‡é’èŠ±æ¤°èœèŠ½çš„ç‡Ÿé¤Šåƒ¹å€¼ã€‚",
    "para4": "ç ”ç©¶çš„ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè”—ç³–è™•ç†èƒ½é¡¯è‘—æé«˜é’èŠ±æ¤°èœèŠ½ä¸­è‘¡è„ç³–è‹·çš„å«é‡ï¼Œå¢å¹…é”316.30%ã€‚æ­¤å¤–ï¼Œç¸½ç•°ç¡«æ°°é…¸é¹½å’ŒèŠ±é’ç´ çš„å«é‡ä¹Ÿåˆ†åˆ¥å¢åŠ äº†42.65%å’Œ70.00%ã€‚é€™äº›è™•ç†ä¸åƒ…æå‡äº†é’èŠ±æ¤°èœèŠ½çš„ç‡Ÿé¤Šå“è³ªï¼Œé‚„å¢å¼·äº†é…µç´ æ´»æ€§ã€‚çœŸç©ºå†·å‡ä¹¾ç‡¥çš„é’èŠ±æ¤°èœèŠ½ç²‰åœ¨ä¿æŒè˜¿è””ç¡«ç´ å’Œç¸½ç•°ç¡«æ°°é…¸é¹½æ–¹é¢è¡¨ç¾è‰¯å¥½ï¼Œä¸¦ä¸”å…·æœ‰å„ªè‰¯çš„æ°´åˆ†ä¿æŒèƒ½åŠ›å’Œæ²¹è„‚ä¿æŒèƒ½åŠ›ã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œçµåˆè”—ç³–å£“åŠ›å’ŒçœŸç©ºå†·å‡ä¹¾ç‡¥çš„æ‡‰ç”¨ï¼Œå¯èƒ½ç‚ºé–‹ç™¼åŠŸèƒ½æ€§é£Ÿå“æä¾›äº†ä¸€å€‹æœ‰å‰æ™¯çš„æ–¹å‘ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›æœ‰è¶£çš„å•Ÿç¤ºã€‚ç ”ç©¶é¡¯ç¤ºï¼Œé€éç‰¹å®šçš„è™•ç†æ–¹æ³•ï¼Œå¯ä»¥æå‡é’èŠ±æ¤°èœèŠ½ä¸­çš„ç‡Ÿé¤Šæˆåˆ†ï¼Œç‰¹åˆ¥æ˜¯è˜¿è””ç¡«ç´ çš„å«é‡ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®è¢«èªç‚ºæœ‰åŠ©æ–¼æŠ—æ°§åŒ–å’ŒæŠ—èŒçš„åŒ–åˆç‰©ï¼Œå¯èƒ½å°æ–¼å¢å¼·å…ç–«ç³»çµ±å’Œé é˜²æŸäº›ç–¾ç—…æœ‰æ­£é¢å½±éŸ¿ã€‚å› æ­¤ï¼Œé€™é …ç ”ç©¶çš„çµæœå¯èƒ½ç‚ºæœªä¾†çš„å¥åº·é£²é£Ÿå’ŒåŠŸèƒ½æ€§é£Ÿå“çš„é–‹ç™¼æä¾›æ–°çš„æ–¹å‘ï¼Œå°¤å…¶æ˜¯åœ¨æå‡é’èŠ±æ¤°èœç­‰è”¬èœçš„ç‡Ÿé¤Šåƒ¹å€¼æ–¹é¢ã€‚\n\næœ¬ç ”ç©¶ä¸»è¦é—œæ³¨çš„æ˜¯é’èŠ±æ¤°èœèŠ½åœ¨ç‰¹å®šè™•ç†ä¸‹çš„ç‡Ÿé¤Šæˆåˆ†è®ŠåŒ–ï¼Œå°¤å…¶æ˜¯è˜¿è””ç¡«ç´ çš„åˆæˆã€‚ç ”ç©¶è€…æ¢è¨äº†ç”²ç¡«æ°¨é…¸-è”—ç³–å£“åŠ›è™•ç†å°é’èŠ±æ¤°èœèŠ½ä¸­è‘¡è„ç³–è‹·çš„ç”Ÿç‰©åˆæˆå½±éŸ¿ï¼Œä¸¦è©•ä¼°çœŸç©ºå†·å‡ä¹¾ç‡¥å°èŠ½ç²‰å“è³ªçš„å½±éŸ¿ã€‚é€™äº›å•é¡Œçš„æ¢è¨ä¸åƒ…æœ‰åŠ©æ–¼äº†è§£é’èŠ±æ¤°èœèŠ½çš„ç‡Ÿé¤Šæ½›åŠ›ï¼Œä¹Ÿç‚ºæœªä¾†çš„é£Ÿå“åŠ å·¥æŠ€è¡“æä¾›äº†åƒè€ƒã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†é’èŠ±æ¤°èœèŠ½ä½œç‚ºç ”ç©¶å°è±¡ï¼Œä¸¦å°å…¶æ–½åŠ äº†ç”²ç¡«æ°¨é…¸å’Œè”—ç³–çš„å£“åŠ›è™•ç†ã€‚é€™äº›èŠ½åœ¨ç¶“éå››å¤©çš„ç”Ÿé•·å¾Œï¼Œé€²è¡Œäº†ç‡Ÿé¤Šæˆåˆ†çš„æ¸¬é‡å’Œåˆ†æã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„æ¢è¨äº†çœŸç©ºå†·å‡ä¹¾ç‡¥æŠ€è¡“å°èŠ½ç²‰çš„å½±éŸ¿ï¼Œè©•ä¼°å…¶åœ¨ä¿æŒç‡Ÿé¤Šæˆåˆ†æ–¹é¢çš„æ•ˆæœã€‚é€™æ¨£çš„å¯¦é©—è¨­è¨ˆæ—¨åœ¨æ‰¾å‡ºæœ€ä½³çš„è™•ç†æ–¹æ³•ï¼Œä»¥æå‡é’èŠ±æ¤°èœèŠ½çš„ç‡Ÿé¤Šåƒ¹å€¼ã€‚\n\nç ”ç©¶çš„ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè”—ç³–è™•ç†èƒ½é¡¯è‘—æé«˜é’èŠ±æ¤°èœèŠ½ä¸­è‘¡è„ç³–è‹·çš„å«é‡ï¼Œå¢å¹…é”316.30%ã€‚æ­¤å¤–ï¼Œç¸½ç•°ç¡«æ°°é…¸é¹½å’ŒèŠ±é’ç´ çš„å«é‡ä¹Ÿåˆ†åˆ¥å¢åŠ äº†42.65%å’Œ70.00%ã€‚é€™äº›è™•ç†ä¸åƒ…æå‡äº†é’èŠ±æ¤°èœèŠ½çš„ç‡Ÿé¤Šå“è³ªï¼Œé‚„å¢å¼·äº†é…µç´ æ´»æ€§ã€‚çœŸç©ºå†·å‡ä¹¾ç‡¥çš„é’èŠ±æ¤°èœèŠ½ç²‰åœ¨ä¿æŒè˜¿è””ç¡«ç´ å’Œç¸½ç•°ç¡«æ°°é…¸é¹½æ–¹é¢è¡¨ç¾è‰¯å¥½ï¼Œä¸¦ä¸”å…·æœ‰å„ªè‰¯çš„æ°´åˆ†ä¿æŒèƒ½åŠ›å’Œæ²¹è„‚ä¿æŒèƒ½åŠ›ã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œçµåˆè”—ç³–å£“åŠ›å’ŒçœŸç©ºå†·å‡ä¹¾ç‡¥çš„æ‡‰ç”¨ï¼Œå¯èƒ½ç‚ºé–‹ç™¼åŠŸèƒ½æ€§é£Ÿå“æä¾›äº†ä¸€å€‹æœ‰å‰æ™¯çš„æ–¹å‘ã€‚",
    "fb_post": "æ ¹æ“šã€ŠFood chemistryã€‹æ–¼ 2026 å¹´ 1 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“é’èŠ±æ¤°èœèŠ½è£¡æœ‰ç¨®ç¥å¥‡çš„æˆåˆ†å«è˜¿è””ç¡«ç´ å—ï¼Ÿé€™ç¨®æˆåˆ†ä¸åƒ…è®“æˆ‘å€‘çš„å…ç–«ç³»çµ±æ›´å¼·å£¯ï¼Œé‚„å¯èƒ½å¹«åŠ©é é˜²ä¸€äº›ç–¾ç—…ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œé€éç‰¹å®šçš„è™•ç†æ–¹æ³•ï¼Œæˆ‘å€‘å¯ä»¥è®“é’èŠ±æ¤°èœèŠ½ä¸­çš„è˜¿è””ç¡«ç´ å«é‡å¤§å¹…æå‡ã€‚  \n\né€™é …ç ”ç©¶ä¸»è¦æ¢è¨äº†å¦‚ä½•åˆ©ç”¨ç”²ç¡«æ°¨é…¸å’Œè”—ç³–çš„å£“åŠ›è™•ç†ä¾†å¢åŠ é’èŠ±æ¤°èœèŠ½ä¸­çš„ç‡Ÿé¤Šæˆåˆ†ã€‚ç ”ç©¶è€…å€‘åœ¨å¯¦é©—ä¸­è§€å¯Ÿäº†é€™äº›èŠ½åœ¨ç”Ÿé•·å››å¤©å¾Œçš„è®ŠåŒ–ï¼Œä¸¦ä¸”æ¸¬è©¦äº†çœŸç©ºå†·å‡ä¹¾ç‡¥å°èŠ½ç²‰å“è³ªçš„å½±éŸ¿ã€‚  \n\nçµæœé¡¯ç¤ºï¼Œè”—ç³–è™•ç†è®“é’èŠ±æ¤°èœèŠ½ä¸­çš„è‘¡è„ç³–è‹·å«é‡å¢åŠ äº†316.30%ï¼è€Œä¸”ï¼Œç¸½ç•°ç¡«æ°°é…¸é¹½å’ŒèŠ±é’ç´ çš„å«é‡ä¹Ÿæœ‰é¡¯è‘—æå‡ï¼Œé€™äº›éƒ½èƒ½å¢å¼·èŠ½çš„ç‡Ÿé¤Šåƒ¹å€¼å’Œé…µç´ æ´»æ€§ã€‚  \n\nç¸½çµä¾†èªªï¼š  \n- è”—ç³–è™•ç†èƒ½é¡¯è‘—æå‡é’èŠ±æ¤°èœèŠ½çš„ç‡Ÿé¤Šæˆåˆ†  \n- çœŸç©ºå†·å‡ä¹¾ç‡¥æŠ€è¡“æœ‰åŠ©æ–¼ä¿æŒè˜¿è””ç¡«ç´   \n- é€™äº›ç™¼ç¾å¯èƒ½ç‚ºæœªä¾†çš„å¥åº·é£Ÿå“é–‹ç™¼æä¾›æ–°æ–¹å‘ï¼",
    "image_prompt": "Create a flat design infographic that explains the experimental method and main results of a study on broccoli sprouts. Include symbols for broccoli and sulforaphane, simplified illustrations of experimental subjects (like humans or cells), arrows or flow lines to indicate the experimental steps, and a section highlighting the main results, such as increased nutrient levels and protective effects. Use a light background with soft colors for a friendly and informative look.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": false,
    "disease_name": "",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41265122/"
  },
  {
    "id": "40580757",
    "title_en": "The effect of graphene oxide-polyethylene glycol on lung cell and treatment of sulforaphane.",
    "pub_date": "2026 Jan",
    "journal": "Talanta",
    "abstract_en": "This study explores the cytotoxic and biochemical effects of PEGylated graphene oxide (GO-PEG) nanoparticles, sulforaphane, and Raphanus sativus L. (black radish) juice on BEAS-2B human bronchial epithelial cells. Sulforaphane was extracted from radish juice through pH-adjusted aqueous treatment followed by organic solvent extraction, and quantified via high-performance liquid chromatography (HPLC) at 202Â nm, with a retention time of 11.0Â min. GO-PEG nanoparticles produced from graphites (50Â nm and 400Â nm) were tested at concentrations ranging from 50-225 Î¼gÂ mL<sup>-1</sup> and 100-1000 Î¼gÂ mL<sup>-1</sup> to have IC<sub>50</sub> values, respectively. Sulforaphane and black radish juice were also administered. The MTT assay revealed IC<sub>50</sub> values of 8.7Â Î¼gÂ mL<sup>-1</sup> for sulforaphane, 197.0 mgÂ mL<sup>-1</sup> for black radish juice, 175.8Â Î¼gÂ mL<sup>-1</sup> for GO-PEG (50Â nm), and 650.6Â Î¼gÂ mL<sup>-1</sup> for GO-PEG (400Â nm). Biochemical analyses showed that sulforaphane and radish juice decreased IL-6 levels and increased antioxidant enzyme activities (GSH-Px and CAT). These results highlight the therapeutic potential of GO-PEG, sulforaphane, and black radish juice for anti-inflammatory and antioxidant applications.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–çš„é ˜åŸŸã€‚ç ”ç©¶é¡¯ç¤ºï¼ŒæŸäº›å¤©ç„¶æˆåˆ†å¦‚è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±å¯èƒ½å°å‘¼å¸é“ç´°èƒæœ‰ä¿è­·ä½œç”¨ï¼Œé€™å°æ–¼æ”¹å–„å‘¼å¸ç³»çµ±å¥åº·å’Œé é˜²ç›¸é—œç–¾ç—…å…·æœ‰æ½›åœ¨çš„æ„ç¾©ã€‚éš¨è‘—ç’°å¢ƒæ±¡æŸ“å’Œç”Ÿæ´»æ–¹å¼çš„æ”¹è®Šï¼Œå‘¼å¸ç³»çµ±çš„å¥åº·è®Šå¾—è¶Šä¾†è¶Šé‡è¦ï¼Œå› æ­¤æ¢ç´¢é€™äº›å¤©ç„¶ç‰©è³ªçš„æ•ˆæœå¯èƒ½æœƒç‚ºæœªä¾†çš„å¥åº·ç®¡ç†æä¾›æ–°çš„æ–¹å‘ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨PEGåŒ–çŸ³å¢¨çƒ¯æ°§åŒ–ç‰©ï¼ˆGO-PEGï¼‰å¥ˆç±³ç²’å­ã€è˜¿è””ç¡«ç´ åŠé»‘è˜¿è””æ±å°äººé¡æ”¯æ°£ç®¡ä¸Šçš®ç´°èƒBEAS-2Bçš„ç´°èƒæ¯’æ€§å’Œç”ŸåŒ–æ•ˆæ‡‰ã€‚ç ”ç©¶è€…é—œå¿ƒé€™äº›ç‰©è³ªå¦‚ä½•å½±éŸ¿å‘¼å¸é“ç´°èƒçš„å¥åº·ï¼Œç‰¹åˆ¥æ˜¯å®ƒå€‘åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–æ–¹é¢çš„æ½›åŠ›ã€‚é€éé€™äº›ç ”ç©¶ï¼Œç§‘å­¸å®¶å¸Œæœ›èƒ½å¤ äº†è§£é€™äº›æˆåˆ†åœ¨ç´°èƒå±¤é¢ä¸Šçš„ä½œç”¨æ©Ÿåˆ¶ï¼Œä¸¦è©•ä¼°å…¶å°å¥åº·çš„å½±éŸ¿ã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†BEAS-2Bäººé¡æ”¯æ°£ç®¡ä¸Šçš®ç´°èƒä½œç‚ºç ”ç©¶å°è±¡ï¼Œä¸¦æ¡ç”¨äº†å¤šç¨®æ–¹æ³•ä¾†æ¸¬è©¦ä¸åŒç‰©è³ªçš„æ•ˆæœã€‚è˜¿è””ç¡«ç´ æ˜¯å¾é»‘è˜¿è””æ±ä¸­æå–çš„ï¼Œç¶“épHèª¿æ•´çš„æ°´è™•ç†å’Œæœ‰æ©Ÿæº¶åŠ‘æå–ï¼Œä¸¦é€éé«˜æ•ˆæ¶²ç›¸è‰²è­œæ³•é€²è¡Œå®šé‡åˆ†æã€‚GO-PEGå¥ˆç±³ç²’å­å‰‡æ˜¯å¾çŸ³å¢¨è£½æˆï¼Œä¸¦åœ¨ä¸åŒæ¿ƒåº¦ä¸‹é€²è¡Œæ¸¬è©¦ã€‚ç ”ç©¶è€…ä½¿ç”¨MTTæ¸¬è©¦ä¾†è©•ä¼°ç´°èƒçš„å­˜æ´»ç‡ï¼Œä¸¦é€²è¡Œç”ŸåŒ–åˆ†æä¾†æ¸¬é‡ç´°èƒå…§çš„æŠ—æ°§åŒ–é…¶æ´»æ€§ã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±èƒ½å¤ é™ä½IL-6çš„æ°´å¹³ï¼Œä¸¦æé«˜æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼ˆå¦‚GSH-Pxå’ŒCATï¼‰ã€‚é€™äº›çµæœè¡¨æ˜ï¼ŒGO-PEGã€è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–æ–¹é¢å…·æœ‰æ½›åœ¨çš„æ‡‰ç”¨åƒ¹å€¼ï¼Œå¯èƒ½å°å‘¼å¸ç³»çµ±çš„å¥åº·æœ‰ç›Šã€‚ç„¶è€Œï¼Œé€™äº›çµæœä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶å…·é«”çš„ç™‚æ•ˆå’Œæ©Ÿåˆ¶ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–çš„é ˜åŸŸã€‚ç ”ç©¶é¡¯ç¤ºï¼ŒæŸäº›å¤©ç„¶æˆåˆ†å¦‚è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±å¯èƒ½å°å‘¼å¸é“ç´°èƒæœ‰ä¿è­·ä½œç”¨ï¼Œé€™å°æ–¼æ”¹å–„å‘¼å¸ç³»çµ±å¥åº·å’Œé é˜²ç›¸é—œç–¾ç—…å…·æœ‰æ½›åœ¨çš„æ„ç¾©ã€‚éš¨è‘—ç’°å¢ƒæ±¡æŸ“å’Œç”Ÿæ´»æ–¹å¼çš„æ”¹è®Šï¼Œå‘¼å¸ç³»çµ±çš„å¥åº·è®Šå¾—è¶Šä¾†è¶Šé‡è¦ï¼Œå› æ­¤æ¢ç´¢é€™äº›å¤©ç„¶ç‰©è³ªçš„æ•ˆæœå¯èƒ½æœƒç‚ºæœªä¾†çš„å¥åº·ç®¡ç†æä¾›æ–°çš„æ–¹å‘ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨PEGåŒ–çŸ³å¢¨çƒ¯æ°§åŒ–ç‰©ï¼ˆGO-PEGï¼‰å¥ˆç±³ç²’å­ã€è˜¿è””ç¡«ç´ åŠé»‘è˜¿è””æ±å°äººé¡æ”¯æ°£ç®¡ä¸Šçš®ç´°èƒBEAS-2Bçš„ç´°èƒæ¯’æ€§å’Œç”ŸåŒ–æ•ˆæ‡‰ã€‚ç ”ç©¶è€…é—œå¿ƒé€™äº›ç‰©è³ªå¦‚ä½•å½±éŸ¿å‘¼å¸é“ç´°èƒçš„å¥åº·ï¼Œç‰¹åˆ¥æ˜¯å®ƒå€‘åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–æ–¹é¢çš„æ½›åŠ›ã€‚é€éé€™äº›ç ”ç©¶ï¼Œç§‘å­¸å®¶å¸Œæœ›èƒ½å¤ äº†è§£é€™äº›æˆåˆ†åœ¨ç´°èƒå±¤é¢ä¸Šçš„ä½œç”¨æ©Ÿåˆ¶ï¼Œä¸¦è©•ä¼°å…¶å°å¥åº·çš„å½±éŸ¿ã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†BEAS-2Bäººé¡æ”¯æ°£ç®¡ä¸Šçš®ç´°èƒä½œç‚ºç ”ç©¶å°è±¡ï¼Œä¸¦æ¡ç”¨äº†å¤šç¨®æ–¹æ³•ä¾†æ¸¬è©¦ä¸åŒç‰©è³ªçš„æ•ˆæœã€‚è˜¿è””ç¡«ç´ æ˜¯å¾é»‘è˜¿è””æ±ä¸­æå–çš„ï¼Œç¶“épHèª¿æ•´çš„æ°´è™•ç†å’Œæœ‰æ©Ÿæº¶åŠ‘æå–ï¼Œä¸¦é€éé«˜æ•ˆæ¶²ç›¸è‰²è­œæ³•é€²è¡Œå®šé‡åˆ†æã€‚GO-PEGå¥ˆç±³ç²’å­å‰‡æ˜¯å¾çŸ³å¢¨è£½æˆï¼Œä¸¦åœ¨ä¸åŒæ¿ƒåº¦ä¸‹é€²è¡Œæ¸¬è©¦ã€‚ç ”ç©¶è€…ä½¿ç”¨MTTæ¸¬è©¦ä¾†è©•ä¼°ç´°èƒçš„å­˜æ´»ç‡ï¼Œä¸¦é€²è¡Œç”ŸåŒ–åˆ†æä¾†æ¸¬é‡ç´°èƒå…§çš„æŠ—æ°§åŒ–é…¶æ´»æ€§ã€‚\n\nä¸»è¦çš„ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±èƒ½å¤ é™ä½IL-6çš„æ°´å¹³ï¼Œä¸¦æé«˜æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼ˆå¦‚GSH-Pxå’ŒCATï¼‰ã€‚é€™äº›çµæœè¡¨æ˜ï¼ŒGO-PEGã€è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–æ–¹é¢å…·æœ‰æ½›åœ¨çš„æ‡‰ç”¨åƒ¹å€¼ï¼Œå¯èƒ½å°å‘¼å¸ç³»çµ±çš„å¥åº·æœ‰ç›Šã€‚ç„¶è€Œï¼Œé€™äº›çµæœä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶å…·é«”çš„ç™‚æ•ˆå’Œæ©Ÿåˆ¶ã€‚",
    "fb_post": "æ ¹æ“šã€ŠTalantaã€‹æ–¼ 2026 å¹´ 1 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ€ è½èªªè˜¿è””ä¸åªæ˜¯å¯ä»¥åšæ²™æ‹‰ï¼Œé‚„èƒ½å¹«åŠ©æˆ‘å€‘çš„å‘¼å¸ç³»çµ±è®Šå¾—æ›´å¥åº·å‘¢ï¼é€™ç¯‡ç ”ç©¶æ¢ç´¢äº†è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±å°æˆ‘å€‘å‘¼å¸é“ç´°èƒçš„å½±éŸ¿ï¼Œç™¼ç¾å®ƒå€‘å¯èƒ½æœ‰æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–çš„æ½›åŠ›ï¼\n\nç ”ç©¶è€…å€‘ç”¨äº†ä¸€äº›äººé¡çš„å‘¼å¸é“ç´°èƒï¼Œçœ‹çœ‹é€™äº›å¤©ç„¶æˆåˆ†å¦‚ä½•å½±éŸ¿ç´°èƒçš„å¥åº·ã€‚ä»–å€‘é€éä¸åŒçš„æ–¹æ³•ä¾†æ¸¬è©¦é€™äº›ç‰©è³ªçš„æ•ˆæœï¼Œåƒæ˜¯ç”¨åŒ–å­¸æ–¹æ³•æå–è˜¿è””ç¡«ç´ ï¼Œä¸¦æ¸¬è©¦ç´°èƒçš„å­˜æ´»ç‡å’ŒæŠ—æ°§åŒ–é…¶çš„æ´»æ€§ã€‚\n\nçµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±èƒ½é™ä½ä¸€ç¨®å«IL-6çš„ç‰©è³ªï¼Œé€™è¡¨ç¤ºå®ƒå€‘å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘ç™¼ç‚ï¼Œä¸¦æå‡æˆ‘å€‘é«”å…§çš„æŠ—æ°§åŒ–èƒ½åŠ›ã€‚é€™å°æˆ‘å€‘çš„å‘¼å¸ç³»çµ±å¥åº·ä¾†èªªï¼Œæœªä¾†å¯èƒ½æœƒæœ‰ä¸å°çš„å¹«åŠ©ï¼\n\nğŸ” ä¸»è¦é‡é»ï¼š  \n1. è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±å¯èƒ½å°å‘¼å¸é“ç´°èƒæœ‰ä¿è­·ä½œç”¨ã€‚  \n2. é€™äº›å¤©ç„¶æˆåˆ†æœ‰åŠ©æ–¼é™ä½ç™¼ç‚æŒ‡æ¨™å’Œæå‡æŠ—æ°§åŒ–èƒ½åŠ›ã€‚  \n3. ç ”ç©¶çµæœéœ€è¦é€²ä¸€æ­¥ç¢ºèªï¼Œä»¥äº†è§£å…·é«”çš„ç™‚æ•ˆå’Œæ©Ÿåˆ¶ã€‚",
    "image_prompt": "Create a flat design infographic with a light background that explains the experiment and main results of a study on the effects of daikon sulforaphane and black radish juice on human bronchial epithelial cells. Include simplified icons of broccoli or daikon, human cells, and arrows or flow lines to depict the experimental steps. Add a section highlighting the main results, such as protective effects and changes in inflammation and antioxidant levels.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "å‘¼å¸ç³»çµ±ç–¾ç—… Respiratory Diseases",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40580757/"
  },
  {
    "id": "41487499",
    "title_en": "The dietary phytochemicals carnosic acid and sulforaphane regulate inflammatory markers in ulcerative colitis patient-derived colonoids.",
    "pub_date": "2025",
    "journal": "Frontiers in pharmacology",
    "abstract_en": "The inflammatory bowel disease (IBD) ulcerative colitis (UC) is characterized by continuous inflammation of the colon with erosion and ulcers. Diagnosis typically occurs in patients between their late teens and mid-30s with no cure. Available therapeutics are efficient at controlling symptoms however, they have many serious adverse effects. Thus, additional therapies with limited adverse effects are needed to complement these drugs. In this study, we evaluated the anti-inflammatory potential of carnosic acid (CA), the most abundant diterpene in rosemary (<i>Salvia rosmarinus</i>) and sulforaphane (SFN), an isothiocyanate found in cruciferous vegetables. We used colonic epithelial organoids (colonoids) derived from non-IBD and UC patients as a physiologically relevant testing platform for both phytochemicals. These patient-derived colonoids are a representative model that recapitulates the parent epithelial tissue including its cellular composition and 3D structure. Moreover, we cultured the colonoids at 2% O<sub>2</sub> to better approximate the low oxygen level (physioxia) observed in the colon crypts. To assess the effects of CA and SFN in the nuclear factor erythroid 2-related factor 2 (NRF2) and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-ÎºB) pathways, we studied modulation of inflammatory cytokines through a 40-plex chemokine assay and ELISA, as well as gene and protein expression of target genes with qPCR and western blot, respectively. Through these techniques, we observed that CA and SFN decreased inflammatory markers and promoted NRF2 activity in patient-derived colonoids. Additionally, SFN and CA modulated the expression and secretion of the NF-ÎºB promoted antibacterial peptide neutrophil gelatinase-associated lipocalin which is highly expressed in the inflamed colonic epithelium and has been suggested as a biomarker for active UC. Together, the results validated the use of colonoids as a pharmacological testing platform for phytochemicals, and that CA and SFN promote NRF2 activation and decrease inflammation in a human physiologically relevant UC model.",
    "para1": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œå°¤å…¶æ˜¯é‡å°ç‚ç—‡æ€§è…¸ç—…ï¼ˆIBDï¼‰ä¸­çš„æ½°ç˜æ€§çµè…¸ç‚ï¼ˆUCï¼‰ã€‚ç›®å‰ï¼Œé›–ç„¶æœ‰ä¸€äº›è—¥ç‰©å¯ä»¥æ§åˆ¶ç—‡ç‹€ï¼Œä½†é€™äº›è—¥ç‰©å¸¸å¸¸ä¼´éš¨è‘—åš´é‡çš„å‰¯ä½œç”¨ã€‚å› æ­¤ï¼Œå°‹æ‰¾æ–°çš„æ²»ç™‚æ–¹æ³•ï¼Œå°¤å…¶æ˜¯é‚£äº›å‰¯ä½œç”¨è¼ƒå°‘çš„é¸æ“‡ï¼Œå°æ–¼æ”¹å–„æ‚£è€…çš„ç”Ÿæ´»å“è³ªæ˜¯éå¸¸é‡è¦çš„ã€‚é€™é …ç ”ç©¶æ¢è¨äº†å…©ç¨®æ¤ç‰©åŒ–å­¸ç‰©è³ªâ€”â€”è¿·è¿­é¦™ä¸­çš„è¿·è¿­é¦™é…¸å’Œé’èŠ±æ¤°èœä¸­çš„è˜¿è””ç¡«ç´ ï¼Œé€™äº›ç‰©è³ªå¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘ç‚ç—‡ï¼Œç‚ºæ½°ç˜æ€§çµè…¸ç‚æ‚£è€…æä¾›æ–°çš„æ²»ç™‚æ€è·¯ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯è©•ä¼°è¿·è¿­é¦™é…¸å’Œè˜¿è””ç¡«ç´ åœ¨æ½°ç˜æ€§çµè…¸ç‚ä¸­çš„æŠ—ç‚æ½›åŠ›ã€‚æ½°ç˜æ€§çµè…¸ç‚æ˜¯ä¸€ç¨®ä»¥çµè…¸æŒçºŒç™¼ç‚ç‚ºç‰¹å¾µçš„ç–¾ç—…ï¼Œé€šå¸¸åœ¨é’å°‘å¹´æ™šæœŸåˆ°ä¸‰åå¤šæ­²ä¹‹é–“è¢«è¨ºæ–·ï¼Œä¸”ç›®å‰å°šç„¡æ²»ç™’æ–¹æ³•ã€‚ç ”ç©¶è€…å¸Œæœ›é€éé€™äº›æ¤ç‰©åŒ–å­¸ç‰©è³ªï¼Œæ‰¾åˆ°èƒ½å¤ è£œå……ç¾æœ‰è—¥ç‰©çš„æ²»ç™‚æ–¹æ¡ˆï¼Œä¸¦æ¸›å°‘æ‚£è€…æ‰€æ‰¿å—çš„å‰¯ä½œç”¨ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ä¾†è‡ªéæ½°ç˜æ€§çµè…¸ç‚å’Œæ½°ç˜æ€§çµè…¸ç‚æ‚£è€…çš„çµè…¸ä¸Šçš®é¡å™¨å®˜ï¼ˆcolonoidsï¼‰ä½œç‚ºæ¸¬è©¦å¹³å°ã€‚é€™äº›é¡å™¨å®˜èƒ½å¤ æ¨¡æ“¬çœŸå¯¦çš„çµè…¸ä¸Šçš®çµ„ç¹”ï¼ŒåŒ…æ‹¬å…¶ç´°èƒçµ„æˆå’Œä¸‰ç¶­çµæ§‹ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…åœ¨2%çš„æ°§æ°£ç’°å¢ƒä¸­åŸ¹é¤Šé€™äº›é¡å™¨å®˜ï¼Œä»¥æ›´å¥½åœ°æ¨¡æ“¬çµè…¸éš±çª©ä¸­çš„ä½æ°§ç’°å¢ƒã€‚æ¥è‘—ï¼Œä»–å€‘è©•ä¼°äº†è¿·è¿­é¦™é…¸å’Œè˜¿è””ç¡«ç´ å°æ–¼ç‚ç—‡ç›¸é—œç´°èƒå› å­çš„å½±éŸ¿ï¼Œä¸¦ä½¿ç”¨äº†å¤šç¨®æŠ€è¡“ä¾†åˆ†æåŸºå› å’Œè›‹ç™½è³ªçš„è¡¨é”ã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œè¿·è¿­é¦™é…¸å’Œè˜¿è””ç¡«ç´ èƒ½å¤ é™ä½ç‚ç—‡æ¨™è¨˜ç‰©ï¼Œä¸¦ä¿ƒé€²NRF2çš„æ´»æ€§ï¼Œé€™æ˜¯ä¸€å€‹èˆ‡æŠ—æ°§åŒ–å’ŒæŠ—ç‚æœ‰é—œçš„é‡è¦é€šè·¯ã€‚æ­¤å¤–ï¼Œé€™äº›åŒ–åˆç‰©é‚„èª¿ç¯€äº†NF-ÎºBä¿ƒé€²çš„æŠ—èŒè‚½çš„è¡¨é”å’Œåˆ†æ³Œï¼Œé€™ç¨®æŠ—èŒè‚½åœ¨ç™¼ç‚çš„çµè…¸ä¸Šçš®ä¸­è¡¨é”é‡å¾ˆé«˜ï¼Œä¸¦è¢«èªç‚ºæ˜¯æ½°ç˜æ€§çµè…¸ç‚æ´»å‹•çš„ç”Ÿç‰©æ¨™è¨˜ã€‚é€™äº›çµæœé©—è­‰äº†çµè…¸é¡å™¨å®˜ä½œç‚ºæ¤ç‰©åŒ–å­¸ç‰©è³ªè—¥ç†æ¸¬è©¦å¹³å°çš„å¯è¡Œæ€§ï¼Œä¸¦é¡¯ç¤ºè¿·è¿­é¦™é…¸å’Œè˜¿è””ç¡«ç´ åœ¨æ¸›å°‘ç‚ç—‡æ–¹é¢çš„æ½›åŠ›ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œå°¤å…¶æ˜¯é‡å°ç‚ç—‡æ€§è…¸ç—…ï¼ˆIBDï¼‰ä¸­çš„æ½°ç˜æ€§çµè…¸ç‚ï¼ˆUCï¼‰ã€‚ç›®å‰ï¼Œé›–ç„¶æœ‰ä¸€äº›è—¥ç‰©å¯ä»¥æ§åˆ¶ç—‡ç‹€ï¼Œä½†é€™äº›è—¥ç‰©å¸¸å¸¸ä¼´éš¨è‘—åš´é‡çš„å‰¯ä½œç”¨ã€‚å› æ­¤ï¼Œå°‹æ‰¾æ–°çš„æ²»ç™‚æ–¹æ³•ï¼Œå°¤å…¶æ˜¯é‚£äº›å‰¯ä½œç”¨è¼ƒå°‘çš„é¸æ“‡ï¼Œå°æ–¼æ”¹å–„æ‚£è€…çš„ç”Ÿæ´»å“è³ªæ˜¯éå¸¸é‡è¦çš„ã€‚é€™é …ç ”ç©¶æ¢è¨äº†å…©ç¨®æ¤ç‰©åŒ–å­¸ç‰©è³ªâ€”â€”è¿·è¿­é¦™ä¸­çš„è¿·è¿­é¦™é…¸å’Œé’èŠ±æ¤°èœä¸­çš„è˜¿è””ç¡«ç´ ï¼Œé€™äº›ç‰©è³ªå¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘ç‚ç—‡ï¼Œç‚ºæ½°ç˜æ€§çµè…¸ç‚æ‚£è€…æä¾›æ–°çš„æ²»ç™‚æ€è·¯ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯è©•ä¼°è¿·è¿­é¦™é…¸å’Œè˜¿è””ç¡«ç´ åœ¨æ½°ç˜æ€§çµè…¸ç‚ä¸­çš„æŠ—ç‚æ½›åŠ›ã€‚æ½°ç˜æ€§çµè…¸ç‚æ˜¯ä¸€ç¨®ä»¥çµè…¸æŒçºŒç™¼ç‚ç‚ºç‰¹å¾µçš„ç–¾ç—…ï¼Œé€šå¸¸åœ¨é’å°‘å¹´æ™šæœŸåˆ°ä¸‰åå¤šæ­²ä¹‹é–“è¢«è¨ºæ–·ï¼Œä¸”ç›®å‰å°šç„¡æ²»ç™’æ–¹æ³•ã€‚ç ”ç©¶è€…å¸Œæœ›é€éé€™äº›æ¤ç‰©åŒ–å­¸ç‰©è³ªï¼Œæ‰¾åˆ°èƒ½å¤ è£œå……ç¾æœ‰è—¥ç‰©çš„æ²»ç™‚æ–¹æ¡ˆï¼Œä¸¦æ¸›å°‘æ‚£è€…æ‰€æ‰¿å—çš„å‰¯ä½œç”¨ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ä¾†è‡ªéæ½°ç˜æ€§çµè…¸ç‚å’Œæ½°ç˜æ€§çµè…¸ç‚æ‚£è€…çš„çµè…¸ä¸Šçš®é¡å™¨å®˜ï¼ˆcolonoidsï¼‰ä½œç‚ºæ¸¬è©¦å¹³å°ã€‚é€™äº›é¡å™¨å®˜èƒ½å¤ æ¨¡æ“¬çœŸå¯¦çš„çµè…¸ä¸Šçš®çµ„ç¹”ï¼ŒåŒ…æ‹¬å…¶ç´°èƒçµ„æˆå’Œä¸‰ç¶­çµæ§‹ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…åœ¨2%çš„æ°§æ°£ç’°å¢ƒä¸­åŸ¹é¤Šé€™äº›é¡å™¨å®˜ï¼Œä»¥æ›´å¥½åœ°æ¨¡æ“¬çµè…¸éš±çª©ä¸­çš„ä½æ°§ç’°å¢ƒã€‚æ¥è‘—ï¼Œä»–å€‘è©•ä¼°äº†è¿·è¿­é¦™é…¸å’Œè˜¿è””ç¡«ç´ å°æ–¼ç‚ç—‡ç›¸é—œç´°èƒå› å­çš„å½±éŸ¿ï¼Œä¸¦ä½¿ç”¨äº†å¤šç¨®æŠ€è¡“ä¾†åˆ†æåŸºå› å’Œè›‹ç™½è³ªçš„è¡¨é”ã€‚\n\nä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œè¿·è¿­é¦™é…¸å’Œè˜¿è””ç¡«ç´ èƒ½å¤ é™ä½ç‚ç—‡æ¨™è¨˜ç‰©ï¼Œä¸¦ä¿ƒé€²NRF2çš„æ´»æ€§ï¼Œé€™æ˜¯ä¸€å€‹èˆ‡æŠ—æ°§åŒ–å’ŒæŠ—ç‚æœ‰é—œçš„é‡è¦é€šè·¯ã€‚æ­¤å¤–ï¼Œé€™äº›åŒ–åˆç‰©é‚„èª¿ç¯€äº†NF-ÎºBä¿ƒé€²çš„æŠ—èŒè‚½çš„è¡¨é”å’Œåˆ†æ³Œï¼Œé€™ç¨®æŠ—èŒè‚½åœ¨ç™¼ç‚çš„çµè…¸ä¸Šçš®ä¸­è¡¨é”é‡å¾ˆé«˜ï¼Œä¸¦è¢«èªç‚ºæ˜¯æ½°ç˜æ€§çµè…¸ç‚æ´»å‹•çš„ç”Ÿç‰©æ¨™è¨˜ã€‚é€™äº›çµæœé©—è­‰äº†çµè…¸é¡å™¨å®˜ä½œç‚ºæ¤ç‰©åŒ–å­¸ç‰©è³ªè—¥ç†æ¸¬è©¦å¹³å°çš„å¯è¡Œæ€§ï¼Œä¸¦é¡¯ç¤ºè¿·è¿­é¦™é…¸å’Œè˜¿è””ç¡«ç´ åœ¨æ¸›å°‘ç‚ç—‡æ–¹é¢çš„æ½›åŠ›ã€‚",
    "fb_post": "æ ¹æ“šã€ŠFrontiers in pharmacologyã€‹æ–¼ 2025 å¹´ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± è½èªªé’èŠ±æ¤°èœè£¡çš„è˜¿è””ç¡«ç´ å°è…¸é“å¥åº·æœ‰å¹«åŠ©ï¼Ÿé€™é …ç ”ç©¶å°±å°ˆé–€åœ¨æ¢è¨é€™å€‹å•é¡Œï¼\n\næ½°ç˜æ€§çµè…¸ç‚ï¼ˆUCï¼‰æ˜¯ä¸€ç¨®è®“è…¸é“æŒçºŒç™¼ç‚çš„ç–¾ç—…ï¼Œå¸¸å¸¸å›°æ“¾è‘—è¨±å¤šæ‚£è€…ã€‚é›–ç„¶ç¾åœ¨æœ‰ä¸€äº›è—¥ç‰©å¯ä»¥ç·©è§£ç—‡ç‹€ï¼Œä½†å‰¯ä½œç”¨å»è®“äººé ­ç—›ã€‚å› æ­¤ï¼Œç§‘å­¸å®¶å€‘é–‹å§‹å°‹æ‰¾å‰¯ä½œç”¨è¼ƒå°‘çš„æ›¿ä»£ç™‚æ³•ã€‚\n\né€™æ¬¡çš„ç ”ç©¶èšç„¦æ–¼è¿·è¿­é¦™ä¸­çš„è¿·è¿­é¦™é…¸å’Œé’èŠ±æ¤°èœä¸­çš„è˜¿è””ç¡«ç´ ã€‚ç ”ç©¶äººå“¡ä½¿ç”¨çµè…¸ä¸Šçš®é¡å™¨å®˜ï¼ˆå°±åƒæ˜¯è…¸é“çš„è¿·ä½ æ¨¡å‹ï¼‰ä¾†æ¸¬è©¦é€™äº›æ¤ç‰©åŒ–å­¸ç‰©è³ªçš„æ•ˆæœã€‚ä»–å€‘ç™¼ç¾é€™äº›åŒ–åˆç‰©èƒ½é™ä½ç‚ç—‡æ¨™è¨˜ç‰©ï¼Œä¸¦ä¿ƒé€²èˆ‡æŠ—æ°§åŒ–å’ŒæŠ—ç‚æœ‰é—œçš„é€šè·¯æ´»æ€§ã€‚\n\nç¸½çµä¸€ä¸‹ï¼š\n1. è¿·è¿­é¦™é…¸å’Œè˜¿è””ç¡«ç´ æœ‰åŠ©æ–¼æ¸›å°‘è…¸é“çš„ç‚ç—‡ã€‚\n2. é€™äº›æ¤ç‰©åŒ–å­¸ç‰©è³ªå¯èƒ½æˆç‚ºæ½°ç˜æ€§çµè…¸ç‚çš„æ–°ç™‚æ³•ã€‚\n3. ç ”ç©¶é¡¯ç¤ºï¼Œçµè…¸é¡å™¨å®˜æ˜¯æ¸¬è©¦é€™äº›åŒ–åˆç‰©çš„å¥½æ–¹æ³•ã€‚\n\né›–ç„¶é€™äº›ç™¼ç¾ä»¤äººæŒ¯å¥®ï¼Œä½†é‚„éœ€è¦æ›´å¤šç ”ç©¶ä¾†ç¢ºèªå®ƒå€‘çš„æ•ˆæœï¼",
    "image_prompt": "Create a flat design infographic with a light background that explains the experimental method and main results of a study on sulforaphane from broccoli and rosmarinic acid from rosemary. Include simplified illustrations of broccoli, rosmarinic acid, and colonoids (miniature colon models). Use arrows or flow lines to indicate the experimental steps. Add a section labeled 'Main Results' highlighting the protective effects against inflammation.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "æ½°ç˜æ€§çµè…¸ç‚ Ulcerative Colitis",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41487499/"
  },
  {
    "id": "41340527",
    "title_en": "Metabolomics and Transcriptomics Analyses Reveal the Mechanisms of Sulforaphane Conversion and Adaptive Strategies in the Absence of Glucose by <i>Lactiplantibacillus plantarum</i>.",
    "pub_date": "2025 Dec",
    "journal": "Journal of agricultural and food chemistry",
    "abstract_en": "Sulforaphane is a beneficial but unstable bioactive compound that can be converted from glucoraphanin by <i>Lactiplantibacillus plantarum</i>. However, the sulforaphane conversion rate is low, and the conversion mechanism of <i>L. plantarum</i> remains unclear. This research utilized the adaptive laboratory evolution technology to enhance the sulforaphane conversion rate of <i>L. plantarum</i>. The results showed that an increase in the glucose replacement ratio significantly downregulated carbohydrate metabolism and upregulated amino acid metabolism. Transcriptomic analysis showed that the ALE-adapted strain significantly upregulated carbohydrate metabolism and amino acid metabolism. In the conversion pathway, glucoraphanin is imported into <i>L. plantarum</i> cells, and its glucose moiety is phosphorylated by bglF (the phosphate group may be derived from phosphoenolpyruvate via the phosphotransferase system). Subsequently, the S-glycosidic bond of phosphorylated glucoraphanin is hydrolyzed by bglA (6-phospho-Î²-glucosidase), followed by nonenzymatic rearrangement and sulfate elimination, ultimately yielding sulforaphane. This research can contribute to revealing the interaction mechanism between microorganisms and natural active substances.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°è˜¿è””ç¡«ç´ çš„è½‰åŒ–éç¨‹ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å°å¥åº·æœ‰ç›Šçš„åŒ–åˆç‰©ï¼Œå¯èƒ½åœ¨æŠ—ç™Œå’ŒæŠ—æ°§åŒ–æ–¹é¢ç™¼æ®ä½œç”¨ã€‚é€éäº†è§£å¦‚ä½•æé«˜è˜¿è””ç¡«ç´ çš„è½‰åŒ–ç‡ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½å¤ æ›´æœ‰æ•ˆåœ°åˆ©ç”¨é’èŠ±æ¤°èœç­‰é£Ÿç‰©ä¸­çš„ç‡Ÿé¤Šæˆåˆ†ï¼Œé€²è€Œä¿ƒé€²å¥åº·æˆ–é é˜²æŸäº›ç–¾ç—…ã€‚é€™å°æ–¼å¸Œæœ›é€éé£²é£Ÿæ”¹å–„å¥åº·çš„äººå€‘ä¾†èªªï¼Œç„¡ç–‘æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„ç ”ç©¶æ–¹å‘ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨å¦‚ä½•æé«˜ä¹³é…¸èŒï¼ˆLactiplantibacillus plantarumï¼‰å°‡é’èŠ±æ¤°èœä¸­çš„ä¸€ç¨®åŒ–åˆç‰©â€”â€”è‘¡è„ç³–è‹·ï¼ˆglucoraphaninï¼‰è½‰åŒ–ç‚ºè˜¿è””ç¡«ç´ çš„æ•ˆç‡ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯é€™ä¸€è½‰åŒ–éç¨‹çš„æ©Ÿåˆ¶ï¼Œä»¥åŠå¦‚ä½•é€éå¯¦é©—æŠ€è¡“ä¾†å¢å¼·é€™ä¸€è½‰åŒ–ç‡ã€‚ç”±æ–¼è˜¿è””ç¡«ç´ çš„è½‰åŒ–ç‡è¼ƒä½ï¼Œé€™é …ç ”ç©¶å¸Œæœ›èƒ½å¤ æ­ç¤ºå…¶èƒŒå¾Œçš„ç”Ÿç‰©å­¸éç¨‹ï¼Œä¸¦ç‚ºæœªä¾†çš„æ‡‰ç”¨æä¾›åŸºç¤ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†é©æ‡‰æ€§å¯¦é©—å®¤é€²åŒ–æŠ€è¡“ä¾†æ”¹é€²ä¹³é…¸èŒçš„è˜¿è””ç¡«ç´ è½‰åŒ–ç‡ã€‚ç ”ç©¶å°è±¡æ˜¯ç¶“éé©æ‡‰æ€§é€²åŒ–çš„ä¹³é…¸èŒæ ªï¼Œç ”ç©¶æ–¹æ³•åŒ…æ‹¬è½‰éŒ„çµ„åˆ†æï¼Œä»¥äº†è§£å…¶ä»£è¬éç¨‹çš„è®ŠåŒ–ã€‚ç ”ç©¶è€…è§€å¯Ÿåˆ°ï¼Œç•¶è‘¡è„ç³–æ›¿ä»£æ¯”ä¾‹å¢åŠ æ™‚ï¼Œç¢³æ°´åŒ–åˆç‰©ä»£è¬è¢«é¡¯è‘—ä¸‹èª¿ï¼Œè€Œæ°¨åŸºé…¸ä»£è¬å‰‡ä¸Šèª¿ï¼Œé€™äº›è®ŠåŒ–å¯èƒ½èˆ‡è˜¿è””ç¡«ç´ çš„è½‰åŒ–æœ‰é—œã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œç¶“éé©æ‡‰æ€§é€²åŒ–çš„ä¹³é…¸èŒæ ªåœ¨ç¢³æ°´åŒ–åˆç‰©å’Œæ°¨åŸºé…¸ä»£è¬æ–¹é¢æœ‰é¡¯è‘—çš„ä¸Šèª¿ï¼Œé€™å¯èƒ½æœ‰åŠ©æ–¼æé«˜è˜¿è””ç¡«ç´ çš„è½‰åŒ–ç‡ã€‚ç ”ç©¶ä¸­é‚„æ­ç¤ºäº†è‘¡è„ç³–è‹·åœ¨ä¹³é…¸èŒç´°èƒå…§çš„è½‰é‹éç¨‹åŠå…¶è½‰åŒ–è·¯å¾‘ï¼Œé€™äº›çµæœç‚ºç†è§£å¾®ç”Ÿç‰©èˆ‡å¤©ç„¶æ´»æ€§ç‰©è³ªä¹‹é–“çš„ç›¸äº’ä½œç”¨æä¾›äº†æ–°çš„è¦–è§’ã€‚é›–ç„¶é€™äº›ç™¼ç¾æ˜¯åˆæ­¥çš„ï¼Œä½†å®ƒå€‘ç‚ºæœªä¾†çš„ç ”ç©¶å’Œæ‡‰ç”¨å¥ å®šäº†åŸºç¤ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°è˜¿è””ç¡«ç´ çš„è½‰åŒ–éç¨‹ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å°å¥åº·æœ‰ç›Šçš„åŒ–åˆç‰©ï¼Œå¯èƒ½åœ¨æŠ—ç™Œå’ŒæŠ—æ°§åŒ–æ–¹é¢ç™¼æ®ä½œç”¨ã€‚é€éäº†è§£å¦‚ä½•æé«˜è˜¿è””ç¡«ç´ çš„è½‰åŒ–ç‡ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½å¤ æ›´æœ‰æ•ˆåœ°åˆ©ç”¨é’èŠ±æ¤°èœç­‰é£Ÿç‰©ä¸­çš„ç‡Ÿé¤Šæˆåˆ†ï¼Œé€²è€Œä¿ƒé€²å¥åº·æˆ–é é˜²æŸäº›ç–¾ç—…ã€‚é€™å°æ–¼å¸Œæœ›é€éé£²é£Ÿæ”¹å–„å¥åº·çš„äººå€‘ä¾†èªªï¼Œç„¡ç–‘æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„ç ”ç©¶æ–¹å‘ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨å¦‚ä½•æé«˜ä¹³é…¸èŒï¼ˆLactiplantibacillus plantarumï¼‰å°‡é’èŠ±æ¤°èœä¸­çš„ä¸€ç¨®åŒ–åˆç‰©â€”â€”è‘¡è„ç³–è‹·ï¼ˆglucoraphaninï¼‰è½‰åŒ–ç‚ºè˜¿è””ç¡«ç´ çš„æ•ˆç‡ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯é€™ä¸€è½‰åŒ–éç¨‹çš„æ©Ÿåˆ¶ï¼Œä»¥åŠå¦‚ä½•é€éå¯¦é©—æŠ€è¡“ä¾†å¢å¼·é€™ä¸€è½‰åŒ–ç‡ã€‚ç”±æ–¼è˜¿è””ç¡«ç´ çš„è½‰åŒ–ç‡è¼ƒä½ï¼Œé€™é …ç ”ç©¶å¸Œæœ›èƒ½å¤ æ­ç¤ºå…¶èƒŒå¾Œçš„ç”Ÿç‰©å­¸éç¨‹ï¼Œä¸¦ç‚ºæœªä¾†çš„æ‡‰ç”¨æä¾›åŸºç¤ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†é©æ‡‰æ€§å¯¦é©—å®¤é€²åŒ–æŠ€è¡“ä¾†æ”¹é€²ä¹³é…¸èŒçš„è˜¿è””ç¡«ç´ è½‰åŒ–ç‡ã€‚ç ”ç©¶å°è±¡æ˜¯ç¶“éé©æ‡‰æ€§é€²åŒ–çš„ä¹³é…¸èŒæ ªï¼Œç ”ç©¶æ–¹æ³•åŒ…æ‹¬è½‰éŒ„çµ„åˆ†æï¼Œä»¥äº†è§£å…¶ä»£è¬éç¨‹çš„è®ŠåŒ–ã€‚ç ”ç©¶è€…è§€å¯Ÿåˆ°ï¼Œç•¶è‘¡è„ç³–æ›¿ä»£æ¯”ä¾‹å¢åŠ æ™‚ï¼Œç¢³æ°´åŒ–åˆç‰©ä»£è¬è¢«é¡¯è‘—ä¸‹èª¿ï¼Œè€Œæ°¨åŸºé…¸ä»£è¬å‰‡ä¸Šèª¿ï¼Œé€™äº›è®ŠåŒ–å¯èƒ½èˆ‡è˜¿è””ç¡«ç´ çš„è½‰åŒ–æœ‰é—œã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œç¶“éé©æ‡‰æ€§é€²åŒ–çš„ä¹³é…¸èŒæ ªåœ¨ç¢³æ°´åŒ–åˆç‰©å’Œæ°¨åŸºé…¸ä»£è¬æ–¹é¢æœ‰é¡¯è‘—çš„ä¸Šèª¿ï¼Œé€™å¯èƒ½æœ‰åŠ©æ–¼æé«˜è˜¿è””ç¡«ç´ çš„è½‰åŒ–ç‡ã€‚ç ”ç©¶ä¸­é‚„æ­ç¤ºäº†è‘¡è„ç³–è‹·åœ¨ä¹³é…¸èŒç´°èƒå…§çš„è½‰é‹éç¨‹åŠå…¶è½‰åŒ–è·¯å¾‘ï¼Œé€™äº›çµæœç‚ºç†è§£å¾®ç”Ÿç‰©èˆ‡å¤©ç„¶æ´»æ€§ç‰©è³ªä¹‹é–“çš„ç›¸äº’ä½œç”¨æä¾›äº†æ–°çš„è¦–è§’ã€‚é›–ç„¶é€™äº›ç™¼ç¾æ˜¯åˆæ­¥çš„ï¼Œä½†å®ƒå€‘ç‚ºæœªä¾†çš„ç ”ç©¶å’Œæ‡‰ç”¨å¥ å®šäº†åŸºç¤ã€‚",
    "fb_post": "æ ¹æ“šã€ŠJournal of agricultural and food chemistryã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ±ä½ çŸ¥é“é’èŠ±æ¤°èœè£¡è—è‘—ä»€éº¼ç§˜å¯†å—ï¼Ÿ\næœ€è¿‘æœ‰ä¸€é …ç ”ç©¶è®“æˆ‘å€‘å°è˜¿è””ç¡«ç´ é€™å€‹åŒ–åˆç‰©æœ‰äº†æ›´æ·±å…¥çš„äº†è§£ï¼è˜¿è””ç¡«ç´ ä¸åƒ…å°å¥åº·æœ‰ç›Šï¼Œé‚„å¯èƒ½åœ¨æŠ—ç™Œå’ŒæŠ—æ°§åŒ–æ–¹é¢ç™¼æ®ä½œç”¨ã€‚é€™é …ç ”ç©¶çš„é‡é»æ˜¯å¦‚ä½•æé«˜ä¹³é…¸èŒå°‡é’èŠ±æ¤°èœä¸­çš„è‘¡è„ç³–è‹·è½‰åŒ–ç‚ºè˜¿è””ç¡«ç´ çš„æ•ˆç‡ã€‚\nç ”ç©¶è€…å€‘ä½¿ç”¨äº†ä¸€ç¨®å«åšé©æ‡‰æ€§å¯¦é©—å®¤é€²åŒ–çš„æŠ€è¡“ä¾†æ”¹é€²ä¹³é…¸èŒçš„è½‰åŒ–ç‡ã€‚ä»–å€‘ç™¼ç¾ï¼Œç•¶é’èŠ±æ¤°èœä¸­çš„è‘¡è„ç³–æ¯”ä¾‹å¢åŠ æ™‚ï¼Œä¹³é…¸èŒçš„ç¢³æ°´åŒ–åˆç‰©ä»£è¬æœƒä¸‹é™ï¼Œè€Œæ°¨åŸºé…¸ä»£è¬å‰‡ä¸Šå‡ï¼Œé€™å¯èƒ½èˆ‡è˜¿è””ç¡«ç´ çš„è½‰åŒ–æœ‰é—œã€‚\né›–ç„¶é€™é …ç ”ç©¶çš„çµæœé‚„åœ¨åˆæ­¥éšæ®µï¼Œä½†å®ƒç‚ºæˆ‘å€‘æœªä¾†å¦‚ä½•åˆ©ç”¨é’èŠ±æ¤°èœä¸­çš„ç‡Ÿé¤Šæˆåˆ†æä¾›äº†æ–°çš„è¦–è§’ï¼\nğŸ” ç ”ç©¶é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æŠ—ç™Œå’ŒæŠ—æ°§åŒ–ã€‚\n2. ä¹³é…¸èŒåœ¨è½‰åŒ–éç¨‹ä¸­å±•ç¾äº†ä»£è¬çš„è®ŠåŒ–ã€‚\n3. é€™é …ç ”ç©¶ç‚ºæœªä¾†çš„å¥åº·é£²é£Ÿæä¾›äº†æ–°çš„æ–¹å‘ï¼",
    "image_prompt": "Create a simple and informative illustration explaining the experimental methods and key findings of a study on sulforaphane. Include symbols representing broccoli and sulforaphane, simplified illustrations of experimental subjects like cells or bacteria, and arrows or flow lines to indicate the experimental steps. Include a section labeled 'Key Findings' highlighting the protective effects or metabolic changes observed in the study.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": false,
    "disease_name": "",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41340527/"
  },
  {
    "id": "41412441",
    "title_en": "Sulforaphane ameliorates DSS-induced colitis and secondary liver injury in mice: Proposed mechanism in the SCFAs-FFAR2/3-macrophage polarization axis.",
    "pub_date": "2025 Dec",
    "journal": "The Journal of nutritional biochemistry",
    "abstract_en": "Sulforaphane (SFN), an isothiocyanate derived from cruciferous vegetables, has shown therapeutic potential in inflammatory diseases. Our previous studies demonstrated that SFN ameliorates ulcerative colitis (UC) and restores gut microbiota composition in dextran sulfate sodium (DSS)-induced mice. In the present study, we further investigate the protective effects and underlying mechanisms of SFN against secondary liver injury associated with UC. The results revealed that SFN significantly alleviated pathological damage in both the colon and liver, improved liver function parameters, upregulated intestinal tight junction proteins and Muc2 expression, and inhibited inflammation in DSS-induced colitis mice. Additionally, SFN significantly elevated short-chain fatty acid (SCFA) concentrations, enhanced the expression of SCFA receptors (free fatty acid receptors 2 and 3, FFAR2/3), and modulated macrophage polarization by inhibiting M1 and promoting M2 phenotypes in the colon and liver. Collectively, these findings suggest that SFN may alleviate colitis and secondary liver injury by enhancing intestinal barrier function and reducing inflammatory responses, potentially via the SCFAs-FFAR2/3-macrophage polarization signaling cascade. Thus, SFN may serve as a promising adjunctive therapeutic agent for the prevention and treatment of UC.",
    "para1": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœçš„åŒ–åˆç‰©ï¼Œå°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æœ‰æ½›åœ¨çš„å•Ÿç¤ºã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°æ–¼æ¸›è¼•ç‚ç—‡æ€§ç–¾ç—…çš„ç—‡ç‹€æœ‰å¹«åŠ©ï¼Œå°¤å…¶æ˜¯åœ¨è…¸é“å¥åº·æ–¹é¢ã€‚é€™æ„å‘³è‘—ï¼Œé€éé£²é£Ÿä¸­å¢åŠ é€™é¡è”¬èœçš„æ”å–ï¼Œæˆ–è¨±èƒ½å¤ æ”¹å–„æˆ‘å€‘çš„è…¸é“å¥åº·ï¼Œä¸¦é™ä½æŸäº›ç–¾ç—…çš„é¢¨éšªï¼Œåƒæ˜¯æ½°ç˜æ€§çµè…¸ç‚ç­‰ã€‚é€™äº›ç™¼ç¾è®“æˆ‘å€‘å°æ–¼å¦‚ä½•é€éé£²é£Ÿä¾†ä¿ƒé€²å¥åº·æœ‰äº†æ–°çš„æ€è€ƒã€‚",
    "para2": "é€™é …ç ”ç©¶ä¸»è¦é—œæ³¨çš„æ˜¯è˜¿è””ç¡«ç´ å°æ–¼æ½°ç˜æ€§çµè…¸ç‚ï¼ˆUCï¼‰ç›¸é—œçš„è‚è‡Ÿæ¬¡ç´šæå‚·çš„ä¿è­·ä½œç”¨ã€‚ç ”ç©¶è€…å¸Œæœ›æ·±å…¥äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿é€™äº›ç—…ç†ç‹€æ³ï¼Œä¸¦æ¢è¨å…¶èƒŒå¾Œçš„æ©Ÿåˆ¶ã€‚æ½°ç˜æ€§çµè…¸ç‚æ˜¯ä¸€ç¨®å½±éŸ¿è…¸é“çš„æ…¢æ€§ç‚ç—‡æ€§ç–¾ç—…ï¼Œå¯èƒ½æœƒå°è‡´å¤šç¨®ä½µç™¼ç—‡ï¼ŒåŒ…æ‹¬è‚è‡Ÿçš„æå‚·ã€‚å› æ­¤ï¼Œäº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨ï¼Œå°æ–¼æ”¹å–„é€™é¡ç–¾ç—…çš„æ²»ç™‚æ–¹æ¡ˆå…·æœ‰é‡è¦æ„ç¾©ã€‚",
    "para3": "åœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ä»¥å³æ—‹ç³–é…ç¡«é…¸éˆ‰ï¼ˆDSSï¼‰èª˜å°çš„é¼ æ¨¡å‹ä¾†æ¨¡æ“¬æ½°ç˜æ€§çµè…¸ç‚çš„æƒ…æ³ã€‚å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…è§€å¯Ÿäº†è˜¿è””ç¡«ç´ å°é€™äº›å°é¼ çš„å½±éŸ¿ï¼ŒåŒ…æ‹¬å…¶å°è…¸é“å’Œè‚è‡Ÿçš„ç—…ç†æå‚·çš„ç·©è§£æ•ˆæœã€‚ç ”ç©¶è€…åˆ†æäº†å°é¼ çš„è‚åŠŸèƒ½åƒæ•¸ã€è…¸é“ç·Šå¯†é€£æ¥è›‹ç™½çš„è¡¨é”ä»¥åŠç‚ç—‡åæ‡‰çš„è®ŠåŒ–ï¼Œä¸¦è©•ä¼°äº†çŸ­éˆè„‚è‚ªé…¸çš„æ¿ƒåº¦å’Œå·¨å™¬ç´°èƒçš„æ¥µåŒ–æƒ…æ³ï¼Œä»¥äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ¸›è¼•å°é¼ çš„è…¸é“å’Œè‚è‡Ÿç—…ç†æå‚·ï¼Œæ”¹å–„è‚åŠŸèƒ½åƒæ•¸ï¼Œä¸¦ä¸Šèª¿è…¸é“ç·Šå¯†é€£æ¥è›‹ç™½å’ŒMuc2çš„è¡¨é”ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½æé«˜çŸ­éˆè„‚è‚ªé…¸çš„æ¿ƒåº¦ï¼Œå¢å¼·çŸ­éˆè„‚è‚ªé…¸å—é«”çš„è¡¨é”ï¼Œä¸¦èª¿ç¯€å·¨å™¬ç´°èƒçš„æ¥µåŒ–ï¼ŒæŠ‘åˆ¶M1å‹ä¸¦ä¿ƒé€²M2å‹çš„ç™¼å±•ã€‚é€™äº›ç™¼ç¾è¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éå¢å¼·è…¸é“å±éšœåŠŸèƒ½å’Œæ¸›å°‘ç‚ç—‡åæ‡‰ä¾†ç·©è§£æ½°ç˜æ€§çµè…¸ç‚åŠå…¶ç›¸é—œçš„è‚è‡Ÿæå‚·ï¼Œé¡¯ç¤ºå‡ºå…¶ä½œç‚ºè¼”åŠ©æ²»ç™‚åŠ‘çš„æ½›åŠ›ã€‚",
    "explanation_zh": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœçš„åŒ–åˆç‰©ï¼Œå°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æœ‰æ½›åœ¨çš„å•Ÿç¤ºã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°æ–¼æ¸›è¼•ç‚ç—‡æ€§ç–¾ç—…çš„ç—‡ç‹€æœ‰å¹«åŠ©ï¼Œå°¤å…¶æ˜¯åœ¨è…¸é“å¥åº·æ–¹é¢ã€‚é€™æ„å‘³è‘—ï¼Œé€éé£²é£Ÿä¸­å¢åŠ é€™é¡è”¬èœçš„æ”å–ï¼Œæˆ–è¨±èƒ½å¤ æ”¹å–„æˆ‘å€‘çš„è…¸é“å¥åº·ï¼Œä¸¦é™ä½æŸäº›ç–¾ç—…çš„é¢¨éšªï¼Œåƒæ˜¯æ½°ç˜æ€§çµè…¸ç‚ç­‰ã€‚é€™äº›ç™¼ç¾è®“æˆ‘å€‘å°æ–¼å¦‚ä½•é€éé£²é£Ÿä¾†ä¿ƒé€²å¥åº·æœ‰äº†æ–°çš„æ€è€ƒã€‚\n\né€™é …ç ”ç©¶ä¸»è¦é—œæ³¨çš„æ˜¯è˜¿è””ç¡«ç´ å°æ–¼æ½°ç˜æ€§çµè…¸ç‚ï¼ˆUCï¼‰ç›¸é—œçš„è‚è‡Ÿæ¬¡ç´šæå‚·çš„ä¿è­·ä½œç”¨ã€‚ç ”ç©¶è€…å¸Œæœ›æ·±å…¥äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿é€™äº›ç—…ç†ç‹€æ³ï¼Œä¸¦æ¢è¨å…¶èƒŒå¾Œçš„æ©Ÿåˆ¶ã€‚æ½°ç˜æ€§çµè…¸ç‚æ˜¯ä¸€ç¨®å½±éŸ¿è…¸é“çš„æ…¢æ€§ç‚ç—‡æ€§ç–¾ç—…ï¼Œå¯èƒ½æœƒå°è‡´å¤šç¨®ä½µç™¼ç—‡ï¼ŒåŒ…æ‹¬è‚è‡Ÿçš„æå‚·ã€‚å› æ­¤ï¼Œäº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨ï¼Œå°æ–¼æ”¹å–„é€™é¡ç–¾ç—…çš„æ²»ç™‚æ–¹æ¡ˆå…·æœ‰é‡è¦æ„ç¾©ã€‚\n\nåœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ä»¥å³æ—‹ç³–é…ç¡«é…¸éˆ‰ï¼ˆDSSï¼‰èª˜å°çš„é¼ æ¨¡å‹ä¾†æ¨¡æ“¬æ½°ç˜æ€§çµè…¸ç‚çš„æƒ…æ³ã€‚å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…è§€å¯Ÿäº†è˜¿è””ç¡«ç´ å°é€™äº›å°é¼ çš„å½±éŸ¿ï¼ŒåŒ…æ‹¬å…¶å°è…¸é“å’Œè‚è‡Ÿçš„ç—…ç†æå‚·çš„ç·©è§£æ•ˆæœã€‚ç ”ç©¶è€…åˆ†æäº†å°é¼ çš„è‚åŠŸèƒ½åƒæ•¸ã€è…¸é“ç·Šå¯†é€£æ¥è›‹ç™½çš„è¡¨é”ä»¥åŠç‚ç—‡åæ‡‰çš„è®ŠåŒ–ï¼Œä¸¦è©•ä¼°äº†çŸ­éˆè„‚è‚ªé…¸çš„æ¿ƒåº¦å’Œå·¨å™¬ç´°èƒçš„æ¥µåŒ–æƒ…æ³ï¼Œä»¥äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ¸›è¼•å°é¼ çš„è…¸é“å’Œè‚è‡Ÿç—…ç†æå‚·ï¼Œæ”¹å–„è‚åŠŸèƒ½åƒæ•¸ï¼Œä¸¦ä¸Šèª¿è…¸é“ç·Šå¯†é€£æ¥è›‹ç™½å’ŒMuc2çš„è¡¨é”ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½æé«˜çŸ­éˆè„‚è‚ªé…¸çš„æ¿ƒåº¦ï¼Œå¢å¼·çŸ­éˆè„‚è‚ªé…¸å—é«”çš„è¡¨é”ï¼Œä¸¦èª¿ç¯€å·¨å™¬ç´°èƒçš„æ¥µåŒ–ï¼ŒæŠ‘åˆ¶M1å‹ä¸¦ä¿ƒé€²M2å‹çš„ç™¼å±•ã€‚é€™äº›ç™¼ç¾è¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éå¢å¼·è…¸é“å±éšœåŠŸèƒ½å’Œæ¸›å°‘ç‚ç—‡åæ‡‰ä¾†ç·©è§£æ½°ç˜æ€§çµè…¸ç‚åŠå…¶ç›¸é—œçš„è‚è‡Ÿæå‚·ï¼Œé¡¯ç¤ºå‡ºå…¶ä½œç‚ºè¼”åŠ©æ²»ç™‚åŠ‘çš„æ½›åŠ›ã€‚",
    "fb_post": "æ ¹æ“šã€ŠThe Journal of nutritional biochemistryã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ±ä½ çŸ¥é“å—ï¼Ÿè˜¿è””ç¡«ç´ é€™å€‹å°åŒ–åˆç‰©ï¼Œå¯èƒ½å°æˆ‘å€‘çš„è…¸é“å¥åº·æœ‰å¤§å¹«åŠ©å“¦ï¼\n\næœ€è¿‘æœ‰ä¸€é …ç ”ç©¶å°ˆæ³¨æ–¼è˜¿è””ç¡«ç´ å°æ½°ç˜æ€§çµè…¸ç‚ï¼ˆUCï¼‰é€™ç¨®æ…¢æ€§ç–¾ç—…çš„å½±éŸ¿ï¼Œé€™ç¨®ç–¾ç—…æœƒè®“è…¸é“ç™¼ç‚ï¼Œç”šè‡³å½±éŸ¿åˆ°è‚è‡Ÿçš„å¥åº·ã€‚ç ”ç©¶è€…å€‘æƒ³çŸ¥é“ï¼Œè˜¿è””ç¡«ç´ æ€éº¼å¹«åŠ©æ”¹å–„é€™äº›ç—…ç†ç‹€æ³ã€‚\n\nä»–å€‘ä½¿ç”¨å°è€é¼ ä¾†æ¨¡æ“¬æ½°ç˜æ€§çµè…¸ç‚çš„æƒ…æ³ï¼Œè§€å¯Ÿè˜¿è””ç¡«ç´ å°å®ƒå€‘çš„å½±éŸ¿ã€‚åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å€‘æª¢æŸ¥äº†å°é¼ çš„è‚åŠŸèƒ½ã€è…¸é“å¥åº·æŒ‡æ¨™å’Œç‚ç—‡åæ‡‰ï¼Œä¸¦è©•ä¼°äº†è…¸é“ä¸­çš„ä¸€äº›é‡è¦ç‰©è³ªã€‚\n\nçµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ¸›è¼•å°é¼ çš„è…¸é“å’Œè‚è‡Ÿæå‚·ï¼Œæ”¹å–„è‚åŠŸèƒ½ï¼Œä¸¦ä¿ƒé€²è…¸é“å¥åº·ã€‚é€™äº›ç™¼ç¾è®“æˆ‘å€‘å°æ–¼å¦‚ä½•é€éé£²é£Ÿä¾†æ”¹å–„å¥åº·æœ‰äº†æ–°çš„æ€è€ƒï¼\n\nğŸ” ç ”ç©¶é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ æœ‰åŠ©æ–¼æ¸›è¼•æ½°ç˜æ€§çµè…¸ç‚çš„ç—‡ç‹€ã€‚\n2. å®ƒæ”¹å–„äº†è…¸é“å’Œè‚è‡Ÿçš„å¥åº·æŒ‡æ¨™ã€‚\n3. å¢å¼·è…¸é“å±éšœåŠŸèƒ½ï¼Œæ¸›å°‘ç‚ç—‡åæ‡‰ï¼Œæˆ–è¨±æˆç‚ºè¼”åŠ©æ²»ç™‚çš„æ½›åŠ›ï¼",
    "image_prompt": "Create a flat design infographic explaining the experiment and main results of a study on sulforaphane. The image should have a light background and soft colors. Include simple icons representing broccoli or sulforaphane, a simplified illustration of experimental subjects like mice or cells, arrows or flow lines showing the experimental steps, and a section labeled 'Main Results' highlighting protective effects and changes observed.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "æ½°ç˜æ€§çµè…¸ç‚ Ulcerative Colitis",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41412441/"
  },
  {
    "id": "40961586",
    "title_en": "Design, synthesis and biological evaluation of magnolol-sulforaphane hybrid analogues as potential therapeutics of triple-negative breast cancer.",
    "pub_date": "2025 Dec",
    "journal": "European journal of medicinal chemistry",
    "abstract_en": "Triple-negative breast cancer (TNBC) is an aggressive subtype that primarily relies on chemotherapy. Natural products like magnolol and sulforaphane, especially their synthetic hybrid, have shown promising antitumor activity. To develop more potent agents, we designed and synthesized 15 novel magnolol-sulforaphane hybrid analogues and evaluated their anticancer efficacy. Among them, compound 17a demonstrated the highest potency, exhibiting an average 7.4-fold increase in antiproliferative activity with IC<sub>50</sub> values ranging from 0.85Â Â±Â 0.04Â Î¼M to 1.34Â Â±Â 0.02Â Î¼M in TNBC cell lines compared to the parent hybrid CT1-3. In vitro, 17a significantly suppressed TNBC cell proliferation, colony formation, migration, and invasion while inducing apoptosis. In vivo, administration of 17a effectively inhibited tumor growth without apparent toxicity in an MDA-MB-231 xenograft model, as evidenced by normal organ morphology. Mechanistically, RNA sequencing revealed that 17a downregulated the nucleotide excision repair (NER) and NF-ÎºB pathways, suppressing expression of NER-related genes (ERCC2, POLE2, LIG1, GTF2H3, and DDB2) at mRNA and protein levels and inhibiting phosphorylation of IKKÎ± and p65. These findings position 17a as a potent therapeutic candidate for TNBC treatment, warranting further clinical investigation.",
    "para1": "é€™é …ç ”ç©¶å¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æœ‰é‡è¦å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨é‡å°ä¸‰é™°æ€§ä¹³ç™Œï¼ˆTNBCï¼‰çš„æ²»ç™‚ä¸Šã€‚TNBCæ˜¯ä¸€ç¨®ä¾µç•¥æ€§å¼·çš„ä¹³ç™Œäºå‹ï¼Œé€šå¸¸ä¾è³´åŒ–ç™‚ä¾†æ²»ç™‚ã€‚ç ”ç©¶ä¸­æåˆ°çš„å¤©ç„¶ç”¢ç‰©ï¼Œå¦‚è˜¿è””ç¡«ç´ ï¼Œé¡¯ç¤ºå‡ºæ½›åœ¨çš„æŠ—è…«ç˜¤æ´»æ€§ï¼Œé€™å¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚æä¾›æ–°çš„æ–¹å‘ã€‚é€éé–‹ç™¼æ›´æœ‰æ•ˆçš„æ²»ç™‚è—¥ç‰©ï¼Œæˆ–è¨±èƒ½æ”¹å–„TNBCæ‚£è€…çš„é å¾Œï¼Œæ¸›å°‘å°å‚³çµ±åŒ–ç™‚çš„ä¾è³´ï¼Œä¸¦æå‡æ²»ç™‚çš„å®‰å…¨æ€§å’Œæœ‰æ•ˆæ€§ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯é–‹ç™¼å’Œè©•ä¼°æ–°å‹çš„æŠ—ç™Œè—¥ç‰©ï¼Œç‰¹åˆ¥æ˜¯é‡å°ä¸‰é™°æ€§ä¹³ç™Œçš„æ²»ç™‚ã€‚ç ”ç©¶è€…è¨­è¨ˆä¸¦åˆæˆäº†15ç¨®æ–°çš„è˜¿è””ç¡«ç´ èˆ‡æœ¨è˜­é…šçš„æ··åˆç‰©ï¼Œä¸¦æ¸¬è©¦å®ƒå€‘çš„æŠ—ç™Œæ•ˆæœã€‚é€™äº›æ–°åŒ–åˆç‰©çš„ç›®çš„æ˜¯è¦æ‰¾åˆ°æ¯”ç¾æœ‰è—¥ç‰©æ›´å¼·æ•ˆçš„æ²»ç™‚é¸æ“‡ï¼Œå°¤å…¶æ˜¯åœ¨å°æŠ—é›£æ²»çš„TNBCæ–¹é¢ï¼Œé€™æ˜¯ä¸€å€‹äºŸéœ€è§£æ±ºçš„é†«ç™‚æŒ‘æˆ°ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å°15ç¨®æ–°åˆæˆçš„åŒ–åˆç‰©é€²è¡Œäº†æŠ—ç™Œæ´»æ€§è©•ä¼°ï¼Œç‰¹åˆ¥æ˜¯åœ¨TNBCç´°èƒæ ªä¸­é€²è¡Œäº†é«”å¤–æ¸¬è©¦ã€‚ç ”ç©¶ä¸­é¸æ“‡äº†åŒ–åˆç‰©17aï¼Œé€™æ˜¯å…¶ä¸­ä¸€ç¨®è¡¨ç¾å‡ºæœ€é«˜æ•ˆèƒ½çš„æ··åˆç‰©ã€‚å¯¦é©—æ–¹æ³•åŒ…æ‹¬æ¸¬é‡ç´°èƒå¢æ®–ã€é›†è½å½¢æˆã€é·ç§»å’Œä¾µè¥²èƒ½åŠ›ï¼Œä¸¦è§€å¯Ÿç´°èƒå‡‹äº¡çš„æƒ…æ³ã€‚æ­¤å¤–ï¼Œé‚„é€²è¡Œäº†é«”å…§å¯¦é©—ï¼Œä½¿ç”¨MDA-MB-231è…«ç˜¤æ¨¡å‹ä¾†è©•ä¼°17aå°è…«ç˜¤ç”Ÿé•·çš„å½±éŸ¿ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼ŒåŒ–åˆç‰©17aåœ¨æŠ‘åˆ¶TNBCç´°èƒå¢æ®–å’Œè…«ç˜¤ç”Ÿé•·æ–¹é¢è¡¨ç¾å‡ºè‰²ï¼Œä¸¦ä¸”åœ¨é«”å…§å¯¦é©—ä¸­æœªé¡¯ç¤ºå‡ºæ˜é¡¯çš„æ¯’æ€§ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œ17aå¯èƒ½é€šéä¸‹èª¿æ ¸è‹·é…¸åˆ‡é™¤ä¿®å¾©ï¼ˆNERï¼‰å’ŒNF-ÎºBé€šè·¯ä¾†ç™¼æ®å…¶æŠ—ç™Œä½œç”¨ï¼Œé€²ä¸€æ­¥æŠ‘åˆ¶ç›¸é—œåŸºå› çš„è¡¨é”ã€‚é€™äº›ç™¼ç¾ä½¿17aæˆç‚ºä¸€å€‹æœ‰æ½›åŠ›çš„æ²»ç™‚å€™é¸è—¥ç‰©ï¼Œå€¼å¾—é€²ä¸€æ­¥çš„è‡¨åºŠç ”ç©¶ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æœ‰é‡è¦å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨é‡å°ä¸‰é™°æ€§ä¹³ç™Œï¼ˆTNBCï¼‰çš„æ²»ç™‚ä¸Šã€‚TNBCæ˜¯ä¸€ç¨®ä¾µç•¥æ€§å¼·çš„ä¹³ç™Œäºå‹ï¼Œé€šå¸¸ä¾è³´åŒ–ç™‚ä¾†æ²»ç™‚ã€‚ç ”ç©¶ä¸­æåˆ°çš„å¤©ç„¶ç”¢ç‰©ï¼Œå¦‚è˜¿è””ç¡«ç´ ï¼Œé¡¯ç¤ºå‡ºæ½›åœ¨çš„æŠ—è…«ç˜¤æ´»æ€§ï¼Œé€™å¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚æä¾›æ–°çš„æ–¹å‘ã€‚é€éé–‹ç™¼æ›´æœ‰æ•ˆçš„æ²»ç™‚è—¥ç‰©ï¼Œæˆ–è¨±èƒ½æ”¹å–„TNBCæ‚£è€…çš„é å¾Œï¼Œæ¸›å°‘å°å‚³çµ±åŒ–ç™‚çš„ä¾è³´ï¼Œä¸¦æå‡æ²»ç™‚çš„å®‰å…¨æ€§å’Œæœ‰æ•ˆæ€§ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯é–‹ç™¼å’Œè©•ä¼°æ–°å‹çš„æŠ—ç™Œè—¥ç‰©ï¼Œç‰¹åˆ¥æ˜¯é‡å°ä¸‰é™°æ€§ä¹³ç™Œçš„æ²»ç™‚ã€‚ç ”ç©¶è€…è¨­è¨ˆä¸¦åˆæˆäº†15ç¨®æ–°çš„è˜¿è””ç¡«ç´ èˆ‡æœ¨è˜­é…šçš„æ··åˆç‰©ï¼Œä¸¦æ¸¬è©¦å®ƒå€‘çš„æŠ—ç™Œæ•ˆæœã€‚é€™äº›æ–°åŒ–åˆç‰©çš„ç›®çš„æ˜¯è¦æ‰¾åˆ°æ¯”ç¾æœ‰è—¥ç‰©æ›´å¼·æ•ˆçš„æ²»ç™‚é¸æ“‡ï¼Œå°¤å…¶æ˜¯åœ¨å°æŠ—é›£æ²»çš„TNBCæ–¹é¢ï¼Œé€™æ˜¯ä¸€å€‹äºŸéœ€è§£æ±ºçš„é†«ç™‚æŒ‘æˆ°ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å°15ç¨®æ–°åˆæˆçš„åŒ–åˆç‰©é€²è¡Œäº†æŠ—ç™Œæ´»æ€§è©•ä¼°ï¼Œç‰¹åˆ¥æ˜¯åœ¨TNBCç´°èƒæ ªä¸­é€²è¡Œäº†é«”å¤–æ¸¬è©¦ã€‚ç ”ç©¶ä¸­é¸æ“‡äº†åŒ–åˆç‰©17aï¼Œé€™æ˜¯å…¶ä¸­ä¸€ç¨®è¡¨ç¾å‡ºæœ€é«˜æ•ˆèƒ½çš„æ··åˆç‰©ã€‚å¯¦é©—æ–¹æ³•åŒ…æ‹¬æ¸¬é‡ç´°èƒå¢æ®–ã€é›†è½å½¢æˆã€é·ç§»å’Œä¾µè¥²èƒ½åŠ›ï¼Œä¸¦è§€å¯Ÿç´°èƒå‡‹äº¡çš„æƒ…æ³ã€‚æ­¤å¤–ï¼Œé‚„é€²è¡Œäº†é«”å…§å¯¦é©—ï¼Œä½¿ç”¨MDA-MB-231è…«ç˜¤æ¨¡å‹ä¾†è©•ä¼°17aå°è…«ç˜¤ç”Ÿé•·çš„å½±éŸ¿ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼ŒåŒ–åˆç‰©17aåœ¨æŠ‘åˆ¶TNBCç´°èƒå¢æ®–å’Œè…«ç˜¤ç”Ÿé•·æ–¹é¢è¡¨ç¾å‡ºè‰²ï¼Œä¸¦ä¸”åœ¨é«”å…§å¯¦é©—ä¸­æœªé¡¯ç¤ºå‡ºæ˜é¡¯çš„æ¯’æ€§ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œ17aå¯èƒ½é€šéä¸‹èª¿æ ¸è‹·é…¸åˆ‡é™¤ä¿®å¾©ï¼ˆNERï¼‰å’ŒNF-ÎºBé€šè·¯ä¾†ç™¼æ®å…¶æŠ—ç™Œä½œç”¨ï¼Œé€²ä¸€æ­¥æŠ‘åˆ¶ç›¸é—œåŸºå› çš„è¡¨é”ã€‚é€™äº›ç™¼ç¾ä½¿17aæˆç‚ºä¸€å€‹æœ‰æ½›åŠ›çš„æ²»ç™‚å€™é¸è—¥ç‰©ï¼Œå€¼å¾—é€²ä¸€æ­¥çš„è‡¨åºŠç ”ç©¶ã€‚",
    "fb_post": "æ ¹æ“šã€ŠEuropean journal of medicinal chemistryã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± å¤§å®¶çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„é£²é£Ÿè£¡ç«Ÿç„¶è—è‘—å°æŠ—ç™Œç—‡çš„æ½›åŠ›ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶æ¢è¨äº†ä¸€ç¨®å«åšè˜¿è””ç¡«ç´ çš„å¤©ç„¶æˆåˆ†ï¼Œç‰¹åˆ¥é‡å°ä¸‰é™°æ€§ä¹³ç™Œï¼ˆTNBCï¼‰é€™ç¨®æ¯”è¼ƒé›£å°ä»˜çš„ä¹³ç™Œã€‚é€™ç¨®ç™Œç—‡é€šå¸¸éœ€è¦åŒ–ç™‚ä¾†æ²»ç™‚ï¼Œä½†ç ”ç©¶è€…å€‘å¸Œæœ›èƒ½æ‰¾åˆ°æ›´å®‰å…¨æœ‰æ•ˆçš„æ›¿ä»£æ–¹æ¡ˆã€‚  \n  \né€™é …ç ”ç©¶çš„åœ˜éšŠåˆæˆäº†15ç¨®æ–°çš„è˜¿è””ç¡«ç´ å’Œæœ¨è˜­é…šçš„æ··åˆç‰©ï¼Œç„¶å¾Œæ¸¬è©¦å®ƒå€‘å°ç™Œç´°èƒçš„å½±éŸ¿ã€‚ç¶“éä¸€ç³»åˆ—çš„å¯¦é©—ï¼Œä»–å€‘ç™¼ç¾å…¶ä¸­ä¸€ç¨®åŒ–åˆç‰©ï¼ˆç¨±ç‚º17aï¼‰å°æ–¼æŠ‘åˆ¶TNBCç´°èƒçš„å¢é•·ç‰¹åˆ¥æœ‰æ•ˆï¼Œç”šè‡³åœ¨å‹•ç‰©å¯¦é©—ä¸­ä¹Ÿæ²’æœ‰é¡¯ç¤ºå‡ºæ˜é¡¯çš„æ¯’æ€§ã€‚  \n  \né€™äº›ç™¼ç¾è®“æˆ‘å€‘çœ‹åˆ°æœªä¾†å¯èƒ½æœ‰æ–°çš„æ²»ç™‚é¸æ“‡ï¼  \n  \nğŸ” é‡é»æ•´ç†ï¼š  \n1. è˜¿è””ç¡«ç´ å¯èƒ½æˆç‚ºå°æŠ—ä¸‰é™°æ€§ä¹³ç™Œçš„æ–°å¸Œæœ›ã€‚  \n2. åŒ–åˆç‰©17aåœ¨å¯¦é©—ä¸­è¡¨ç¾å‡ºè‰²ï¼Œä¸”å®‰å…¨æ€§é«˜ã€‚  \n3. é€™äº›ç ”ç©¶çµæœå€¼å¾—é€²ä¸€æ­¥çš„è‡¨åºŠæ¢ç´¢ï¼",
    "image_prompt": "Create a flat design infographic with a light background that explains the experimental methods and main results of a study on a compound called 17a derived from sulforaphane. Include simplified icons of broccoli or radish to represent sulforaphane, and simplified human, animal, or cell icons to represent the experimental subjects. Use arrows or flow lines to indicate the experimental steps, and have a designated section labeled 'Main Results' highlighting protective effects and observed changes.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "ä¸‰é™°æ€§ä¹³ç™Œ Triple-negative Breast Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40961586/"
  },
  {
    "id": "41399453",
    "title_en": "Dual effect of sulforaphane on multi-walled carbon nanotube-induced lung inflammation in mice.",
    "pub_date": "2025 Dec",
    "journal": "Toxicology research",
    "abstract_en": "A previous study demonstrated that Nrf2, a transcription factor, unexpectedly promoted multi-walled carbon nanotube (MWCNT)-induced lung inflammation in mice. This finding contrasts with the well-established role of Nrf2 in suppressing inflammatory responses induced by environmental chemicals, highlighting a critical knowledge gap. The present study investigated the effect of sulforaphane, a known activator of Nrf2, on MWCNT-induced lung inflammation in mice, in order to better understand the underlying mechanisms of this response. Each of 48 C57BL/6Â J male mouse was anesthetized and exposed once via pharyngeal aspiration to MWCNTs (Mitsui-7) at doses of 0, 10, or 20Â Î¼g in 40Â Î¼l of dispersion medium per mouse and treated thereafter with subcutaneous 25Â mg/kg/day sulforaphane or vehicle for 14Â days. Bronchoalveolar lavage fluid (BALF) was collected for differential cell counts. Lung tissues were processed for histopathological analysis and quantification of cytokine or chemokine mRNA expression and Nrf2 protein in nuclear extracts. MWCNTs exposure increased lung weight, BALF lymphocytes, and lung IL-6 expression. Sulforaphane attenuated MWCNTs-induced lung weight gain, lymphocytic infiltration, and upregulation of IL-6 expression, but paradoxically enhanced low-dose MWCNT-induced neutrophil infiltration in BALF, MIP-2 expression, and histopathological inflammation scores. These effects were accompanied by increased levels of active Nrf2 protein in nuclear extracts from lung tissue. Overall, the results indicate that sulforaphane suppresses lymphocyte infiltration while promoting neutrophil recruitment in response to low-dose MWCNTs, suggesting a dual effect of sulforaphane on MWCNT-induced lung inflammation mediated through Nrf2 activation.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç’°å¢ƒæ±¡æŸ“ç‰©å¼•èµ·çš„è‚ºéƒ¨ç‚ç—‡æ–¹é¢ã€‚ç ”ç©¶ç™¼ç¾ï¼Œé›–ç„¶è˜¿è””ç¡«ç´ é€šå¸¸è¢«èªç‚ºèƒ½å¤ æŠ‘åˆ¶ç‚ç—‡åæ‡‰ï¼Œä½†åœ¨æŸäº›æƒ…æ³ä¸‹ï¼Œå®ƒçš„ä½œç”¨å¯èƒ½æœƒæœ‰æ‰€ä¸åŒã€‚é€™æé†’æˆ‘å€‘ï¼Œå°æ–¼æŸäº›åŒ–å­¸ç‰©è³ªçš„åæ‡‰ï¼Œå¯èƒ½éœ€è¦æ›´æ·±å…¥çš„äº†è§£ï¼Œä»¥ä¾¿æ‰¾åˆ°æ›´æœ‰æ•ˆçš„é é˜²å’Œæ²»ç™‚æ–¹æ³•ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°å¤šå£ç¢³ç´ç±³ç®¡ï¼ˆMWCNTï¼‰å¼•èµ·çš„è‚ºéƒ¨ç‚ç—‡çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•é€šéæ¿€æ´»Nrf2é€™å€‹è½‰éŒ„å› å­ä¾†å½±éŸ¿é€™ç¨®ç‚ç—‡åæ‡‰ã€‚é€™æ˜¯ä¸€å€‹é‡è¦çš„ç ”ç©¶æ–¹å‘ï¼Œå› ç‚ºä¹‹å‰çš„ç ”ç©¶é¡¯ç¤ºNrf2åœ¨ç’°å¢ƒåŒ–å­¸ç‰©è³ªå¼•èµ·çš„ç‚ç—‡ä¸­æ‰®æ¼”è‘—æŠ‘åˆ¶è€…çš„è§’è‰²ï¼Œä½†åœ¨é€™ç¨®æƒ…æ³ä¸‹å»å‡ºç¾äº†ç›¸åçš„çµæœã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†48éš»C57BL/6 Jé›„æ€§å°é¼ ï¼Œé€™äº›å°é¼ åœ¨éº»é†‰å¾Œé€šéå’½å–‰å¸å…¥çš„æ–¹å¼æ¥è§¸ä¸åŒåŠ‘é‡çš„å¤šå£ç¢³ç´ç±³ç®¡ï¼ˆ0ã€10æˆ–20å¾®å…‹ï¼‰ï¼Œä¸¦åœ¨æ¥ä¸‹ä¾†çš„14å¤©å…§æ¥å—æ¯æ—¥25æ¯«å…‹/å…¬æ–¤çš„è˜¿è””ç¡«ç´ æˆ–å°ç…§è™•ç†ã€‚ç ”ç©¶è€…æ”¶é›†äº†æ”¯æ°£ç®¡è‚ºæ³¡çŒæ´—æ¶²ï¼ˆBALFï¼‰é€²è¡Œç´°èƒè¨ˆæ•¸ï¼Œä¸¦å°è‚ºéƒ¨çµ„ç¹”é€²è¡Œäº†çµ„ç¹”ç—…ç†å­¸åˆ†æåŠç´°èƒå› å­æˆ–è¶¨åŒ–å› å­mRNAè¡¨é”å’ŒNrf2è›‹ç™½çš„å®šé‡åˆ†æã€‚",
    "para4": "ä¸»è¦çš„ç ”ç©¶ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æ¸›å°‘ç”±å¤šå£ç¢³ç´ç±³ç®¡å¼•èµ·çš„æ·‹å·´ç´°èƒæµ¸æ½¤å’Œè‚ºéƒ¨é‡é‡å¢åŠ ï¼Œä¸¦é™ä½IL-6çš„è¡¨é”ã€‚ç„¶è€Œï¼Œä»¤äººé©šè¨çš„æ˜¯ï¼Œåœ¨ä½åŠ‘é‡çš„å¤šå£ç¢³ç´ç±³ç®¡æš´éœ²ä¸‹ï¼Œè˜¿è””ç¡«ç´ å»ä¿ƒé€²äº†ä¸­æ€§ç²’ç´°èƒçš„æµ¸æ½¤å’Œç‚ç—‡åæ‡‰çš„åŠ åŠ‡ã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨å¤šå£ç¢³ç´ç±³ç®¡å¼•èµ·çš„è‚ºéƒ¨ç‚ç—‡ä¸­å¯èƒ½å…·æœ‰é›™é‡ä½œç”¨ï¼Œé€éNrf2çš„æ¿€æ´»ä¾†èª¿ç¯€ä¸åŒçš„å…ç–«åæ‡‰ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç’°å¢ƒæ±¡æŸ“ç‰©å¼•èµ·çš„è‚ºéƒ¨ç‚ç—‡æ–¹é¢ã€‚ç ”ç©¶ç™¼ç¾ï¼Œé›–ç„¶è˜¿è””ç¡«ç´ é€šå¸¸è¢«èªç‚ºèƒ½å¤ æŠ‘åˆ¶ç‚ç—‡åæ‡‰ï¼Œä½†åœ¨æŸäº›æƒ…æ³ä¸‹ï¼Œå®ƒçš„ä½œç”¨å¯èƒ½æœƒæœ‰æ‰€ä¸åŒã€‚é€™æé†’æˆ‘å€‘ï¼Œå°æ–¼æŸäº›åŒ–å­¸ç‰©è³ªçš„åæ‡‰ï¼Œå¯èƒ½éœ€è¦æ›´æ·±å…¥çš„äº†è§£ï¼Œä»¥ä¾¿æ‰¾åˆ°æ›´æœ‰æ•ˆçš„é é˜²å’Œæ²»ç™‚æ–¹æ³•ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°å¤šå£ç¢³ç´ç±³ç®¡ï¼ˆMWCNTï¼‰å¼•èµ·çš„è‚ºéƒ¨ç‚ç—‡çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•é€šéæ¿€æ´»Nrf2é€™å€‹è½‰éŒ„å› å­ä¾†å½±éŸ¿é€™ç¨®ç‚ç—‡åæ‡‰ã€‚é€™æ˜¯ä¸€å€‹é‡è¦çš„ç ”ç©¶æ–¹å‘ï¼Œå› ç‚ºä¹‹å‰çš„ç ”ç©¶é¡¯ç¤ºNrf2åœ¨ç’°å¢ƒåŒ–å­¸ç‰©è³ªå¼•èµ·çš„ç‚ç—‡ä¸­æ‰®æ¼”è‘—æŠ‘åˆ¶è€…çš„è§’è‰²ï¼Œä½†åœ¨é€™ç¨®æƒ…æ³ä¸‹å»å‡ºç¾äº†ç›¸åçš„çµæœã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†48éš»C57BL/6 Jé›„æ€§å°é¼ ï¼Œé€™äº›å°é¼ åœ¨éº»é†‰å¾Œé€šéå’½å–‰å¸å…¥çš„æ–¹å¼æ¥è§¸ä¸åŒåŠ‘é‡çš„å¤šå£ç¢³ç´ç±³ç®¡ï¼ˆ0ã€10æˆ–20å¾®å…‹ï¼‰ï¼Œä¸¦åœ¨æ¥ä¸‹ä¾†çš„14å¤©å…§æ¥å—æ¯æ—¥25æ¯«å…‹/å…¬æ–¤çš„è˜¿è””ç¡«ç´ æˆ–å°ç…§è™•ç†ã€‚ç ”ç©¶è€…æ”¶é›†äº†æ”¯æ°£ç®¡è‚ºæ³¡çŒæ´—æ¶²ï¼ˆBALFï¼‰é€²è¡Œç´°èƒè¨ˆæ•¸ï¼Œä¸¦å°è‚ºéƒ¨çµ„ç¹”é€²è¡Œäº†çµ„ç¹”ç—…ç†å­¸åˆ†æåŠç´°èƒå› å­æˆ–è¶¨åŒ–å› å­mRNAè¡¨é”å’ŒNrf2è›‹ç™½çš„å®šé‡åˆ†æã€‚\n\nä¸»è¦çš„ç ”ç©¶ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æ¸›å°‘ç”±å¤šå£ç¢³ç´ç±³ç®¡å¼•èµ·çš„æ·‹å·´ç´°èƒæµ¸æ½¤å’Œè‚ºéƒ¨é‡é‡å¢åŠ ï¼Œä¸¦é™ä½IL-6çš„è¡¨é”ã€‚ç„¶è€Œï¼Œä»¤äººé©šè¨çš„æ˜¯ï¼Œåœ¨ä½åŠ‘é‡çš„å¤šå£ç¢³ç´ç±³ç®¡æš´éœ²ä¸‹ï¼Œè˜¿è””ç¡«ç´ å»ä¿ƒé€²äº†ä¸­æ€§ç²’ç´°èƒçš„æµ¸æ½¤å’Œç‚ç—‡åæ‡‰çš„åŠ åŠ‡ã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨å¤šå£ç¢³ç´ç±³ç®¡å¼•èµ·çš„è‚ºéƒ¨ç‚ç—‡ä¸­å¯èƒ½å…·æœ‰é›™é‡ä½œç”¨ï¼Œé€éNrf2çš„æ¿€æ´»ä¾†èª¿ç¯€ä¸åŒçš„å…ç–«åæ‡‰ã€‚",
    "fb_post": "æ ¹æ“šã€ŠToxicology researchã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± å¤§å®¶çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„èº«é«”æœ‰æ™‚å€™æœƒå°ç’°å¢ƒä¸­çš„æ±¡æŸ“ç‰©ç”¢ç”Ÿåæ‡‰ï¼Œåƒæ˜¯è‚ºéƒ¨çš„ç‚ç—‡ã€‚è€Œæœ€è¿‘æœ‰ä¸€é …ç ”ç©¶è®“æˆ‘å€‘å°è˜¿è””ç¡«ç´ ï¼ˆå¾è˜¿è””ä¸­æå–çš„æˆåˆ†ï¼‰æœ‰äº†æ–°çš„èªè­˜ï¼\n\né€™é …ç ”ç©¶ç‰¹åˆ¥é—œæ³¨è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç”±å¤šå£ç¢³ç´ç±³ç®¡ï¼ˆMWCNTï¼‰å¼•èµ·çš„è‚ºéƒ¨ç‚ç—‡ã€‚ç ”ç©¶è€…å€‘ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ å¯ä»¥é€éä¸€å€‹å«åšNrf2çš„è½‰éŒ„å› å­ä¾†å½±éŸ¿é€™ç¨®ç‚ç—‡åæ‡‰ã€‚Nrf2é€šå¸¸æ˜¯å€‹å¥½å¹«æ‰‹ï¼Œä½†é€™æ¬¡å»å‡ºç¾äº†æ„æƒ³ä¸åˆ°çš„æ•ˆæœï¼\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†å°é¼ ï¼Œè®“ç‰ å€‘æ¥è§¸ä¸åŒåŠ‘é‡çš„å¤šå£ç¢³ç´ç±³ç®¡ï¼Œä¸¦çµ¦äºˆè˜¿è””ç¡«ç´ æˆ–å°ç…§è™•ç†ã€‚çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½æ¸›å°‘æ·‹å·´ç´°èƒçš„æµ¸æ½¤å’Œè‚ºéƒ¨é‡é‡å¢åŠ ï¼Œä¸¦é™ä½ä¸€ç¨®å«IL-6çš„ç´°èƒå› å­çš„è¡¨é”ã€‚ä¸éï¼Œå¥‡å¦™çš„æ˜¯ï¼Œåœ¨ä½åŠ‘é‡çš„å¤šå£ç¢³ç´ç±³ç®¡ä¸‹ï¼Œè˜¿è””ç¡«ç´ å»ä¿ƒé€²äº†ç‚ç—‡åæ‡‰çš„åŠ åŠ‡ï¼\n\né€™å‘Šè¨´æˆ‘å€‘ï¼Œè˜¿è””ç¡«ç´ åœ¨è‚ºéƒ¨ç‚ç—‡ä¸­å¯èƒ½æœ‰é›™é‡ä½œç”¨ï¼Œè®“æˆ‘å€‘æ›´äº†è§£é€™ç¨®æˆåˆ†çš„æ½›åŠ›ã€‚\n\nğŸ” é‡é»æ•´ç†ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘æŸäº›è‚ºéƒ¨ç‚ç—‡ã€‚\n2. åœ¨ç‰¹å®šæƒ…æ³ä¸‹ï¼Œå®ƒä¹Ÿå¯èƒ½åŠ åŠ‡ç‚ç—‡åæ‡‰ã€‚\n3. ç ”ç©¶è®“æˆ‘å€‘æ›´æ·±å…¥äº†è§£ç’°å¢ƒåŒ–å­¸ç‰©è³ªå°å¥åº·çš„å½±éŸ¿ã€‚",
    "image_prompt": "Create an infographic that explains the experimental process and main results of a study on the effects of sulforaphane on lung inflammation caused by multi-walled carbon nanotubes. Include simple illustrations of broccoli or a symbol representing sulforaphane, simplified representations of experimental subjects like mice or cells, arrows or flow lines indicating the experimental steps, and a section that highlights the main results, such as protective effects and changes observed.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "è‚ºéƒ¨ç‚ç—‡ Lung Inflammation",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41399453/"
  },
  {
    "id": "41409171",
    "title_en": "Investigating the Anticancer Effects of Sulforaphane in an In Vitro Coculture Model of Prostate Cancer Cells with Engineered Heart Tissue.",
    "pub_date": "2025 Dec",
    "journal": "ACS pharmacology & translational science",
    "abstract_en": "Sulforaphane (SFN) is a phytoderived compound abundant in cruciferous plants that possesses a broad spectrum of anticancer properties. We showed that SFN-induced caspase-mediated apoptosis in grade IV bone metastasis-derived androgen-insensitive PC-3 (IC<sub>50</sub> = 4.2 Î¼M), and lymph node metastasis-derived androgen-sensitive LNCaP (IC<sub>50</sub> = 2.8 Î¼M) prostate adenocarcinoma cells. SFN-mediated cardiotoxic side effects were tested in a preclinical in vitro model that enables the study simultaneously of the impact of drugs on cancer cell death and contractile properties of engineered heart tissues generated from human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM EHT). Thereby, SFN exposure induced PC-3 cell death without affecting the contractile force of hiPSC-CM EHT. Interestingly, the irregular beating pattern of hiPSC-CM EHT observed in the presence of PC-3 coculture was normalized compared to vehicle treatment. Overall, this in vitro coculture model of hiPSC-CM EHT and cancer cells could facilitate the study of cardiotoxic cancer drug side-effects.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç™Œç—‡æ²»ç™‚æ–¹é¢ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªåå­—èŠ±ç§‘æ¤ç‰©çš„åŒ–åˆç‰©ï¼Œå·²è¢«è­‰å¯¦å…·æœ‰æŠ—ç™Œç‰¹æ€§ã€‚é€™æ„å‘³è‘—ï¼Œé€éé£²é£Ÿä¸­å¢åŠ é€™é¡æ¤ç‰©çš„æ”å–ï¼Œå¯èƒ½æœ‰åŠ©æ–¼é™ä½æŸäº›ç™Œç—‡çš„é¢¨éšªï¼Œä¸¦ä¸”åœ¨æ²»ç™‚éç¨‹ä¸­ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æˆç‚ºä¸€ç¨®è¼”åŠ©ç™‚æ³•ï¼Œå¹«åŠ©ç™Œç—‡æ‚£è€…æ”¹å–„ç—…æƒ…æˆ–æ¸›å°‘æ²»ç™‚çš„å‰¯ä½œç”¨ã€‚é€™äº›ç™¼ç¾å°æ–¼å°‹æ±‚è‡ªç„¶ç™‚æ³•çš„æ‚£è€…ä¾†èªªï¼Œæä¾›äº†ä¸€å€‹æ–°çš„æ–¹å‘ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°å‰åˆ—è…ºç™Œç´°èƒçš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯é‡å°ä¸åŒé¡å‹çš„å‰åˆ—è…ºç™Œç´°èƒï¼ŒåŒ…æ‹¬å°é›„æ¿€ç´ ä¸æ•æ„Ÿçš„PC-3ç´°èƒå’Œå°é›„æ¿€ç´ æ•æ„Ÿçš„LNCaPç´°èƒã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•èª˜å°ç™Œç´°èƒæ­»äº¡ï¼Œä¸¦åŒæ™‚è©•ä¼°å…¶å°å¿ƒè‡Ÿç´°èƒçš„å½±éŸ¿ï¼Œé€™å°æ–¼ç™Œç—‡æ²»ç™‚ä¸­çš„å¿ƒè‡Ÿæ¯’æ€§å‰¯ä½œç”¨å…·æœ‰é‡è¦æ„ç¾©ã€‚",
    "para3": "é€™é …ç ”ç©¶ä½¿ç”¨äº†é«”å¤–å¯¦é©—æ¨¡å‹ï¼Œä¸»è¦å°è±¡æ˜¯ä¾†è‡ªäººé¡èª˜å°å¤šèƒ½å¹¹ç´°èƒçš„å¿ƒè‚Œç´°èƒå’Œå‰åˆ—è…ºç™Œç´°èƒã€‚ç ”ç©¶è€…å°‡é€™äº›ç´°èƒé€²è¡Œå…±åŸ¹é¤Šï¼Œä»¥è§€å¯Ÿè˜¿è””ç¡«ç´ å°ç™Œç´°èƒçš„å½±éŸ¿ï¼Œä»¥åŠå…¶å°å¿ƒè‡Ÿçµ„ç¹”çš„æ”¶ç¸®ç‰¹æ€§æ˜¯å¦æœ‰å½±éŸ¿ã€‚é€™ç¨®å¯¦é©—è¨­è¨ˆä½¿å¾—ç ”ç©¶è€…èƒ½å¤ åŒæ™‚è©•ä¼°ç™Œç—‡è—¥ç‰©å°ç™Œç´°èƒæ­»äº¡å’Œå¿ƒè‡Ÿç´°èƒåŠŸèƒ½çš„å½±éŸ¿ï¼Œå¾è€Œæ›´å…¨é¢åœ°äº†è§£è—¥ç‰©çš„æ½›åœ¨å‰¯ä½œç”¨ã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆèª˜å°PC-3ç´°èƒæ­»äº¡ï¼Œä½†å°å¿ƒè‚Œç´°èƒçš„æ”¶ç¸®åŠ›æ²’æœ‰é¡¯è‘—å½±éŸ¿ã€‚æ­¤å¤–ï¼Œç•¶PC-3ç´°èƒèˆ‡å¿ƒè‚Œç´°èƒå…±åŸ¹é¤Šæ™‚ï¼Œå¿ƒè‚Œç´°èƒçš„ä¸è¦å‰‡è·³å‹•æ¨¡å¼å¾—åˆ°äº†æ”¹å–„ï¼Œé€™è¡¨æ˜è˜¿è””ç¡«ç´ å¯èƒ½åœ¨æŸç¨®ç¨‹åº¦ä¸Šæ¸›å°‘äº†ç™Œç´°èƒå°å¿ƒè‡Ÿç´°èƒçš„è² é¢å½±éŸ¿ã€‚é€™äº›ç™¼ç¾ç‚ºæœªä¾†ç ”ç©¶ç™Œç—‡è—¥ç‰©çš„å¿ƒè‡Ÿæ¯’æ€§å‰¯ä½œç”¨æä¾›äº†æ–°çš„å¯¦é©—æ¨¡å‹å’Œæ€è·¯ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç™Œç—‡æ²»ç™‚æ–¹é¢ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªåå­—èŠ±ç§‘æ¤ç‰©çš„åŒ–åˆç‰©ï¼Œå·²è¢«è­‰å¯¦å…·æœ‰æŠ—ç™Œç‰¹æ€§ã€‚é€™æ„å‘³è‘—ï¼Œé€éé£²é£Ÿä¸­å¢åŠ é€™é¡æ¤ç‰©çš„æ”å–ï¼Œå¯èƒ½æœ‰åŠ©æ–¼é™ä½æŸäº›ç™Œç—‡çš„é¢¨éšªï¼Œä¸¦ä¸”åœ¨æ²»ç™‚éç¨‹ä¸­ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æˆç‚ºä¸€ç¨®è¼”åŠ©ç™‚æ³•ï¼Œå¹«åŠ©ç™Œç—‡æ‚£è€…æ”¹å–„ç—…æƒ…æˆ–æ¸›å°‘æ²»ç™‚çš„å‰¯ä½œç”¨ã€‚é€™äº›ç™¼ç¾å°æ–¼å°‹æ±‚è‡ªç„¶ç™‚æ³•çš„æ‚£è€…ä¾†èªªï¼Œæä¾›äº†ä¸€å€‹æ–°çš„æ–¹å‘ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°å‰åˆ—è…ºç™Œç´°èƒçš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯é‡å°ä¸åŒé¡å‹çš„å‰åˆ—è…ºç™Œç´°èƒï¼ŒåŒ…æ‹¬å°é›„æ¿€ç´ ä¸æ•æ„Ÿçš„PC-3ç´°èƒå’Œå°é›„æ¿€ç´ æ•æ„Ÿçš„LNCaPç´°èƒã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•èª˜å°ç™Œç´°èƒæ­»äº¡ï¼Œä¸¦åŒæ™‚è©•ä¼°å…¶å°å¿ƒè‡Ÿç´°èƒçš„å½±éŸ¿ï¼Œé€™å°æ–¼ç™Œç—‡æ²»ç™‚ä¸­çš„å¿ƒè‡Ÿæ¯’æ€§å‰¯ä½œç”¨å…·æœ‰é‡è¦æ„ç¾©ã€‚\n\né€™é …ç ”ç©¶ä½¿ç”¨äº†é«”å¤–å¯¦é©—æ¨¡å‹ï¼Œä¸»è¦å°è±¡æ˜¯ä¾†è‡ªäººé¡èª˜å°å¤šèƒ½å¹¹ç´°èƒçš„å¿ƒè‚Œç´°èƒå’Œå‰åˆ—è…ºç™Œç´°èƒã€‚ç ”ç©¶è€…å°‡é€™äº›ç´°èƒé€²è¡Œå…±åŸ¹é¤Šï¼Œä»¥è§€å¯Ÿè˜¿è””ç¡«ç´ å°ç™Œç´°èƒçš„å½±éŸ¿ï¼Œä»¥åŠå…¶å°å¿ƒè‡Ÿçµ„ç¹”çš„æ”¶ç¸®ç‰¹æ€§æ˜¯å¦æœ‰å½±éŸ¿ã€‚é€™ç¨®å¯¦é©—è¨­è¨ˆä½¿å¾—ç ”ç©¶è€…èƒ½å¤ åŒæ™‚è©•ä¼°ç™Œç—‡è—¥ç‰©å°ç™Œç´°èƒæ­»äº¡å’Œå¿ƒè‡Ÿç´°èƒåŠŸèƒ½çš„å½±éŸ¿ï¼Œå¾è€Œæ›´å…¨é¢åœ°äº†è§£è—¥ç‰©çš„æ½›åœ¨å‰¯ä½œç”¨ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆèª˜å°PC-3ç´°èƒæ­»äº¡ï¼Œä½†å°å¿ƒè‚Œç´°èƒçš„æ”¶ç¸®åŠ›æ²’æœ‰é¡¯è‘—å½±éŸ¿ã€‚æ­¤å¤–ï¼Œç•¶PC-3ç´°èƒèˆ‡å¿ƒè‚Œç´°èƒå…±åŸ¹é¤Šæ™‚ï¼Œå¿ƒè‚Œç´°èƒçš„ä¸è¦å‰‡è·³å‹•æ¨¡å¼å¾—åˆ°äº†æ”¹å–„ï¼Œé€™è¡¨æ˜è˜¿è””ç¡«ç´ å¯èƒ½åœ¨æŸç¨®ç¨‹åº¦ä¸Šæ¸›å°‘äº†ç™Œç´°èƒå°å¿ƒè‡Ÿç´°èƒçš„è² é¢å½±éŸ¿ã€‚é€™äº›ç™¼ç¾ç‚ºæœªä¾†ç ”ç©¶ç™Œç—‡è—¥ç‰©çš„å¿ƒè‡Ÿæ¯’æ€§å‰¯ä½œç”¨æä¾›äº†æ–°çš„å¯¦é©—æ¨¡å‹å’Œæ€è·¯ã€‚",
    "fb_post": "æ ¹æ“šã€ŠACS pharmacology & translational scienceã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ½ï¸ åƒå¾—å¥åº·ï¼Œç™Œç—‡é é›¢ï¼ä½ çŸ¥é“è˜¿è””ç¡«ç´ å—ï¼Ÿé€™æ˜¯ä¸€ç¨®ä¾†è‡ªé’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘æ¤ç‰©çš„å¤©ç„¶åŒ–åˆç‰©ï¼Œæœ€è¿‘çš„ç ”ç©¶ç™¼ç¾å®ƒå¯èƒ½å°ç™Œç—‡æ²»ç™‚æœ‰å¹«åŠ©ï¼\n\né€™é …ç ”ç©¶å°ˆæ³¨æ–¼è˜¿è””ç¡«ç´ å°å‰åˆ—è…ºç™Œç´°èƒçš„å½±éŸ¿ï¼Œå°¤å…¶æ˜¯å…©ç¨®ä¸åŒé¡å‹çš„å‰åˆ—è…ºç™Œç´°èƒã€‚ç ”ç©¶è€…å€‘æƒ³äº†è§£é€™ç¨®åŒ–åˆç‰©å¦‚ä½•èƒ½è®“ç™Œç´°èƒæ­»äº¡ï¼ŒåŒæ™‚ä¹Ÿè©•ä¼°å®ƒå°å¿ƒè‡Ÿç´°èƒçš„å½±éŸ¿ï¼Œå› ç‚ºè¨±å¤šç™Œç—‡æ²»ç™‚æœƒå°å¿ƒè‡Ÿé€ æˆå‰¯ä½œç”¨ã€‚\n\nä»–å€‘ä½¿ç”¨äº†ä¾†è‡ªäººé¡å¹¹ç´°èƒçš„å¿ƒè‚Œç´°èƒå’Œå‰åˆ—è…ºç™Œç´°èƒé€²è¡Œå…±åŸ¹é¤Šï¼Œè§€å¯Ÿè˜¿è””ç¡«ç´ å°é€™äº›ç´°èƒçš„å½±éŸ¿ã€‚çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆèª˜å°ç™Œç´°èƒæ­»äº¡ï¼Œå»ä¸æœƒå°å¿ƒè‚Œç´°èƒçš„æ”¶ç¸®åŠ›é€ æˆå½±éŸ¿ï¼è€Œä¸”ï¼Œç•¶ç™Œç´°èƒå’Œå¿ƒè‚Œç´°èƒå…±åŸ¹é¤Šæ™‚ï¼Œå¿ƒè‚Œç´°èƒçš„è·³å‹•æ¨¡å¼é‚„å¾—åˆ°äº†æ”¹å–„ï¼Œé€™å¯èƒ½æ„å‘³è‘—è˜¿è””ç¡«ç´ èƒ½æ¸›å°‘ç™Œç´°èƒå°å¿ƒè‡Ÿçš„è² é¢å½±éŸ¿ã€‚\n\nğŸ” é€™è£¡æœ‰å¹¾å€‹é‡é»è¦è¨˜ä½ï¼š\n1. è˜¿è””ç¡«ç´ ä¾†è‡ªåå­—èŠ±ç§‘æ¤ç‰©ï¼Œå…·æœ‰æŠ—ç™Œç‰¹æ€§ã€‚\n2. ç ”ç©¶é¡¯ç¤ºå®ƒèƒ½æœ‰æ•ˆèª˜å°å‰åˆ—è…ºç™Œç´°èƒæ­»äº¡ã€‚\n3. å°å¿ƒè‡Ÿç´°èƒçš„å½±éŸ¿ç›¸å°è¼ƒå°ï¼Œç”šè‡³å¯èƒ½æœ‰ä¿è­·ä½œç”¨ï¼",
    "image_prompt": "Create an infographic that explains the experiment and main results of a study on sulforaphane. Include simple illustrations of broccoli or symbols representing sulforaphane, simplified representations of human or animal cells, and arrows or flow lines showing the experimental steps. Include a section labeled 'Main Results' highlighting the protective effect on heart cells and the induction of cancer cell death.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "å‰åˆ—è…ºç™Œ Prostate Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41409171/"
  },
  {
    "id": "41387309",
    "title_en": "Monovalent mannose-glycoconjugates of sulforaphane reprogram human dendritic cells via NFATc1 to induce immune tolerance under inflammatory conditions.",
    "pub_date": "2025 Dec",
    "journal": "British journal of pharmacology",
    "abstract_en": "Immune tolerance prevents inflammation and autoimmunity, with dendritic cells (DCs) playing a key role. Reprogramming DCs towards a tolerogenic state represents a promising therapeutic strategy. Sulforaphane (SFN) has known immunomodulatory effects, but its clinical application is limited by poor stability and bioavailability. To enhance its therapeutic potential, SFN was conjugated with mannose (SFNMan) or fucose (SFNFuc), aiming to induce a tolerogenic phenotype in human monocyte-derived DCs (moDCs) under inflammation and to explore NFATc1's involvement. moDCs were exposed to inflammatory conditions and treated with SFN, SFNMan or SFNFuc. Their phenotype, cytokine profile, T cell-modulating capacity and NFATc1 signalling were evaluated. SFNMan selectively induced a tolerogenic phenotype, characterised by an increased PD-L1/CD86 ratio and IL-10 production; up-regulation of SOCS1 and IDO transcripts; and Treg expansion and reduced proliferation of cytotoxic T cell proliferation. Functional assays and confocal microscopy revealed that SFNMan, but not SFNFuc, promoted NFATc1 nuclear translocation. Pharmacological inhibition of NFATc1 with cyclosporin A (CsA) abolished these effects, confirming NFATc1 as a central mediator of SFNMan-induced immune tolerance. Our findings identify NFATc1 as a key transcriptional switch in moDCs tolerogenic programming and highlight the carbohydrate-dependent specificity of SFN conjugates. SFNMan represents a novel carbohydrate-engineered immunomodulator capable of driving immune tolerance through NFATc1 activation. These results provide a mechanistic framework for the development of precision therapies targeting inflammatory and autoimmune diseases.",
    "para1": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›é‡è¦çš„å•Ÿç¤ºã€‚å…ç–«è€å—æ€§æ˜¯é˜²æ­¢ç‚ç—‡å’Œè‡ªé«”å…ç–«çš„é‡è¦æ©Ÿåˆ¶ï¼Œè€Œæ¨¹çªç´°èƒåœ¨é€™å€‹éç¨‹ä¸­æ‰®æ¼”è‘—é—œéµè§’è‰²ã€‚é€éèª¿æ•´æ¨¹çªç´°èƒçš„åŠŸèƒ½ï¼Œä½¿å…¶æœå‘è€å—æ€§ç‹€æ…‹ï¼Œå¯èƒ½æˆç‚ºä¸€ç¨®æœ‰æ•ˆçš„æ²»ç™‚ç­–ç•¥ã€‚é€™é …ç ”ç©¶æ¢ç´¢äº†è˜¿è””ç¡«ç´ çš„æ‡‰ç”¨ï¼Œä¸¦è©¦åœ–æ”¹å–„å…¶ç©©å®šæ€§å’Œç”Ÿç‰©åˆ©ç”¨åº¦ï¼Œé€™å°æ–¼æœªä¾†çš„å…ç–«ç›¸é—œç–¾ç—…æ²»ç™‚å…·æœ‰æ½›åœ¨çš„æ„ç¾©ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åŠå…¶è¡ç”Ÿç‰©åœ¨èª¿ç¯€æ¨¹çªç´°èƒçš„å…ç–«è€å—æ€§æ–¹é¢çš„ä½œç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯å¦‚ä½•åˆ©ç”¨è˜¿è””ç¡«ç´ çš„å…ç–«èª¿ç¯€ç‰¹æ€§ï¼Œä¸¦é€éåŒ–å­¸æ”¹é€ ä¾†å¢å¼·å…¶åœ¨è‡¨åºŠä¸Šçš„æ‡‰ç”¨æ½›åŠ›ã€‚å…·é«”è€Œè¨€ï¼Œç ”ç©¶é›†ä¸­åœ¨è˜¿è””ç¡«ç´ èˆ‡ç”˜éœ²ç³–æˆ–å‘‹å–ƒç³–çš„çµåˆï¼Œé€™äº›æ”¹é€ çš„ç›®çš„æ˜¯å¸Œæœ›èƒ½åœ¨ç‚ç—‡ç‹€æ…‹ä¸‹èª˜å°äººé¡å–®æ ¸ç´°èƒè¡ç”Ÿçš„æ¨¹çªç´°èƒç”¢ç”Ÿè€å—æ€§è¡¨å‹ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å°‡äººé¡å–®æ ¸ç´°èƒè¡ç”Ÿçš„æ¨¹çªç´°èƒæš´éœ²æ–¼ç‚ç—‡ç’°å¢ƒä¸­ï¼Œä¸¦åˆ†åˆ¥ç”¨è˜¿è””ç¡«ç´ ã€ç”˜éœ²ç³–çµåˆçš„è˜¿è””ç¡«ç´ ï¼ˆSFNManï¼‰æˆ–å‘‹å–ƒç³–çµåˆçš„è˜¿è””ç¡«ç´ ï¼ˆSFNFucï¼‰é€²è¡Œè™•ç†ã€‚æ¥è‘—ï¼Œä»–å€‘è©•ä¼°é€™äº›ç´°èƒçš„è¡¨å‹ã€ç´°èƒå› å­ç”¢ç”Ÿã€å°Tç´°èƒçš„èª¿ç¯€èƒ½åŠ›ä»¥åŠNFATc1ä¿¡è™Ÿå‚³å°çš„æƒ…æ³ã€‚é€™æ¨£çš„è¨­è¨ˆæ—¨åœ¨äº†è§£ä¸åŒè™•ç†å°æ¨¹çªç´°èƒåŠŸèƒ½çš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯å¦‚ä½•å½±éŸ¿å…ç–«è€å—æ€§ã€‚",
    "para4": "ç ”ç©¶çš„ä¸»è¦ç™¼ç¾æ˜¯ï¼ŒSFNManèƒ½å¤ é¸æ“‡æ€§åœ°èª˜å°æ¨¹çªç´°èƒç”¢ç”Ÿè€å—æ€§è¡¨å‹ï¼Œé€™è¡¨ç¾ç‚ºPD-L1/CD86æ¯”ç‡çš„å¢åŠ å’ŒIL-10çš„ç”¢ç”Ÿï¼Œä¸¦ä¸”ä¸Šèª¿äº†SOCS1å’ŒIDOçš„è½‰éŒ„æœ¬ï¼ŒåŒæ™‚ä¿ƒé€²äº†èª¿ç¯€æ€§Tç´°èƒçš„æ“´å¢ï¼Œæ¸›å°‘äº†ç´°èƒæ¯’æ€§Tç´°èƒçš„å¢æ®–ã€‚æ­¤å¤–ï¼ŒåŠŸèƒ½æ€§å¯¦é©—å’Œå…±èšç„¦é¡¯å¾®é¡çš„çµæœé¡¯ç¤ºï¼Œåªæœ‰SFNManä¿ƒé€²äº†NFATc1çš„æ ¸è½‰ä½ï¼Œä¸¦ä¸”ä½¿ç”¨ç’°å­¢ç´ AæŠ‘åˆ¶NFATc1çš„æ´»æ€§æœƒæ¶ˆé™¤é€™äº›æ•ˆæœï¼Œé€™è¡¨æ˜NFATc1åœ¨SFNManèª˜å°çš„å…ç–«è€å—ä¸­æ‰®æ¼”äº†é‡è¦è§’è‰²ã€‚é€™äº›çµæœç‚ºé‡å°ç‚ç—‡å’Œè‡ªé«”å…ç–«ç–¾ç—…çš„ç²¾æº–æ²»ç™‚æä¾›äº†æ©Ÿåˆ¶åŸºç¤ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›é‡è¦çš„å•Ÿç¤ºã€‚å…ç–«è€å—æ€§æ˜¯é˜²æ­¢ç‚ç—‡å’Œè‡ªé«”å…ç–«çš„é‡è¦æ©Ÿåˆ¶ï¼Œè€Œæ¨¹çªç´°èƒåœ¨é€™å€‹éç¨‹ä¸­æ‰®æ¼”è‘—é—œéµè§’è‰²ã€‚é€éèª¿æ•´æ¨¹çªç´°èƒçš„åŠŸèƒ½ï¼Œä½¿å…¶æœå‘è€å—æ€§ç‹€æ…‹ï¼Œå¯èƒ½æˆç‚ºä¸€ç¨®æœ‰æ•ˆçš„æ²»ç™‚ç­–ç•¥ã€‚é€™é …ç ”ç©¶æ¢ç´¢äº†è˜¿è””ç¡«ç´ çš„æ‡‰ç”¨ï¼Œä¸¦è©¦åœ–æ”¹å–„å…¶ç©©å®šæ€§å’Œç”Ÿç‰©åˆ©ç”¨åº¦ï¼Œé€™å°æ–¼æœªä¾†çš„å…ç–«ç›¸é—œç–¾ç—…æ²»ç™‚å…·æœ‰æ½›åœ¨çš„æ„ç¾©ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åŠå…¶è¡ç”Ÿç‰©åœ¨èª¿ç¯€æ¨¹çªç´°èƒçš„å…ç–«è€å—æ€§æ–¹é¢çš„ä½œç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯å¦‚ä½•åˆ©ç”¨è˜¿è””ç¡«ç´ çš„å…ç–«èª¿ç¯€ç‰¹æ€§ï¼Œä¸¦é€éåŒ–å­¸æ”¹é€ ä¾†å¢å¼·å…¶åœ¨è‡¨åºŠä¸Šçš„æ‡‰ç”¨æ½›åŠ›ã€‚å…·é«”è€Œè¨€ï¼Œç ”ç©¶é›†ä¸­åœ¨è˜¿è””ç¡«ç´ èˆ‡ç”˜éœ²ç³–æˆ–å‘‹å–ƒç³–çš„çµåˆï¼Œé€™äº›æ”¹é€ çš„ç›®çš„æ˜¯å¸Œæœ›èƒ½åœ¨ç‚ç—‡ç‹€æ…‹ä¸‹èª˜å°äººé¡å–®æ ¸ç´°èƒè¡ç”Ÿçš„æ¨¹çªç´°èƒç”¢ç”Ÿè€å—æ€§è¡¨å‹ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å°‡äººé¡å–®æ ¸ç´°èƒè¡ç”Ÿçš„æ¨¹çªç´°èƒæš´éœ²æ–¼ç‚ç—‡ç’°å¢ƒä¸­ï¼Œä¸¦åˆ†åˆ¥ç”¨è˜¿è””ç¡«ç´ ã€ç”˜éœ²ç³–çµåˆçš„è˜¿è””ç¡«ç´ ï¼ˆSFNManï¼‰æˆ–å‘‹å–ƒç³–çµåˆçš„è˜¿è””ç¡«ç´ ï¼ˆSFNFucï¼‰é€²è¡Œè™•ç†ã€‚æ¥è‘—ï¼Œä»–å€‘è©•ä¼°é€™äº›ç´°èƒçš„è¡¨å‹ã€ç´°èƒå› å­ç”¢ç”Ÿã€å°Tç´°èƒçš„èª¿ç¯€èƒ½åŠ›ä»¥åŠNFATc1ä¿¡è™Ÿå‚³å°çš„æƒ…æ³ã€‚é€™æ¨£çš„è¨­è¨ˆæ—¨åœ¨äº†è§£ä¸åŒè™•ç†å°æ¨¹çªç´°èƒåŠŸèƒ½çš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯å¦‚ä½•å½±éŸ¿å…ç–«è€å—æ€§ã€‚\n\nç ”ç©¶çš„ä¸»è¦ç™¼ç¾æ˜¯ï¼ŒSFNManèƒ½å¤ é¸æ“‡æ€§åœ°èª˜å°æ¨¹çªç´°èƒç”¢ç”Ÿè€å—æ€§è¡¨å‹ï¼Œé€™è¡¨ç¾ç‚ºPD-L1/CD86æ¯”ç‡çš„å¢åŠ å’ŒIL-10çš„ç”¢ç”Ÿï¼Œä¸¦ä¸”ä¸Šèª¿äº†SOCS1å’ŒIDOçš„è½‰éŒ„æœ¬ï¼ŒåŒæ™‚ä¿ƒé€²äº†èª¿ç¯€æ€§Tç´°èƒçš„æ“´å¢ï¼Œæ¸›å°‘äº†ç´°èƒæ¯’æ€§Tç´°èƒçš„å¢æ®–ã€‚æ­¤å¤–ï¼ŒåŠŸèƒ½æ€§å¯¦é©—å’Œå…±èšç„¦é¡¯å¾®é¡çš„çµæœé¡¯ç¤ºï¼Œåªæœ‰SFNManä¿ƒé€²äº†NFATc1çš„æ ¸è½‰ä½ï¼Œä¸¦ä¸”ä½¿ç”¨ç’°å­¢ç´ AæŠ‘åˆ¶NFATc1çš„æ´»æ€§æœƒæ¶ˆé™¤é€™äº›æ•ˆæœï¼Œé€™è¡¨æ˜NFATc1åœ¨SFNManèª˜å°çš„å…ç–«è€å—ä¸­æ‰®æ¼”äº†é‡è¦è§’è‰²ã€‚é€™äº›çµæœç‚ºé‡å°ç‚ç—‡å’Œè‡ªé«”å…ç–«ç–¾ç—…çš„ç²¾æº–æ²»ç™‚æä¾›äº†æ©Ÿåˆ¶åŸºç¤ã€‚",
    "fb_post": "æ ¹æ“šã€ŠBritish journal of pharmacologyã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ±ä½ çŸ¥é“å—ï¼Ÿè˜¿è””ä¸åªæ˜¯ç¾å‘³çš„è”¬èœï¼Œé‚„æœ‰å¯èƒ½æˆç‚ºæˆ‘å€‘å¥åº·çš„å®ˆè­·è€…ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶å°ˆæ³¨æ–¼ä¸€ç¨®å«åšè˜¿è””ç¡«ç´ çš„æˆåˆ†ï¼Œç™¼ç¾å®ƒå°æˆ‘å€‘çš„å…ç–«ç³»çµ±æœ‰ç‰¹åˆ¥çš„å½±éŸ¿ã€‚ ç ”ç©¶è€…å€‘æƒ³çŸ¥é“ï¼Œè˜¿è””ç¡«ç´ æ€éº¼èƒ½å¹«åŠ©æˆ‘å€‘çš„å…ç–«ç´°èƒæ›´å¥½åœ°å·¥ä½œï¼Œç‰¹åˆ¥æ˜¯åœ¨ç‚ç—‡çš„æƒ…æ³ä¸‹ã€‚ æ–¼æ˜¯ï¼Œä»–å€‘é€²è¡Œäº†ä¸€ç³»åˆ—å¯¦é©—ï¼Œå°‡äººé¡çš„å…ç–«ç´°èƒæ”¾åœ¨ä¸åŒçš„ç’°å¢ƒè£¡ï¼Œä¸¦åˆ†åˆ¥ç”¨è˜¿è””ç¡«ç´ å’Œå®ƒçš„æ”¹è‰¯ç‰ˆæœ¬é€²è¡Œè™•ç†ã€‚æœ€çµ‚ï¼Œä»–å€‘ç™¼ç¾æ”¹è‰¯å¾Œçš„è˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆèª˜å°å…ç–«ç´°èƒç”¢ç”Ÿè€å—æ€§ï¼Œé€™æ„å‘³è‘—å®ƒèƒ½å¹«åŠ©æˆ‘å€‘çš„èº«é«”æ›´å¥½åœ°æ‡‰å°ç‚ç—‡ã€‚ é€™é …ç ”ç©¶çš„çµæœè®“æˆ‘å€‘çœ‹åˆ°ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½åœ¨æœªä¾†çš„å…ç–«ç›¸é—œç–¾ç—…æ²»ç™‚ä¸­æ‰®æ¼”é‡è¦è§’è‰²ï¼  ğŸ¤”é‡é»æ•´ç†ï¼š\n1. è˜¿è””ç¡«ç´ æœ‰åŠ©æ–¼èª¿ç¯€å…ç–«ç´°èƒçš„åŠŸèƒ½ã€‚\n2. æ”¹è‰¯ç‰ˆæœ¬çš„è˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆèª˜å°è€å—æ€§ã€‚\n3. é€™äº›ç™¼ç¾å°æ–¼æœªä¾†çš„ç–¾ç—…æ²»ç™‚æœ‰æ½›åœ¨æ„ç¾©ï¼",
    "image_prompt": "Create a flat design infographic explaining the experiment and main results of a study on sulforaphane. Include symbols representing broccoli or sulforaphane, simplified illustrations of human or animal cells, and arrows or flow lines to indicate the experimental steps. Add a section highlighting the main results, such as protective effects or changes observed in immune cells. Use a light background with soft colors to make it visually appealing and easy to understand.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "è‡ªé«”å…ç–«ç–¾ç—… Autoimmune Diseases",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41387309/"
  },
  {
    "id": "41108925",
    "title_en": "Enhancing myocardial injury recovery: Nrf2 activation by sulforaphane regulates ferroptosis and oxidative stress in takotsubo-like models.",
    "pub_date": "2025 Dec",
    "journal": "International immunopharmacology",
    "abstract_en": "Takotsubo syndrome (TTS), once considered benign, can cause life-threatening myocardial injury. Although oxidative stress and ferroptosis are implicated in its pathogenesis, targeted therapies are not available for TTS. We demonstrate that sulforaphane (SFN), a natural Nrf2 activator, mitigates TTS-related injury in isoproterenol-induced rat models and AC16 cardiomyocytes. Isoproterenol induced ferroptosis and oxidative stress by impairing Nrf2 signaling. SFN treatment restored myocardial structure and function while enhancing antioxidant capacity, reducing mitochondrial damage, and suppressing ferroptosis markers. Additionally, similar to Fer-1 (a ferroptosis inhibitor), SFN reduced intracellular ferrous levels but uniquely activated Nrf2-driven endogenous defenses. Notably, Nrf2 inhibition abrogated the benefits of SFN in both in vitro and in vivo experiments. These findings highlight SFN as a dual-action therapeutic for TTS, simultaneously targeting oxidative stress and ferroptosis via Nrf2 activation. The therapeutic efficacy of SFN, combined with endogenous pathway modulation, underscores its translational potential for improving TTS outcomes.",
    "para1": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›é‡è¦çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°ä¸€ç¨®åç‚ºå¡”ç§‘èŒ²åšç—‡å€™ç¾¤ï¼ˆTTSï¼‰çš„å¿ƒè‡Ÿç–¾ç—…ã€‚é€™ç¨®ç–¾ç—…é›–ç„¶éå»è¢«èªç‚ºæ˜¯è‰¯æ€§çš„ï¼Œä½†å¯¦éš›ä¸Šå¯èƒ½å°è‡´å±åŠç”Ÿå‘½çš„å¿ƒè‚Œæå‚·ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œé€éæ”¹å–„èº«é«”çš„æŠ—æ°§åŒ–èƒ½åŠ›å’Œæ¸›å°‘ç´°èƒæ­»äº¡ï¼ŒæŸäº›å¤©ç„¶æˆåˆ†å¯èƒ½æœ‰åŠ©æ–¼æ¸›è¼•é€™ç¨®ç–¾ç—…çš„å½±éŸ¿ï¼Œé€™å°æ–¼æœªä¾†çš„æ²»ç™‚æ–¹æ³•é–‹ç™¼å…·æœ‰æ½›åœ¨çš„æŒ‡å°æ„ç¾©ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰åœ¨å¡”ç§‘èŒ²åšç—‡å€™ç¾¤ï¼ˆTTSï¼‰ä¸­çš„æ½›åœ¨ç™‚æ•ˆã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯ï¼Œå¦‚ä½•åˆ©ç”¨é€™ç¨®å¤©ç„¶åŒ–åˆç‰©ä¾†æ¸›è¼•ç”±æ–¼æ°§åŒ–å£“åŠ›å’Œç´°èƒæ­»äº¡æ‰€å¼•èµ·çš„å¿ƒè‚Œæå‚·ã€‚ç”±æ–¼ç›®å‰é‡å°TTSçš„ç‰¹å®šæ²»ç™‚æ–¹æ³•å°šæœªå‡ºç¾ï¼Œå› æ­¤é€™é …ç ”ç©¶çš„çµæœå¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚ç­–ç•¥æä¾›æ–°çš„æ€è·¯ã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†å¤§é¼ æ¨¡å‹å’Œå¿ƒè‡Ÿè‚Œè‚‰ç´°èƒï¼ˆAC16ï¼‰ä¾†æ¨¡æ“¬TTSçš„æƒ…æ³ã€‚ä»–å€‘é€šéæ³¨å°„ç•°ä¸™è…ä¸Šè…ºç´ ä¾†èª˜å°æ°§åŒ–å£“åŠ›å’Œç´°èƒæ­»äº¡ï¼Œç„¶å¾Œè§€å¯Ÿè˜¿è””ç¡«ç´ çš„æ²»ç™‚æ•ˆæœã€‚ç ”ç©¶è€…è©•ä¼°äº†å¿ƒè‚Œçš„çµæ§‹å’ŒåŠŸèƒ½ï¼Œä¸¦æ¸¬é‡äº†æŠ—æ°§åŒ–èƒ½åŠ›åŠç´°èƒæå‚·çš„æ¨™è¨˜ï¼Œä»¥äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æ”¹å–„å¿ƒè‚Œçš„çµæ§‹å’ŒåŠŸèƒ½ï¼Œä¸¦å¢å¼·æŠ—æ°§åŒ–èƒ½åŠ›ï¼Œæ¸›å°‘ç·šç²’é«”æå‚·ï¼ŒæŠ‘åˆ¶ç´°èƒæ­»äº¡çš„æ¨™è¨˜ã€‚èˆ‡å…¶ä»–ç´°èƒæ­»äº¡æŠ‘åˆ¶åŠ‘ç›¸æ¯”ï¼Œè˜¿è””ç¡«ç´ ç¨ç‰¹åœ°æ¿€æ´»äº†å…§æºæ€§é˜²ç¦¦æ©Ÿåˆ¶ï¼Œé¡¯ç¤ºå‡ºå…¶é›™é‡ä½œç”¨çš„æ½›åŠ›ã€‚ç„¶è€Œï¼Œç•¶æŠ‘åˆ¶Nrf2æ™‚ï¼Œè˜¿è””ç¡«ç´ çš„ç™‚æ•ˆæœƒå—åˆ°å½±éŸ¿ï¼Œé€™è¡¨æ˜Nrf2åœ¨å…¶ä½œç”¨ä¸­æ‰®æ¼”äº†é—œéµè§’è‰²ã€‚é€™äº›çµæœå¼·èª¿äº†è˜¿è””ç¡«ç´ åœ¨æ”¹å–„TTSçµæœæ–¹é¢çš„æ½›åœ¨æ‡‰ç”¨åƒ¹å€¼ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›é‡è¦çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°ä¸€ç¨®åç‚ºå¡”ç§‘èŒ²åšç—‡å€™ç¾¤ï¼ˆTTSï¼‰çš„å¿ƒè‡Ÿç–¾ç—…ã€‚é€™ç¨®ç–¾ç—…é›–ç„¶éå»è¢«èªç‚ºæ˜¯è‰¯æ€§çš„ï¼Œä½†å¯¦éš›ä¸Šå¯èƒ½å°è‡´å±åŠç”Ÿå‘½çš„å¿ƒè‚Œæå‚·ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œé€éæ”¹å–„èº«é«”çš„æŠ—æ°§åŒ–èƒ½åŠ›å’Œæ¸›å°‘ç´°èƒæ­»äº¡ï¼ŒæŸäº›å¤©ç„¶æˆåˆ†å¯èƒ½æœ‰åŠ©æ–¼æ¸›è¼•é€™ç¨®ç–¾ç—…çš„å½±éŸ¿ï¼Œé€™å°æ–¼æœªä¾†çš„æ²»ç™‚æ–¹æ³•é–‹ç™¼å…·æœ‰æ½›åœ¨çš„æŒ‡å°æ„ç¾©ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰åœ¨å¡”ç§‘èŒ²åšç—‡å€™ç¾¤ï¼ˆTTSï¼‰ä¸­çš„æ½›åœ¨ç™‚æ•ˆã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯ï¼Œå¦‚ä½•åˆ©ç”¨é€™ç¨®å¤©ç„¶åŒ–åˆç‰©ä¾†æ¸›è¼•ç”±æ–¼æ°§åŒ–å£“åŠ›å’Œç´°èƒæ­»äº¡æ‰€å¼•èµ·çš„å¿ƒè‚Œæå‚·ã€‚ç”±æ–¼ç›®å‰é‡å°TTSçš„ç‰¹å®šæ²»ç™‚æ–¹æ³•å°šæœªå‡ºç¾ï¼Œå› æ­¤é€™é …ç ”ç©¶çš„çµæœå¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚ç­–ç•¥æä¾›æ–°çš„æ€è·¯ã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†å¤§é¼ æ¨¡å‹å’Œå¿ƒè‡Ÿè‚Œè‚‰ç´°èƒï¼ˆAC16ï¼‰ä¾†æ¨¡æ“¬TTSçš„æƒ…æ³ã€‚ä»–å€‘é€šéæ³¨å°„ç•°ä¸™è…ä¸Šè…ºç´ ä¾†èª˜å°æ°§åŒ–å£“åŠ›å’Œç´°èƒæ­»äº¡ï¼Œç„¶å¾Œè§€å¯Ÿè˜¿è””ç¡«ç´ çš„æ²»ç™‚æ•ˆæœã€‚ç ”ç©¶è€…è©•ä¼°äº†å¿ƒè‚Œçš„çµæ§‹å’ŒåŠŸèƒ½ï¼Œä¸¦æ¸¬é‡äº†æŠ—æ°§åŒ–èƒ½åŠ›åŠç´°èƒæå‚·çš„æ¨™è¨˜ï¼Œä»¥äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æ”¹å–„å¿ƒè‚Œçš„çµæ§‹å’ŒåŠŸèƒ½ï¼Œä¸¦å¢å¼·æŠ—æ°§åŒ–èƒ½åŠ›ï¼Œæ¸›å°‘ç·šç²’é«”æå‚·ï¼ŒæŠ‘åˆ¶ç´°èƒæ­»äº¡çš„æ¨™è¨˜ã€‚èˆ‡å…¶ä»–ç´°èƒæ­»äº¡æŠ‘åˆ¶åŠ‘ç›¸æ¯”ï¼Œè˜¿è””ç¡«ç´ ç¨ç‰¹åœ°æ¿€æ´»äº†å…§æºæ€§é˜²ç¦¦æ©Ÿåˆ¶ï¼Œé¡¯ç¤ºå‡ºå…¶é›™é‡ä½œç”¨çš„æ½›åŠ›ã€‚ç„¶è€Œï¼Œç•¶æŠ‘åˆ¶Nrf2æ™‚ï¼Œè˜¿è””ç¡«ç´ çš„ç™‚æ•ˆæœƒå—åˆ°å½±éŸ¿ï¼Œé€™è¡¨æ˜Nrf2åœ¨å…¶ä½œç”¨ä¸­æ‰®æ¼”äº†é—œéµè§’è‰²ã€‚é€™äº›çµæœå¼·èª¿äº†è˜¿è””ç¡«ç´ åœ¨æ”¹å–„TTSçµæœæ–¹é¢çš„æ½›åœ¨æ‡‰ç”¨åƒ¹å€¼ã€‚",
    "fb_post": "æ ¹æ“šã€ŠInternational immunopharmacologyã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿæœ‰ä¸€ç¨®å¤©ç„¶æˆåˆ†å«è˜¿è””ç¡«ç´ ï¼Œå¯èƒ½å°å¿ƒè‡Ÿå¥åº·æœ‰å¹«åŠ©å“¦ï¼æœ€è¿‘æœ‰ç ”ç©¶å°ˆæ³¨æ–¼ä¸€ç¨®å¿ƒè‡Ÿç–¾ç—…ï¼Œå«åšå¡”ç§‘èŒ²åšç—‡å€™ç¾¤ï¼ˆTTSï¼‰ï¼Œé€™ç¨®ç—…é›–ç„¶ä»¥å‰è¢«èªç‚ºä¸åš´é‡ï¼Œä½†å…¶å¯¦å¯èƒ½æœƒå°è‡´å¿ƒè‚Œå—æï¼Œå½±éŸ¿æˆ‘å€‘çš„å¿ƒè‡ŸåŠŸèƒ½ã€‚  \n  \né€™é …ç ”ç©¶çš„ç§‘å­¸å®¶å€‘æƒ³çŸ¥é“ï¼Œè˜¿è””ç¡«ç´ æ€éº¼å¹«åŠ©æ”¹å–„é€™ç¨®ç—…ã€‚ä»–å€‘ä½¿ç”¨äº†å¤§é¼ å’Œå¿ƒè‡Ÿç´°èƒé€²è¡Œå¯¦é©—ï¼Œæ¨¡æ“¬å‡ºTTSçš„æƒ…æ³ï¼Œç„¶å¾Œçµ¦äºˆè˜¿è””ç¡«ç´ ï¼Œè§€å¯Ÿå®ƒçš„æ•ˆæœã€‚ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ä¸åƒ…èƒ½æ”¹å–„å¿ƒè‡Ÿçš„çµæ§‹å’ŒåŠŸèƒ½ï¼Œé‚„èƒ½å¢å¼·æŠ—æ°§åŒ–èƒ½åŠ›ï¼Œæ¸›å°‘ç´°èƒçš„æå‚·ã€‚  \n  \nç¸½çµä¸€ä¸‹é€™é …ç ”ç©¶çš„é‡é»ï¼š  \n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„å¿ƒè‡Ÿå¥åº·ï¼Œç‰¹åˆ¥æ˜¯å°æŠ—TTSã€‚  \n2. å®ƒèƒ½å¢å¼·å¿ƒè‡Ÿçš„æŠ—æ°§åŒ–èƒ½åŠ›ï¼Œæ¸›å°‘ç´°èƒæ­»äº¡ã€‚  \n3. Nrf2é€™å€‹è›‹ç™½åœ¨è˜¿è””ç¡«ç´ çš„ä½œç”¨ä¸­æ‰®æ¼”äº†é‡è¦è§’è‰²ã€‚  \n  \nä¸éï¼Œé€™é‚„åªæ˜¯åˆæ­¥çš„ç ”ç©¶çµæœï¼Œæœªä¾†é‚„éœ€è¦æ›´å¤šçš„å¯¦é©—ä¾†ç¢ºèªé€™äº›æ•ˆæœå“¦ï¼",
    "image_prompt": "Create an infographic that explains the experiment and main results of a study on sulforaphane (SFN) and Takotsubo syndrome (TTS). Use a flat design style with a light background and soft colors. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects like rats or heart cells, arrows or flow lines to indicate the experimental steps, and a section that highlights the main results, such as protective effects and improvements in heart function.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "å¡”ç§‘èŒ²åšç—‡å€™ç¾¤ Takotsubo Syndrome",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41108925/"
  },
  {
    "id": "41352012",
    "title_en": "Protection against deoxynivalenol (DON)-induced intestinal injury by sulforaphane via modulation of lysosomal function.",
    "pub_date": "2025 Dec",
    "journal": "Journal of hazardous materials",
    "abstract_en": "Deoxynivalenol (DON) is a prevalent mycotoxin commonly detected in both human and animal diets, representing a significant health risk. Sulforaphane (SFN), a bioactive compound from cruciferous vegetables known for its antioxidant. This study aimed to confirm SFN's protective effect against DON-induced intestinal injury and clarify its underlying molecular mechanism. In vivo, C57BL/6 male mice (nâ€¯=â€¯8/group) were treated with DON (2â€¯mg/kg BW) and SFN (10â€¯mg/kg BW) to assess the overall protective effects of SFN; in vitro, intestinal porcine epithelial cells (IPEC-J2) and pig intestinal organoids were treated with DON (1â€¯Î¼g/mL) and SFN (2â€¯Î¼M) to investigate the protective mechanism of SFN. Hematoxylin-eosin staining, western blot and flow cytometry were used to confirm the protective effects of SFN. RNA-seq, CETSA, ITDRF and non-targeted metabolomics was employed to investigate the mechanism of SFN supplementation. This study demonstrated that SFN significantly alleviated DON-induced intestinal toxicity: in vivo, SFN restored jejunal villus height/crypt depth and restored the balance of redox homeostasis (decreased MDA, LDH, SOD and CAT); in vitro, SFN lowered DON-induced cell apoptosis and ROS accumulation. Mechanistically, lysosomal function was critical for SFN's protection-SFN directly targeted ATP6AP1 to enhance lysosomal acidification Moreover, ATP supplementation further potentiated this acidification and SFN's cytoprotective effect. This study identified ATP6AP1-mediated lysosomal acidification as a novel mechanism for SFN to mitigate DON-induced intestinal injury. Therefore, investigating the crosstalk between the SFN-ATP6AP1 axis and gut microbiota warrants further investigation to elucidate a broader protective mechanism.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°é£Ÿç‰©ä¸­å¸¸è¦‹çš„çœŸèŒæ¯’ç´ è„«æ°§é›ªè…éœ‰ç´ ï¼ˆDONï¼‰ã€‚é€™ç¨®æ¯’ç´ åœ¨æˆ‘å€‘çš„é£²é£Ÿä¸­æ™®éå­˜åœ¨ï¼Œå°äººé«”å’Œå‹•ç‰©çš„å¥åº·æ§‹æˆäº†é‡å¤§é¢¨éšªã€‚ç ”ç©¶æŒ‡å‡ºï¼Œè˜¿è””ç¡«ç´ é€™ç¨®ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœçš„ç”Ÿç‰©æ´»æ€§åŒ–åˆç‰©ï¼Œå¯èƒ½å°æŠ—é€™ç¨®æ¯’ç´ å¼•èµ·çš„è…¸é“æå‚·ï¼Œé€™å°æ–¼æ”¹å–„é£²é£Ÿå®‰å…¨å’Œä¿ƒé€²è…¸é“å¥åº·å…·æœ‰æ½›åœ¨çš„æ„ç¾©ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°è„«æ°§é›ªè…éœ‰ç´ å¼•èµ·çš„è…¸é“æå‚·çš„ä¿è­·ä½œç”¨ï¼Œä¸¦é€²ä¸€æ­¥äº†è§£å…¶èƒŒå¾Œçš„åˆ†å­æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…å¸Œæœ›èƒ½å¤ ç¢ºèªè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æœ‰æ•ˆæ¸›è¼•é€™ç¨®æ¯’ç´ å°è…¸é“çš„å‚·å®³ï¼Œä¸¦æ­ç¤ºå…¶ä½œç”¨çš„å…·é«”éç¨‹ï¼Œé€™å°æ–¼æœªä¾†çš„å¥åº·ç ”ç©¶å’Œæ‡‰ç”¨å…·æœ‰é‡è¦çš„åƒè€ƒåƒ¹å€¼ã€‚",
    "para3": "åœ¨å¯¦é©—è¨­è¨ˆä¸Šï¼Œç ”ç©¶è€…ä½¿ç”¨äº†C57BL/6å°é¼ ä½œç‚ºå¯¦é©—å°è±¡ï¼Œå°‡å…¶åˆ†ç‚ºä¸åŒçµ„åˆ¥ï¼Œåˆ†åˆ¥çµ¦äºˆè„«æ°§é›ªè…éœ‰ç´ å’Œè˜¿è””ç¡«ç´ ï¼Œä»¥è©•ä¼°è˜¿è””ç¡«ç´ çš„ä¿è­·æ•ˆæœã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„åœ¨é«”å¤–ä½¿ç”¨è±¬è…¸é“ä¸Šçš®ç´°èƒå’Œè…¸é“å™¨å®˜é¡ä¼¼ç‰©é€²è¡Œæ¸¬è©¦ï¼Œä»¥æ¢è¨è˜¿è””ç¡«ç´ çš„ä¿è­·æ©Ÿåˆ¶ã€‚å¯¦é©—ä¸­ä½¿ç”¨äº†å¤šç¨®æŠ€è¡“ï¼Œå¦‚çµ„ç¹”åˆ‡ç‰‡æŸ“è‰²ã€è›‹ç™½è³ªå°è·¡æ³•å’Œæµå¼ç´°èƒè¡“ç­‰ï¼Œä»¥ç¢ºèªè˜¿è””ç¡«ç´ çš„ä¿è­·æ•ˆæœã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ¸›è¼•è„«æ°§é›ªè…éœ‰ç´ å¼•èµ·çš„è…¸é“æ¯’æ€§ã€‚åœ¨å°é¼ å¯¦é©—ä¸­ï¼Œè˜¿è””ç¡«ç´ æ¢å¾©äº†è…¸é“çµ¨æ¯›çš„é«˜åº¦å’Œè…ºé«”çš„æ·±åº¦ï¼Œä¸¦æ”¹å–„äº†æ°§åŒ–é‚„åŸå¹³è¡¡ã€‚åœ¨é«”å¤–å¯¦é©—ä¸­ï¼Œè˜¿è””ç¡«ç´ é™ä½äº†è„«æ°§é›ªè…éœ‰ç´ å¼•èµ·çš„ç´°èƒå‡‹äº¡å’Œæ´»æ€§æ°§çš„ç©ç´¯ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ é€šéç›´æ¥ä½œç”¨æ–¼ATP6AP1ä¾†å¢å¼·æº¶é…¶é«”çš„é…¸åŒ–ï¼Œé€™ä¸€æ©Ÿåˆ¶å¯èƒ½æ˜¯å…¶ä¿è­·ä½œç”¨çš„é—œéµã€‚å› æ­¤ï¼Œé€²ä¸€æ­¥æ¢è¨è˜¿è””ç¡«ç´ èˆ‡è…¸é“å¾®ç”Ÿç‰©ä¹‹é–“çš„ç›¸äº’ä½œç”¨ï¼Œå°‡æœ‰åŠ©æ–¼æ›´å…¨é¢åœ°ç†è§£å…¶ä¿è­·æ©Ÿåˆ¶ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°é£Ÿç‰©ä¸­å¸¸è¦‹çš„çœŸèŒæ¯’ç´ è„«æ°§é›ªè…éœ‰ç´ ï¼ˆDONï¼‰ã€‚é€™ç¨®æ¯’ç´ åœ¨æˆ‘å€‘çš„é£²é£Ÿä¸­æ™®éå­˜åœ¨ï¼Œå°äººé«”å’Œå‹•ç‰©çš„å¥åº·æ§‹æˆäº†é‡å¤§é¢¨éšªã€‚ç ”ç©¶æŒ‡å‡ºï¼Œè˜¿è””ç¡«ç´ é€™ç¨®ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœçš„ç”Ÿç‰©æ´»æ€§åŒ–åˆç‰©ï¼Œå¯èƒ½å°æŠ—é€™ç¨®æ¯’ç´ å¼•èµ·çš„è…¸é“æå‚·ï¼Œé€™å°æ–¼æ”¹å–„é£²é£Ÿå®‰å…¨å’Œä¿ƒé€²è…¸é“å¥åº·å…·æœ‰æ½›åœ¨çš„æ„ç¾©ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°è„«æ°§é›ªè…éœ‰ç´ å¼•èµ·çš„è…¸é“æå‚·çš„ä¿è­·ä½œç”¨ï¼Œä¸¦é€²ä¸€æ­¥äº†è§£å…¶èƒŒå¾Œçš„åˆ†å­æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…å¸Œæœ›èƒ½å¤ ç¢ºèªè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æœ‰æ•ˆæ¸›è¼•é€™ç¨®æ¯’ç´ å°è…¸é“çš„å‚·å®³ï¼Œä¸¦æ­ç¤ºå…¶ä½œç”¨çš„å…·é«”éç¨‹ï¼Œé€™å°æ–¼æœªä¾†çš„å¥åº·ç ”ç©¶å’Œæ‡‰ç”¨å…·æœ‰é‡è¦çš„åƒè€ƒåƒ¹å€¼ã€‚\n\nåœ¨å¯¦é©—è¨­è¨ˆä¸Šï¼Œç ”ç©¶è€…ä½¿ç”¨äº†C57BL/6å°é¼ ä½œç‚ºå¯¦é©—å°è±¡ï¼Œå°‡å…¶åˆ†ç‚ºä¸åŒçµ„åˆ¥ï¼Œåˆ†åˆ¥çµ¦äºˆè„«æ°§é›ªè…éœ‰ç´ å’Œè˜¿è””ç¡«ç´ ï¼Œä»¥è©•ä¼°è˜¿è””ç¡«ç´ çš„ä¿è­·æ•ˆæœã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„åœ¨é«”å¤–ä½¿ç”¨è±¬è…¸é“ä¸Šçš®ç´°èƒå’Œè…¸é“å™¨å®˜é¡ä¼¼ç‰©é€²è¡Œæ¸¬è©¦ï¼Œä»¥æ¢è¨è˜¿è””ç¡«ç´ çš„ä¿è­·æ©Ÿåˆ¶ã€‚å¯¦é©—ä¸­ä½¿ç”¨äº†å¤šç¨®æŠ€è¡“ï¼Œå¦‚çµ„ç¹”åˆ‡ç‰‡æŸ“è‰²ã€è›‹ç™½è³ªå°è·¡æ³•å’Œæµå¼ç´°èƒè¡“ç­‰ï¼Œä»¥ç¢ºèªè˜¿è””ç¡«ç´ çš„ä¿è­·æ•ˆæœã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ¸›è¼•è„«æ°§é›ªè…éœ‰ç´ å¼•èµ·çš„è…¸é“æ¯’æ€§ã€‚åœ¨å°é¼ å¯¦é©—ä¸­ï¼Œè˜¿è””ç¡«ç´ æ¢å¾©äº†è…¸é“çµ¨æ¯›çš„é«˜åº¦å’Œè…ºé«”çš„æ·±åº¦ï¼Œä¸¦æ”¹å–„äº†æ°§åŒ–é‚„åŸå¹³è¡¡ã€‚åœ¨é«”å¤–å¯¦é©—ä¸­ï¼Œè˜¿è””ç¡«ç´ é™ä½äº†è„«æ°§é›ªè…éœ‰ç´ å¼•èµ·çš„ç´°èƒå‡‹äº¡å’Œæ´»æ€§æ°§çš„ç©ç´¯ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ é€šéç›´æ¥ä½œç”¨æ–¼ATP6AP1ä¾†å¢å¼·æº¶é…¶é«”çš„é…¸åŒ–ï¼Œé€™ä¸€æ©Ÿåˆ¶å¯èƒ½æ˜¯å…¶ä¿è­·ä½œç”¨çš„é—œéµã€‚å› æ­¤ï¼Œé€²ä¸€æ­¥æ¢è¨è˜¿è””ç¡«ç´ èˆ‡è…¸é“å¾®ç”Ÿç‰©ä¹‹é–“çš„ç›¸äº’ä½œç”¨ï¼Œå°‡æœ‰åŠ©æ–¼æ›´å…¨é¢åœ°ç†è§£å…¶ä¿è­·æ©Ÿåˆ¶ã€‚",
    "fb_post": "æ ¹æ“šã€ŠJournal of hazardous materialsã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ±ä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„é£²é£Ÿä¸­å¯èƒ½æ½›è—è‘—ä¸€ç¨®å°å¥åº·æœ‰å®³çš„çœŸèŒæ¯’ç´ ï¼Œå«åšè„«æ°§é›ªè…éœ‰ç´ ï¼ˆDONï¼‰ã€‚é€™ç¨®æ¯’ç´ ä¸åƒ…å½±éŸ¿æˆ‘å€‘çš„è…¸é“å¥åº·ï¼Œé‚„å¯èƒ½å¼•ç™¼å…¶ä»–å¥åº·å•é¡Œã€‚ä¸éï¼Œæœ€è¿‘æœ‰ç ”ç©¶ç™¼ç¾ï¼Œä¾†è‡ªé’èŠ±èœç­‰åå­—èŠ±ç§‘è”¬èœçš„è˜¿è””ç¡«ç´ ï¼Œå¯èƒ½èƒ½å¹«åŠ©æˆ‘å€‘å°æŠ—é€™ç¨®æ¯’ç´ ï¼\n\né€™é …ç ”ç©¶ä¸»è¦æ¢è¨è˜¿è””ç¡«ç´ å°è„«æ°§é›ªè…éœ‰ç´ å¼•èµ·çš„è…¸é“æå‚·çš„ä¿è­·ä½œç”¨ã€‚ç ”ç©¶äººå“¡ä½¿ç”¨å°é¼ å’Œè±¬è…¸é“ç´°èƒé€²è¡Œå¯¦é©—ï¼Œè§€å¯Ÿè˜¿è””ç¡«ç´ å¦‚ä½•æ¸›è¼•è…¸é“çš„å‚·å®³ã€‚çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ä¸åƒ…èƒ½æ”¹å–„è…¸é“çµæ§‹ï¼Œé‚„èƒ½æ¸›å°‘ç´°èƒå‡‹äº¡å’Œæ°§åŒ–å£“åŠ›ï¼Œé€™æ„å‘³è‘—å®ƒå¯èƒ½åœ¨ä¿è­·è…¸é“å¥åº·æ–¹é¢ç™¼æ®äº†é‡è¦ä½œç”¨ï¼\n\nğŸ” é€™è£¡æœ‰å¹¾å€‹é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœï¼Œå¯èƒ½å°æŠ—é£²é£Ÿä¸­çš„çœŸèŒæ¯’ç´ ã€‚\n2. å¯¦é©—çµæœé¡¯ç¤ºè˜¿è””ç¡«ç´ èƒ½æ”¹å–„è…¸é“çµæ§‹ï¼Œæ¸›å°‘ç´°èƒæå‚·ã€‚\n3. é€²ä¸€æ­¥ç ”ç©¶è˜¿è””ç¡«ç´ èˆ‡è…¸é“å¾®ç”Ÿç‰©çš„äº’å‹•å°‡æœ‰åŠ©æ–¼æ›´æ·±å…¥äº†è§£å…¶ä¿è­·æ©Ÿåˆ¶ã€‚",
    "image_prompt": "Create a flat design infographic that explains the experimental methods and main results of a study on the protective effects of sulforaphane against deoxynivalenol (DON) induced intestinal damage. Include simplified illustrations of broccoli or sulforaphane, experimental subjects like mice and intestinal cells, arrows or flow lines indicating the experimental steps, and a section highlighting 'Main Results' such as protective effects and observed changes. Use a white or light-colored background with soft color palettes.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "è…¸é“æå‚· Intestinal Injury",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41352012/"
  },
  {
    "id": "41341174",
    "title_en": "Sulforaphane attenuates oxidative stress, senescence, and ferroptosis induced by cigarette smoke extract <i>in vitro</i> and <i>in vivo via</i> upregulating the expression of SIRT1.",
    "pub_date": "2025 Dec",
    "journal": "Research in pharmaceutical sciences",
    "abstract_en": "Cigarette smoking induces lung toxicity by triggering oxidative stress, leading to apoptosis, ferroptosis, and senescence. Sulforaphane (SFN), a potent antioxidant, activates the SIRT1 pathway, enhancing cellular stress resistance and survival. This study aimed to evaluate the protective effects of SFN against cigarette smoke extract (CSE)-induced damage in human airway epithelial cells (BEAS-2B) and in mouse lungs, focusing on its role in upregulating SIRT1 expression. BEAS-2B cells were treated with CSE and SFN, and cell viability was assessed using the MTT assay. Cellular senescence was assessed using the SA-Î²-gal assay and the expression of genes associated with senescence (p16 and p21). The expression levels of SIRT1, senescence-associated secretory phenotype (SASP) cytokines (IL-1Î², IL-6, IL-8, TNF-Î±), GPX4, and SLC7A11 were quantified using qRT-PCR. Additionally, ROS production, GSH and MDA levels, and iron content were measured. An emphysema mouse model was induced by intraperitoneal administration of CSE (7.2 mg/kg) alone or in combination with SFN (10.2 mg/kg) over 28 days, and subsequent histopathological changes were evaluated. Our findings revealed that SFN co-treatment effectively mitigated CSE-induced cytotoxicity, senescence, and SASP cytokine secretion, as well as the pronounced emphysematous changes in lung tissues. Furthermore, SFN reversed CSE-induced downregulation of SIRT1 and upregulation of NF-ÎºB. Notably, SFN also inhibited CSE-induced ferroptosis by increasing GPX4 and SLC7A11 expression while reducing iron and MDA levels. The findings of the present study demonstrated that sulforaphane offers protective effects against CSE-induced toxicity by mitigating oxidative stress, ferroptosis, and cellular senescence.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°å¸ç…™æ‰€é€ æˆçš„è‚ºéƒ¨æå‚·ã€‚å¸ç…™æœƒå¼•ç™¼æ°§åŒ–å£“åŠ›ï¼Œå°è‡´ç´°èƒæ­»äº¡å’Œè€åŒ–ï¼Œè€Œè˜¿è””ç¡«ç´ ä½œç‚ºä¸€ç¨®å¼·æ•ˆæŠ—æ°§åŒ–åŠ‘ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ¸›è¼•é€™äº›æå®³ã€‚é€™æ„å‘³è‘—ï¼Œé€éå¢åŠ è˜¿è””ç¡«ç´ çš„æ”å–ï¼Œæˆ–è¨±èƒ½åœ¨ä¸€å®šç¨‹åº¦ä¸Šä¿è­·æˆ‘å€‘çš„è‚ºéƒ¨ï¼Œæ¸›å°‘å¸ç…™å¸¶ä¾†çš„è² é¢å½±éŸ¿ï¼Œé€™å°æ–¼å¸ç…™è€…æˆ–é•·æœŸæ¥è§¸ç…™éœ§çš„äººä¾†èªªï¼Œå°¤å…¶é‡è¦ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°æ–¼å¸ç…™å¼•èµ·çš„è‚ºéƒ¨æå‚·çš„ä¿è­·ä½œç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œå¸ç…™æ‰€é‡‹æ”¾çš„ç…™éœ§æå–ç‰©æœƒå°äººé¡æ°£é“ä¸Šçš®ç´°èƒå’Œå°é¼ è‚ºéƒ¨é€ æˆä»€éº¼æ¨£çš„æå®³ï¼Œä»¥åŠè˜¿è””ç¡«ç´ å¦‚ä½•åœ¨é€™å€‹éç¨‹ä¸­ç™¼æ®ä½œç”¨ã€‚ç‰¹åˆ¥æ˜¯ï¼Œç ”ç©¶é‡é»åœ¨æ–¼è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½ä¿ƒé€²SIRT1çš„è¡¨é”ï¼Œé€²è€Œå¢å¼·ç´°èƒå°å£“åŠ›çš„æŠµæŠ—èƒ½åŠ›ã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†äººé¡æ°£é“ä¸Šçš®ç´°èƒï¼ˆBEAS-2Bï¼‰å’Œå°é¼ ä½œç‚ºç ”ç©¶å°è±¡ã€‚BEAS-2Bç´°èƒè¢«è™•ç†äº†å¸ç…™ç…™éœ§æå–ç‰©å’Œè˜¿è””ç¡«ç´ ï¼Œä¸¦é€éMTTæ¸¬è©¦ä¾†è©•ä¼°ç´°èƒçš„å­˜æ´»ç‡ã€‚æ­¤å¤–ï¼Œé‚„ä½¿ç”¨SA-Î²-galæ¸¬è©¦ä¾†è©•ä¼°ç´°èƒè€åŒ–çš„æƒ…æ³ï¼Œä¸¦é‡æ¸¬èˆ‡è€åŒ–ç›¸é—œçš„åŸºå› è¡¨é”ã€‚å°æ–¼å°é¼ çš„å¯¦é©—ï¼Œå‰‡æ˜¯é€éè…¹è…”æ³¨å°„çš„æ–¹å¼æ–½åŠ ç…™éœ§æå–ç‰©å’Œè˜¿è””ç¡«ç´ ï¼ŒæŒçºŒ28å¤©ï¼Œä¸¦è©•ä¼°å…¶çµ„ç¹”çš„ç—…ç†è®ŠåŒ–ã€‚",
    "para4": "ä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ çš„å…±åŒè™•ç†æœ‰æ•ˆæ¸›è¼•äº†å¸ç…™ç…™éœ§æå–ç‰©å¼•èµ·çš„ç´°èƒæ¯’æ€§ã€è€åŒ–åŠç›¸é—œç´°èƒå› å­çš„åˆ†æ³Œï¼Œä¸¦æ”¹å–„äº†å°é¼ è‚ºéƒ¨çš„è‚ºæ°£è…«è®ŠåŒ–ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½é€†è½‰å¸ç…™ç…™éœ§æå–ç‰©å¼•èµ·çš„SIRT1ä¸‹èª¿å’ŒNF-ÎºBä¸Šèª¿ç¾è±¡ã€‚å€¼å¾—æ³¨æ„çš„æ˜¯ï¼Œè˜¿è””ç¡«ç´ ä¹ŸæŠ‘åˆ¶äº†å¸ç…™ç…™éœ§å¼•èµ·çš„éµæ­»äº¡ï¼Œé€šéæé«˜GPX4å’ŒSLC7A11çš„è¡¨é”ï¼Œä¸¦é™ä½éµå’ŒMDAçš„æ°´å¹³ã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨æ¸›è¼•æ°§åŒ–å£“åŠ›ã€éµæ­»äº¡å’Œç´°èƒè€åŒ–æ–¹é¢å…·æœ‰æ½›åœ¨çš„ä¿è­·ä½œç”¨ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°å¸ç…™æ‰€é€ æˆçš„è‚ºéƒ¨æå‚·ã€‚å¸ç…™æœƒå¼•ç™¼æ°§åŒ–å£“åŠ›ï¼Œå°è‡´ç´°èƒæ­»äº¡å’Œè€åŒ–ï¼Œè€Œè˜¿è””ç¡«ç´ ä½œç‚ºä¸€ç¨®å¼·æ•ˆæŠ—æ°§åŒ–åŠ‘ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ¸›è¼•é€™äº›æå®³ã€‚é€™æ„å‘³è‘—ï¼Œé€éå¢åŠ è˜¿è””ç¡«ç´ çš„æ”å–ï¼Œæˆ–è¨±èƒ½åœ¨ä¸€å®šç¨‹åº¦ä¸Šä¿è­·æˆ‘å€‘çš„è‚ºéƒ¨ï¼Œæ¸›å°‘å¸ç…™å¸¶ä¾†çš„è² é¢å½±éŸ¿ï¼Œé€™å°æ–¼å¸ç…™è€…æˆ–é•·æœŸæ¥è§¸ç…™éœ§çš„äººä¾†èªªï¼Œå°¤å…¶é‡è¦ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°æ–¼å¸ç…™å¼•èµ·çš„è‚ºéƒ¨æå‚·çš„ä¿è­·ä½œç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œå¸ç…™æ‰€é‡‹æ”¾çš„ç…™éœ§æå–ç‰©æœƒå°äººé¡æ°£é“ä¸Šçš®ç´°èƒå’Œå°é¼ è‚ºéƒ¨é€ æˆä»€éº¼æ¨£çš„æå®³ï¼Œä»¥åŠè˜¿è””ç¡«ç´ å¦‚ä½•åœ¨é€™å€‹éç¨‹ä¸­ç™¼æ®ä½œç”¨ã€‚ç‰¹åˆ¥æ˜¯ï¼Œç ”ç©¶é‡é»åœ¨æ–¼è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½ä¿ƒé€²SIRT1çš„è¡¨é”ï¼Œé€²è€Œå¢å¼·ç´°èƒå°å£“åŠ›çš„æŠµæŠ—èƒ½åŠ›ã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†äººé¡æ°£é“ä¸Šçš®ç´°èƒï¼ˆBEAS-2Bï¼‰å’Œå°é¼ ä½œç‚ºç ”ç©¶å°è±¡ã€‚BEAS-2Bç´°èƒè¢«è™•ç†äº†å¸ç…™ç…™éœ§æå–ç‰©å’Œè˜¿è””ç¡«ç´ ï¼Œä¸¦é€éMTTæ¸¬è©¦ä¾†è©•ä¼°ç´°èƒçš„å­˜æ´»ç‡ã€‚æ­¤å¤–ï¼Œé‚„ä½¿ç”¨SA-Î²-galæ¸¬è©¦ä¾†è©•ä¼°ç´°èƒè€åŒ–çš„æƒ…æ³ï¼Œä¸¦é‡æ¸¬èˆ‡è€åŒ–ç›¸é—œçš„åŸºå› è¡¨é”ã€‚å°æ–¼å°é¼ çš„å¯¦é©—ï¼Œå‰‡æ˜¯é€éè…¹è…”æ³¨å°„çš„æ–¹å¼æ–½åŠ ç…™éœ§æå–ç‰©å’Œè˜¿è””ç¡«ç´ ï¼ŒæŒçºŒ28å¤©ï¼Œä¸¦è©•ä¼°å…¶çµ„ç¹”çš„ç—…ç†è®ŠåŒ–ã€‚\n\nä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ çš„å…±åŒè™•ç†æœ‰æ•ˆæ¸›è¼•äº†å¸ç…™ç…™éœ§æå–ç‰©å¼•èµ·çš„ç´°èƒæ¯’æ€§ã€è€åŒ–åŠç›¸é—œç´°èƒå› å­çš„åˆ†æ³Œï¼Œä¸¦æ”¹å–„äº†å°é¼ è‚ºéƒ¨çš„è‚ºæ°£è…«è®ŠåŒ–ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½é€†è½‰å¸ç…™ç…™éœ§æå–ç‰©å¼•èµ·çš„SIRT1ä¸‹èª¿å’ŒNF-ÎºBä¸Šèª¿ç¾è±¡ã€‚å€¼å¾—æ³¨æ„çš„æ˜¯ï¼Œè˜¿è””ç¡«ç´ ä¹ŸæŠ‘åˆ¶äº†å¸ç…™ç…™éœ§å¼•èµ·çš„éµæ­»äº¡ï¼Œé€šéæé«˜GPX4å’ŒSLC7A11çš„è¡¨é”ï¼Œä¸¦é™ä½éµå’ŒMDAçš„æ°´å¹³ã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨æ¸›è¼•æ°§åŒ–å£“åŠ›ã€éµæ­»äº¡å’Œç´°èƒè€åŒ–æ–¹é¢å…·æœ‰æ½›åœ¨çš„ä¿è­·ä½œç”¨ã€‚",
    "fb_post": "æ ¹æ“šã€ŠResearch in pharmaceutical sciencesã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± å¸ç…™å°è‚ºéƒ¨çš„å‚·å®³å¤§å®¶éƒ½çŸ¥é“ï¼Œä½†ä½ çŸ¥é“è˜¿è””ç¡«ç´ èƒ½å¹«åŠ©æ¸›è¼•é€™äº›æå®³å—ï¼Ÿ\n\næœ€è¿‘æœ‰ä¸€é …ç ”ç©¶å°ˆæ³¨æ–¼é€™å€‹è©±é¡Œï¼Œç ”ç©¶è€…æƒ³äº†è§£å¸ç…™çš„ç…™éœ§å°æˆ‘å€‘çš„è‚ºéƒ¨æœ‰ä»€éº¼å½±éŸ¿ï¼Œä¸¦æ¢è¨è˜¿è””ç¡«ç´ é€™ç¨®å¤©ç„¶æŠ—æ°§åŒ–åŠ‘å¦‚ä½•ç™¼æ®ä½œç”¨ã€‚ä»–å€‘ä½¿ç”¨äº†äººé¡æ°£é“ä¸Šçš®ç´°èƒå’Œå°é¼ é€²è¡Œå¯¦é©—ï¼Œè§€å¯Ÿè˜¿è””ç¡«ç´ å°ç´°èƒå­˜æ´»ç‡å’Œè€åŒ–çš„å½±éŸ¿ã€‚\n\nçµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ä¸åƒ…èƒ½æ¸›è¼•å¸ç…™å¼•èµ·çš„ç´°èƒæå‚·ï¼Œé‚„èƒ½æ”¹å–„å°é¼ çš„è‚ºéƒ¨ç‹€æ³ï¼Œç”šè‡³é€†è½‰ä¸€äº›ä¸è‰¯çš„ç”ŸåŒ–è®ŠåŒ–ã€‚é€™æ„å‘³è‘—ï¼Œå¢åŠ è˜¿è””ç¡«ç´ çš„æ”å–ï¼Œæˆ–è¨±èƒ½ç‚ºæˆ‘å€‘çš„è‚ºéƒ¨æä¾›é¡å¤–çš„ä¿è­·ï¼Œç‰¹åˆ¥æ˜¯å°æ–¼å¸ç…™è€…å’Œé•·æœŸæ¥è§¸ç…™éœ§çš„äººä¾†èªªã€‚\n\nğŸ” ç ”ç©¶é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ èƒ½æ¸›è¼•å¸ç…™é€ æˆçš„ç´°èƒæ¯’æ€§å’Œè€åŒ–ã€‚\n2. å®ƒæ”¹å–„äº†å°é¼ çš„è‚ºæ°£è…«è®ŠåŒ–ã€‚\n3. è˜¿è””ç¡«ç´ æœ‰åŠ©æ–¼é€†è½‰ä¸è‰¯çš„ç”ŸåŒ–è®ŠåŒ–ï¼Œæä¾›æ½›åœ¨çš„ä¿è­·æ•ˆæœã€‚ \n\nè®“æˆ‘å€‘ä¸€èµ·é—œå¿ƒè‚ºéƒ¨å¥åº·ï¼Œå¾é£²é£Ÿé–‹å§‹ï¼",
    "image_prompt": "Create an infographic that visually explains the experimental process and main results of a study on the protective effects of sulforaphane against smoking-induced lung damage. Include simplified illustrations of broccoli or sulforaphane, human airway epithelial cells, and mice as experimental subjects. Use arrows or flow lines to indicate the steps of the experiment. Include a section that highlights the main results, such as reduced cell toxicity, improvements in lung condition, and biochemical reversals. The style should be flat design with a white or light-colored background and soft color palette.",
    "is_human_study": true,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "è‚ºæ°£è…« Emphysema",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41341174/"
  },
  {
    "id": "41039785",
    "title_en": "Integrative Network Pharmacology and Proteomics Decipher the Immunomodulatory Mechanism of Sulforaphane Against Intrinsic Skin Aging.",
    "pub_date": "2025 Dec",
    "journal": "Molecular nutrition & food research",
    "abstract_en": "Skin aging is characterized by declines in structural functions, contributing to age-associated frailty. Sulforaphane (SFN), a natural anti-inflammatory substance, has been widely applied in multiple types of cancer therapies. However, its role in alleviating intrinsic skin aging remains to be elucidated. Integrative network pharmacology and proteomics were utilized to investigate the underlying mechanisms of SFN in intrinsic skin aging. Fifty-one anti-aging targets of SFN were identified, highlighting its promising regulatory impact on the aging process. Based on an 18-month-old natural aging mouse model, significant alleviation in skin structure, redox homeostasis, and immune cell composition was noted after 2 months of SFN supplementation. Additionally, proteomic analysis demonstrated that SFN reversed the proteomic profile of intrinsic skin aging, with 233 differentially expressed proteins (DEPs) identified in SFN-fed aging mice. Of note, the up-regulated DEPs were highly enriched in the apelin signaling pathway (pÂ =Â 0.010). Furthermore, immune cell infiltration and whole blood cell analysis revealed that SFN rescued T cells depletion in dermal tissue, which was strongly correlated with DEPs enriched in the SFN-activated apelin signaling pathway. SFN improves skin morphology and immune functions via activating the apelin signaling pathway, suggesting new prime targets in counteracting intrinsic skin aging.",
    "para1": "éš¨è‘—å¹´é½¡å¢é•·ï¼Œçš®è†šçš„çµæ§‹åŠŸèƒ½æœƒé€æ¼¸ä¸‹é™ï¼Œé€™å¯èƒ½å°è‡´èˆ‡å¹´é½¡ç›¸é—œçš„è„†å¼±æ€§ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ä½œç‚ºä¸€ç¨®å¤©ç„¶çš„æŠ—ç™¼ç‚ç‰©è³ªï¼Œå·²è¢«å»£æ³›æ‡‰ç”¨æ–¼å¤šç¨®ç™Œç—‡æ²»ç™‚ä¸­ã€‚ç„¶è€Œï¼Œè˜¿è””ç¡«ç´ åœ¨æ¸›ç·©å…§åœ¨çš®è†šè€åŒ–æ–¹é¢çš„ä½œç”¨å°šæœªæ˜ç¢ºã€‚å› æ­¤ï¼Œäº†è§£è˜¿è””ç¡«ç´ å°çš®è†šè€åŒ–çš„å½±éŸ¿ï¼Œå¯èƒ½ç‚ºå¥åº·ä¿ƒé€²å’Œç–¾ç—…é é˜²æä¾›æ–°çš„æ€è·¯ï¼Œå°¤å…¶æ˜¯åœ¨æ”¹å–„çš®è†šçµæ§‹å’Œå…ç–«åŠŸèƒ½æ–¹é¢ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å…§åœ¨çš®è†šè€åŒ–ä¸­çš„ä½œç”¨åŠå…¶æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿çš®è†šçš„è€åŒ–éç¨‹ï¼Œä¸¦å°‹æ‰¾å…¶å¯èƒ½çš„æŠ—è€åŒ–ç›®æ¨™ã€‚é€éæ•´åˆçš„ç¶²çµ¡è—¥ç†å­¸å’Œè›‹ç™½è³ªçµ„å­¸æ–¹æ³•ï¼Œç ”ç©¶è€…å¸Œæœ›æ­ç¤ºè˜¿è””ç¡«ç´ å°çš®è†šè€åŒ–çš„èª¿ç¯€å½±éŸ¿ï¼Œä¸¦æ‰¾å‡ºèˆ‡è€åŒ–ç›¸é—œçš„ç”Ÿç‰©æ¨™è¨˜ã€‚",
    "para3": "ç ”ç©¶ä¸­ä½¿ç”¨äº†ä¸€å€‹18å€‹æœˆå¤§çš„è‡ªç„¶è€åŒ–å°é¼ æ¨¡å‹ï¼Œä¾†æ¨¡æ“¬çš®è†šè€åŒ–çš„éç¨‹ã€‚ç ”ç©¶è€…å°é€™äº›å°é¼ é€²è¡Œäº†ç‚ºæœŸå…©å€‹æœˆçš„è˜¿è””ç¡«ç´ è£œå……ï¼Œä¸¦è§€å¯Ÿå…¶å°çš®è†šçµæ§‹ã€æ°§åŒ–é‚„åŸå¹³è¡¡åŠå…ç–«ç´°èƒçµ„æˆçš„å½±éŸ¿ã€‚æ­¤å¤–ï¼Œé€éè›‹ç™½è³ªçµ„å­¸åˆ†æï¼Œç ”ç©¶è€…è­˜åˆ¥å‡º233ç¨®åœ¨è˜¿è””ç¡«ç´ é¤µé¤Šçš„è€åŒ–å°é¼ ä¸­è¡¨é”å·®ç•°çš„è›‹ç™½è³ªï¼Œé€²ä¸€æ­¥äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ”¹å–„çš®è†šçš„å½¢æ…‹å’Œå…ç–«åŠŸèƒ½ï¼Œä¸¦é€éæ¿€æ´»apelinä¿¡è™Ÿé€šè·¯ä¾†é”æˆé€™äº›æ•ˆæœã€‚ç ”ç©¶ä¸­ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ é€†è½‰å…§åœ¨çš®è†šè€åŒ–çš„è›‹ç™½è³ªçµ„ç‰¹å¾µï¼Œä¸¦ä¸”åœ¨çš®è†šçµ„ç¹”ä¸­æ¢å¾©äº†Tç´°èƒçš„æ•¸é‡ï¼Œé€™èˆ‡è˜¿è””ç¡«ç´ æ¿€æ´»çš„apelinä¿¡è™Ÿé€šè·¯ä¸­çš„å·®ç•°è¡¨é”è›‹ç™½è³ªæœ‰å¼·çƒˆçš„ç›¸é—œæ€§ã€‚é€™äº›çµæœæš—ç¤ºäº†è˜¿è””ç¡«ç´ åœ¨å°æŠ—å…§åœ¨çš®è†šè€åŒ–æ–¹é¢çš„æ½›åœ¨æ‡‰ç”¨ã€‚",
    "explanation_zh": "éš¨è‘—å¹´é½¡å¢é•·ï¼Œçš®è†šçš„çµæ§‹åŠŸèƒ½æœƒé€æ¼¸ä¸‹é™ï¼Œé€™å¯èƒ½å°è‡´èˆ‡å¹´é½¡ç›¸é—œçš„è„†å¼±æ€§ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ä½œç‚ºä¸€ç¨®å¤©ç„¶çš„æŠ—ç™¼ç‚ç‰©è³ªï¼Œå·²è¢«å»£æ³›æ‡‰ç”¨æ–¼å¤šç¨®ç™Œç—‡æ²»ç™‚ä¸­ã€‚ç„¶è€Œï¼Œè˜¿è””ç¡«ç´ åœ¨æ¸›ç·©å…§åœ¨çš®è†šè€åŒ–æ–¹é¢çš„ä½œç”¨å°šæœªæ˜ç¢ºã€‚å› æ­¤ï¼Œäº†è§£è˜¿è””ç¡«ç´ å°çš®è†šè€åŒ–çš„å½±éŸ¿ï¼Œå¯èƒ½ç‚ºå¥åº·ä¿ƒé€²å’Œç–¾ç—…é é˜²æä¾›æ–°çš„æ€è·¯ï¼Œå°¤å…¶æ˜¯åœ¨æ”¹å–„çš®è†šçµæ§‹å’Œå…ç–«åŠŸèƒ½æ–¹é¢ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å…§åœ¨çš®è†šè€åŒ–ä¸­çš„ä½œç”¨åŠå…¶æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿çš®è†šçš„è€åŒ–éç¨‹ï¼Œä¸¦å°‹æ‰¾å…¶å¯èƒ½çš„æŠ—è€åŒ–ç›®æ¨™ã€‚é€éæ•´åˆçš„ç¶²çµ¡è—¥ç†å­¸å’Œè›‹ç™½è³ªçµ„å­¸æ–¹æ³•ï¼Œç ”ç©¶è€…å¸Œæœ›æ­ç¤ºè˜¿è””ç¡«ç´ å°çš®è†šè€åŒ–çš„èª¿ç¯€å½±éŸ¿ï¼Œä¸¦æ‰¾å‡ºèˆ‡è€åŒ–ç›¸é—œçš„ç”Ÿç‰©æ¨™è¨˜ã€‚\n\nç ”ç©¶ä¸­ä½¿ç”¨äº†ä¸€å€‹18å€‹æœˆå¤§çš„è‡ªç„¶è€åŒ–å°é¼ æ¨¡å‹ï¼Œä¾†æ¨¡æ“¬çš®è†šè€åŒ–çš„éç¨‹ã€‚ç ”ç©¶è€…å°é€™äº›å°é¼ é€²è¡Œäº†ç‚ºæœŸå…©å€‹æœˆçš„è˜¿è””ç¡«ç´ è£œå……ï¼Œä¸¦è§€å¯Ÿå…¶å°çš®è†šçµæ§‹ã€æ°§åŒ–é‚„åŸå¹³è¡¡åŠå…ç–«ç´°èƒçµ„æˆçš„å½±éŸ¿ã€‚æ­¤å¤–ï¼Œé€éè›‹ç™½è³ªçµ„å­¸åˆ†æï¼Œç ”ç©¶è€…è­˜åˆ¥å‡º233ç¨®åœ¨è˜¿è””ç¡«ç´ é¤µé¤Šçš„è€åŒ–å°é¼ ä¸­è¡¨é”å·®ç•°çš„è›‹ç™½è³ªï¼Œé€²ä¸€æ­¥äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ”¹å–„çš®è†šçš„å½¢æ…‹å’Œå…ç–«åŠŸèƒ½ï¼Œä¸¦é€éæ¿€æ´»apelinä¿¡è™Ÿé€šè·¯ä¾†é”æˆé€™äº›æ•ˆæœã€‚ç ”ç©¶ä¸­ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ é€†è½‰å…§åœ¨çš®è†šè€åŒ–çš„è›‹ç™½è³ªçµ„ç‰¹å¾µï¼Œä¸¦ä¸”åœ¨çš®è†šçµ„ç¹”ä¸­æ¢å¾©äº†Tç´°èƒçš„æ•¸é‡ï¼Œé€™èˆ‡è˜¿è””ç¡«ç´ æ¿€æ´»çš„apelinä¿¡è™Ÿé€šè·¯ä¸­çš„å·®ç•°è¡¨é”è›‹ç™½è³ªæœ‰å¼·çƒˆçš„ç›¸é—œæ€§ã€‚é€™äº›çµæœæš—ç¤ºäº†è˜¿è””ç¡«ç´ åœ¨å°æŠ—å…§åœ¨çš®è†šè€åŒ–æ–¹é¢çš„æ½›åœ¨æ‡‰ç”¨ã€‚",
    "fb_post": "æ ¹æ“šã€ŠMolecular nutrition & food researchã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿéš¨è‘—å¹´é½¡å¢é•·ï¼Œæˆ‘å€‘çš„çš®è†šæœƒè®Šå¾—è¶Šä¾†è¶Šè„†å¼±ï¼Œé€™æ˜¯è‡ªç„¶çš„è€åŒ–éç¨‹ã€‚ä¸éï¼Œæœ€è¿‘çš„ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ é€™ç¨®å¤©ç„¶ç‰©è³ªå¯èƒ½å°æŠ—çš®è†šè€åŒ–æœ‰å¹«åŠ©ï¼é€™ç¯‡ç ”ç©¶ä¸»è¦æ¢è¨è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿æˆ‘å€‘çš„çš®è†šè€åŒ–ï¼Œä¸¦å°‹æ‰¾å®ƒçš„æŠ—è€åŒ–ç›®æ¨™ã€‚ç ”ç©¶è€…ä½¿ç”¨äº†ä¸€ç¨®18å€‹æœˆå¤§çš„å°é¼ æ¨¡å‹ï¼Œé€™äº›å°é¼ å°±åƒæˆ‘å€‘çš„çš®è†šä¸€æ¨£ï¼Œéš¨è‘—æ™‚é–“è®Šè€ã€‚ä»–å€‘çµ¦å°é¼ è£œå……äº†è˜¿è””ç¡«ç´ ï¼Œè§€å¯Ÿåˆ°çš®è†šçµæ§‹ã€æ°§åŒ–é‚„åŸå¹³è¡¡å’Œå…ç–«ç´°èƒçš„è®ŠåŒ–ã€‚çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ä¸åƒ…æ”¹å–„äº†çš®è†šçš„å½¢æ…‹ï¼Œé‚„å¢å¼·äº†å…ç–«åŠŸèƒ½ï¼Œé€™éƒ½æ˜¯å› ç‚ºå®ƒæ¿€æ´»äº†ä¸€æ¢å«åšapelinçš„ä¿¡è™Ÿé€šè·¯ã€‚é€™äº›ç™¼ç¾è®“æˆ‘å€‘çœ‹åˆ°ï¼Œè˜¿è””ç¡«ç´ åœ¨å°æŠ—çš®è†šè€åŒ–æ–¹é¢çš„æ½›åŠ›ï¼\n\nğŸ” ä¸»è¦é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ æœ‰åŠ©æ–¼æ”¹å–„çš®è†šçµæ§‹å’Œå…ç–«åŠŸèƒ½ã€‚\n2. å®ƒèƒ½é€†è½‰çš®è†šè€åŒ–çš„ç‰¹å¾µã€‚\n3. èˆ‡apelinä¿¡è™Ÿé€šè·¯çš„é—œè¯ï¼Œå¯èƒ½æˆç‚ºæŠ—è€åŒ–çš„æ–°æ–¹å‘ï¼",
    "image_prompt": "Create an infographic explaining the experiment and main findings of the study on sulforaphane. Use a flat design style with a light background and soft colors. Include simplified icons representing broccoli or sulforaphane, a simplified illustration of aging mice as experimental subjects, arrows or flow lines to indicate the experimental steps, and a section labeled 'Main Findings' highlighting protective effects and changes observed.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "çš®è†šè€åŒ– Skin Aging",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41039785/"
  },
  {
    "id": "41027171",
    "title_en": "Multi-omics analysis of gut-liver axis reveals the mechanism by which sulforaphane alleviates liver injury in Cyprinus carpio exposed to triphenyltin.",
    "pub_date": "2025 Dec",
    "journal": "Comparative biochemistry and physiology. Part D, Genomics & proteomics",
    "abstract_en": "This study investigates the protective effects of sulforaphane (SFN) against triphenyltin (TPT)-induced hepatotoxicity, immune dysfunction and gut microbiota dysbiosis in Cyprinus carpio. Cyprinus carpio were divided into three groups and exposed for 8Â weeks, including control, 10Â Î¼g/L TPT and 10Â Î¼g/L TPTÂ +Â 10Â mg/kg SFN group. This result showed that TPT exposure induced significantly (PÂ <Â 0.05) hepatotoxicity, evidenced by increasing hepatic total bile acid (TBA) and total cholesterol levels, while upregulating Hsp70/90 and downregulating lysozyme gene expression. SFN supplementation reduced TBA accumulation, normalized Hsp90 and lysozyme expression, mitigating TPT-induced lipid dysregulation and immunosuppression. Transcriptomic analysis revealed that TPT exposure activated lipid metabolism pathways (PPAR signaling and cholesterol metabolism), but suppressed immune-related pathways. SFN supplementation restored metabolic homeostasis by enriching glucose and amino acid metabolism pathways and activating AMPK signaling, while also modulating the expression of key genes (PLIN1, ME1, CPT1B). The microbiota composition were changed in SFNÂ +Â TPT, including the increased of beneficial Fusobacteriota and Cetobacterium, and the decreased of pathogenic Proteobacteria and Aeromonas. The gut transcriptome dysregulation were restored in SFNÂ +Â TPT by enhancing immune pathways in Toll-like/NOD-like receptors. The significant correlations linked were found in gut microbes (Kaistia, Vagococcus) to hepatic/intestinal gene expression in SFNÂ +Â TPT. Overall, these findings elucidate novel mechanisms underlying TPT-induced immunotoxicity in liver and intestine and demonstrate the protective role of SFN, providing a theoretical foundation for its application in toxicity mitigation strategies.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è‚è‡Ÿå¥åº·å’Œå…ç–«ç³»çµ±çš„ä¿è­·æ–¹é¢ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°æŠ—ç”±ä¸‰è‹¯éŒ«å¼•èµ·çš„è‚æ¯’æ€§å’Œå…ç–«åŠŸèƒ½éšœç¤™ï¼Œé€™å°æ–¼å°‹æ‰¾æ–°çš„ä¿è­·æ€§ç‡Ÿé¤Šç´ å’Œæ²»ç™‚æ–¹æ³•å…·æœ‰æ½›åœ¨æ„ç¾©ã€‚é€™äº›ç™¼ç¾å¯èƒ½å¹«åŠ©æˆ‘å€‘äº†è§£å¦‚ä½•é€éé£²é£Ÿä¾†æ¸›å°‘ç’°å¢ƒæ¯’ç´ å°å¥åº·çš„å½±éŸ¿ï¼Œä¸¦ä¿ƒé€²æ›´å¥½çš„å…ç–«åŠŸèƒ½ï¼Œé€²è€Œæé«˜æ•´é«”å¥åº·æ°´å¹³ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°ä¸‰è‹¯éŒ«å¼•èµ·çš„è‚æ¯’æ€§ã€å…ç–«åŠŸèƒ½éšœç¤™å’Œè…¸é“å¾®ç”Ÿç‰©å¤±èª¿çš„ä¿è­·ä½œç”¨ã€‚ç ”ç©¶è€…é—œæ³¨çš„æ˜¯ä¸‰è‹¯éŒ«é€™ç¨®ç’°å¢ƒæ±¡æŸ“ç‰©å°é­šé¡å¥åº·çš„å½±éŸ¿ï¼Œä¸¦è©¦åœ–äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å¹«åŠ©æ¸›è¼•é€™äº›ä¸è‰¯å½±éŸ¿ã€‚é€™é …ç ”ç©¶ä¸åƒ…æœ‰åŠ©æ–¼äº†è§£æ¯’ç´ å°ç”Ÿç‰©é«”çš„å½±éŸ¿ï¼Œé‚„èƒ½ç‚ºæœªä¾†çš„å¥åº·å¹²é æªæ–½æä¾›ä¾æ“šã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å°‡é¯‰é­šï¼ˆCyprinus carpioï¼‰åˆ†ç‚ºä¸‰çµ„ï¼Œé€²è¡Œç‚ºæœŸå…«é€±çš„å¯¦é©—ã€‚é€™ä¸‰çµ„åˆ†åˆ¥æ˜¯å°ç…§çµ„ã€æ¥å—10å¾®å…‹/å‡ä¸‰è‹¯éŒ«çš„çµ„åˆ¥ï¼Œä»¥åŠåŒæ™‚æ¥å—10å¾®å…‹/å‡ä¸‰è‹¯éŒ«å’Œ10æ¯«å…‹/å…¬æ–¤è˜¿è””ç¡«ç´ çš„çµ„åˆ¥ã€‚é€éé€™æ¨£çš„è¨­è¨ˆï¼Œç ”ç©¶è€…èƒ½å¤ æ¯”è¼ƒä¸åŒè™•ç†å°é­šé¡å¥åº·çš„å½±éŸ¿ï¼Œä¸¦åˆ†æè˜¿è””ç¡«ç´ çš„æ½›åœ¨ä¿è­·æ•ˆæœã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œä¸‰è‹¯éŒ«çš„æš´éœ²ç¢ºå¯¦å¼•èµ·äº†è‚æ¯’æ€§ï¼Œä¸¦ä¸”å½±éŸ¿äº†å…ç–«ç³»çµ±å’Œè…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆã€‚ç„¶è€Œï¼Œè˜¿è””ç¡«ç´ çš„è£œå……èƒ½å¤ æ¸›å°‘è‚è‡Ÿä¸­çš„è†½é…¸ç©ç´¯ï¼Œä¸¦æ¢å¾©ä¸€äº›åŸºå› çš„è¡¨é”ï¼Œé¡¯ç¤ºå‡ºå…¶åœ¨æ”¹å–„è„‚è³ªä»£è¬å’Œå…ç–«åŠŸèƒ½æ–¹é¢çš„æ½›åŠ›ã€‚æ­¤å¤–ï¼Œè…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆä¹Ÿå› è˜¿è””ç¡«ç´ çš„è£œå……è€Œç™¼ç”Ÿè®ŠåŒ–ï¼Œé€™äº›çµæœç‚ºç†è§£ä¸‰è‹¯éŒ«å¼•èµ·çš„å…ç–«æ¯’æ€§æä¾›äº†æ–°çš„æ©Ÿåˆ¶ï¼Œä¸¦é¡¯ç¤ºäº†è˜¿è””ç¡«ç´ çš„ä¿è­·ä½œç”¨ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è‚è‡Ÿå¥åº·å’Œå…ç–«ç³»çµ±çš„ä¿è­·æ–¹é¢ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°æŠ—ç”±ä¸‰è‹¯éŒ«å¼•èµ·çš„è‚æ¯’æ€§å’Œå…ç–«åŠŸèƒ½éšœç¤™ï¼Œé€™å°æ–¼å°‹æ‰¾æ–°çš„ä¿è­·æ€§ç‡Ÿé¤Šç´ å’Œæ²»ç™‚æ–¹æ³•å…·æœ‰æ½›åœ¨æ„ç¾©ã€‚é€™äº›ç™¼ç¾å¯èƒ½å¹«åŠ©æˆ‘å€‘äº†è§£å¦‚ä½•é€éé£²é£Ÿä¾†æ¸›å°‘ç’°å¢ƒæ¯’ç´ å°å¥åº·çš„å½±éŸ¿ï¼Œä¸¦ä¿ƒé€²æ›´å¥½çš„å…ç–«åŠŸèƒ½ï¼Œé€²è€Œæé«˜æ•´é«”å¥åº·æ°´å¹³ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°ä¸‰è‹¯éŒ«å¼•èµ·çš„è‚æ¯’æ€§ã€å…ç–«åŠŸèƒ½éšœç¤™å’Œè…¸é“å¾®ç”Ÿç‰©å¤±èª¿çš„ä¿è­·ä½œç”¨ã€‚ç ”ç©¶è€…é—œæ³¨çš„æ˜¯ä¸‰è‹¯éŒ«é€™ç¨®ç’°å¢ƒæ±¡æŸ“ç‰©å°é­šé¡å¥åº·çš„å½±éŸ¿ï¼Œä¸¦è©¦åœ–äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å¹«åŠ©æ¸›è¼•é€™äº›ä¸è‰¯å½±éŸ¿ã€‚é€™é …ç ”ç©¶ä¸åƒ…æœ‰åŠ©æ–¼äº†è§£æ¯’ç´ å°ç”Ÿç‰©é«”çš„å½±éŸ¿ï¼Œé‚„èƒ½ç‚ºæœªä¾†çš„å¥åº·å¹²é æªæ–½æä¾›ä¾æ“šã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å°‡é¯‰é­šï¼ˆCyprinus carpioï¼‰åˆ†ç‚ºä¸‰çµ„ï¼Œé€²è¡Œç‚ºæœŸå…«é€±çš„å¯¦é©—ã€‚é€™ä¸‰çµ„åˆ†åˆ¥æ˜¯å°ç…§çµ„ã€æ¥å—10å¾®å…‹/å‡ä¸‰è‹¯éŒ«çš„çµ„åˆ¥ï¼Œä»¥åŠåŒæ™‚æ¥å—10å¾®å…‹/å‡ä¸‰è‹¯éŒ«å’Œ10æ¯«å…‹/å…¬æ–¤è˜¿è””ç¡«ç´ çš„çµ„åˆ¥ã€‚é€éé€™æ¨£çš„è¨­è¨ˆï¼Œç ”ç©¶è€…èƒ½å¤ æ¯”è¼ƒä¸åŒè™•ç†å°é­šé¡å¥åº·çš„å½±éŸ¿ï¼Œä¸¦åˆ†æè˜¿è””ç¡«ç´ çš„æ½›åœ¨ä¿è­·æ•ˆæœã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œä¸‰è‹¯éŒ«çš„æš´éœ²ç¢ºå¯¦å¼•èµ·äº†è‚æ¯’æ€§ï¼Œä¸¦ä¸”å½±éŸ¿äº†å…ç–«ç³»çµ±å’Œè…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆã€‚ç„¶è€Œï¼Œè˜¿è””ç¡«ç´ çš„è£œå……èƒ½å¤ æ¸›å°‘è‚è‡Ÿä¸­çš„è†½é…¸ç©ç´¯ï¼Œä¸¦æ¢å¾©ä¸€äº›åŸºå› çš„è¡¨é”ï¼Œé¡¯ç¤ºå‡ºå…¶åœ¨æ”¹å–„è„‚è³ªä»£è¬å’Œå…ç–«åŠŸèƒ½æ–¹é¢çš„æ½›åŠ›ã€‚æ­¤å¤–ï¼Œè…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆä¹Ÿå› è˜¿è””ç¡«ç´ çš„è£œå……è€Œç™¼ç”Ÿè®ŠåŒ–ï¼Œé€™äº›çµæœç‚ºç†è§£ä¸‰è‹¯éŒ«å¼•èµ·çš„å…ç–«æ¯’æ€§æä¾›äº†æ–°çš„æ©Ÿåˆ¶ï¼Œä¸¦é¡¯ç¤ºäº†è˜¿è””ç¡«ç´ çš„ä¿è­·ä½œç”¨ã€‚",
    "fb_post": "æ ¹æ“šã€ŠComparative biochemistry and physiology. Part D, Genomics & proteomicsã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ€ å˜¿ï¼Œå¤§å®¶çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„é£²é£Ÿä¸åƒ…èƒ½è®“æˆ‘å€‘å¥åº·ï¼Œé‚„å¯èƒ½å¹«åŠ©æˆ‘å€‘æŠµæŠ—ç’°å¢ƒä¸­çš„æ¯’ç´ ï¼æœ€è¿‘æœ‰ä¸€é …æœ‰è¶£çš„ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ é€™ç¨®ä¾†è‡ªé’èŠ±æ¤°èœçš„æˆåˆ†ï¼Œå°æ–¼ä¿è­·è‚è‡Ÿå’Œå…ç–«ç³»çµ±æœ‰è‘—ä¸å°çš„æ½›åŠ›ï¼\n\né€™é …ç ”ç©¶ä¸»è¦é—œæ³¨ä¸‰è‹¯éŒ«ï¼Œä¸€ç¨®ç’°å¢ƒæ±¡æŸ“ç‰©ï¼Œå°é­šé¡å¥åº·çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å€‘å°‡é¯‰é­šåˆ†æˆä¸‰çµ„ï¼Œè§€å¯Ÿåœ¨ä¸åŒæƒ…æ³ä¸‹çš„å¥åº·ç‹€æ³ã€‚å…¶ä¸­ä¸€çµ„é­šæ¥å—äº†ä¸‰è‹¯éŒ«çš„å½±éŸ¿ï¼Œå¦ä¸€çµ„å‰‡åŒæ™‚çµ¦äºˆäº†è˜¿è””ç¡«ç´ ã€‚\n\nçµæœé¡¯ç¤ºï¼Œä¸‰è‹¯éŒ«ç¢ºå¯¦æœƒå°è‚è‡Ÿå’Œå…ç–«ç³»çµ±é€ æˆå‚·å®³ï¼Œä½†è˜¿è””ç¡«ç´ çš„è£œå……èƒ½æœ‰æ•ˆæ¸›å°‘é€™äº›æå®³ï¼Œç”šè‡³æ”¹å–„äº†è„‚è³ªä»£è¬ï¼é€™æ„å‘³è‘—ï¼Œé€éé£²é£Ÿä¸­çš„æŸäº›æˆåˆ†ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ¸›å°‘ç’°å¢ƒæ¯’ç´ å°å¥åº·çš„å½±éŸ¿ã€‚\n\nğŸ” ç ”ç©¶é‡é»ï¼š  \n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼ä¿è­·è‚è‡Ÿå’Œå…ç–«ç³»çµ±ã€‚  \n2. ä¸‰è‹¯éŒ«æœƒå½±éŸ¿é­šé¡çš„å¥åº·ï¼Œä½†è˜¿è””ç¡«ç´ èƒ½æ¸›å°‘é€™äº›å½±éŸ¿ã€‚  \n3. å¥åº·çš„é£²é£Ÿç¿’æ…£å¯èƒ½å¹«åŠ©æˆ‘å€‘æŠµæŠ—ç’°å¢ƒä¸­çš„æ¯’ç´ ï¼",
    "image_prompt": "Create a flat design infographic showing the experiment and main results of a study on the protective effects of sulforaphane from broccoli. Include simplified illustrations of fish as experimental subjects, arrows or flow lines indicating the steps of the experiment (control group, exposure to tributyltin, and exposure to both tributyltin and sulforaphane). Add symbols representing sulforaphane and a section highlighting the main results, such as improved liver function and immune response.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "è‚æ¯’æ€§ Hepatotoxicity",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41027171/"
  },
  {
    "id": "40714240",
    "title_en": "Gut microbiota-related glutathione metabolism is key mechanism for sulforaphane ameliorating ulcerative colitis.",
    "pub_date": "2025 Dec",
    "journal": "The Journal of nutritional biochemistry",
    "abstract_en": "Gut barrier dysfunction is associated with dysbiosis of the gut microbiota and its metabolites, which is closely linked to the pathogenesis of ulcerative colitis (UC). Recent studies have demonstrated that Sulforaphane (SFN) exerts beneficial effects on UC. However, the role of the gut microbiota and microbial metabolism in the anti-UC mechanisms of SFN remains inadequately understood. In this study, we observed that SFN administration significantly improved the pathological phenotype, restored gut barrier integrity, and reduced colon inflammation in dextran sulfate sodium (DSS)-induced colitis mice. Gut microbiota analysis illustrated that SFN administration rebalances the alterations in gut microbiota composition, including genera such as Turicibacter, Lactobacillus and Bacteroides, in DSS-induced mice. Furthermore, untargeted metabolomics analysis indicated that the levels of microbial arachidonic acid metabolism, as well as the metabolism of alanine, aspartate, and glutamate, and glutathione metabolism in the gastrointestinal tract, were significantly altered in DSS-induced mice. Interestingly, SFN treatment significantly restore the alterations in glutathione metabolism and the levels of associated metabolites. Additionally, we observed that the MAPK/NF-ÎºB signaling pathway, regulated by glutathione metabolism, was inhibited in the colon of DSS-induced mice following SFN treatment. Collectively, these results suggest that SFN can alleviate DSS-induced colitis in mice by restoring dysregulated gut microbiota and glutathione metabolism, thereby modulating the MAPK/NF-ÎºB signaling pathway, enhancing intestinal barrier function and reducing colonic inflammation. Importantly, our findings elucidate a novel mechanism by which SFN improves gut barrier function, highlighting its potential to advance the development of SFN-derived therapeutics for the clinical management of colitis.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›æœ‰é—œå¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°æ½°ç˜æ€§çµè…¸ç‚ï¼ˆUCï¼‰é€™ç¨®ç–¾ç—…ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè…¸é“å±éšœåŠŸèƒ½çš„å¤±èª¿èˆ‡è…¸é“å¾®ç”Ÿç‰©ç¾¤çš„è®ŠåŒ–æœ‰é—œï¼Œè€Œé€™äº›è®ŠåŒ–å¯èƒ½æœƒå½±éŸ¿ç–¾ç—…çš„ç™¼å±•ã€‚é€éæ”¹å–„è…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆå’ŒåŠŸèƒ½ï¼Œæˆ–è¨±èƒ½å¤ å¹«åŠ©æ¸›è¼•æ½°ç˜æ€§çµè…¸ç‚çš„ç—‡ç‹€ï¼Œé€™å°æ–¼æœªä¾†çš„æ²»ç™‚æ–¹æ³•é–‹ç™¼å…·æœ‰é‡è¦æ„ç¾©ã€‚",
    "para2": "æœ¬ç ”ç©¶ä¸»è¦é—œæ³¨è˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰åœ¨æ½°ç˜æ€§çµè…¸ç‚ä¸­çš„ä½œç”¨ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•å½±éŸ¿è…¸é“å¾®ç”Ÿç‰©ç¾¤å’Œå¾®ç”Ÿç‰©ä»£è¬ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•æ”¹å–„è…¸é“å±éšœåŠŸèƒ½ï¼Œä¸¦æ¸›å°‘ç”±æ–¼è…¸é“å¾®ç”Ÿç‰©å¤±èª¿æ‰€å¼•èµ·çš„ç‚ç—‡åæ‡‰ã€‚é€™å€‹å•é¡Œçš„æ¢è¨å°æ–¼é–‹ç™¼æ–°çš„æ²»ç™‚ç­–ç•¥éå¸¸é‡è¦ï¼Œå› ç‚ºç›®å‰å°æ–¼æ½°ç˜æ€§çµè…¸ç‚çš„æ²»ç™‚ä»ç„¶æœ‰é™ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†èª˜å°æ½°ç˜æ€§çµè…¸ç‚çš„å°é¼ æ¨¡å‹ï¼Œé€™äº›å°é¼ æ˜¯é€šéçµ¦äºˆç¡«é…¸å³æ—‹ç³–ï¼ˆDSSï¼‰ä¾†æ¨¡æ“¬ç—…ç†ç‹€æ…‹ã€‚ç ”ç©¶åœ˜éšŠçµ¦äºˆå°é¼ è˜¿è””ç¡«ç´ ï¼Œä¸¦è§€å¯Ÿå…¶å°è…¸é“ç—…ç†è¡¨ç¾çš„å½±éŸ¿ã€‚ä»–å€‘åˆ†æäº†è…¸é“å¾®ç”Ÿç‰©ç¾¤çš„çµ„æˆè®ŠåŒ–ï¼Œä»¥åŠç›¸é—œçš„ä»£è¬ç‰©è³ªï¼Œä¸¦è©•ä¼°äº†è…¸é“å±éšœçš„å®Œæ•´æ€§å’Œç‚ç—‡ç¨‹åº¦ã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ çš„çµ¦äºˆé¡¯è‘—æ”¹å–„äº†å°é¼ çš„ç—…ç†è¡¨ç¾ï¼Œæ¢å¾©äº†è…¸é“å±éšœçš„å®Œæ•´æ€§ï¼Œä¸¦æ¸›å°‘äº†çµè…¸çš„ç‚ç—‡ã€‚æ­¤å¤–ï¼Œè…¸é“å¾®ç”Ÿç‰©ç¾¤çš„åˆ†æé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ é‡æ–°å¹³è¡¡è…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆï¼Œä¸¦ä¸”åœ¨ä»£è¬ç‰©çš„è®ŠåŒ–ä¸Šä¹Ÿæœ‰é¡¯è‘—çš„å½±éŸ¿ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éèª¿ç¯€è…¸é“å¾®ç”Ÿç‰©å’Œä»£è¬éç¨‹ä¾†æ”¹å–„è…¸é“åŠŸèƒ½ï¼Œä¸¦æ¸›è¼•æ½°ç˜æ€§çµè…¸ç‚çš„ç—‡ç‹€ï¼Œé€™ç‚ºæœªä¾†çš„è‡¨åºŠæ‡‰ç”¨æä¾›äº†æ–°çš„æ€è·¯ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›æœ‰é—œå¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°æ½°ç˜æ€§çµè…¸ç‚ï¼ˆUCï¼‰é€™ç¨®ç–¾ç—…ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè…¸é“å±éšœåŠŸèƒ½çš„å¤±èª¿èˆ‡è…¸é“å¾®ç”Ÿç‰©ç¾¤çš„è®ŠåŒ–æœ‰é—œï¼Œè€Œé€™äº›è®ŠåŒ–å¯èƒ½æœƒå½±éŸ¿ç–¾ç—…çš„ç™¼å±•ã€‚é€éæ”¹å–„è…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆå’ŒåŠŸèƒ½ï¼Œæˆ–è¨±èƒ½å¤ å¹«åŠ©æ¸›è¼•æ½°ç˜æ€§çµè…¸ç‚çš„ç—‡ç‹€ï¼Œé€™å°æ–¼æœªä¾†çš„æ²»ç™‚æ–¹æ³•é–‹ç™¼å…·æœ‰é‡è¦æ„ç¾©ã€‚\n\næœ¬ç ”ç©¶ä¸»è¦é—œæ³¨è˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰åœ¨æ½°ç˜æ€§çµè…¸ç‚ä¸­çš„ä½œç”¨ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•å½±éŸ¿è…¸é“å¾®ç”Ÿç‰©ç¾¤å’Œå¾®ç”Ÿç‰©ä»£è¬ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•æ”¹å–„è…¸é“å±éšœåŠŸèƒ½ï¼Œä¸¦æ¸›å°‘ç”±æ–¼è…¸é“å¾®ç”Ÿç‰©å¤±èª¿æ‰€å¼•èµ·çš„ç‚ç—‡åæ‡‰ã€‚é€™å€‹å•é¡Œçš„æ¢è¨å°æ–¼é–‹ç™¼æ–°çš„æ²»ç™‚ç­–ç•¥éå¸¸é‡è¦ï¼Œå› ç‚ºç›®å‰å°æ–¼æ½°ç˜æ€§çµè…¸ç‚çš„æ²»ç™‚ä»ç„¶æœ‰é™ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†èª˜å°æ½°ç˜æ€§çµè…¸ç‚çš„å°é¼ æ¨¡å‹ï¼Œé€™äº›å°é¼ æ˜¯é€šéçµ¦äºˆç¡«é…¸å³æ—‹ç³–ï¼ˆDSSï¼‰ä¾†æ¨¡æ“¬ç—…ç†ç‹€æ…‹ã€‚ç ”ç©¶åœ˜éšŠçµ¦äºˆå°é¼ è˜¿è””ç¡«ç´ ï¼Œä¸¦è§€å¯Ÿå…¶å°è…¸é“ç—…ç†è¡¨ç¾çš„å½±éŸ¿ã€‚ä»–å€‘åˆ†æäº†è…¸é“å¾®ç”Ÿç‰©ç¾¤çš„çµ„æˆè®ŠåŒ–ï¼Œä»¥åŠç›¸é—œçš„ä»£è¬ç‰©è³ªï¼Œä¸¦è©•ä¼°äº†è…¸é“å±éšœçš„å®Œæ•´æ€§å’Œç‚ç—‡ç¨‹åº¦ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ çš„çµ¦äºˆé¡¯è‘—æ”¹å–„äº†å°é¼ çš„ç—…ç†è¡¨ç¾ï¼Œæ¢å¾©äº†è…¸é“å±éšœçš„å®Œæ•´æ€§ï¼Œä¸¦æ¸›å°‘äº†çµè…¸çš„ç‚ç—‡ã€‚æ­¤å¤–ï¼Œè…¸é“å¾®ç”Ÿç‰©ç¾¤çš„åˆ†æé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ é‡æ–°å¹³è¡¡è…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆï¼Œä¸¦ä¸”åœ¨ä»£è¬ç‰©çš„è®ŠåŒ–ä¸Šä¹Ÿæœ‰é¡¯è‘—çš„å½±éŸ¿ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éèª¿ç¯€è…¸é“å¾®ç”Ÿç‰©å’Œä»£è¬éç¨‹ä¾†æ”¹å–„è…¸é“åŠŸèƒ½ï¼Œä¸¦æ¸›è¼•æ½°ç˜æ€§çµè…¸ç‚çš„ç—‡ç‹€ï¼Œé€™ç‚ºæœªä¾†çš„è‡¨åºŠæ‡‰ç”¨æä¾›äº†æ–°çš„æ€è·¯ã€‚",
    "fb_post": "æ ¹æ“šã€ŠThe Journal of nutritional biochemistryã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿåƒè˜¿è””å¯èƒ½ä¸åªè®“ä½ èº«é«”å¥åº·ï¼Œé‚„èƒ½å¹«åŠ©æ”¹å–„ä¸€äº›è…¸é“ç–¾ç—…ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶å°ˆæ³¨æ–¼æ½°ç˜æ€§çµè…¸ç‚ï¼ˆUCï¼‰ï¼Œé€™æ˜¯ä¸€ç¨®å½±éŸ¿è…¸é“çš„ç–¾ç—…ï¼Œè®“äººæ„Ÿåˆ°ä¸é©ã€‚ç ”ç©¶ç™¼ç¾ï¼Œè…¸é“çš„å¥åº·èˆ‡æˆ‘å€‘é«”å…§çš„å¾®ç”Ÿç‰©ç¾¤æœ‰å¾ˆå¤§é—œä¿‚ï¼Œè€Œè˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰é€™å€‹æˆåˆ†ä¼¼ä¹èƒ½å¹«åŠ©æ”¹å–„é€™ä¸€åˆ‡ã€‚  \n  \né€™é …ç ”ç©¶ä¸­ï¼Œç§‘å­¸å®¶å€‘ä½¿ç”¨å°é¼ æ¨¡å‹ä¾†æ¨¡æ“¬æ½°ç˜æ€§çµè…¸ç‚çš„æƒ…æ³ï¼Œä¸¦çµ¦äºˆå®ƒå€‘è˜¿è””ç¡«ç´ ï¼Œè§€å¯Ÿå®ƒå€‘çš„è…¸é“è®ŠåŒ–ã€‚ä»–å€‘ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ ä¸åƒ…èƒ½æ¢å¾©è…¸é“çš„å¥åº·ï¼Œé‚„èƒ½æ¸›å°‘ç‚ç—‡ï¼Œè®“è…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆè®Šå¾—æ›´å¹³è¡¡ã€‚é€™äº›çµæœè®“äººæŒ¯å¥®ï¼Œå› ç‚ºå®ƒå€‘ç‚ºæœªä¾†çš„æ²»ç™‚æ–¹æ³•æä¾›äº†æ–°çš„æ€è·¯ï¼  \n  \n**é‡é»å›é¡§ï¼š**  \n- è˜¿è””ç¡«ç´ æœ‰åŠ©æ–¼æ”¹å–„æ½°ç˜æ€§çµè…¸ç‚çš„ç—‡ç‹€  \n- ç ”ç©¶é¡¯ç¤ºå®ƒèƒ½æ¢å¾©è…¸é“å±éšœçš„å®Œæ•´æ€§  \n- é€éèª¿æ•´è…¸é“å¾®ç”Ÿç‰©ï¼Œå¯èƒ½æ¸›å°‘ç‚ç—‡åæ‡‰  \n  \nè®“æˆ‘å€‘ä¸€èµ·æœŸå¾…æœªä¾†æ›´å¤šçš„å¥åº·ç™¼ç¾å§ï¼",
    "image_prompt": "Create a flat design infographic that explains the experiment and main results of a study on sulforaphane (SFN) and ulcerative colitis. The image should have a light background with soft colors. Include symbols for broccoli or sulforaphane, simplified representations of experimental subjects (like mice or cells), and arrows or flow lines to indicate the steps of the experiment. There should also be a section labeled 'Main Results' that highlights protective effects and changes observed in the study.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "æ½°ç˜æ€§çµè…¸ç‚ Ulcerative Colitis",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40714240/"
  },
  {
    "id": "41291551",
    "title_en": "Nanoliposome-mediated delivery of sulforaphane suppresses Ehrlich ascites carcinoma growth and improves liver integrity and therapeutic outcomes in a murine model.",
    "pub_date": "2025 Nov",
    "journal": "BMC cancer",
    "abstract_en": "The anticancer activity of sulforaphane (SFN) involves multiple signaling pathways, but its mechanism against Ehrlich Ascites Carcinoma (EAC) in mice remains unclear. This study evaluated the antitumor efficacy of SFN-loaded nanoliposomes (SFN-NLPs). Ninety female Swiss albino mice were allocated into six groups: (1) untreated control, (2) SFN alone (50Â mg/kg/day, orally), (3) SFN-NLPs alone (50Â mg/kg/day, orally), (4) EAC-bearing mice (2.5â€‰Ã—â€‰10â¶ cells, intraperitoneally), (5) EACâ€‰+â€‰SFN, and (6) EACâ€‰+â€‰SFN-NLPs. with treatment lasting 20 days in tumor-bearing groups. SFN-NLPs significantly reduced EAC tumor volume, viable cell count, and tumor marker levels, while prolonging survival more effectively than free SFN. SFN-NLPs modulated key molecular pathways by suppressing inflammatory gene expression (NF-ÎºB, COX-2) and shifting the balance toward apoptosis via upregulation of TP53 and Bax and concomitant downregulation of Bcl-2. Regarding liver integrity, SFN-NLPs significantly reduced DNA fragmentation and hepatic oxidative stress, while modulating systemic inflammation through reductions in total leukocyte count, TNF-Î±, and C-reactive protein. In addition, SFN-NLPs conferred superior protection against both histopathological and ultrastructural liver damage. Furthermore, molecular docking analysis suggested plausible interactions of SFN with proteins associated with antioxidant defense, inflammation regulation, and apoptosis, indicating a potential modulatory role. In conclusion, nanoformulated SFN enhances stability, augments efficacy, and facilitates sustained release and bioavailability, thereby strengthening its antitumor, anti-inflammatory, antioxidant, and pro-apoptotic effects in EAC-bearing mice. These findings highlight the potential of SFN-NLPs to suppress tumor growth by modulating inflammatory and apoptotic gene expression while preserving liver integrity.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™Œæ–¹é¢ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰å¯èƒ½é€éèª¿ç¯€å¤šæ¢ä¿¡è™Ÿé€šè·¯ä¾†å°æŠ—ç™Œç—‡ï¼Œé€™æ„å‘³è‘—å®ƒæœ‰æ½›åŠ›æˆç‚ºç™Œç—‡æ²»ç™‚çš„ä¸€éƒ¨åˆ†ã€‚ç‰¹åˆ¥æ˜¯é‡å°æŸäº›ç™Œç—‡é¡å‹ï¼Œåƒæ˜¯Ehrlichè…¹æ°´ç™Œï¼ˆEACï¼‰ï¼Œè˜¿è””ç¡«ç´ çš„æ•ˆæœå¯èƒ½æœƒæ›´åŠ æ˜é¡¯ã€‚é€™äº›ç™¼ç¾å¯èƒ½æœƒä¿ƒä½¿æœªä¾†çš„ç ”ç©¶é€²ä¸€æ­¥æ¢ç´¢è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡é é˜²å’Œæ²»ç™‚ä¸­çš„æ‡‰ç”¨ï¼Œä¸¦ä¸”å¯èƒ½ç‚ºé–‹ç™¼æ–°å‹æŠ—ç™Œè—¥ç‰©æä¾›æ–°çš„æ€è·¯ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å°é¼ Ehrlichè…¹æ°´ç™Œï¼ˆEACï¼‰ä¸­çš„æŠ—è…«ç˜¤æ•ˆæœã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ çš„æŠ—ç™Œæ©Ÿåˆ¶ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•å½±éŸ¿è…«ç˜¤çš„ç”Ÿé•·å’Œç™¼å±•ã€‚ç ”ç©¶ä¸­ä½¿ç”¨äº†è˜¿è””ç¡«ç´ è² è¼‰çš„ç´ç±³è„‚è³ªé«”ï¼ˆSFN-NLPsï¼‰ï¼Œä¸¦å°‡å…¶èˆ‡å–®ç¨ä½¿ç”¨çš„è˜¿è””ç¡«ç´ é€²è¡Œæ¯”è¼ƒï¼Œä»¥è©•ä¼°å…¶æ•ˆæœã€‚é€™é …ç ”ç©¶ä¸åƒ…é—œæ³¨è˜¿è””ç¡«ç´ çš„æŠ—è…«ç˜¤èƒ½åŠ›ï¼Œé‚„æ¢è¨äº†å…¶å°è‚è‡Ÿå¥åº·çš„å½±éŸ¿ï¼Œé€™å°æ–¼æ•´é«”å¥åº·éå¸¸é‡è¦ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†90éš»é›Œæ€§ç‘å£«ç™½é¼ ï¼Œå°‡å®ƒå€‘åˆ†ç‚ºå…­çµ„ï¼Œåˆ†åˆ¥æ¥å—ä¸åŒçš„è™•ç†ã€‚é€™äº›çµ„åˆ¥åŒ…æ‹¬æœªè™•ç†çš„å°ç…§çµ„ã€å–®ç¨ä½¿ç”¨è˜¿è””ç¡«ç´ çš„çµ„åˆ¥ã€å–®ç¨ä½¿ç”¨è˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”çš„çµ„åˆ¥ã€EACè…«ç˜¤å°é¼ çµ„åˆ¥ï¼Œä»¥åŠå…©å€‹çµåˆEACèˆ‡è˜¿è””ç¡«ç´ æˆ–è˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”çš„çµ„åˆ¥ã€‚æ‰€æœ‰çš„æ²»ç™‚æŒçºŒäº†20å¤©ï¼Œç ”ç©¶è€…è§€å¯Ÿäº†è…«ç˜¤é«”ç©ã€å­˜æ´»ç‡ã€åŸºå› è¡¨é”ç­‰å¤šå€‹æŒ‡æ¨™ï¼Œä»¥è©•ä¼°æ²»ç™‚çš„æ•ˆæœã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”åœ¨æ¸›å°‘EACè…«ç˜¤é«”ç©ã€æ´»ç´°èƒæ•¸é‡å’Œè…«ç˜¤æ¨™è¨˜ç‰©æ°´å¹³æ–¹é¢ï¼Œæ•ˆæœé¡¯è‘—å„ªæ–¼å–®ç¨ä½¿ç”¨çš„è˜¿è””ç¡«ç´ ã€‚æ­¤å¤–ï¼Œé€™äº›ç´ç±³è„‚è³ªé«”é‚„èƒ½æœ‰æ•ˆå»¶é•·å°é¼ çš„å­˜æ´»æ™‚é–“ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”èƒ½èª¿ç¯€é—œéµçš„åˆ†å­é€šè·¯ï¼ŒæŠ‘åˆ¶ç‚ç—‡åŸºå› çš„è¡¨é”ï¼Œä¸¦ä¿ƒé€²ç´°èƒå‡‹äº¡ã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”åœ¨æŠ—è…«ç˜¤ã€æŠ—ç‚å’ŒæŠ—æ°§åŒ–æ–¹é¢çš„æ½›åŠ›ï¼Œä¸¦ä¸”å°è‚è‡Ÿçš„ä¿è­·ä½œç”¨ä¹Ÿç›¸ç•¶æ˜é¡¯ï¼Œé€™äº›éƒ½ç‚ºæœªä¾†çš„ç ”ç©¶æä¾›äº†é‡è¦çš„åƒè€ƒã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™Œæ–¹é¢ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰å¯èƒ½é€éèª¿ç¯€å¤šæ¢ä¿¡è™Ÿé€šè·¯ä¾†å°æŠ—ç™Œç—‡ï¼Œé€™æ„å‘³è‘—å®ƒæœ‰æ½›åŠ›æˆç‚ºç™Œç—‡æ²»ç™‚çš„ä¸€éƒ¨åˆ†ã€‚ç‰¹åˆ¥æ˜¯é‡å°æŸäº›ç™Œç—‡é¡å‹ï¼Œåƒæ˜¯Ehrlichè…¹æ°´ç™Œï¼ˆEACï¼‰ï¼Œè˜¿è””ç¡«ç´ çš„æ•ˆæœå¯èƒ½æœƒæ›´åŠ æ˜é¡¯ã€‚é€™äº›ç™¼ç¾å¯èƒ½æœƒä¿ƒä½¿æœªä¾†çš„ç ”ç©¶é€²ä¸€æ­¥æ¢ç´¢è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡é é˜²å’Œæ²»ç™‚ä¸­çš„æ‡‰ç”¨ï¼Œä¸¦ä¸”å¯èƒ½ç‚ºé–‹ç™¼æ–°å‹æŠ—ç™Œè—¥ç‰©æä¾›æ–°çš„æ€è·¯ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å°é¼ Ehrlichè…¹æ°´ç™Œï¼ˆEACï¼‰ä¸­çš„æŠ—è…«ç˜¤æ•ˆæœã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ çš„æŠ—ç™Œæ©Ÿåˆ¶ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•å½±éŸ¿è…«ç˜¤çš„ç”Ÿé•·å’Œç™¼å±•ã€‚ç ”ç©¶ä¸­ä½¿ç”¨äº†è˜¿è””ç¡«ç´ è² è¼‰çš„ç´ç±³è„‚è³ªé«”ï¼ˆSFN-NLPsï¼‰ï¼Œä¸¦å°‡å…¶èˆ‡å–®ç¨ä½¿ç”¨çš„è˜¿è””ç¡«ç´ é€²è¡Œæ¯”è¼ƒï¼Œä»¥è©•ä¼°å…¶æ•ˆæœã€‚é€™é …ç ”ç©¶ä¸åƒ…é—œæ³¨è˜¿è””ç¡«ç´ çš„æŠ—è…«ç˜¤èƒ½åŠ›ï¼Œé‚„æ¢è¨äº†å…¶å°è‚è‡Ÿå¥åº·çš„å½±éŸ¿ï¼Œé€™å°æ–¼æ•´é«”å¥åº·éå¸¸é‡è¦ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†90éš»é›Œæ€§ç‘å£«ç™½é¼ ï¼Œå°‡å®ƒå€‘åˆ†ç‚ºå…­çµ„ï¼Œåˆ†åˆ¥æ¥å—ä¸åŒçš„è™•ç†ã€‚é€™äº›çµ„åˆ¥åŒ…æ‹¬æœªè™•ç†çš„å°ç…§çµ„ã€å–®ç¨ä½¿ç”¨è˜¿è””ç¡«ç´ çš„çµ„åˆ¥ã€å–®ç¨ä½¿ç”¨è˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”çš„çµ„åˆ¥ã€EACè…«ç˜¤å°é¼ çµ„åˆ¥ï¼Œä»¥åŠå…©å€‹çµåˆEACèˆ‡è˜¿è””ç¡«ç´ æˆ–è˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”çš„çµ„åˆ¥ã€‚æ‰€æœ‰çš„æ²»ç™‚æŒçºŒäº†20å¤©ï¼Œç ”ç©¶è€…è§€å¯Ÿäº†è…«ç˜¤é«”ç©ã€å­˜æ´»ç‡ã€åŸºå› è¡¨é”ç­‰å¤šå€‹æŒ‡æ¨™ï¼Œä»¥è©•ä¼°æ²»ç™‚çš„æ•ˆæœã€‚\n\nä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”åœ¨æ¸›å°‘EACè…«ç˜¤é«”ç©ã€æ´»ç´°èƒæ•¸é‡å’Œè…«ç˜¤æ¨™è¨˜ç‰©æ°´å¹³æ–¹é¢ï¼Œæ•ˆæœé¡¯è‘—å„ªæ–¼å–®ç¨ä½¿ç”¨çš„è˜¿è””ç¡«ç´ ã€‚æ­¤å¤–ï¼Œé€™äº›ç´ç±³è„‚è³ªé«”é‚„èƒ½æœ‰æ•ˆå»¶é•·å°é¼ çš„å­˜æ´»æ™‚é–“ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”èƒ½èª¿ç¯€é—œéµçš„åˆ†å­é€šè·¯ï¼ŒæŠ‘åˆ¶ç‚ç—‡åŸºå› çš„è¡¨é”ï¼Œä¸¦ä¿ƒé€²ç´°èƒå‡‹äº¡ã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”åœ¨æŠ—è…«ç˜¤ã€æŠ—ç‚å’ŒæŠ—æ°§åŒ–æ–¹é¢çš„æ½›åŠ›ï¼Œä¸¦ä¸”å°è‚è‡Ÿçš„ä¿è­·ä½œç”¨ä¹Ÿç›¸ç•¶æ˜é¡¯ï¼Œé€™äº›éƒ½ç‚ºæœªä¾†çš„ç ”ç©¶æä¾›äº†é‡è¦çš„åƒè€ƒã€‚",
    "fb_post": "æ ¹æ“šã€ŠBMC cancerã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ±ä½ çŸ¥é“å—ï¼Ÿæœ‰äº›é£Ÿç‰©è£¡çš„æˆåˆ†å¯èƒ½å°æˆ‘å€‘çš„å¥åº·æœ‰é©šäººçš„å½±éŸ¿ï¼æœ€è¿‘ä¸€é …ç ”ç©¶èšç„¦åœ¨è˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰é€™å€‹å¤©ç„¶æˆåˆ†ï¼Œç™¼ç¾å®ƒåœ¨æŠ—ç™Œæ–¹é¢æœ‰è‘—ä¸å°çš„æ½›åŠ›ã€‚é€™é …ç ”ç©¶ä¸»è¦é‡å°å°é¼ çš„Ehrlichè…¹æ°´ç™Œï¼ˆEACï¼‰ï¼Œå¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿è…«ç˜¤çš„ç”Ÿé•·ã€‚ \n\nç ”ç©¶è€…å€‘ä½¿ç”¨äº†è˜¿è””ç¡«ç´ è² è¼‰çš„ç´ç±³è„‚è³ªé«”ï¼ˆé€™æ˜¯ä¸€ç¨®èƒ½æ›´å¥½é‡‹æ”¾æˆåˆ†çš„å°é¡†ç²’ï¼‰ï¼Œä¸¦èˆ‡å–®ç¨çš„è˜¿è””ç¡«ç´ é€²è¡Œæ¯”è¼ƒã€‚å¯¦é©—ä¸­ï¼Œ90éš»å°é¼ è¢«åˆ†æˆä¸åŒçµ„åˆ¥ï¼Œæ¥å—äº†ä¸åŒçš„è™•ç†ï¼Œä¸¦åœ¨20å¤©å…§è§€å¯Ÿå®ƒå€‘çš„è…«ç˜¤è®ŠåŒ–å’Œå­˜æ´»æƒ…æ³ã€‚ \n\nçµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”åœ¨æ¸›å°‘è…«ç˜¤é«”ç©å’Œæé«˜å­˜æ´»ç‡æ–¹é¢ï¼Œè¡¨ç¾å¾—æ¯”å–®ç¨ä½¿ç”¨çš„è˜¿è””ç¡«ç´ è¦å¥½å¾—å¤šï¼é€™ä¸åƒ…è®“æˆ‘å€‘çœ‹åˆ°è˜¿è””ç¡«ç´ åœ¨æŠ—è…«ç˜¤å’ŒæŠ—ç‚æ–¹é¢çš„æ½›åŠ›ï¼Œé‚„é¡¯ç¤ºå®ƒå°è‚è‡Ÿçš„ä¿è­·ä½œç”¨ä¹Ÿç›¸ç•¶æ˜é¡¯ã€‚ \n\nğŸ” ä¸»è¦é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼å°æŠ—æŸäº›ç™Œç—‡ã€‚\n2. ä½¿ç”¨ç´ç±³è„‚è³ªé«”èƒ½æé«˜è˜¿è””ç¡«ç´ çš„æ•ˆæœã€‚\n3. è˜¿è””ç¡«ç´ å°è‚è‡Ÿæœ‰ä¿è­·ä½œç”¨ï¼Œå€¼å¾—é€²ä¸€æ­¥ç ”ç©¶ï¼",
    "image_prompt": "Create an infographic that explains the experimental process and main results of a study on sulforaphane (SFN). Use a flat design style with a white or light-colored background and soft colors. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects like mice or cells, arrows or flow lines indicating the steps of the experiment, and a section labeled 'Main Results' highlighting protective effects and changes observed.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "Ehrlichè…¹æ°´ç™Œ Ehrlich Ascites Carcinoma",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41291551/"
  },
  {
    "id": "41135276",
    "title_en": "Sulforaphane targets STAT3-CKMT2-AS1 to suppress gastric cancer via PSMB8 downregulation and AIMP1 stabilization.",
    "pub_date": "2025 Nov",
    "journal": "Phytomedicine : international journal of phytotherapy and phytopharmacology",
    "abstract_en": "Gastric cancer (GC) remains one of the most formidable threats to human health with limited therapeutic options. Sulforaphane (SFN), a natural isothiocyanate, exhibits antitumor activity; however, its molecular mechanisms of action in GC remain unclear. To investigate the mechanism of action of SFN in gastric cancer. The antitumor effects of SFN were comprehensively assessed in vitro and in vivo, followed by sequencing analysis to identify the targeted lncRNA. Subsequently, the mechanical verification experiments were carried out to determine the upstream and downstream regulatory components involved in the STAT3-CKMT2-AS1 regulatory axis. We demonstrated that SFN strongly inhibits GC. SFN downregulated the expression of the lncRNA CKMT2-AS1. Elevated expression levels of CKMT2-AS1 in human GC tissues are correlated with poor patient survival rates. Knockdown of CKMT2-AS1 significantly inhibited GC proliferation and migration both in vivo and in vitro, whereas CKMT2-AS1 overexpression enhanced malignant phenotypes. Mechanistically, we identified STAT3 as the transcriptional activator driving CKMT2-AS1 expression, with SFN directly binding to, and inhibiting, STAT3 phosphorylation to decrease its transcriptional activity. Interestingly, cytoplasmic CKMT2-AS1 competitively adsorbs miR-451a, leading to the expression of PSMB8, ultimately promoting the progression of the malignant phenotype of GC. Moreover, we discovered that CKMT2-AS1 directly binds to the RNA-binding protein (RBP) AIMP1, promoting ubiquitination-mediated degradation of AIMP1 protein via the proteasomal pathway. The highly expressed AIMP1 protein, in turn, inhibits the phosphorylation of the PI3K/AKT signaling pathway, which is hyperactivated in virtually all solid tumors. Our findings not only elucidate a novel SFN-mediated tumor-suppressive mechanism via the STAT3/CKMT2-AS1 regulatory axis, but also validate CKMT2-AS1 as a promising therapeutic target for GC intervention.",
    "para1": "èƒƒç™Œä»ç„¶æ˜¯å°äººé¡å¥åº·çš„ä¸€å¤§å¨è„…ï¼Œä¸”ç›®å‰å¯ç”¨çš„æ²»ç™‚é¸æ“‡æœ‰é™ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ åœ¨èƒƒç™Œä¸­çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œå¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚æä¾›æ–°çš„æ€è·¯ã€‚é€éäº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·å’Œæ“´æ•£ï¼Œæˆ–è¨±èƒ½å¹«åŠ©æˆ‘å€‘æ‰¾åˆ°æ›´æœ‰æ•ˆçš„é é˜²å’Œæ²»ç™‚èƒƒç™Œçš„æ–¹æ³•ï¼Œé€²è€Œæ”¹å–„æ‚£è€…çš„ç”Ÿå­˜ç‡ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨èƒƒç™Œä¸­çš„æŠ—è…«ç˜¤ä½œç”¨åŠå…¶åˆ†å­æ©Ÿåˆ¶ã€‚ç ”ç©¶äººå“¡å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿èƒƒç™Œç´°èƒçš„è¡Œç‚ºï¼Œä¸¦æ‰¾å‡ºå…¶ä½œç”¨çš„å…·é«”åˆ†å­è·¯å¾‘ï¼Œé€™å°æ–¼é–‹ç™¼æ–°çš„æ²»ç™‚ç­–ç•¥è‡³é—œé‡è¦ã€‚",
    "para3": "ç ”ç©¶åœ˜éšŠé€²è¡Œäº†é«”å…§å’Œé«”å¤–çš„å¯¦é©—ï¼Œä»¥å…¨é¢è©•ä¼°è˜¿è””ç¡«ç´ çš„æŠ—è…«ç˜¤æ•ˆæœã€‚é¦–å…ˆï¼Œä»–å€‘é€²è¡Œäº†åŸºå› æ¸¬åºåˆ†æï¼Œä»¥è­˜åˆ¥ç›®æ¨™é•·éˆéç·¨ç¢¼RNAï¼ˆlncRNAï¼‰ã€‚æ¥è‘—ï¼Œé€²è¡Œäº†æ©Ÿåˆ¶é©—è­‰å¯¦é©—ï¼Œä»¥ç¢ºå®šåœ¨STAT3-CKMT2-AS1èª¿æ§è»¸ä¸­æ¶‰åŠçš„ä¸Šæ¸¸å’Œä¸‹æ¸¸èª¿æ§æˆåˆ†ï¼Œé€™æ¨£çš„è¨­è¨ˆèƒ½å¤ æ·±å…¥äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¼·çƒˆæŠ‘åˆ¶èƒƒç™Œçš„ç”Ÿé•·ï¼Œä¸¦é™ä½lncRNA CKMT2-AS1çš„è¡¨é”ã€‚CKMT2-AS1åœ¨èƒƒç™Œçµ„ç¹”ä¸­çš„é«˜è¡¨é”èˆ‡æ‚£è€…çš„ç”Ÿå­˜ç‡è¼ƒä½ç›¸é—œã€‚ç•¶CKMT2-AS1è¢«æŠ‘åˆ¶æ™‚ï¼Œèƒƒç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»é¡¯è‘—æ¸›å°‘ï¼Œè€ŒCKMT2-AS1çš„éåº¦è¡¨é”å‰‡æœƒåŠ åŠ‡è…«ç˜¤çš„æƒ¡æ€§ç‰¹å¾µã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„ç™¼ç¾STAT3æ˜¯é©…å‹•CKMT2-AS1è¡¨é”çš„è½‰éŒ„æ¿€æ´»å› å­ï¼Œè˜¿è””ç¡«ç´ èƒ½ç›´æ¥çµåˆä¸¦æŠ‘åˆ¶STAT3çš„ç£·é…¸åŒ–ï¼Œå¾è€Œé™ä½å…¶è½‰éŒ„æ´»æ€§ï¼Œé€™äº›ç™¼ç¾ç‚ºèƒƒç™Œçš„æ²»ç™‚æä¾›äº†æ–°çš„æ½›åœ¨é¶é»ã€‚",
    "explanation_zh": "èƒƒç™Œä»ç„¶æ˜¯å°äººé¡å¥åº·çš„ä¸€å¤§å¨è„…ï¼Œä¸”ç›®å‰å¯ç”¨çš„æ²»ç™‚é¸æ“‡æœ‰é™ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ åœ¨èƒƒç™Œä¸­çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œå¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚æä¾›æ–°çš„æ€è·¯ã€‚é€éäº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·å’Œæ“´æ•£ï¼Œæˆ–è¨±èƒ½å¹«åŠ©æˆ‘å€‘æ‰¾åˆ°æ›´æœ‰æ•ˆçš„é é˜²å’Œæ²»ç™‚èƒƒç™Œçš„æ–¹æ³•ï¼Œé€²è€Œæ”¹å–„æ‚£è€…çš„ç”Ÿå­˜ç‡ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨èƒƒç™Œä¸­çš„æŠ—è…«ç˜¤ä½œç”¨åŠå…¶åˆ†å­æ©Ÿåˆ¶ã€‚ç ”ç©¶äººå“¡å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿èƒƒç™Œç´°èƒçš„è¡Œç‚ºï¼Œä¸¦æ‰¾å‡ºå…¶ä½œç”¨çš„å…·é«”åˆ†å­è·¯å¾‘ï¼Œé€™å°æ–¼é–‹ç™¼æ–°çš„æ²»ç™‚ç­–ç•¥è‡³é—œé‡è¦ã€‚\n\nç ”ç©¶åœ˜éšŠé€²è¡Œäº†é«”å…§å’Œé«”å¤–çš„å¯¦é©—ï¼Œä»¥å…¨é¢è©•ä¼°è˜¿è””ç¡«ç´ çš„æŠ—è…«ç˜¤æ•ˆæœã€‚é¦–å…ˆï¼Œä»–å€‘é€²è¡Œäº†åŸºå› æ¸¬åºåˆ†æï¼Œä»¥è­˜åˆ¥ç›®æ¨™é•·éˆéç·¨ç¢¼RNAï¼ˆlncRNAï¼‰ã€‚æ¥è‘—ï¼Œé€²è¡Œäº†æ©Ÿåˆ¶é©—è­‰å¯¦é©—ï¼Œä»¥ç¢ºå®šåœ¨STAT3-CKMT2-AS1èª¿æ§è»¸ä¸­æ¶‰åŠçš„ä¸Šæ¸¸å’Œä¸‹æ¸¸èª¿æ§æˆåˆ†ï¼Œé€™æ¨£çš„è¨­è¨ˆèƒ½å¤ æ·±å…¥äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¼·çƒˆæŠ‘åˆ¶èƒƒç™Œçš„ç”Ÿé•·ï¼Œä¸¦é™ä½lncRNA CKMT2-AS1çš„è¡¨é”ã€‚CKMT2-AS1åœ¨èƒƒç™Œçµ„ç¹”ä¸­çš„é«˜è¡¨é”èˆ‡æ‚£è€…çš„ç”Ÿå­˜ç‡è¼ƒä½ç›¸é—œã€‚ç•¶CKMT2-AS1è¢«æŠ‘åˆ¶æ™‚ï¼Œèƒƒç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»é¡¯è‘—æ¸›å°‘ï¼Œè€ŒCKMT2-AS1çš„éåº¦è¡¨é”å‰‡æœƒåŠ åŠ‡è…«ç˜¤çš„æƒ¡æ€§ç‰¹å¾µã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„ç™¼ç¾STAT3æ˜¯é©…å‹•CKMT2-AS1è¡¨é”çš„è½‰éŒ„æ¿€æ´»å› å­ï¼Œè˜¿è””ç¡«ç´ èƒ½ç›´æ¥çµåˆä¸¦æŠ‘åˆ¶STAT3çš„ç£·é…¸åŒ–ï¼Œå¾è€Œé™ä½å…¶è½‰éŒ„æ´»æ€§ï¼Œé€™äº›ç™¼ç¾ç‚ºèƒƒç™Œçš„æ²»ç™‚æä¾›äº†æ–°çš„æ½›åœ¨é¶é»ã€‚",
    "fb_post": "æ ¹æ“šã€ŠPhytomedicine : international journal of phytotherapy and phytopharmacologyã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ½ï¸ ä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„é¤ç›¤è£¡ç«Ÿç„¶è—è‘—å°æŠ—èƒƒç™Œçš„æ½›åŠ›ï¼ğŸŒ± æœ€è¿‘æœ‰ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ é€™å€‹æˆåˆ†å¯èƒ½å°èƒƒç™Œæœ‰æŠ—è…«ç˜¤çš„æ•ˆæœï¼Œé€™å¯è®“æˆ‘å€‘å°æœªä¾†çš„æ²»ç™‚æœ‰äº†æ–°çš„å¸Œæœ›ï¼  \n é€™é …ç ”ç©¶ä¸»è¦åœ¨æ¢è¨è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿èƒƒç™Œç´°èƒçš„è¡Œç‚ºï¼Œç ”ç©¶åœ˜éšŠé€éå¯¦é©—ï¼Œè©¦åœ–æ‰¾å‡ºå®ƒçš„ä½œç”¨æ©Ÿåˆ¶ã€‚ä»–å€‘é€²è¡Œäº†åŸºå› æ¸¬åºï¼Œä¸¦ç¢ºèªäº†èˆ‡è…«ç˜¤ç”Ÿé•·ç›¸é—œçš„åˆ†å­ï¼Œé€™æ¨£æ‰èƒ½æ›´å¥½åœ°ç†è§£è˜¿è””ç¡«ç´ çš„ç¥å¥‡ä¹‹è™•ã€‚  \n ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆæŠ‘åˆ¶èƒƒç™Œçš„ç”Ÿé•·ï¼Œä¸¦é™ä½ä¸€ç¨®åç‚º CKMT2-AS1 çš„åˆ†å­çš„è¡¨é”ã€‚é€™å€‹åˆ†å­åœ¨èƒƒç™Œæ‚£è€…ä¸­è¡¨ç¾éé«˜ï¼Œèˆ‡è¼ƒä½çš„ç”Ÿå­˜ç‡æœ‰é—œã€‚ç•¶é€™å€‹åˆ†å­è¢«æŠ‘åˆ¶å¾Œï¼Œèƒƒç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»æ˜é¡¯æ¸›å°‘ï¼Œé€™æ„å‘³è‘—è˜¿è””ç¡«ç´ å¯èƒ½æˆç‚ºæœªä¾†æ²»ç™‚çš„æ–°é¶é»ï¼  \n ç¸½çµä¾†èªªï¼š  \n 1. è˜¿è””ç¡«ç´ å¯èƒ½å°æŠ—èƒƒç™Œï¼Œæä¾›æ–°çš„æ²»ç™‚æ€è·¯ã€‚  \n 2. æŠ‘åˆ¶ CKMT2-AS1 å¯æ¸›å°‘è…«ç˜¤ç´°èƒçš„ç”Ÿé•·ã€‚  \n 3. STAT3 æ˜¯å½±éŸ¿ CKMT2-AS1 çš„é—œéµå› å­ï¼Œè˜¿è””ç¡«ç´ èƒ½é™ä½å®ƒçš„æ´»æ€§ã€‚  \n è®“æˆ‘å€‘ä¸€èµ·æœŸå¾…æ›´æœ‰æ•ˆçš„èƒƒç™Œé é˜²å’Œæ²»ç™‚æ–¹æ³•å§ï¼ğŸ’ª",
    "image_prompt": "Create an informative infographic illustrating the experimental approach and main results of a study on the anti-tumor effects of sulforaphane in gastric cancer. Use a flat design style with a light background and soft colors. Include visual representations of broccoli or sulforaphane, simplified images of experimental subjects like humans or cells, and arrows or flow lines to indicate the experimental steps. Include a section highlighting the main results, such as protective effects and changes observed.",
    "is_human_study": true,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "èƒƒç™Œ Gastric Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41135276/"
  },
  {
    "id": "41275316",
    "title_en": "Investigating the clinical efficacy, safety and molecular mechanism of sulforaphane in autism spectrum disorder: an integrated study combining meta-analysis, network pharmacology, and computational biology.",
    "pub_date": "2025 Nov",
    "journal": "BMC pharmacology & toxicology",
    "abstract_en": "Sulforaphane, a natural antioxidant rich in cruciferous vegetables, has emerged as a promising dietary supplement for autism spectrum disorder (ASD). However, its therapeutic efficacy remains controversial, and the pharmacological mechanisms are not fully elucidated. Eligible randomized controlled trials were retrieved from PubMed, Web of Science, Embase, and Cochrane Library databases. Review Manager 5.4 was used for meta-analysis and bias risk assessment. Network pharmacology, Mendelian randomization, GEO data analyses, molecular docking, and molecular dynamics simulation were employed to explore the mechanisms of sulforaphane in ASD. Six trials involving 333 participants were included in the meta-analysis. Pooled results demonstrated that both 4-5 weeks and 8-10 weeks of sulforaphane supplementation significantly decreased the scores on the Social Responsiveness Scale compared to placebo controls. No significant difference was observed in the incidence of adverse events. Network pharmacology identified 10 core targets of sulforaphane in ASD, including AKT1, EGFR, HSP90AA1, SRC, CASP3, STAT1, MAPK1, MMP9, MAPK8, and JAK2. These targets were implicated in the PI3K-Akt signaling pathway, MAPK signaling pathway, Chemokine signaling pathway, Chemical carcinogenesis - reactive oxygen species, TNF signaling pathway, Th17 cell differentiation, mTOR signaling pathway, and IL-17 signaling pathway. Mendelian randomization further revealed an inverse association between STAT1 levels and ASD risk. GEO transcriptomic data provided independent validation for the network pharmacology predictions. The binding energies between sulforaphane and the top 10 core targets are all â‰¤ -4.0Â kcal/mol. Molecular dynamics simulations further validated the stable interaction between MMP-9 and sulforaphane. Sulforaphane may serve as an efficacious and safe adjunctive therapy for ASD, mediated by its anti-oxidant and anti-inflammatory effects along with the modulation of autophagy. CRD42025635045.",
    "para1": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å¤©ç„¶æŠ—æ°§åŒ–åŠ‘ï¼Œä¸»è¦å­˜åœ¨æ–¼åå­—èŠ±ç§‘è”¬èœä¸­ï¼Œè¿‘ä¾†è¢«èªç‚ºå¯èƒ½å°è‡ªé–‰ç—‡è­œç³»éšœç¤™ï¼ˆASDï¼‰æœ‰å¹«åŠ©ã€‚é›–ç„¶å®ƒçš„ç™‚æ•ˆä»å­˜åœ¨çˆ­è­°ï¼Œä½†é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›æœ‰è¶£çš„è¦‹è§£ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„è‡ªé–‰ç—‡æ‚£è€…çš„ç¤¾äº¤èƒ½åŠ›ã€‚é€™å°æ–¼å®¶é•·å’Œé†«ç™‚å°ˆæ¥­äººå“¡ä¾†èªªï¼Œéƒ½æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„æ–¹å‘ï¼Œå› ç‚ºå¦‚æœèƒ½æ‰¾åˆ°æœ‰æ•ˆçš„è¼”åŠ©ç™‚æ³•ï¼Œå°‡æœ‰åŠ©æ–¼æå‡æ‚£è€…çš„ç”Ÿæ´»å“è³ªã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°è‡ªé–‰ç—‡è­œç³»éšœç¤™ï¼ˆASDï¼‰çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™ç¨®å¤©ç„¶æˆåˆ†æ˜¯å¦èƒ½æ”¹å–„è‡ªé–‰ç—‡æ‚£è€…çš„ç¤¾äº¤åæ‡‰èƒ½åŠ›ï¼Œä»¥åŠå…¶èƒŒå¾Œçš„è—¥ç†æ©Ÿåˆ¶ã€‚ç”±æ–¼ç›®å‰å°æ–¼è˜¿è””ç¡«ç´ çš„ç™‚æ•ˆå°šç„¡å®šè«–ï¼Œå› æ­¤é€™é …ç ”ç©¶çš„çµæœå°‡æœ‰åŠ©æ–¼å¡«è£œé€™æ–¹é¢çš„çŸ¥è­˜ç©ºç™½ï¼Œä¸¦ç‚ºæœªä¾†çš„ç ”ç©¶æä¾›åŸºç¤ã€‚",
    "para3": "ç ”ç©¶è€…å¾å¤šå€‹è³‡æ–™åº«ä¸­æª¢ç´¢äº†ç¬¦åˆæ¢ä»¶çš„éš¨æ©Ÿå°ç…§è©¦é©—ï¼Œæœ€çµ‚ç´å…¥äº†å…­é …è©¦é©—ï¼Œå…±æœ‰333ååƒèˆ‡è€…ã€‚é€™äº›è©¦é©—ä½¿ç”¨äº†è˜¿è””ç¡«ç´ è£œå……åŠ‘ï¼Œä¸¦èˆ‡å®‰æ…°åŠ‘é€²è¡Œæ¯”è¼ƒã€‚ç ”ç©¶ä¸­æ¡ç”¨äº†å¤šç¨®æ–¹æ³•ï¼ŒåŒ…æ‹¬ç¶²çµ¡è—¥ç†å­¸ã€å­Ÿå¾·çˆ¾éš¨æ©ŸåŒ–ã€åŸºå› è¡¨é”æ•¸æ“šåˆ†æç­‰ï¼Œä¾†æ¢è¨è˜¿è””ç¡«ç´ åœ¨è‡ªé–‰ç—‡ä¸­çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œä¸¦é€²è¡Œäº†å…ƒåˆ†æå’Œåå€šé¢¨éšªè©•ä¼°ã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œç„¡è«–æ˜¯4-5é€±é‚„æ˜¯8-10é€±çš„è˜¿è””ç¡«ç´ è£œå……ï¼Œéƒ½é¡¯è‘—é™ä½äº†åƒèˆ‡è€…åœ¨ç¤¾äº¤åæ‡‰é‡è¡¨ä¸Šçš„å¾—åˆ†ï¼Œèˆ‡å®‰æ…°åŠ‘çµ„ç›¸æ¯”æœ‰æ˜é¡¯æ”¹å–„ã€‚æ­¤å¤–ï¼Œç ”ç©¶ä¸­ä¸¦æœªè§€å¯Ÿåˆ°é¡¯è‘—çš„å‰¯ä½œç”¨ç™¼ç”Ÿç‡ã€‚ç¶²çµ¡è—¥ç†å­¸åˆ†ææ‰¾å‡ºäº†è˜¿è””ç¡«ç´ åœ¨è‡ªé–‰ç—‡ä¸­çš„åå€‹æ ¸å¿ƒé¶é»ï¼Œé€™äº›é¶é»èˆ‡å¤šæ¢ä¿¡è™Ÿå‚³å°è·¯å¾‘æœ‰é—œï¼Œé¡¯ç¤ºå‡ºè˜¿è””ç¡«ç´ å¯èƒ½é€éæŠ—æ°§åŒ–å’ŒæŠ—ç™¼ç‚çš„ä½œç”¨ä¾†æ”¹å–„è‡ªé–‰ç—‡çš„ç—‡ç‹€ï¼Œä¸¦ä¸”é€™äº›çµæœå¾—åˆ°äº†å…¶ä»–æ•¸æ“šçš„ç¨ç«‹é©—è­‰ã€‚",
    "explanation_zh": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å¤©ç„¶æŠ—æ°§åŒ–åŠ‘ï¼Œä¸»è¦å­˜åœ¨æ–¼åå­—èŠ±ç§‘è”¬èœä¸­ï¼Œè¿‘ä¾†è¢«èªç‚ºå¯èƒ½å°è‡ªé–‰ç—‡è­œç³»éšœç¤™ï¼ˆASDï¼‰æœ‰å¹«åŠ©ã€‚é›–ç„¶å®ƒçš„ç™‚æ•ˆä»å­˜åœ¨çˆ­è­°ï¼Œä½†é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›æœ‰è¶£çš„è¦‹è§£ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„è‡ªé–‰ç—‡æ‚£è€…çš„ç¤¾äº¤èƒ½åŠ›ã€‚é€™å°æ–¼å®¶é•·å’Œé†«ç™‚å°ˆæ¥­äººå“¡ä¾†èªªï¼Œéƒ½æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„æ–¹å‘ï¼Œå› ç‚ºå¦‚æœèƒ½æ‰¾åˆ°æœ‰æ•ˆçš„è¼”åŠ©ç™‚æ³•ï¼Œå°‡æœ‰åŠ©æ–¼æå‡æ‚£è€…çš„ç”Ÿæ´»å“è³ªã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°è‡ªé–‰ç—‡è­œç³»éšœç¤™ï¼ˆASDï¼‰çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™ç¨®å¤©ç„¶æˆåˆ†æ˜¯å¦èƒ½æ”¹å–„è‡ªé–‰ç—‡æ‚£è€…çš„ç¤¾äº¤åæ‡‰èƒ½åŠ›ï¼Œä»¥åŠå…¶èƒŒå¾Œçš„è—¥ç†æ©Ÿåˆ¶ã€‚ç”±æ–¼ç›®å‰å°æ–¼è˜¿è””ç¡«ç´ çš„ç™‚æ•ˆå°šç„¡å®šè«–ï¼Œå› æ­¤é€™é …ç ”ç©¶çš„çµæœå°‡æœ‰åŠ©æ–¼å¡«è£œé€™æ–¹é¢çš„çŸ¥è­˜ç©ºç™½ï¼Œä¸¦ç‚ºæœªä¾†çš„ç ”ç©¶æä¾›åŸºç¤ã€‚\n\nç ”ç©¶è€…å¾å¤šå€‹è³‡æ–™åº«ä¸­æª¢ç´¢äº†ç¬¦åˆæ¢ä»¶çš„éš¨æ©Ÿå°ç…§è©¦é©—ï¼Œæœ€çµ‚ç´å…¥äº†å…­é …è©¦é©—ï¼Œå…±æœ‰333ååƒèˆ‡è€…ã€‚é€™äº›è©¦é©—ä½¿ç”¨äº†è˜¿è””ç¡«ç´ è£œå……åŠ‘ï¼Œä¸¦èˆ‡å®‰æ…°åŠ‘é€²è¡Œæ¯”è¼ƒã€‚ç ”ç©¶ä¸­æ¡ç”¨äº†å¤šç¨®æ–¹æ³•ï¼ŒåŒ…æ‹¬ç¶²çµ¡è—¥ç†å­¸ã€å­Ÿå¾·çˆ¾éš¨æ©ŸåŒ–ã€åŸºå› è¡¨é”æ•¸æ“šåˆ†æç­‰ï¼Œä¾†æ¢è¨è˜¿è””ç¡«ç´ åœ¨è‡ªé–‰ç—‡ä¸­çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œä¸¦é€²è¡Œäº†å…ƒåˆ†æå’Œåå€šé¢¨éšªè©•ä¼°ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œç„¡è«–æ˜¯4-5é€±é‚„æ˜¯8-10é€±çš„è˜¿è””ç¡«ç´ è£œå……ï¼Œéƒ½é¡¯è‘—é™ä½äº†åƒèˆ‡è€…åœ¨ç¤¾äº¤åæ‡‰é‡è¡¨ä¸Šçš„å¾—åˆ†ï¼Œèˆ‡å®‰æ…°åŠ‘çµ„ç›¸æ¯”æœ‰æ˜é¡¯æ”¹å–„ã€‚æ­¤å¤–ï¼Œç ”ç©¶ä¸­ä¸¦æœªè§€å¯Ÿåˆ°é¡¯è‘—çš„å‰¯ä½œç”¨ç™¼ç”Ÿç‡ã€‚ç¶²çµ¡è—¥ç†å­¸åˆ†ææ‰¾å‡ºäº†è˜¿è””ç¡«ç´ åœ¨è‡ªé–‰ç—‡ä¸­çš„åå€‹æ ¸å¿ƒé¶é»ï¼Œé€™äº›é¶é»èˆ‡å¤šæ¢ä¿¡è™Ÿå‚³å°è·¯å¾‘æœ‰é—œï¼Œé¡¯ç¤ºå‡ºè˜¿è””ç¡«ç´ å¯èƒ½é€éæŠ—æ°§åŒ–å’ŒæŠ—ç™¼ç‚çš„ä½œç”¨ä¾†æ”¹å–„è‡ªé–‰ç—‡çš„ç—‡ç‹€ï¼Œä¸¦ä¸”é€™äº›çµæœå¾—åˆ°äº†å…¶ä»–æ•¸æ“šçš„ç¨ç«‹é©—è­‰ã€‚",
    "fb_post": "æ ¹æ“šã€ŠBMC pharmacology & toxicologyã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ±ä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„é¤æ¡Œä¸Šå¯èƒ½éš±è—è‘—å¹«åŠ©è‡ªé–‰ç—‡æ‚£è€…çš„å¤©ç„¶æˆåˆ†ï¼\n\næœ€è¿‘æœ‰ä¸€é …æœ‰è¶£çš„ç ”ç©¶ï¼Œå°ˆæ³¨æ–¼ä¸€ç¨®å«åšã€Œè˜¿è””ç¡«ç´ ã€çš„å¤©ç„¶æŠ—æ°§åŒ–åŠ‘ï¼Œé€™ç¨®æˆåˆ†ä¸»è¦å­˜åœ¨æ–¼é’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœä¸­ã€‚ç ”ç©¶è€…å€‘æƒ³äº†è§£é€™ç¨®æˆåˆ†æ˜¯å¦èƒ½æ”¹å–„è‡ªé–‰ç—‡è­œç³»éšœç¤™ï¼ˆASDï¼‰æ‚£è€…çš„ç¤¾äº¤èƒ½åŠ›ã€‚ä»–å€‘é€²è¡Œäº†å¤šé …éš¨æ©Ÿå°ç…§è©¦é©—ï¼Œæœ€çµ‚ç´å…¥äº†333ååƒèˆ‡è€…ï¼Œä¸¦æ¯”è¼ƒäº†ä½¿ç”¨è˜¿è””ç¡«ç´ è£œå……åŠ‘å’Œå®‰æ…°åŠ‘çš„æ•ˆæœã€‚\n\nçµæœé¡¯ç¤ºï¼Œç„¡è«–æ˜¯çŸ­æœŸï¼ˆ4-5é€±ï¼‰é‚„æ˜¯é•·æœŸï¼ˆ8-10é€±ï¼‰çš„è£œå……ï¼Œåƒèˆ‡è€…åœ¨ç¤¾äº¤åæ‡‰é‡è¡¨ä¸Šçš„å¾—åˆ†éƒ½æœ‰æ˜é¡¯æ”¹å–„ï¼Œä¸¦ä¸”æ²’æœ‰è§€å¯Ÿåˆ°é¡¯è‘—çš„å‰¯ä½œç”¨ã€‚é€™æ„å‘³è‘—è˜¿è””ç¡«ç´ å¯èƒ½é€éæŠ—æ°§åŒ–å’ŒæŠ—ç™¼ç‚çš„æ–¹å¼ï¼Œå°è‡ªé–‰ç—‡çš„ç—‡ç‹€æœ‰æ½›åœ¨çš„æ­£é¢å½±éŸ¿ã€‚\n\nğŸ”é‡é»æ•´ç†ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„è‡ªé–‰ç—‡æ‚£è€…çš„ç¤¾äº¤èƒ½åŠ›ã€‚\n2. ç ”ç©¶ä¸­ä½¿ç”¨äº†333ååƒèˆ‡è€…ï¼Œçµæœé¡¯ç¤ºæœ‰é¡¯è‘—æ”¹å–„ã€‚\n3. ç„¡æ˜é¡¯å‰¯ä½œç”¨ï¼Œæœªä¾†ç ”ç©¶å€¼å¾—æœŸå¾…ï¼",
    "image_prompt": "Create an infographic that explains the experimental methods and main results of a study on sulforaphane, a natural compound found in cruciferous vegetables like broccoli. The image should have a flat design style with a light background and soft colors. Include simplified icons representing sulforaphane (like broccoli), human or animal subjects, and arrows or flow lines to illustrate the experimental steps. There should be a section clearly labeled 'Main Results' highlighting the protective effects and improvements observed in social response scores.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "è‡ªé–‰ç—‡è­œç³»éšœç¤™ Autism Spectrum Disorder",
    "is_clinical_trial": true,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41275316/"
  },
  {
    "id": "41159773",
    "title_en": "Sulforaphane-Loaded Hydrogel Prolongs Fully MHC-Mismatched Skin Allograft Survival.",
    "pub_date": "2025 Nov",
    "journal": "ACS applied bio materials",
    "abstract_en": "Despite immunosuppression, acute rejection (AR) is still a common setback among transplantation patients and is a risk factor for graft survival. Sulforaphane (SFN), a phytochemical present in crucifers, has been shown to have anti-inflammatory and immunoregulatory properties, yet its influences on immune cell activation as well as in graft survival are still unknown. Thus, the aim was to evaluate SFN's effect, and to improve efficacy, efficiency, and availability, it was incorporated into thermosensitive polymeric hydrogels, to prevent AR in skin transplant (Tx) model mice. A thermosensitive hydrogel containing SFN (0.1%) and hyaluronic acid (HA) (0.5%) dispersed in a poloxamer matrix (PL407 at 20% w/v) was developed (GS-PL407 20%, HA and SFN) and characterized as a liquid-viscous hydrogel. The fully MHC-incompatible skin Tx procedure was performed by using donor skin Balb/c mice, transplanted into C57BL/6 recipient mice. The cytotoxicity test of GS was performed using in vitro assays with bone marrow-derived dendritic cells (BMDC). Treatment of BMDC with GS for 24 h presents no cytotoxicity. Untreated allograft mice present 100% of graft loss at day 9 post Tx. Remarkably, subcutaneous GS injection every 3 days promoted 80% of allograft survival for more than 14 days when compared with untreated recipients (<i>p</i> < 0.001). Histological analysis showed a lower level of inflammatory cells in the skin Tx of GS-treated mice. Flow cytometry analysis of draining lymph nodes at day 5 post Tx revealed that GS treatment reduced the frequency of DC and subtypes and function of the CD4<sup>+</sup> T cells. In vitro GS-treated lipopolysaccharide-activated BMDC present less activation of costimulatory markers. Taken together, GS treatment reduced immune cell activation, postponing AR onset and prolonging allograft survival in Tx animals. This strategy highlights the role of SFN as a promising candidate for further studies in organ transplantation experiments and being tested combined with current immunosuppression protocols.",
    "para1": "åœ¨å™¨å®˜ç§»æ¤çš„éç¨‹ä¸­ï¼Œæ€¥æ€§æ’æ–¥åæ‡‰æ˜¯ä¸€å€‹å¸¸è¦‹çš„å•é¡Œï¼Œé€™æœƒå½±éŸ¿åˆ°ç§»æ¤å™¨å®˜çš„å­˜æ´»ç‡ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ é€™ç¨®æ¤ç‰©åŒ–å­¸ç‰©è³ªå°å…ç–«ç³»çµ±çš„å½±éŸ¿ï¼Œä¸¦ä¸”å¸Œæœ›èƒ½æ‰¾åˆ°æ¸›å°‘æ€¥æ€§æ’æ–¥åæ‡‰çš„æ–¹æ³•ã€‚é€™å°æ–¼æœªä¾†çš„å¥åº·ç®¡ç†å’Œç–¾ç—…é é˜²æœ‰è‘—é‡è¦çš„å•Ÿç¤ºï¼Œå°¤å…¶æ˜¯åœ¨å™¨å®˜ç§»æ¤çš„é ˜åŸŸï¼Œè‹¥èƒ½æœ‰æ•ˆæ¸›å°‘æ’æ–¥åæ‡‰ï¼Œå°‡èƒ½æé«˜æ‚£è€…çš„ç”Ÿæ´»å“è³ªå’Œå™¨å®˜å­˜æ´»ç‡ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯è©•ä¼°è˜¿è””ç¡«ç´ å°æ–¼æ€¥æ€§æ’æ–¥åæ‡‰çš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯åœ¨çš®è†šç§»æ¤æ¨¡å‹ä¸­çš„æ‡‰ç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿å…ç–«ç´°èƒçš„æ´»åŒ–ï¼Œä»¥åŠå®ƒå°ç§»æ¤å™¨å®˜å­˜æ´»çš„æ½›åœ¨å½±éŸ¿ã€‚é€éé€™é …ç ”ç©¶ï¼Œç§‘å­¸å®¶å¸Œæœ›èƒ½æ›´æ·±å…¥äº†è§£è˜¿è””ç¡«ç´ çš„å…ç–«èª¿ç¯€ç‰¹æ€§ï¼Œä¸¦æ¢ç´¢å…¶åœ¨å™¨å®˜ç§»æ¤ä¸­çš„æ‡‰ç”¨æ½›åŠ›ã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†å«æœ‰0.1%è˜¿è””ç¡«ç´ å’Œ0.5%é€æ˜è³ªé…¸çš„ç†±æ•èšåˆç‰©æ°´å‡è† ï¼Œä¸¦å°‡å…¶æ‡‰ç”¨æ–¼å°é¼ çš„çš®è†šç§»æ¤æ¨¡å‹ã€‚é€™äº›å°é¼ åˆ†ç‚ºä¾›é«”å’Œå—é«”ï¼Œä¾›é«”å°é¼ çš„çš®è†šè¢«ç§»æ¤åˆ°å—é«”å°é¼ èº«ä¸Šã€‚ç ”ç©¶è€…é‚„é€²è¡Œäº†ç´°èƒæ¯’æ€§æ¸¬è©¦ï¼Œä»¥ç¢ºä¿é€™ç¨®æ°´å‡è† å°å…ç–«ç´°èƒä¸æœƒé€ æˆå‚·å®³ã€‚é€éé€™äº›æ–¹æ³•ï¼Œç ”ç©¶è€…èƒ½å¤ è§€å¯Ÿåˆ°è˜¿è””ç¡«ç´ å°æ–¼ç§»æ¤å¾Œå…ç–«åæ‡‰çš„å½±éŸ¿ã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œä½¿ç”¨è˜¿è””ç¡«ç´ çš„æ°´å‡è† èƒ½é¡¯è‘—æé«˜ç§»æ¤å™¨å®˜çš„å­˜æ´»ç‡ï¼Œèˆ‡æœªæ¥å—æ²»ç™‚çš„å—é«”å°é¼ ç›¸æ¯”ï¼Œè˜¿è””ç¡«ç´ æ²»ç™‚çµ„çš„å°é¼ åœ¨14å¤©å…§æœ‰80%çš„ç§»æ¤å™¨å®˜å­˜æ´»ã€‚çµ„ç¹”å­¸åˆ†æé¡¯ç¤ºï¼Œæ¥å—æ²»ç™‚çš„å°é¼ çš®è†šä¸­ç‚ç—‡ç´°èƒçš„æ•¸é‡è¼ƒå°‘ï¼Œé€™è¡¨æ˜è˜¿è””ç¡«ç´ èƒ½æ¸›å°‘å…ç–«ç´°èƒçš„æ´»åŒ–ï¼Œå»¶ç·©æ€¥æ€§æ’æ–¥åæ‡‰çš„ç™¼ç”Ÿã€‚é€™äº›çµæœé¡¯ç¤ºè˜¿è””ç¡«ç´ åœ¨å™¨å®˜ç§»æ¤ä¸­å…·æœ‰æ½›åœ¨çš„æ‡‰ç”¨åƒ¹å€¼ï¼Œä½†ä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶æ•ˆæœã€‚",
    "explanation_zh": "åœ¨å™¨å®˜ç§»æ¤çš„éç¨‹ä¸­ï¼Œæ€¥æ€§æ’æ–¥åæ‡‰æ˜¯ä¸€å€‹å¸¸è¦‹çš„å•é¡Œï¼Œé€™æœƒå½±éŸ¿åˆ°ç§»æ¤å™¨å®˜çš„å­˜æ´»ç‡ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ é€™ç¨®æ¤ç‰©åŒ–å­¸ç‰©è³ªå°å…ç–«ç³»çµ±çš„å½±éŸ¿ï¼Œä¸¦ä¸”å¸Œæœ›èƒ½æ‰¾åˆ°æ¸›å°‘æ€¥æ€§æ’æ–¥åæ‡‰çš„æ–¹æ³•ã€‚é€™å°æ–¼æœªä¾†çš„å¥åº·ç®¡ç†å’Œç–¾ç—…é é˜²æœ‰è‘—é‡è¦çš„å•Ÿç¤ºï¼Œå°¤å…¶æ˜¯åœ¨å™¨å®˜ç§»æ¤çš„é ˜åŸŸï¼Œè‹¥èƒ½æœ‰æ•ˆæ¸›å°‘æ’æ–¥åæ‡‰ï¼Œå°‡èƒ½æé«˜æ‚£è€…çš„ç”Ÿæ´»å“è³ªå’Œå™¨å®˜å­˜æ´»ç‡ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯è©•ä¼°è˜¿è””ç¡«ç´ å°æ–¼æ€¥æ€§æ’æ–¥åæ‡‰çš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯åœ¨çš®è†šç§»æ¤æ¨¡å‹ä¸­çš„æ‡‰ç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿å…ç–«ç´°èƒçš„æ´»åŒ–ï¼Œä»¥åŠå®ƒå°ç§»æ¤å™¨å®˜å­˜æ´»çš„æ½›åœ¨å½±éŸ¿ã€‚é€éé€™é …ç ”ç©¶ï¼Œç§‘å­¸å®¶å¸Œæœ›èƒ½æ›´æ·±å…¥äº†è§£è˜¿è””ç¡«ç´ çš„å…ç–«èª¿ç¯€ç‰¹æ€§ï¼Œä¸¦æ¢ç´¢å…¶åœ¨å™¨å®˜ç§»æ¤ä¸­çš„æ‡‰ç”¨æ½›åŠ›ã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†å«æœ‰0.1%è˜¿è””ç¡«ç´ å’Œ0.5%é€æ˜è³ªé…¸çš„ç†±æ•èšåˆç‰©æ°´å‡è† ï¼Œä¸¦å°‡å…¶æ‡‰ç”¨æ–¼å°é¼ çš„çš®è†šç§»æ¤æ¨¡å‹ã€‚é€™äº›å°é¼ åˆ†ç‚ºä¾›é«”å’Œå—é«”ï¼Œä¾›é«”å°é¼ çš„çš®è†šè¢«ç§»æ¤åˆ°å—é«”å°é¼ èº«ä¸Šã€‚ç ”ç©¶è€…é‚„é€²è¡Œäº†ç´°èƒæ¯’æ€§æ¸¬è©¦ï¼Œä»¥ç¢ºä¿é€™ç¨®æ°´å‡è† å°å…ç–«ç´°èƒä¸æœƒé€ æˆå‚·å®³ã€‚é€éé€™äº›æ–¹æ³•ï¼Œç ”ç©¶è€…èƒ½å¤ è§€å¯Ÿåˆ°è˜¿è””ç¡«ç´ å°æ–¼ç§»æ¤å¾Œå…ç–«åæ‡‰çš„å½±éŸ¿ã€‚\n\nä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œä½¿ç”¨è˜¿è””ç¡«ç´ çš„æ°´å‡è† èƒ½é¡¯è‘—æé«˜ç§»æ¤å™¨å®˜çš„å­˜æ´»ç‡ï¼Œèˆ‡æœªæ¥å—æ²»ç™‚çš„å—é«”å°é¼ ç›¸æ¯”ï¼Œè˜¿è””ç¡«ç´ æ²»ç™‚çµ„çš„å°é¼ åœ¨14å¤©å…§æœ‰80%çš„ç§»æ¤å™¨å®˜å­˜æ´»ã€‚çµ„ç¹”å­¸åˆ†æé¡¯ç¤ºï¼Œæ¥å—æ²»ç™‚çš„å°é¼ çš®è†šä¸­ç‚ç—‡ç´°èƒçš„æ•¸é‡è¼ƒå°‘ï¼Œé€™è¡¨æ˜è˜¿è””ç¡«ç´ èƒ½æ¸›å°‘å…ç–«ç´°èƒçš„æ´»åŒ–ï¼Œå»¶ç·©æ€¥æ€§æ’æ–¥åæ‡‰çš„ç™¼ç”Ÿã€‚é€™äº›çµæœé¡¯ç¤ºè˜¿è””ç¡«ç´ åœ¨å™¨å®˜ç§»æ¤ä¸­å…·æœ‰æ½›åœ¨çš„æ‡‰ç”¨åƒ¹å€¼ï¼Œä½†ä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶æ•ˆæœã€‚",
    "fb_post": "æ ¹æ“šã€ŠACS applied bio materialsã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± ä½ çŸ¥é“å—ï¼Ÿè˜¿è””è£¡çš„æˆåˆ†å¯èƒ½å°å™¨å®˜ç§»æ¤æœ‰å¹«åŠ©ï¼é€™é …ç ”ç©¶å°ˆæ³¨æ–¼ä¸€ç¨®å«åšè˜¿è””ç¡«ç´ çš„æ¤ç‰©åŒ–å­¸ç‰©è³ªï¼Œå®ƒå¯èƒ½èƒ½æ¸›å°‘å™¨å®˜ç§»æ¤å¾Œçš„æ’æ–¥åæ‡‰ï¼Œé€™å¯æ˜¯å€‹å¤§å•é¡Œå‘¢ï¼\n\nç ”ç©¶è€…å€‘åœ¨çš®è†šç§»æ¤çš„å¯¦é©—ä¸­ï¼Œä½¿ç”¨äº†å«æœ‰è˜¿è””ç¡«ç´ çš„æ°´å‡è† ï¼Œå°‡å…¶æ‡‰ç”¨åˆ°å°é¼ èº«ä¸Šï¼Œè§€å¯Ÿç§»æ¤å¾Œçš„å…ç–«åæ‡‰ã€‚ä»–å€‘ç™¼ç¾ï¼Œé€™ç¨®æ°´å‡è† ä¸åƒ…å°å…ç–«ç´°èƒå®‰å…¨ï¼Œé‚„èƒ½é¡¯è‘—æé«˜ç§»æ¤å™¨å®˜çš„å­˜æ´»ç‡ï¼\n\nåœ¨14å¤©å…§ï¼Œä½¿ç”¨è˜¿è””ç¡«ç´ çš„æ²»ç™‚çµ„å°é¼ æœ‰80%çš„ç§»æ¤å™¨å®˜å­˜æ´»ï¼Œé€™å¯æ¯”æœªæ¥å—æ²»ç™‚çš„å°é¼ å¥½å¤šäº†ï¼è€Œä¸”ï¼Œæ¥å—æ²»ç™‚çš„å°é¼ çš®è†šè£¡çš„ç‚ç—‡ç´°èƒæ•¸é‡ä¹Ÿè¼ƒå°‘ï¼Œé€™æ„å‘³è‘—è˜¿è””ç¡«ç´ èƒ½å¹«åŠ©æ¸›å°‘å…ç–«ç³»çµ±çš„éåº¦åæ‡‰ã€‚\n\nğŸ’¡ é‡é»æ•´ç†ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘å™¨å®˜ç§»æ¤çš„æ’æ–¥åæ‡‰ã€‚\n2. å¯¦é©—ä¸­ï¼Œä½¿ç”¨è˜¿è””ç¡«ç´ çš„æ°´å‡è† é¡¯è‘—æé«˜äº†å™¨å®˜çš„å­˜æ´»ç‡ã€‚\n3. ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ä¾†ç¢ºèªé€™äº›çµæœçš„æœ‰æ•ˆæ€§ã€‚",
    "image_prompt": "Create a flat design infographic on a light background that explains the experiment and main results of a study on the effects of sulforaphane on organ transplant rejection. Include simplified illustrations of broccoli or sulforaphane, experimental subjects like mice, and arrows or flow lines indicating the steps of the experiment. Add a section labeled 'Main Results' highlighting the protective effects observed, such as increased organ survival rates and reduced inflammation.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "æ€¥æ€§æ’æ–¥åæ‡‰ Acute Rejection",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41159773/"
  },
  {
    "id": "41196460",
    "title_en": "Sulforaphane: a natural organosulfur having potential to modulate apoptosis and survival signalling in cancer.",
    "pub_date": "2025 Nov",
    "journal": "Discover oncology",
    "abstract_en": "Owing to its ever-growing range of pharmacological advantages, sulforaphane, an isothiocyanate from cruciferous vegetables such as broccoli, is becoming increasingly popular. This review aims to provide a thorough understanding and a current update on the application of sulforaphane in cancer treatment. Sulforaphane interacts with many signaling molecules that control various pathways in malignant cells, including angiogenesis, apoptosis, cell cycle arrest, metastasis, and inflammation pathways. This review examines the effects of this isothiocyanate on inflammatory mediators, caspases, MMPs, cytokines, and the proteins Bax and Bcl-2. Furthermore, the advantages of nanotechnology and synergistic effects in sulforaphane applications are also reviewed. As per evidence, sulforaphane is a shining example of how ethno-pharmacological expertise can be used to create modern medications.",
    "para1": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªé’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœçš„åŒ–åˆç‰©ï¼Œå› å…¶æ½›åœ¨çš„è—¥ç†å„ªå‹¢è€Œå—åˆ°è¶Šä¾†è¶Šå¤šçš„é—œæ³¨ã€‚é€™é …ç ”ç©¶æä¾›äº†å°è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­æ‡‰ç”¨çš„æ·±å…¥äº†è§£ï¼Œé¡¯ç¤ºå‡ºå®ƒå¯èƒ½åœ¨ç–¾ç—…é é˜²å’Œæ²»ç™‚æ–¹é¢çš„æ½›åŠ›ã€‚é€éäº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„å¤šç¨®ç”Ÿç‰©é€”å¾‘ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ–°çš„æ–¹æ³•ä¾†å°æŠ—ç™Œç—‡ï¼Œé€™å°æ–¼æå‡äººé¡å¥åº·å’Œé é˜²ç–¾ç—…å…·æœ‰é‡è¦æ„ç¾©ã€‚",
    "para2": "é€™ç¯‡æ–‡ç« çš„ç ”ç©¶ä¸»é¡Œæ˜¯è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ‡‰ç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯è˜¿è””ç¡«ç´ å¦‚ä½•èˆ‡ç™Œç´°èƒä¸­çš„ä¿¡è™Ÿåˆ†å­äº’å‹•ï¼Œä¸¦å½±éŸ¿å¤šç¨®èˆ‡ç™Œç—‡ç›¸é—œçš„ç”Ÿç‰©é€”å¾‘ï¼ŒåŒ…æ‹¬è¡€ç®¡ç”Ÿæˆã€ç´°èƒå‡‹äº¡ã€ç´°èƒé€±æœŸåœæ»¯ã€è½‰ç§»ä»¥åŠç‚ç—‡åæ‡‰ç­‰ã€‚é€™äº›å•é¡Œçš„æ¢è¨æœ‰åŠ©æ–¼æˆ‘å€‘æ›´å¥½åœ°ç†è§£è˜¿è””ç¡«ç´ çš„æ½›åœ¨ç™‚æ•ˆåŠå…¶åœ¨è‡¨åºŠä¸Šçš„æ‡‰ç”¨ã€‚",
    "para3": "åœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…å›é¡§äº†è˜¿è””ç¡«ç´ å°å¤šç¨®ç”Ÿç‰©æ¨™è¨˜ç‰©çš„å½±éŸ¿ï¼ŒåŒ…æ‹¬ç‚ç—‡ä»‹è³ªã€åŠèƒ±å¤©å†¬é…¶ã€åŸºè³ªé‡‘å±¬è›‹ç™½é…¶ã€ç´°èƒå› å­ä»¥åŠBaxå’ŒBcl-2ç­‰è›‹ç™½è³ªã€‚ç ”ç©¶è€…é‚„æ¢è¨äº†ç´ç±³æŠ€è¡“å’Œè˜¿è””ç¡«ç´ æ‡‰ç”¨ä¸­çš„å”åŒæ•ˆæ‡‰ï¼Œé€™äº›æ–¹æ³•æœ‰åŠ©æ–¼æå‡è˜¿è””ç¡«ç´ çš„æ•ˆæœã€‚é€™é …ç ”ç©¶çš„è¨­è¨ˆä½¿å¾—æˆ‘å€‘èƒ½å¤ å…¨é¢äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶åŠå…¶åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ½›åœ¨æ‡‰ç”¨ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ å½±éŸ¿å¤šç¨®èˆ‡ç™Œç—‡ç›¸é—œçš„ç”Ÿç‰©é€”å¾‘ï¼Œä¸¦å¯èƒ½å°ç™Œç´°èƒçš„ç”Ÿé•·å’Œæ“´æ•£ç”¢ç”Ÿå½±éŸ¿ã€‚é›–ç„¶é€™äº›çµæœé¡¯ç¤ºå‡ºè˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ½›åŠ›ï¼Œä½†ä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶å…·é«”çš„ç™‚æ•ˆå’Œæ‡‰ç”¨æ–¹å¼ã€‚é€™é …ç ”ç©¶å¼·èª¿äº†å‚³çµ±è—¥ç†çŸ¥è­˜å¦‚ä½•èƒ½å¤ è½‰åŒ–ç‚ºç¾ä»£é†«ç™‚çš„æ½›åŠ›ï¼Œç‚ºæœªä¾†çš„ç™Œç—‡æ²»ç™‚æä¾›äº†æ–°çš„æ€è·¯ã€‚",
    "explanation_zh": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªé’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœçš„åŒ–åˆç‰©ï¼Œå› å…¶æ½›åœ¨çš„è—¥ç†å„ªå‹¢è€Œå—åˆ°è¶Šä¾†è¶Šå¤šçš„é—œæ³¨ã€‚é€™é …ç ”ç©¶æä¾›äº†å°è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­æ‡‰ç”¨çš„æ·±å…¥äº†è§£ï¼Œé¡¯ç¤ºå‡ºå®ƒå¯èƒ½åœ¨ç–¾ç—…é é˜²å’Œæ²»ç™‚æ–¹é¢çš„æ½›åŠ›ã€‚é€éäº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„å¤šç¨®ç”Ÿç‰©é€”å¾‘ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ–°çš„æ–¹æ³•ä¾†å°æŠ—ç™Œç—‡ï¼Œé€™å°æ–¼æå‡äººé¡å¥åº·å’Œé é˜²ç–¾ç—…å…·æœ‰é‡è¦æ„ç¾©ã€‚\n\né€™ç¯‡æ–‡ç« çš„ç ”ç©¶ä¸»é¡Œæ˜¯è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ‡‰ç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯è˜¿è””ç¡«ç´ å¦‚ä½•èˆ‡ç™Œç´°èƒä¸­çš„ä¿¡è™Ÿåˆ†å­äº’å‹•ï¼Œä¸¦å½±éŸ¿å¤šç¨®èˆ‡ç™Œç—‡ç›¸é—œçš„ç”Ÿç‰©é€”å¾‘ï¼ŒåŒ…æ‹¬è¡€ç®¡ç”Ÿæˆã€ç´°èƒå‡‹äº¡ã€ç´°èƒé€±æœŸåœæ»¯ã€è½‰ç§»ä»¥åŠç‚ç—‡åæ‡‰ç­‰ã€‚é€™äº›å•é¡Œçš„æ¢è¨æœ‰åŠ©æ–¼æˆ‘å€‘æ›´å¥½åœ°ç†è§£è˜¿è””ç¡«ç´ çš„æ½›åœ¨ç™‚æ•ˆåŠå…¶åœ¨è‡¨åºŠä¸Šçš„æ‡‰ç”¨ã€‚\n\nåœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…å›é¡§äº†è˜¿è””ç¡«ç´ å°å¤šç¨®ç”Ÿç‰©æ¨™è¨˜ç‰©çš„å½±éŸ¿ï¼ŒåŒ…æ‹¬ç‚ç—‡ä»‹è³ªã€åŠèƒ±å¤©å†¬é…¶ã€åŸºè³ªé‡‘å±¬è›‹ç™½é…¶ã€ç´°èƒå› å­ä»¥åŠBaxå’ŒBcl-2ç­‰è›‹ç™½è³ªã€‚ç ”ç©¶è€…é‚„æ¢è¨äº†ç´ç±³æŠ€è¡“å’Œè˜¿è””ç¡«ç´ æ‡‰ç”¨ä¸­çš„å”åŒæ•ˆæ‡‰ï¼Œé€™äº›æ–¹æ³•æœ‰åŠ©æ–¼æå‡è˜¿è””ç¡«ç´ çš„æ•ˆæœã€‚é€™é …ç ”ç©¶çš„è¨­è¨ˆä½¿å¾—æˆ‘å€‘èƒ½å¤ å…¨é¢äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶åŠå…¶åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ½›åœ¨æ‡‰ç”¨ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ å½±éŸ¿å¤šç¨®èˆ‡ç™Œç—‡ç›¸é—œçš„ç”Ÿç‰©é€”å¾‘ï¼Œä¸¦å¯èƒ½å°ç™Œç´°èƒçš„ç”Ÿé•·å’Œæ“´æ•£ç”¢ç”Ÿå½±éŸ¿ã€‚é›–ç„¶é€™äº›çµæœé¡¯ç¤ºå‡ºè˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ½›åŠ›ï¼Œä½†ä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶å…·é«”çš„ç™‚æ•ˆå’Œæ‡‰ç”¨æ–¹å¼ã€‚é€™é …ç ”ç©¶å¼·èª¿äº†å‚³çµ±è—¥ç†çŸ¥è­˜å¦‚ä½•èƒ½å¤ è½‰åŒ–ç‚ºç¾ä»£é†«ç™‚çš„æ½›åŠ›ï¼Œç‚ºæœªä¾†çš„ç™Œç—‡æ²»ç™‚æä¾›äº†æ–°çš„æ€è·¯ã€‚",
    "fb_post": "æ ¹æ“šã€ŠDiscover oncologyã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± ä½ çŸ¥é“å—ï¼Ÿé’èŠ±æ¤°èœè£¡é¢æœ‰ä¸€ç¨®å«åšã€Œè˜¿è””ç¡«ç´ ã€çš„æˆåˆ†ï¼Œæœ€è¿‘å—åˆ°äº†ç§‘å­¸å®¶çš„é—œæ³¨ï¼é€™ç¨®åŒ–åˆç‰©å¯èƒ½åœ¨å°æŠ—ç™Œç—‡æ–¹é¢æœ‰æ½›åŠ›ï¼Œè®“æˆ‘å€‘ä¸€èµ·ä¾†çœ‹çœ‹é€™ç¯‡æ–°ç ”ç©¶çš„ç™¼ç¾å§ï¼\n\né€™ç¯‡ç ”ç©¶ä¸»è¦æ¢è¨äº†è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„è¡Œç‚ºã€‚ç ”ç©¶äººå“¡é—œå¿ƒçš„æ˜¯ï¼Œé€™ç¨®æˆåˆ†å¦‚ä½•èˆ‡ç™Œç´°èƒå…§çš„ä¿¡è™Ÿåˆ†å­äº’å‹•ï¼Œä¸¦å½±éŸ¿èˆ‡ç™Œç—‡ç›¸é—œçš„éç¨‹ï¼Œä¾‹å¦‚ç´°èƒæ­»äº¡ã€è¡€ç®¡ç”Ÿæˆï¼ˆæ–°è¡€ç®¡çš„å½¢æˆï¼‰ã€ç´°èƒé€±æœŸï¼ˆç´°èƒç”Ÿé•·çš„éç¨‹ï¼‰ç­‰ã€‚\n\nä»–å€‘å›é¡§äº†è˜¿è””ç¡«ç´ å°å¤šç¨®ç”Ÿç‰©æ¨™è¨˜ç‰©çš„å½±éŸ¿ï¼Œåƒæ˜¯ç‚ç—‡ä»‹è³ªå’Œä¸€äº›ç‰¹å®šçš„è›‹ç™½è³ªï¼Œä¸¦ä¸”é‚„æ¢è¨äº†ç´ç±³æŠ€è¡“å¦‚ä½•æå‡è˜¿è””ç¡«ç´ çš„æ•ˆæœã€‚ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æœƒå½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·å’Œæ“´æ•£ã€‚\n\né›–ç„¶é€™äº›ç™¼ç¾ä»¤äººèˆˆå¥®ï¼Œä½†æˆ‘å€‘é‚„éœ€è¦æ›´å¤šçš„ç ”ç©¶ä¾†ç¢ºèªå®ƒçš„å…·é«”æ•ˆæœå’Œæ‡‰ç”¨æ–¹å¼ã€‚é€™ç¯‡ç ”ç©¶æé†’æˆ‘å€‘ï¼Œå‚³çµ±çš„è—¥ç†çŸ¥è­˜å¯ä»¥ç‚ºç¾ä»£é†«ç™‚å¸¶ä¾†æ–°çš„æ€è·¯ï¼\n\nğŸ” ä¸»è¦é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ ä¾†è‡ªé’èŠ±æ¤°èœï¼Œå¯èƒ½å°æŠ—ç™Œç—‡æœ‰æ½›åŠ›ã€‚\n2. ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„å¤šç¨®ç”Ÿç‰©é€”å¾‘ã€‚\n3. ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ä¾†ç¢ºèªå…¶ç™‚æ•ˆå’Œæ‡‰ç”¨æ–¹å¼ã€‚",
    "image_prompt": "Create a flat design infographic with a light background that explains the experimental method and main results of a study on sulforaphane from broccoli. Include simplified icons of broccoli or sulforaphane, experimental subjects like human or animal cells, arrows or flow lines indicating the experimental steps, and a section labeled 'Main Results' highlighting protective effects or changes observed in cancer cells.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "ç™Œç—‡ Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41196460/"
  },
  {
    "id": "41184790",
    "title_en": "Efficacy and safety of sulforaphane in schizophrenia: a systematic review and meta-analysis of randomized controlled trials.",
    "pub_date": "2025 Nov",
    "journal": "BMC psychiatry",
    "abstract_en": "Sulforaphane, an isothiocyanate derived from cruciferous vegetables (e.g., broccoli sprouts), has been explored for its antioxidant and anti-inflammatory properties. This is the first systematic review and meta-analysis to explore the therapeutic potentials of sulforaphane in schizophrenia. We searched PubMed, Scopus, Web of Science, and Cochrane Central for studies from inception to April 2025. We included randomized controlled trials (RCTs) evaluating the efficacy of sulforaphane in schizophrenia. The primary outcomes were changes in the Positive and Negative Syndrome Scale (PANSS) total and its subscales. Secondary outcomes included cognitive measures, metabolic markers, and safety. Four RCTs with 369 schizophrenia patients were included. Sulforaphane did not significantly improve PANSS total or positive symptom scores at the latest follow-up (ranging from 24 weeks to 18 weeks) or at a consistent 12-week time point. However, a modest improvement in negative symptoms was found at 12 week- time point (MD= -1.06; 95% CI: -1.95 to -0.16; pâ€‰=â€‰0.02), which was not maintained at the latest follow-up. General psychopathology scores improved significantly (MD= -1.5; 95% CI: -2.78 to -0.23; pâ€‰=â€‰0.02). No cognitive benefits were observed. Sulforaphane led to significant reductions in metabolic markers, including LDL, triglycerides, and cholesterol. Discontinuation rates were lower in the sulforaphane group (RRâ€‰=â€‰0.68; 95% CI: 0.49 to 0.95; pâ€‰=â€‰0.02). The study provides initial insights into sulforaphane's potential therapeutic effects in schizophrenia, showing modest improvements in general psychopathology and negative symptoms, with favorable metabolic changes and lower discontinuation rates. Due to limited data and heterogeneity, the study findings should be interpreted with caution. Not applicable.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç²¾ç¥å¥åº·æ–¹é¢ã€‚ç ”ç©¶æŒ‡å‡ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°ç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…æœ‰ä¸€å®šçš„å¹«åŠ©ï¼Œå°¤å…¶æ˜¯åœ¨æ”¹å–„ä¸€äº›è² é¢ç—‡ç‹€å’Œæ•´é«”å¿ƒç†ç—…ç†æ–¹é¢ã€‚é›–ç„¶é€™äº›æ”¹å–„æ˜¯æœ‰é™çš„ï¼Œä½†ä»ç„¶é¡¯ç¤ºå‡ºè˜¿è””ç¡«ç´ åœ¨ç²¾ç¥å¥åº·é ˜åŸŸçš„æ½›åŠ›ï¼Œé€™å°æ–¼å°‹æ±‚æ–°ç™‚æ³•çš„æ‚£è€…ä¾†èªªï¼Œå¯èƒ½æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„æ–¹å‘ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨ç²¾ç¥åˆ†è£‚ç—‡æ²»ç™‚ä¸­çš„æ½›åœ¨ç™‚æ•ˆã€‚ç²¾ç¥åˆ†è£‚ç—‡æ˜¯ä¸€ç¨®è¤‡é›œçš„ç²¾ç¥ç–¾ç—…ï¼Œå½±éŸ¿æ‚£è€…çš„æ€ç¶­ã€æƒ…æ„Ÿå’Œè¡Œç‚ºã€‚ç ”ç©¶è€…å¸Œæœ›é€šéç³»çµ±æ€§å›é¡§å’Œçµ±åˆåˆ†æï¼Œäº†è§£è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æ”¹å–„ç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…çš„ç—‡ç‹€ï¼Œä¸¦è©•ä¼°å…¶å®‰å…¨æ€§å’Œæœ‰æ•ˆæ€§ã€‚",
    "para3": "ç ”ç©¶åœ˜éšŠé€²è¡Œäº†ä¸€ç³»åˆ—çš„æ–‡ç»æœå°‹ï¼Œå¾å¤šå€‹è³‡æ–™åº«ä¸­æ”¶é›†ç›¸é—œçš„éš¨æ©Ÿå°ç…§è©¦é©—ï¼ˆRCTsï¼‰ï¼Œé€™äº›è©¦é©—è©•ä¼°äº†è˜¿è””ç¡«ç´ å°ç²¾ç¥åˆ†è£‚ç—‡çš„ç™‚æ•ˆã€‚æœ€çµ‚ç´å…¥äº†å››é …RCTï¼Œç¸½å…±369åç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…åƒèˆ‡äº†é€™äº›ç ”ç©¶ã€‚ä¸»è¦çš„è©•ä¼°æŒ‡æ¨™åŒ…æ‹¬ç²¾ç¥ç—…ç—‡ç‹€çš„è®ŠåŒ–ï¼Œä»¥åŠä¸€äº›èªçŸ¥æ¸¬é‡å’Œä»£è¬æ¨™è¨˜çš„è®ŠåŒ–ã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨æ”¹å–„ç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…çš„ç¸½é«”ç—‡ç‹€å’Œè² é¢ç—‡ç‹€æ–¹é¢æœ‰ä¸€å®šçš„æˆæ•ˆï¼Œä½†é€™äº›æ”¹å–„ä¸¦ä¸æŒä¹…ã€‚æ­¤å¤–ï¼Œç ”ç©¶ç™¼ç¾è˜¿è””ç¡«ç´ èƒ½é¡¯è‘—é™ä½ä¸€äº›ä»£è¬æ¨™è¨˜ï¼Œå¦‚ä½å¯†åº¦è„‚è›‹ç™½ï¼ˆLDLï¼‰ã€ä¸‰é…¸ç”˜æ²¹è„‚å’Œè†½å›ºé†‡ï¼Œä¸¦ä¸”åœ¨è˜¿è””ç¡«ç´ çµ„çš„æ‚£è€…ä¸­ï¼Œåœè—¥ç‡è¼ƒä½ã€‚å„˜ç®¡å¦‚æ­¤ï¼Œç”±æ–¼æ•¸æ“šæœ‰é™ä¸”å­˜åœ¨ç•°è³ªæ€§ï¼Œé€™äº›çµæœæ‡‰è¬¹æ…è§£è®€ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç²¾ç¥å¥åº·æ–¹é¢ã€‚ç ”ç©¶æŒ‡å‡ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°ç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…æœ‰ä¸€å®šçš„å¹«åŠ©ï¼Œå°¤å…¶æ˜¯åœ¨æ”¹å–„ä¸€äº›è² é¢ç—‡ç‹€å’Œæ•´é«”å¿ƒç†ç—…ç†æ–¹é¢ã€‚é›–ç„¶é€™äº›æ”¹å–„æ˜¯æœ‰é™çš„ï¼Œä½†ä»ç„¶é¡¯ç¤ºå‡ºè˜¿è””ç¡«ç´ åœ¨ç²¾ç¥å¥åº·é ˜åŸŸçš„æ½›åŠ›ï¼Œé€™å°æ–¼å°‹æ±‚æ–°ç™‚æ³•çš„æ‚£è€…ä¾†èªªï¼Œå¯èƒ½æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„æ–¹å‘ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨ç²¾ç¥åˆ†è£‚ç—‡æ²»ç™‚ä¸­çš„æ½›åœ¨ç™‚æ•ˆã€‚ç²¾ç¥åˆ†è£‚ç—‡æ˜¯ä¸€ç¨®è¤‡é›œçš„ç²¾ç¥ç–¾ç—…ï¼Œå½±éŸ¿æ‚£è€…çš„æ€ç¶­ã€æƒ…æ„Ÿå’Œè¡Œç‚ºã€‚ç ”ç©¶è€…å¸Œæœ›é€šéç³»çµ±æ€§å›é¡§å’Œçµ±åˆåˆ†æï¼Œäº†è§£è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æ”¹å–„ç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…çš„ç—‡ç‹€ï¼Œä¸¦è©•ä¼°å…¶å®‰å…¨æ€§å’Œæœ‰æ•ˆæ€§ã€‚\n\nç ”ç©¶åœ˜éšŠé€²è¡Œäº†ä¸€ç³»åˆ—çš„æ–‡ç»æœå°‹ï¼Œå¾å¤šå€‹è³‡æ–™åº«ä¸­æ”¶é›†ç›¸é—œçš„éš¨æ©Ÿå°ç…§è©¦é©—ï¼ˆRCTsï¼‰ï¼Œé€™äº›è©¦é©—è©•ä¼°äº†è˜¿è””ç¡«ç´ å°ç²¾ç¥åˆ†è£‚ç—‡çš„ç™‚æ•ˆã€‚æœ€çµ‚ç´å…¥äº†å››é …RCTï¼Œç¸½å…±369åç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…åƒèˆ‡äº†é€™äº›ç ”ç©¶ã€‚ä¸»è¦çš„è©•ä¼°æŒ‡æ¨™åŒ…æ‹¬ç²¾ç¥ç—…ç—‡ç‹€çš„è®ŠåŒ–ï¼Œä»¥åŠä¸€äº›èªçŸ¥æ¸¬é‡å’Œä»£è¬æ¨™è¨˜çš„è®ŠåŒ–ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨æ”¹å–„ç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…çš„ç¸½é«”ç—‡ç‹€å’Œè² é¢ç—‡ç‹€æ–¹é¢æœ‰ä¸€å®šçš„æˆæ•ˆï¼Œä½†é€™äº›æ”¹å–„ä¸¦ä¸æŒä¹…ã€‚æ­¤å¤–ï¼Œç ”ç©¶ç™¼ç¾è˜¿è””ç¡«ç´ èƒ½é¡¯è‘—é™ä½ä¸€äº›ä»£è¬æ¨™è¨˜ï¼Œå¦‚ä½å¯†åº¦è„‚è›‹ç™½ï¼ˆLDLï¼‰ã€ä¸‰é…¸ç”˜æ²¹è„‚å’Œè†½å›ºé†‡ï¼Œä¸¦ä¸”åœ¨è˜¿è””ç¡«ç´ çµ„çš„æ‚£è€…ä¸­ï¼Œåœè—¥ç‡è¼ƒä½ã€‚å„˜ç®¡å¦‚æ­¤ï¼Œç”±æ–¼æ•¸æ“šæœ‰é™ä¸”å­˜åœ¨ç•°è³ªæ€§ï¼Œé€™äº›çµæœæ‡‰è¬¹æ…è§£è®€ã€‚",
    "fb_post": "æ ¹æ“šã€ŠBMC psychiatryã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± æœ€è¿‘æœ‰å€‹æœ‰è¶£çš„ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°ç²¾ç¥å¥åº·æœ‰äº›å¹«åŠ©ï¼é€™é …ç ”ç©¶å°ˆæ³¨æ–¼ç²¾ç¥åˆ†è£‚ç—‡ï¼Œé€™æ˜¯ä¸€ç¨®å½±éŸ¿æ€ç¶­å’Œæƒ…æ„Ÿçš„è¤‡é›œç–¾ç—…ã€‚ç ”ç©¶è€…å€‘æƒ³çŸ¥é“ï¼Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æ”¹å–„é€™äº›æ‚£è€…çš„ç—‡ç‹€ï¼Œä¸¦è©•ä¼°å®ƒçš„å®‰å…¨æ€§å’Œæ•ˆæœã€‚\n\nä»–å€‘å¾è¨±å¤šè³‡æ–™åº«ä¸­æ‰¾åˆ°äº†ç›¸é—œçš„éš¨æ©Ÿå°ç…§è©¦é©—ï¼Œå…±æœ‰369åæ‚£è€…åƒèˆ‡äº†é€™äº›ç ”ç©¶ã€‚ä¸»è¦è§€å¯Ÿçš„æŒ‡æ¨™åŒ…æ‹¬ç²¾ç¥ç—…ç—‡ç‹€çš„è®ŠåŒ–ï¼Œä»¥åŠä¸€äº›ç›¸é—œçš„å¥åº·æŒ‡æ¨™ã€‚\n\nçµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å°æ”¹å–„æ‚£è€…çš„æ•´é«”ç—‡ç‹€å’Œè² é¢ç—‡ç‹€æœ‰ä¸€å®šçš„æ•ˆæœï¼Œä½†é€™äº›æ”¹å–„ä¸¦ä¸æŒä¹…ã€‚æ­¤å¤–ï¼Œå®ƒé‚„èƒ½é™ä½ä¸€äº›ä¸å¥½çš„ä»£è¬æŒ‡æ¨™ï¼Œæ¯”å¦‚å£è†½å›ºé†‡ï¼ˆLDLï¼‰å’Œä¸‰é…¸ç”˜æ²¹è„‚ï¼Œä¸¦ä¸”åœ¨ä½¿ç”¨è˜¿è””ç¡«ç´ çš„æ‚£è€…ä¸­ï¼Œåœè—¥çš„æ¯”ä¾‹è¼ƒä½ã€‚ç•¶ç„¶ï¼Œç”±æ–¼æ•¸æ“šæœ‰é™ï¼Œé€™äº›çµæœé‚„éœ€è¦è¬¹æ…è§£è®€ã€‚\n\nğŸ” é€™è£¡æœ‰å¹¾å€‹é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å°ç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…çš„ç—‡ç‹€æœ‰ä¸€å®šæ”¹å–„ã€‚\n2. å®ƒèƒ½é™ä½ä¸€äº›ä¸å¥åº·çš„ä»£è¬æŒ‡æ¨™ã€‚\n3. æ•¸æ“šæœ‰é™ï¼Œçµæœéœ€è¬¹æ…çœ‹å¾…ã€‚",
    "image_prompt": "Create a flat design infographic with a light background that visually explains the experiment and main results of the study on sulforaphane. Include simple icons representing broccoli or sulforaphane, simplified illustrations of human subjects, and arrows or flow lines to depict the experimental steps. Add a section labeled 'Main Results' highlighting protective effects and changes observed.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "ç²¾ç¥åˆ†è£‚ç—‡ Schizophrenia",
    "is_clinical_trial": true,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41184790/"
  },
  {
    "id": "40992247",
    "title_en": "Assessing the transplacental passage and breastmilk levels of broccoli sprout-derived sulforaphane.",
    "pub_date": "2025 Nov",
    "journal": "Placenta",
    "abstract_en": "Preeclampsia is characterised by hypertension with maternal end-organ dysfunction and/or fetal growth restriction. Sulforaphane, an antioxidant found in broccoli sprouts, has potential as a future therapeutic. With its ability to attenuate the injurious impacts of endothelial dysfunction in vitro, sulforaphane is uniquely positioned to protect against the harmful effects of preeclampsia. However, the transferability of sulforaphane from mother to fetus/baby remains unknown in humans. Uncomplicated pregnant patients (nÂ =Â 8) scheduled for elective caesarean sections (>37 weeks gestation) provided written and informed consent. A single oral dose of EnduraCell, a broccoli sprout extract (equivalent to 21Â mg of sulforaphane), was administered prior to caesarean section. Baseline blood pressure, blood and urine were collected and again at time of operation, alongside umbilical cord blood (vein and artery) and placental samples. 2-4 days post-delivery, a second dose was administered. Two hours later, maternal bloods and breast milk were collected. Samples were processed and analysed by liquid-chromatography mass-spectrometry to measure sulforaphane. Besides an increase in peripheral diastolic blood pressure on the day of caesarean section (pÂ =Â 0.028), there were no changes in maternal blood pressure or heart rate after ingestion of EnduraCell. Sulforaphane was found in maternal serum (70.10Â ng/mlÂ Â±Â 11.90), umbilical cord blood (vein: 25.18Â ng/mLÂ Â±Â 3.11, artery: 18.81Â ng/mLÂ Â±Â 2.36), urine (5726.00Â ng/mLÂ Â±Â 1175.00), placental tissue (10.99Â ng/mgÂ Â±Â 2.11) and breast milk (1.33Â ng/mLÂ Â±Â 2.29). Sulforaphane is present in the umbilical cord and breast milk, providing the world's first evidence of sulforaphane maternal-fetal transfer in humans, and opening avenues for future research into relevant fetal implications.",
    "para1": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°å­•å©¦åŠå…¶èƒå…’æœ‰æ½›åœ¨çš„ä¿è­·ä½œç”¨ã€‚å¦Šå¨ é«˜è¡€å£“ç—‡ï¼ˆå³å­ç™²å‰ç—‡ï¼‰æ˜¯ä¸€ç¨®å½±éŸ¿å­•å©¦å¥åº·çš„ç–¾ç—…ï¼Œå¯èƒ½å°è‡´æ¯é«”å’Œèƒå…’çš„åš´é‡ä½µç™¼ç—‡ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æ¸›å°‘å…§çš®åŠŸèƒ½éšœç¤™çš„æœ‰å®³å½±éŸ¿ï¼Œé€™ä½¿å¾—å®ƒæˆç‚ºä¸€å€‹æœ‰å¸Œæœ›çš„æ²»ç™‚é¸æ“‡ã€‚é›–ç„¶ç›®å‰å°šä¸æ¸…æ¥šè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æœ‰æ•ˆè½‰ç§»åˆ°èƒå…’èº«ä¸Šï¼Œä½†é€™é …ç ”ç©¶çš„çµæœç‚ºæœªä¾†çš„ç›¸é—œç ”ç©¶æä¾›äº†åŸºç¤ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„å­•å©¦å’Œèƒå…’çš„å¥åº·ç‹€æ³ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å­•å©¦ä¸­çš„æ‡‰ç”¨ï¼Œç‰¹åˆ¥æ˜¯å®ƒæ˜¯å¦èƒ½å¤ å¾æ¯é«”è½‰ç§»åˆ°èƒå…’ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½åœ¨å­•å©¦é«”å…§è¢«æœ‰æ•ˆå¸æ”¶ä¸¦é€²ä¸€æ­¥è½‰ç§»åˆ°èƒå…’ï¼Œé€™å°æ–¼ç†è§£å…¶æ½›åœ¨çš„å¥åº·ç›Šè™•è‡³é—œé‡è¦ã€‚å¦Šå¨ é«˜è¡€å£“ç—‡æ˜¯ä¸€å€‹é‡è¦çš„å…¬å…±å¥åº·å•é¡Œï¼Œå› æ­¤äº†è§£é€™ç¨®å¤©ç„¶æŠ—æ°§åŒ–åŠ‘çš„ä½œç”¨å¯èƒ½æœƒå°æœªä¾†çš„æ²»ç™‚ç­–ç•¥ç”¢ç”Ÿå½±éŸ¿ã€‚",
    "para3": "åœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…æ‹›å‹Ÿäº†8ä½å¥åº·çš„å­•å©¦ï¼Œé€™äº›å­•å©¦åœ¨æ‡·å­•è¶…é37é€±æ™‚ï¼Œè¨ˆåŠƒé€²è¡Œå‰–è…¹ç”¢æ‰‹è¡“ã€‚åƒèˆ‡è€…åœ¨æ‰‹è¡“å‰æ¥å—äº†è˜¿è””ç¡«ç´ æå–ç‰©ï¼ˆEnduraCellï¼‰çš„å–®æ¬¡å£æœåŠ‘é‡ï¼Œé€™ç›¸ç•¶æ–¼21æ¯«å…‹çš„è˜¿è””ç¡«ç´ ã€‚ç ”ç©¶åœ˜éšŠåœ¨æ‰‹è¡“å‰å’Œæ‰‹è¡“æ™‚æ”¶é›†äº†æ¯é«”çš„è¡€å£“ã€è¡€æ¶²å’Œå°¿æ¶²æ¨£æœ¬ï¼Œä¸¦åœ¨æ‰‹è¡“å¾Œ2-4å¤©å†æ¬¡çµ¦äºˆç¬¬äºŒåŠ‘é‡çš„è˜¿è””ç¡«ç´ ï¼Œéš¨å¾Œæ”¶é›†æ¯é«”è¡€æ¶²å’Œæ¯ä¹³æ¨£æœ¬ã€‚æ‰€æœ‰æ¨£æœ¬éƒ½ç¶“éæ¶²ç›¸è‰²è­œè³ªè­œåˆ†æï¼Œä»¥æ¸¬é‡è˜¿è””ç¡«ç´ çš„å«é‡ã€‚",
    "para4": "ç ”ç©¶çš„ä¸»è¦ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ åœ¨æ¯é«”è¡€æ¸…ã€è‡å¸¶è¡€ã€å°¿æ¶²ã€èƒç›¤çµ„ç¹”å’Œæ¯ä¹³ä¸­å‡æœ‰æª¢æ¸¬åˆ°ï¼Œé€™æ˜¯å…¨çƒé¦–æ¬¡è­‰å¯¦è˜¿è””ç¡«ç´ èƒ½å¤ åœ¨å­•å©¦å’Œèƒå…’ä¹‹é–“è½‰ç§»çš„è­‰æ“šã€‚é›–ç„¶åœ¨å‰–è…¹ç”¢ç•¶å¤©ï¼Œæ¯é«”çš„å¤–å‘¨èˆ’å¼µå£“æœ‰æ‰€ä¸Šå‡ï¼Œä½†åœ¨æ”å–è˜¿è””ç¡«ç´ å¾Œï¼Œæ¯é«”çš„è¡€å£“å’Œå¿ƒç‡ä¸¦æœªé¡¯è‘—è®ŠåŒ–ã€‚é€™äº›çµæœç‚ºæœªä¾†ç ”ç©¶æä¾›äº†æ–°çš„æ–¹å‘ï¼Œç‰¹åˆ¥æ˜¯é—œæ–¼è˜¿è””ç¡«ç´ å°èƒå…’çš„æ½›åœ¨å½±éŸ¿ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°å­•å©¦åŠå…¶èƒå…’æœ‰æ½›åœ¨çš„ä¿è­·ä½œç”¨ã€‚å¦Šå¨ é«˜è¡€å£“ç—‡ï¼ˆå³å­ç™²å‰ç—‡ï¼‰æ˜¯ä¸€ç¨®å½±éŸ¿å­•å©¦å¥åº·çš„ç–¾ç—…ï¼Œå¯èƒ½å°è‡´æ¯é«”å’Œèƒå…’çš„åš´é‡ä½µç™¼ç—‡ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æ¸›å°‘å…§çš®åŠŸèƒ½éšœç¤™çš„æœ‰å®³å½±éŸ¿ï¼Œé€™ä½¿å¾—å®ƒæˆç‚ºä¸€å€‹æœ‰å¸Œæœ›çš„æ²»ç™‚é¸æ“‡ã€‚é›–ç„¶ç›®å‰å°šä¸æ¸…æ¥šè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æœ‰æ•ˆè½‰ç§»åˆ°èƒå…’èº«ä¸Šï¼Œä½†é€™é …ç ”ç©¶çš„çµæœç‚ºæœªä¾†çš„ç›¸é—œç ”ç©¶æä¾›äº†åŸºç¤ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„å­•å©¦å’Œèƒå…’çš„å¥åº·ç‹€æ³ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å­•å©¦ä¸­çš„æ‡‰ç”¨ï¼Œç‰¹åˆ¥æ˜¯å®ƒæ˜¯å¦èƒ½å¤ å¾æ¯é«”è½‰ç§»åˆ°èƒå…’ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½åœ¨å­•å©¦é«”å…§è¢«æœ‰æ•ˆå¸æ”¶ä¸¦é€²ä¸€æ­¥è½‰ç§»åˆ°èƒå…’ï¼Œé€™å°æ–¼ç†è§£å…¶æ½›åœ¨çš„å¥åº·ç›Šè™•è‡³é—œé‡è¦ã€‚å¦Šå¨ é«˜è¡€å£“ç—‡æ˜¯ä¸€å€‹é‡è¦çš„å…¬å…±å¥åº·å•é¡Œï¼Œå› æ­¤äº†è§£é€™ç¨®å¤©ç„¶æŠ—æ°§åŒ–åŠ‘çš„ä½œç”¨å¯èƒ½æœƒå°æœªä¾†çš„æ²»ç™‚ç­–ç•¥ç”¢ç”Ÿå½±éŸ¿ã€‚\n\nåœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…æ‹›å‹Ÿäº†8ä½å¥åº·çš„å­•å©¦ï¼Œé€™äº›å­•å©¦åœ¨æ‡·å­•è¶…é37é€±æ™‚ï¼Œè¨ˆåŠƒé€²è¡Œå‰–è…¹ç”¢æ‰‹è¡“ã€‚åƒèˆ‡è€…åœ¨æ‰‹è¡“å‰æ¥å—äº†è˜¿è””ç¡«ç´ æå–ç‰©ï¼ˆEnduraCellï¼‰çš„å–®æ¬¡å£æœåŠ‘é‡ï¼Œé€™ç›¸ç•¶æ–¼21æ¯«å…‹çš„è˜¿è””ç¡«ç´ ã€‚ç ”ç©¶åœ˜éšŠåœ¨æ‰‹è¡“å‰å’Œæ‰‹è¡“æ™‚æ”¶é›†äº†æ¯é«”çš„è¡€å£“ã€è¡€æ¶²å’Œå°¿æ¶²æ¨£æœ¬ï¼Œä¸¦åœ¨æ‰‹è¡“å¾Œ2-4å¤©å†æ¬¡çµ¦äºˆç¬¬äºŒåŠ‘é‡çš„è˜¿è””ç¡«ç´ ï¼Œéš¨å¾Œæ”¶é›†æ¯é«”è¡€æ¶²å’Œæ¯ä¹³æ¨£æœ¬ã€‚æ‰€æœ‰æ¨£æœ¬éƒ½ç¶“éæ¶²ç›¸è‰²è­œè³ªè­œåˆ†æï¼Œä»¥æ¸¬é‡è˜¿è””ç¡«ç´ çš„å«é‡ã€‚\n\nç ”ç©¶çš„ä¸»è¦ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ åœ¨æ¯é«”è¡€æ¸…ã€è‡å¸¶è¡€ã€å°¿æ¶²ã€èƒç›¤çµ„ç¹”å’Œæ¯ä¹³ä¸­å‡æœ‰æª¢æ¸¬åˆ°ï¼Œé€™æ˜¯å…¨çƒé¦–æ¬¡è­‰å¯¦è˜¿è””ç¡«ç´ èƒ½å¤ åœ¨å­•å©¦å’Œèƒå…’ä¹‹é–“è½‰ç§»çš„è­‰æ“šã€‚é›–ç„¶åœ¨å‰–è…¹ç”¢ç•¶å¤©ï¼Œæ¯é«”çš„å¤–å‘¨èˆ’å¼µå£“æœ‰æ‰€ä¸Šå‡ï¼Œä½†åœ¨æ”å–è˜¿è””ç¡«ç´ å¾Œï¼Œæ¯é«”çš„è¡€å£“å’Œå¿ƒç‡ä¸¦æœªé¡¯è‘—è®ŠåŒ–ã€‚é€™äº›çµæœç‚ºæœªä¾†ç ”ç©¶æä¾›äº†æ–°çš„æ–¹å‘ï¼Œç‰¹åˆ¥æ˜¯é—œæ–¼è˜¿è””ç¡«ç´ å°èƒå…’çš„æ½›åœ¨å½±éŸ¿ã€‚",
    "fb_post": "æ ¹æ“šã€ŠPlacentaã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒŸä½ çŸ¥é“å—ï¼Ÿè˜¿è””è£¡çš„ç§˜å¯†æˆåˆ†ï¼Œå¯èƒ½å°å­•åª½å’ªå’Œå°å¯¶å¯¶æœ‰å¤§å¹«åŠ©ï¼ğŸŒŸæœ€è¿‘æœ‰ä¸€é …ç ”ç©¶èšç„¦æ–¼è˜¿è””ç¡«ç´ ï¼Œé€™æ˜¯ä¸€ç¨®å¤©ç„¶çš„æŠ—æ°§åŒ–åŠ‘ï¼Œç§‘å­¸å®¶å€‘æƒ³äº†è§£å®ƒæ˜¯å¦èƒ½å¤ å¾å­•å©¦çš„èº«é«”è½‰ç§»åˆ°èƒå…’èº«ä¸Šï¼Œç‰¹åˆ¥æ˜¯å°æ–¼å¦Šå¨ é«˜è¡€å£“ç—‡ï¼ˆé€™æ˜¯ä¸€ç¨®å½±éŸ¿å­•å©¦å¥åº·çš„ç–¾ç—…ï¼‰æœ‰æ²’æœ‰æ­£é¢çš„å½±éŸ¿ã€‚  \n  \né€™é …ç ”ç©¶æ‹›å‹Ÿäº†8ä½å¥åº·çš„å­•å©¦ï¼Œåœ¨å¥¹å€‘å³å°‡é€²è¡Œå‰–è…¹ç”¢æ‰‹è¡“å‰ï¼Œçµ¦äºˆå¥¹å€‘ä¸€æ¬¡æ€§çš„è˜¿è””ç¡«ç´ æå–ç‰©ã€‚ç ”ç©¶åœ˜éšŠåœ¨æ‰‹è¡“å‰å¾Œæ”¶é›†äº†æ¯é«”çš„è¡€å£“ã€è¡€æ¶²å’Œå°¿æ¶²æ¨£æœ¬ï¼Œä¸¦åˆ†æäº†é€™äº›æ¨£æœ¬ä¸­çš„è˜¿è””ç¡«ç´ å«é‡ã€‚  \n  \nçµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ä¸åƒ…åœ¨å­•å©¦çš„è¡€æ¶²ä¸­è¢«æª¢æ¸¬åˆ°ï¼Œé‚„èƒ½é€éè‡å¸¶è½‰ç§»åˆ°èƒå…’ï¼Œé€™æ˜¯å…¨çƒé¦–æ¬¡çš„è­‰æ“šï¼é›–ç„¶åœ¨æ‰‹è¡“ç•¶å¤©ï¼Œå­•å©¦çš„è¡€å£“ç•¥æœ‰ä¸Šå‡ï¼Œä½†æ•´é«”ä¸Šä¸¦æœªé€ æˆé¡¯è‘—è®ŠåŒ–ã€‚é€™äº›ç™¼ç¾ç‚ºæœªä¾†çš„ç ”ç©¶é–‹å•Ÿäº†æ–°çš„æ–¹å‘ï¼Œå°¤å…¶æ˜¯è˜¿è””ç¡«ç´ å°èƒå…’çš„æ½›åœ¨å½±éŸ¿ã€‚  \n  \nğŸ” é‡é»æ•´ç†ï¼š  \n1. è˜¿è””ç¡«ç´ å¯èƒ½å°å­•å©¦åŠèƒå…’æœ‰ä¿è­·ä½œç”¨ã€‚  \n2. ç ”ç©¶è­‰å¯¦è˜¿è””ç¡«ç´ å¯ä»¥åœ¨å­•å©¦èˆ‡èƒå…’ä¹‹é–“è½‰ç§»ã€‚  \n3. é€™é …ç ”ç©¶ç‚ºæœªä¾†çš„å¥åº·ç­–ç•¥æä¾›äº†æ–°æ€è·¯ï¼",
    "image_prompt": "Create a flat design infographic on the study of sulforaphane in pregnant women. Include symbols representing broccoli or sulforaphane, simplified illustrations of human subjects, arrows or flow lines showing the experimental steps. Highlight a section labeled 'Main Findings' that summarizes the protective effects and changes observed. Use a light-colored background with soft colors for a friendly and educational look.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "å¦Šå¨ é«˜è¡€å£“ç—‡ Preeclampsia",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40992247/"
  },
  {
    "id": "40633511",
    "title_en": "Synthesis and biological evaluation of Sulforaphane derivatives with dual functions: Ischemia-reperfusion injury protection and antitumor effects.",
    "pub_date": "2025 Nov",
    "journal": "Bioorganic & medicinal chemistry",
    "abstract_en": "Reperfusion therapy for the treatment of acute myocardial infarction (AMI) often leads to ischemia-reperfusion (I/R) injuries, characterized by excessive ROS. Sulforaphane (SFN) homologous, known for their anti-inflammatory and antioxidant properties, activate the nuclear factor-erythroid 2-related factor 2 (Nrf2) pathway and reduce mitochondrial ROS but are limited by poor stability and short half-life. SFN derivatives were synthesized through structural modifications of the dithiocarbamate and thiourea moieties at the isothiocyanate group, aiming to enhance stability and maintain therapeutic efficacy. Compound 3g emerged as a promising candidate, demonstrating superior protection against hypoxia-reoxygenation (H/R) injury in cardiac microvascular endothelial cells (CMECs) and exhibiting good antitumor activity. Specifically, 3g reduced ROS levels by 24.5Â % (compared to nifedipine at 17.8Â %), increased NO production to 48.0Â Î¼M (vs. 44.0Â Î¼M), lowered TNF-Î± secretion to 22.6Â pg/mL (vs. 23.9Â pg/mL). Concurrently, 3g showed potent antiproliferative activity (IC<sub>50</sub>Â =Â 7.5Â Î¼M), with 3.8-fold greater potency than 5-fluorouracil (IC<sub>50</sub>Â =Â 28.2Â Î¼M). Stability studies showed enhanced resistance in both protic and aprotic solvents. Density functional theory (DFT) was applied to characterize the molecular properties of the optimal compounds. Molecular docking and ADMET analysis revealed that aromatic substitution and sulfur oxidation significantly improved Nrf2/Keap1 pathway targeting, highlighting the derivative's potential for stability and therapeutic efficacy. These findings suggest that 3g is a promising candidate for treating I/R-induced injury and oxidative stress-related cardiovascular conditions.",
    "para1": "é€™é …ç ”ç©¶å°æ–¼å¿ƒè¡€ç®¡å¥åº·å’Œæ€¥æ€§å¿ƒè‚Œæ¢—å¡çš„é é˜²æœ‰é‡è¦çš„å•Ÿç¤ºã€‚æ€¥æ€§å¿ƒè‚Œæ¢—å¡çš„æ²»ç™‚é€šå¸¸éœ€è¦å†çŒæ³¨ç™‚æ³•ï¼Œä½†é€™ç¨®ç™‚æ³•å¯èƒ½æœƒå°è‡´ç¼ºè¡€å†çŒæ³¨æå‚·ï¼Œé€™ç¨®æå‚·æœƒç”¢ç”Ÿéå¤šçš„æ´»æ€§æ°§ï¼ˆROSï¼‰ï¼Œå°å¿ƒè‡Ÿé€ æˆé€²ä¸€æ­¥çš„å‚·å®³ã€‚å› æ­¤ï¼Œå°‹æ‰¾èƒ½å¤ æ¸›å°‘é€™äº›æå‚·çš„æ²»ç™‚æ–¹æ³•æ˜¯éå¸¸é‡è¦çš„ã€‚ç ”ç©¶ä¸­æåˆ°çš„è˜¿è””ç¡«ç´ åŠå…¶è¡ç”Ÿç‰©ï¼Œå› ç‚ºå…·æœ‰æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–çš„ç‰¹æ€§ï¼Œå¯èƒ½æˆç‚ºæ”¹å–„å¿ƒè¡€ç®¡å¥åº·çš„æ½›åœ¨é¸æ“‡ï¼Œå°¤å…¶æ˜¯åœ¨é¢å°å†çŒæ³¨æå‚·æ™‚ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯é‡å°æ€¥æ€§å¿ƒè‚Œæ¢—å¡å¾Œçš„ç¼ºè¡€å†çŒæ³¨æå‚·é€²è¡Œæ¢è¨ï¼Œç‰¹åˆ¥æ˜¯å¦‚ä½•åˆ©ç”¨è˜¿è””ç¡«ç´ åŠå…¶è¡ç”Ÿç‰©ä¾†æ¸›å°‘é€™ç¨®æå‚·ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œå¦‚ä½•é€éæ”¹è‰¯è˜¿è””ç¡«ç´ çš„çµæ§‹ä¾†æé«˜å…¶ç©©å®šæ€§å’Œç™‚æ•ˆï¼Œé€²è€Œæ¸›å°‘å¿ƒè‡Ÿå¾®è¡€ç®¡å…§çš®ç´°èƒåœ¨ç¼ºæ°§å†çŒæ³¨éç¨‹ä¸­å—åˆ°çš„æå®³ã€‚é€™äº›ç ”ç©¶çµæœå¯èƒ½å°å¿ƒè¡€ç®¡ç–¾ç—…çš„æ²»ç™‚æä¾›æ–°çš„æ€è·¯ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…åˆæˆäº†å¹¾ç¨®è˜¿è””ç¡«ç´ çš„è¡ç”Ÿç‰©ï¼Œç‰¹åˆ¥æ˜¯é€šéå°äºŒç¡«æ°¨åŸºé…¸å’Œç¡«è„²åŸºåœ˜é€²è¡Œçµæ§‹ä¿®é£¾ï¼Œä»¥æé«˜å…¶ç©©å®šæ€§ã€‚ç ”ç©¶çš„å°è±¡ä¸»è¦æ˜¯å¿ƒè‡Ÿå¾®è¡€ç®¡å…§çš®ç´°èƒï¼Œé€éæ¸¬è©¦é€™äº›è¡ç”Ÿç‰©åœ¨ç¼ºæ°§å†çŒæ³¨æå‚·ä¸­çš„ä¿è­·ä½œç”¨ï¼Œä¾†è©•ä¼°å…¶æ½›åœ¨çš„ç™‚æ•ˆã€‚ç ”ç©¶è€…é‚„ä½¿ç”¨äº†åˆ†å­å°æ¥å’ŒADMETåˆ†æä¾†æ¢è¨é€™äº›åŒ–åˆç‰©çš„åˆ†å­ç‰¹æ€§ï¼Œé€²ä¸€æ­¥äº†è§£å…¶ä½œç”¨æ©Ÿåˆ¶ã€‚",
    "para4": "ä¸»è¦çš„ç ”ç©¶ç™¼ç¾æ˜¯ï¼Œåˆæˆçš„åŒ–åˆç‰©3gåœ¨æ¸›å°‘ç¼ºæ°§å†çŒæ³¨æå‚·æ–¹é¢è¡¨ç¾å‡ºè‰²ï¼Œèƒ½å¤ æœ‰æ•ˆé™ä½æ´»æ€§æ°§çš„æ°´å¹³ï¼Œä¸¦æé«˜ä¸€æ°§åŒ–æ°®çš„ç”¢ç”Ÿã€‚æ­¤å¤–ï¼Œ3gåœ¨æŠ—è…«ç˜¤æ´»æ€§æ–¹é¢ä¹Ÿé¡¯ç¤ºå‡ºè‰¯å¥½çš„æ•ˆæœï¼Œé¡¯ç¤ºå‡ºå…¶åœ¨å¿ƒè¡€ç®¡ç–¾ç—…å’Œç™Œç—‡æ²»ç™‚ä¸­çš„æ½›åŠ›ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œ3gå¯èƒ½æˆç‚ºæ²»ç™‚ç¼ºè¡€å†çŒæ³¨æå‚·åŠç›¸é—œå¿ƒè¡€ç®¡ç–¾ç—…çš„æœ‰å‰æ™¯çš„å€™é¸è—¥ç‰©ï¼Œä½†ä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶ç™‚æ•ˆã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°æ–¼å¿ƒè¡€ç®¡å¥åº·å’Œæ€¥æ€§å¿ƒè‚Œæ¢—å¡çš„é é˜²æœ‰é‡è¦çš„å•Ÿç¤ºã€‚æ€¥æ€§å¿ƒè‚Œæ¢—å¡çš„æ²»ç™‚é€šå¸¸éœ€è¦å†çŒæ³¨ç™‚æ³•ï¼Œä½†é€™ç¨®ç™‚æ³•å¯èƒ½æœƒå°è‡´ç¼ºè¡€å†çŒæ³¨æå‚·ï¼Œé€™ç¨®æå‚·æœƒç”¢ç”Ÿéå¤šçš„æ´»æ€§æ°§ï¼ˆROSï¼‰ï¼Œå°å¿ƒè‡Ÿé€ æˆé€²ä¸€æ­¥çš„å‚·å®³ã€‚å› æ­¤ï¼Œå°‹æ‰¾èƒ½å¤ æ¸›å°‘é€™äº›æå‚·çš„æ²»ç™‚æ–¹æ³•æ˜¯éå¸¸é‡è¦çš„ã€‚ç ”ç©¶ä¸­æåˆ°çš„è˜¿è””ç¡«ç´ åŠå…¶è¡ç”Ÿç‰©ï¼Œå› ç‚ºå…·æœ‰æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–çš„ç‰¹æ€§ï¼Œå¯èƒ½æˆç‚ºæ”¹å–„å¿ƒè¡€ç®¡å¥åº·çš„æ½›åœ¨é¸æ“‡ï¼Œå°¤å…¶æ˜¯åœ¨é¢å°å†çŒæ³¨æå‚·æ™‚ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯é‡å°æ€¥æ€§å¿ƒè‚Œæ¢—å¡å¾Œçš„ç¼ºè¡€å†çŒæ³¨æå‚·é€²è¡Œæ¢è¨ï¼Œç‰¹åˆ¥æ˜¯å¦‚ä½•åˆ©ç”¨è˜¿è””ç¡«ç´ åŠå…¶è¡ç”Ÿç‰©ä¾†æ¸›å°‘é€™ç¨®æå‚·ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œå¦‚ä½•é€éæ”¹è‰¯è˜¿è””ç¡«ç´ çš„çµæ§‹ä¾†æé«˜å…¶ç©©å®šæ€§å’Œç™‚æ•ˆï¼Œé€²è€Œæ¸›å°‘å¿ƒè‡Ÿå¾®è¡€ç®¡å…§çš®ç´°èƒåœ¨ç¼ºæ°§å†çŒæ³¨éç¨‹ä¸­å—åˆ°çš„æå®³ã€‚é€™äº›ç ”ç©¶çµæœå¯èƒ½å°å¿ƒè¡€ç®¡ç–¾ç—…çš„æ²»ç™‚æä¾›æ–°çš„æ€è·¯ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…åˆæˆäº†å¹¾ç¨®è˜¿è””ç¡«ç´ çš„è¡ç”Ÿç‰©ï¼Œç‰¹åˆ¥æ˜¯é€šéå°äºŒç¡«æ°¨åŸºé…¸å’Œç¡«è„²åŸºåœ˜é€²è¡Œçµæ§‹ä¿®é£¾ï¼Œä»¥æé«˜å…¶ç©©å®šæ€§ã€‚ç ”ç©¶çš„å°è±¡ä¸»è¦æ˜¯å¿ƒè‡Ÿå¾®è¡€ç®¡å…§çš®ç´°èƒï¼Œé€éæ¸¬è©¦é€™äº›è¡ç”Ÿç‰©åœ¨ç¼ºæ°§å†çŒæ³¨æå‚·ä¸­çš„ä¿è­·ä½œç”¨ï¼Œä¾†è©•ä¼°å…¶æ½›åœ¨çš„ç™‚æ•ˆã€‚ç ”ç©¶è€…é‚„ä½¿ç”¨äº†åˆ†å­å°æ¥å’ŒADMETåˆ†æä¾†æ¢è¨é€™äº›åŒ–åˆç‰©çš„åˆ†å­ç‰¹æ€§ï¼Œé€²ä¸€æ­¥äº†è§£å…¶ä½œç”¨æ©Ÿåˆ¶ã€‚\n\nä¸»è¦çš„ç ”ç©¶ç™¼ç¾æ˜¯ï¼Œåˆæˆçš„åŒ–åˆç‰©3gåœ¨æ¸›å°‘ç¼ºæ°§å†çŒæ³¨æå‚·æ–¹é¢è¡¨ç¾å‡ºè‰²ï¼Œèƒ½å¤ æœ‰æ•ˆé™ä½æ´»æ€§æ°§çš„æ°´å¹³ï¼Œä¸¦æé«˜ä¸€æ°§åŒ–æ°®çš„ç”¢ç”Ÿã€‚æ­¤å¤–ï¼Œ3gåœ¨æŠ—è…«ç˜¤æ´»æ€§æ–¹é¢ä¹Ÿé¡¯ç¤ºå‡ºè‰¯å¥½çš„æ•ˆæœï¼Œé¡¯ç¤ºå‡ºå…¶åœ¨å¿ƒè¡€ç®¡ç–¾ç—…å’Œç™Œç—‡æ²»ç™‚ä¸­çš„æ½›åŠ›ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œ3gå¯èƒ½æˆç‚ºæ²»ç™‚ç¼ºè¡€å†çŒæ³¨æå‚·åŠç›¸é—œå¿ƒè¡€ç®¡ç–¾ç—…çš„æœ‰å‰æ™¯çš„å€™é¸è—¥ç‰©ï¼Œä½†ä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶ç™‚æ•ˆã€‚",
    "fb_post": "æ ¹æ“šã€ŠBioorganic & medicinal chemistryã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ±ä½ çŸ¥é“å—ï¼Ÿè˜¿è””è£¡é¢è—è‘—æ”¹å–„å¿ƒè‡Ÿå¥åº·çš„ç§˜å¯†ï¼é€™ç¯‡ç ”ç©¶è®“æˆ‘å€‘çœ‹åˆ°äº†è˜¿è””ç¡«ç´ çš„æ½›åŠ›ï¼Œå°¤å…¶æ˜¯åœ¨å¿ƒè‚Œæ¢—å¡å¾Œçš„æ²»ç™‚ä¸­ã€‚\n\nç ”ç©¶è€…å€‘å°ˆæ³¨æ–¼æ€¥æ€§å¿ƒè‚Œæ¢—å¡å¾Œçš„å†çŒæ³¨æå‚·ï¼Œé€™ç¨®æƒ…æ³æœƒå°è‡´å¿ƒè‡Ÿç´°èƒå—æï¼Œä¸¦ç”¢ç”Ÿéå¤šçš„æ´»æ€§æ°§ï¼Œå°å¿ƒè‡Ÿé€ æˆé€²ä¸€æ­¥çš„å‚·å®³ã€‚æ‰€ä»¥ï¼Œä»–å€‘å˜—è©¦æ”¹è‰¯è˜¿è””ç¡«ç´ çš„çµæ§‹ï¼Œè®“å®ƒæ›´ç©©å®šï¼Œå¾è€Œæå‡ç™‚æ•ˆï¼Œå¹«åŠ©å¿ƒè‡Ÿå¾®è¡€ç®¡å…§çš®ç´°èƒæŠµæŠ—é€™ç¨®æå‚·ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œä»–å€‘åˆæˆäº†å¹¾ç¨®æ–°çš„è˜¿è””ç¡«ç´ è¡ç”Ÿç‰©ï¼Œä¸¦ç™¼ç¾å…¶ä¸­ä¸€ç¨®å«åš3gçš„åŒ–åˆç‰©åœ¨ä¿è­·å¿ƒè‡Ÿç´°èƒæ–¹é¢è¡¨ç¾å‡ºè‰²ï¼å®ƒä¸åƒ…èƒ½é™ä½æ´»æ€§æ°§çš„æ°´å¹³ï¼Œé‚„èƒ½å¢åŠ ä¸€æ°§åŒ–æ°®çš„ç”¢ç”Ÿï¼Œç”šè‡³åœ¨æŠ—è…«ç˜¤æ–¹é¢ä¹Ÿæœ‰è‰¯å¥½æ•ˆæœã€‚\n\né€™äº›ç™¼ç¾è®“æˆ‘å€‘å°å¿ƒè¡€ç®¡ç–¾ç—…çš„æ²»ç™‚æœ‰äº†æ–°çš„å¸Œæœ›ï¼Œé›–ç„¶é‚„éœ€è¦æ›´å¤šç ”ç©¶ä¾†ç¢ºèªé€™äº›çµæœï¼Œä½†3gæœ‰æ½›åŠ›æˆç‚ºæœªä¾†çš„æ²»ç™‚é¸æ“‡ï¼\n\nğŸ” ä¸»è¦é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„å¿ƒè‡Ÿå¥åº·ã€‚\n2. æ–°åˆæˆçš„åŒ–åˆç‰©3gåœ¨æ¸›å°‘å¿ƒè‡Ÿæå‚·æ–¹é¢è¡¨ç¾è‰¯å¥½ã€‚\n3. é€™äº›ç ”ç©¶ç‚ºå¿ƒè¡€ç®¡ç–¾ç—…çš„æ²»ç™‚æä¾›äº†æ–°æ€è·¯ï¼",
    "image_prompt": "Create a flat design infographic that explains the experimental process and main results of a study on the protective effects of a compound derived from broccoli and radish sulforaphane. Include simplified icons representing broccoli or radish, experimental subjects like cells, and arrows indicating the steps of the experiment. Highlight a section labeled 'Main Results' showing protective effects and changes observed, using a light background and soft colors.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "å¿ƒè‚Œæ¢—å¡ Myocardial Infarction",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40633511/"
  },
  {
    "id": "40617372",
    "title_en": "Antioxidant effect of esculin and sulforaphane in zebrafish larvae: A comparative study.",
    "pub_date": "2025 Nov",
    "journal": "Comparative biochemistry and physiology. Toxicology & pharmacology : CBP",
    "abstract_en": "Antioxidants are crucial for maintaining cellular redox homeostasis by neutralizing free radicals, including reactive oxygen species (ROS). Nuclear factor erythroid-2-related factor 2 (Nrf2) is a transcription factor that activates various cytoprotective genes to counteract oxidative damage. The present study aimed to compare the antioxidant potential of natural phytochemicals, esculin (ESC), and sulforaphane (SFN) in zebrafish larvae, focusing on Nrf2 activation. Zebrafish larvae were treated with ESC (100Â Î¼M) and SFN (40Â Î¼M) along with control for 6Â h. The levels of ROS, lipid peroxidation (LPO), nitric oxide (NO), glutathione S-transferase (GST), glutathione peroxidase (GPx), catalase (CAT), and reduced glutathione (GSH) were measured. Further, RT-PCR and Western blotting methods were employed to determine the antioxidant genes and protein levels, respectively. In addition, Nrf2 localization within the cell was assessed using nuclear/cytosolic fractionation assay and wholemount immunohistochemistry method. Our results demonstrate that ESC treatment significantly increased antioxidant enzyme activities (GST, GPx, CAT), similar to the effects observed with SFN. Further, ESC enhanced the mRNA levels of antioxidant genes expression, such as nrf2, gstp1, hmox1a, prdx1, nqo1, gss, gsr, sqstm1, hsp90aa1.2 than SFN. Antioxidant proteins Nrf2, Gstp1, Cat, and Sod2 were upregulated in the ESC-treated groups. Subsequently, nuclear localization of Nrf2 was detected in both SFN- and ESC-treated groups, confirming Nrf2 translocation into the nucleus. Our findings suggest that ESC possesses potent antioxidant activity as SFN in 72-hpf zebrafish larvae through the Keap1-Nrf2 signaling pathway.",
    "para1": "é€™é …ç ”ç©¶çš„çµæœå°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æœ‰ä¸€å®šçš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—æ°§åŒ–åŠ‘çš„ä½œç”¨ä¸Šã€‚æŠ—æ°§åŒ–åŠ‘èƒ½å¤ ä¸­å’Œè‡ªç”±åŸºï¼Œé€™äº›è‡ªç”±åŸºèˆ‡è¨±å¤šç–¾ç—…çš„ç™¼å±•æœ‰é—œï¼ŒåŒ…æ‹¬è€åŒ–å’Œæ…¢æ€§ç—…ã€‚å› æ­¤ï¼Œäº†è§£ä¸åŒå¤©ç„¶æ¤ç‰©åŒ–å­¸ç‰©è³ªçš„æŠ—æ°§åŒ–æ½›åŠ›ï¼Œå¯èƒ½æœ‰åŠ©æ–¼é–‹ç™¼æ–°çš„é é˜²ç­–ç•¥ï¼Œä¿ƒé€²å¥åº·ï¼Œæ¸›å°‘ç–¾ç—…é¢¨éšªã€‚ç‰¹åˆ¥æ˜¯é€™é …ç ”ç©¶ä¸­æåˆ°çš„è˜¿è””ç¡«ç´ å’Œå…¶ä»–æ¤ç‰©åŒ–å­¸ç‰©è³ªï¼Œå¯èƒ½æˆç‚ºæœªä¾†å¥åº·é£²é£Ÿçš„é‡è¦çµ„æˆéƒ¨åˆ†ï¼Œå¹«åŠ©æˆ‘å€‘æŠµæŠ—æ°§åŒ–å£“åŠ›ï¼Œç¶­æŒèº«é«”çš„å¥åº·ç‹€æ…‹ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¯”è¼ƒå…©ç¨®å¤©ç„¶æ¤ç‰©åŒ–å­¸ç‰©è³ªâ€”â€”è˜¿è””ç¡«ç´ å’Œå¦ä¸€ç¨®åç‚ºesculinçš„åŒ–åˆç‰©ï¼Œåœ¨æ–‘é¦¬é­šå¹¼é«”ä¸­çš„æŠ—æ°§åŒ–æ½›åŠ›ï¼Œç‰¹åˆ¥æ˜¯å®ƒå€‘å°æ–¼Nrf2é€™ç¨®è½‰éŒ„å› å­çš„æ¿€æ´»æ•ˆæœã€‚Nrf2æ˜¯ä¸€ç¨®é‡è¦çš„è›‹ç™½è³ªï¼Œèƒ½å¤ å•Ÿå‹•å¤šç¨®ä¿è­·ç´°èƒçš„åŸºå› ï¼Œå°æŠ—æ°§åŒ–æå‚·ã€‚ç ”ç©¶è€…å¸Œæœ›é€éé€™é …ç ”ç©¶ï¼Œæ·±å…¥äº†è§£é€™äº›å¤©ç„¶åŒ–åˆç‰©å¦‚ä½•å½±éŸ¿ç´°èƒçš„æŠ—æ°§åŒ–èƒ½åŠ›ï¼Œä¸¦é€²ä¸€æ­¥æ¢è¨å…¶æ½›åœ¨çš„å¥åº·ç›Šè™•ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨72å°æ™‚çš„æ–‘é¦¬é­šå¹¼é«”ä½œç‚ºå¯¦é©—å°è±¡ï¼Œä¸¦å°‡å…¶åˆ†ç‚ºä¸åŒçµ„åˆ¥ï¼Œåˆ†åˆ¥è™•ç†esculinï¼ˆ100Î¼Mï¼‰å’Œè˜¿è””ç¡«ç´ ï¼ˆ40Î¼Mï¼‰ï¼Œä»¥åŠå°ç…§çµ„ï¼ŒæŒçºŒ6å°æ™‚ã€‚å¯¦é©—ä¸­æ¸¬é‡äº†å¤šç¨®æŒ‡æ¨™ï¼ŒåŒ…æ‹¬æ´»æ€§æ°§ï¼ˆROSï¼‰ã€è„‚è³ªéæ°§åŒ–ï¼ˆLPOï¼‰ã€ä¸€æ°§åŒ–æ°®ï¼ˆNOï¼‰ã€ä»¥åŠå¹¾ç¨®æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„ä½¿ç”¨äº†RT-PCRå’Œè¥¿æ–¹å°è·¡æ³•ä¾†åˆ†ææŠ—æ°§åŒ–åŸºå› å’Œè›‹ç™½è³ªçš„è¡¨é”ï¼Œä¸¦é€éç´°èƒæ ¸/ç´°èƒè³ªåˆ†é¤¾å’Œå…¨èº«å…ç–«çµ„ç¹”åŒ–å­¸æ–¹æ³•ä¾†è©•ä¼°Nrf2åœ¨ç´°èƒå…§çš„å®šä½ã€‚",
    "para4": "ä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œesculinè™•ç†çµ„çš„æŠ—æ°§åŒ–é…¶æ´»æ€§é¡¯è‘—å¢åŠ ï¼Œèˆ‡è˜¿è””ç¡«ç´ çš„æ•ˆæœç›¸ä¼¼ã€‚æ­¤å¤–ï¼Œesculiné‚„ä¿ƒé€²äº†å¤šå€‹æŠ—æ°§åŒ–åŸºå› çš„mRNAè¡¨é”ï¼Œé¡¯ç¤ºå‡ºå…¶åœ¨æŠ—æ°§åŒ–æ–¹é¢çš„æ½›åŠ›ã€‚ç ”ç©¶ä¸­è§€å¯Ÿåˆ°ï¼Œç„¡è«–æ˜¯è˜¿è””ç¡«ç´ é‚„æ˜¯esculinè™•ç†çµ„ï¼ŒNrf2å‡èƒ½å¤ è½‰ç§»åˆ°ç´°èƒæ ¸ä¸­ï¼Œé€™è¡¨æ˜é€™äº›åŒ–åˆç‰©èƒ½æœ‰æ•ˆæ¿€æ´»Nrf2ä¿¡è™Ÿé€šè·¯ã€‚é€™äº›çµæœæš—ç¤ºesculinåœ¨æŠ—æ°§åŒ–æ´»æ€§ä¸Šèˆ‡è˜¿è””ç¡«ç´ ç›¸ç•¶ï¼Œä¸¦å¯èƒ½æˆç‚ºæœªä¾†å¥åº·ä¿ƒé€²çš„æ½›åœ¨æˆåˆ†ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶çš„çµæœå°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æœ‰ä¸€å®šçš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—æ°§åŒ–åŠ‘çš„ä½œç”¨ä¸Šã€‚æŠ—æ°§åŒ–åŠ‘èƒ½å¤ ä¸­å’Œè‡ªç”±åŸºï¼Œé€™äº›è‡ªç”±åŸºèˆ‡è¨±å¤šç–¾ç—…çš„ç™¼å±•æœ‰é—œï¼ŒåŒ…æ‹¬è€åŒ–å’Œæ…¢æ€§ç—…ã€‚å› æ­¤ï¼Œäº†è§£ä¸åŒå¤©ç„¶æ¤ç‰©åŒ–å­¸ç‰©è³ªçš„æŠ—æ°§åŒ–æ½›åŠ›ï¼Œå¯èƒ½æœ‰åŠ©æ–¼é–‹ç™¼æ–°çš„é é˜²ç­–ç•¥ï¼Œä¿ƒé€²å¥åº·ï¼Œæ¸›å°‘ç–¾ç—…é¢¨éšªã€‚ç‰¹åˆ¥æ˜¯é€™é …ç ”ç©¶ä¸­æåˆ°çš„è˜¿è””ç¡«ç´ å’Œå…¶ä»–æ¤ç‰©åŒ–å­¸ç‰©è³ªï¼Œå¯èƒ½æˆç‚ºæœªä¾†å¥åº·é£²é£Ÿçš„é‡è¦çµ„æˆéƒ¨åˆ†ï¼Œå¹«åŠ©æˆ‘å€‘æŠµæŠ—æ°§åŒ–å£“åŠ›ï¼Œç¶­æŒèº«é«”çš„å¥åº·ç‹€æ…‹ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¯”è¼ƒå…©ç¨®å¤©ç„¶æ¤ç‰©åŒ–å­¸ç‰©è³ªâ€”â€”è˜¿è””ç¡«ç´ å’Œå¦ä¸€ç¨®åç‚ºesculinçš„åŒ–åˆç‰©ï¼Œåœ¨æ–‘é¦¬é­šå¹¼é«”ä¸­çš„æŠ—æ°§åŒ–æ½›åŠ›ï¼Œç‰¹åˆ¥æ˜¯å®ƒå€‘å°æ–¼Nrf2é€™ç¨®è½‰éŒ„å› å­çš„æ¿€æ´»æ•ˆæœã€‚Nrf2æ˜¯ä¸€ç¨®é‡è¦çš„è›‹ç™½è³ªï¼Œèƒ½å¤ å•Ÿå‹•å¤šç¨®ä¿è­·ç´°èƒçš„åŸºå› ï¼Œå°æŠ—æ°§åŒ–æå‚·ã€‚ç ”ç©¶è€…å¸Œæœ›é€éé€™é …ç ”ç©¶ï¼Œæ·±å…¥äº†è§£é€™äº›å¤©ç„¶åŒ–åˆç‰©å¦‚ä½•å½±éŸ¿ç´°èƒçš„æŠ—æ°§åŒ–èƒ½åŠ›ï¼Œä¸¦é€²ä¸€æ­¥æ¢è¨å…¶æ½›åœ¨çš„å¥åº·ç›Šè™•ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨72å°æ™‚çš„æ–‘é¦¬é­šå¹¼é«”ä½œç‚ºå¯¦é©—å°è±¡ï¼Œä¸¦å°‡å…¶åˆ†ç‚ºä¸åŒçµ„åˆ¥ï¼Œåˆ†åˆ¥è™•ç†esculinï¼ˆ100Î¼Mï¼‰å’Œè˜¿è””ç¡«ç´ ï¼ˆ40Î¼Mï¼‰ï¼Œä»¥åŠå°ç…§çµ„ï¼ŒæŒçºŒ6å°æ™‚ã€‚å¯¦é©—ä¸­æ¸¬é‡äº†å¤šç¨®æŒ‡æ¨™ï¼ŒåŒ…æ‹¬æ´»æ€§æ°§ï¼ˆROSï¼‰ã€è„‚è³ªéæ°§åŒ–ï¼ˆLPOï¼‰ã€ä¸€æ°§åŒ–æ°®ï¼ˆNOï¼‰ã€ä»¥åŠå¹¾ç¨®æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„ä½¿ç”¨äº†RT-PCRå’Œè¥¿æ–¹å°è·¡æ³•ä¾†åˆ†ææŠ—æ°§åŒ–åŸºå› å’Œè›‹ç™½è³ªçš„è¡¨é”ï¼Œä¸¦é€éç´°èƒæ ¸/ç´°èƒè³ªåˆ†é¤¾å’Œå…¨èº«å…ç–«çµ„ç¹”åŒ–å­¸æ–¹æ³•ä¾†è©•ä¼°Nrf2åœ¨ç´°èƒå…§çš„å®šä½ã€‚\n\nä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œesculinè™•ç†çµ„çš„æŠ—æ°§åŒ–é…¶æ´»æ€§é¡¯è‘—å¢åŠ ï¼Œèˆ‡è˜¿è””ç¡«ç´ çš„æ•ˆæœç›¸ä¼¼ã€‚æ­¤å¤–ï¼Œesculiné‚„ä¿ƒé€²äº†å¤šå€‹æŠ—æ°§åŒ–åŸºå› çš„mRNAè¡¨é”ï¼Œé¡¯ç¤ºå‡ºå…¶åœ¨æŠ—æ°§åŒ–æ–¹é¢çš„æ½›åŠ›ã€‚ç ”ç©¶ä¸­è§€å¯Ÿåˆ°ï¼Œç„¡è«–æ˜¯è˜¿è””ç¡«ç´ é‚„æ˜¯esculinè™•ç†çµ„ï¼ŒNrf2å‡èƒ½å¤ è½‰ç§»åˆ°ç´°èƒæ ¸ä¸­ï¼Œé€™è¡¨æ˜é€™äº›åŒ–åˆç‰©èƒ½æœ‰æ•ˆæ¿€æ´»Nrf2ä¿¡è™Ÿé€šè·¯ã€‚é€™äº›çµæœæš—ç¤ºesculinåœ¨æŠ—æ°§åŒ–æ´»æ€§ä¸Šèˆ‡è˜¿è””ç¡«ç´ ç›¸ç•¶ï¼Œä¸¦å¯èƒ½æˆç‚ºæœªä¾†å¥åº·ä¿ƒé€²çš„æ½›åœ¨æˆåˆ†ã€‚",
    "fb_post": "æ ¹æ“šã€ŠComparative biochemistry and physiology. Toxicology & pharmacology : CBPã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ½ï¸ å¤§å®¶çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„é£²é£Ÿä¸­æœ‰äº›å¤©ç„¶æˆåˆ†å¯ä»¥å¹«åŠ©æˆ‘å€‘æŠµæŠ—æ°§åŒ–å£“åŠ›ï¼Œå°å¥åº·éå¸¸æœ‰å¹«åŠ©ï¼æœ€è¿‘æœ‰ä¸€é …æœ‰è¶£çš„ç ”ç©¶ï¼Œç‰¹åˆ¥é—œæ³¨äº†ã€Œè˜¿è””ç¡«ç´ ã€å’Œå¦ä¸€ç¨®å«ã€Œesculinã€çš„å¤©ç„¶åŒ–åˆç‰©ï¼Œçœ‹çœ‹å®ƒå€‘å°æˆ‘å€‘èº«é«”çš„æŠ—æ°§åŒ–èƒ½åŠ›æœ‰ä»€éº¼å½±éŸ¿ã€‚  \n  \nç ”ç©¶è€…å€‘ç”¨æ–‘é¦¬é­šå¹¼é«”ä¾†é€²è¡Œå¯¦é©—ï¼Œé€™äº›å°é­šåœ¨æ°´ä¸­æ¸¸æ³³æ™‚ï¼Œåˆ†åˆ¥æ¥å—äº†é€™å…©ç¨®åŒ–åˆç‰©çš„è™•ç†ã€‚ä»–å€‘æ¸¬é‡äº†åƒæ˜¯æ´»æ€§æ°§ã€è„‚è³ªéæ°§åŒ–ç­‰æŒ‡æ¨™ï¼Œé‚„æª¢æ¸¬äº†æŠ—æ°§åŒ–åŸºå› å’Œè›‹ç™½è³ªçš„è¡¨é”ã€‚çµæœé¡¯ç¤ºï¼Œesculinå’Œè˜¿è””ç¡«ç´ éƒ½èƒ½æœ‰æ•ˆæ¿€æ´»ä¸€ç¨®å«Nrf2çš„è›‹ç™½è³ªï¼Œé€™å°ä¿è­·ç´°èƒéå¸¸é‡è¦ï¼  \n  \nä»¥ä¸‹æ˜¯é€™é …ç ”ç©¶çš„å¹¾å€‹é‡é»ï¼š  \n1. è˜¿è””ç¡«ç´ å’Œesculinéƒ½èƒ½æå‡æŠ—æ°§åŒ–èƒ½åŠ›ï¼Œå°æŠ—è‡ªç”±åŸºçš„æå®³ã€‚  \n2. é€™äº›å¤©ç„¶æˆåˆ†å¯èƒ½æˆç‚ºå¥åº·é£²é£Ÿçš„é‡è¦è§’è‰²ï¼Œå¹«åŠ©æˆ‘å€‘ç¶­æŒèº«é«”å¥åº·ã€‚  \n3. ç ”ç©¶çµæœæš—ç¤ºï¼Œesculinçš„æŠ—æ°§åŒ–æ•ˆæœèˆ‡è˜¿è””ç¡«ç´ ç›¸ä¼¼ï¼Œæœªä¾†å¯èƒ½æœ‰æ›´å¤šæ‡‰ç”¨ï¼  \n  \nå¸Œæœ›å¤§å®¶éƒ½èƒ½åœ¨é£²é£Ÿä¸­å¤šåŠ æ³¨æ„ï¼Œé¸æ“‡å°å¥åº·æœ‰ç›Šçš„é£Ÿæï¼",
    "image_prompt": "Create a flat design infographic with a light background. Include symbols representing broccoli or daikon sulforaphane. Simplified illustrations of experimental subjects like humans, animals, or cells should be present. Use arrows or flow lines to show the experimental process. Include a section labeled 'Main Results' that highlights protective effects or changes observed in the study.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": false,
    "disease_name": "",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40617372/"
  },
  {
    "id": "40533430",
    "title_en": "Monovalent glycoconjugates of sulforaphane prevent inflammation induced by lipopolysaccharide in human dendritic cells by inhibiting NF-Ä¸B signalling pathway.",
    "pub_date": "2025 Nov",
    "journal": "British journal of pharmacology",
    "abstract_en": "Sulforaphane (SFN) has notable health benefits but faces challenges due to its poor solubility and delivery. This study investigates SFN-glycoconjugates effects on lipopolysaccharide (LPS)-induced inflammation in dendritic cells (DCs). With the aiming to enhance their therapeutic potential against inflammatory diseases. Novel monovalent SFN-glycoconjugates with mannose (Man) and fucose (0Fuc) were developed and tested for their anti-inflammatory and immune-modulatory properties in DCs from healthy donors under chronic LPS exposure. By leveraging therapeutic strategies, SFN-glycoconjugates significantly improved the solubility and bioavailability of SFN, thereby overcoming the limitations of traditional delivery methods. Monocyte-derived DCs were treated with SFN-glycoconjugates and subsequently exposed to a chronic inflammatory environment induced by LPS. Our results showed that SFN-glycoconjugates enhance effectiveness in suppressing inflammation by targeting the p65 NF-ÎºB pathway, without affecting MAPK signalling. SFN-glycoconjugates induce a tolerogenic immune response, characterized by increased IL-10 production and enhanced regulatory T- and B-cell proliferation. These effects surpass those of p65 NF-ÎºB inhibition alone, highlighting a distinct and potent regulatory mechanism independent of MAPK pathways. The integration of food therapeutic strategies not only enhances the stability and delivery of bioactive compounds but also broadens their potential applications in functional foods and therapeutic approaches. In particular, SFN-glycoconjugates represent a promising option as biologically active compounds for inflammatory diseases, offering enhanced anti-inflammatory and immunomodulatory effects through optimized delivery systems and the activation of specific molecular pathways.",
    "para1": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å…·æœ‰é¡¯è‘—å¥åº·ç›Šè™•çš„åŒ–åˆç‰©ï¼Œä½†ç”±æ–¼å…¶æº¶è§£åº¦å·®å’Œå‚³éå›°é›£ï¼Œé€™ä½¿å¾—å®ƒçš„æ‡‰ç”¨å—åˆ°æŒ‘æˆ°ã€‚é€™é …ç ”ç©¶çš„çµæœå¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æœ‰é‡è¦å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨å°æŠ—ç‚ç—‡ç›¸é—œç–¾ç—…æ–¹é¢ã€‚é€éæ”¹å–„è˜¿è””ç¡«ç´ çš„å‚³éæ–¹å¼ï¼Œé€™é …ç ”ç©¶å¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚æ–¹æ³•æä¾›æ–°çš„æ€è·¯ï¼Œè®“æˆ‘å€‘èƒ½æ›´æœ‰æ•ˆåœ°åˆ©ç”¨é€™ç¨®å¤©ç„¶åŒ–åˆç‰©ä¾†ä¿ƒé€²å¥åº·å’Œæ¸›å°‘ç–¾ç—…é¢¨éšªã€‚",
    "para2": "é€™é …ç ”ç©¶ä¸»è¦é—œæ³¨è˜¿è””ç¡«ç´ -ç³–è‹·çµåˆç‰©å°æ–¼ç”±è„‚å¤šé†£ï¼ˆLPSï¼‰å¼•èµ·çš„ç‚ç—‡åæ‡‰çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å¸Œæœ›é€éé€™äº›æ–°å‹çš„è˜¿è””ç¡«ç´ -ç³–è‹·çµåˆç‰©ä¾†å¢å¼·å…¶å°æŠ—ç‚ç—‡ç–¾ç—…çš„ç™‚æ•ˆã€‚é€™é …ç ”ç©¶ä¸åƒ…æ¢è¨äº†é€™äº›åŒ–åˆç‰©çš„æŠ—ç‚ç‰¹æ€§ï¼Œé‚„é—œå¿ƒå®ƒå€‘å¦‚ä½•å½±éŸ¿å…ç–«ç³»çµ±çš„èª¿ç¯€ï¼Œç‰¹åˆ¥æ˜¯åœ¨æ…¢æ€§ç‚ç—‡ç’°å¢ƒä¸­çš„ä½œç”¨ã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ä¾†è‡ªå¥åº·æè´ˆè€…çš„æ¨¹çªç´°èƒï¼Œä¸¦å°‡å…¶æš´éœ²æ–¼æ…¢æ€§LPSç’°å¢ƒä¸­ã€‚ç ”ç©¶è€…é–‹ç™¼äº†æ–°å‹çš„å–®åƒ¹è˜¿è””ç¡«ç´ -ç³–è‹·çµåˆç‰©ï¼Œä¸¦å°å…¶æŠ—ç‚å’Œå…ç–«èª¿ç¯€ç‰¹æ€§é€²è¡Œäº†æ¸¬è©¦ã€‚é€™äº›ç³–è‹·çµåˆç‰©çš„è¨­è¨ˆæ—¨åœ¨æé«˜è˜¿è””ç¡«ç´ çš„æº¶è§£åº¦å’Œç”Ÿç‰©åˆ©ç”¨åº¦ï¼Œä»¥å…‹æœå‚³çµ±å‚³éæ–¹æ³•çš„é™åˆ¶ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ -ç³–è‹·çµåˆç‰©åœ¨æŠ‘åˆ¶ç‚ç—‡æ–¹é¢çš„æ•ˆæœé¡¯è‘—ï¼Œç‰¹åˆ¥æ˜¯é€šéé‡å°p65 NF-ÎºBé€”å¾‘ä¾†å¯¦ç¾ï¼Œè€Œä¸å½±éŸ¿MAPKä¿¡è™Ÿå‚³å°ã€‚é€™äº›çµåˆç‰©èƒ½èª˜å°è€å—æ€§å…ç–«åæ‡‰ï¼Œå¢åŠ IL-10çš„ç”¢ç”Ÿï¼Œä¸¦ä¿ƒé€²èª¿ç¯€æ€§Tç´°èƒå’ŒBç´°èƒçš„å¢æ®–ã€‚é€™äº›æ•ˆæœè¶…éäº†å–®ç´”æŠ‘åˆ¶p65 NF-ÎºBçš„ä½œç”¨ï¼Œé¡¯ç¤ºå‡ºä¸€ç¨®ç¨ç‰¹ä¸”å¼·æ•ˆçš„èª¿ç¯€æ©Ÿåˆ¶ï¼Œé€™ç‚ºæœªä¾†åœ¨åŠŸèƒ½æ€§é£Ÿå“å’Œæ²»ç™‚æ–¹æ³•ä¸­çš„æ‡‰ç”¨æä¾›äº†æ–°çš„å¯èƒ½æ€§ã€‚",
    "explanation_zh": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å…·æœ‰é¡¯è‘—å¥åº·ç›Šè™•çš„åŒ–åˆç‰©ï¼Œä½†ç”±æ–¼å…¶æº¶è§£åº¦å·®å’Œå‚³éå›°é›£ï¼Œé€™ä½¿å¾—å®ƒçš„æ‡‰ç”¨å—åˆ°æŒ‘æˆ°ã€‚é€™é …ç ”ç©¶çš„çµæœå¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æœ‰é‡è¦å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨å°æŠ—ç‚ç—‡ç›¸é—œç–¾ç—…æ–¹é¢ã€‚é€éæ”¹å–„è˜¿è””ç¡«ç´ çš„å‚³éæ–¹å¼ï¼Œé€™é …ç ”ç©¶å¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚æ–¹æ³•æä¾›æ–°çš„æ€è·¯ï¼Œè®“æˆ‘å€‘èƒ½æ›´æœ‰æ•ˆåœ°åˆ©ç”¨é€™ç¨®å¤©ç„¶åŒ–åˆç‰©ä¾†ä¿ƒé€²å¥åº·å’Œæ¸›å°‘ç–¾ç—…é¢¨éšªã€‚\n\né€™é …ç ”ç©¶ä¸»è¦é—œæ³¨è˜¿è””ç¡«ç´ -ç³–è‹·çµåˆç‰©å°æ–¼ç”±è„‚å¤šé†£ï¼ˆLPSï¼‰å¼•èµ·çš„ç‚ç—‡åæ‡‰çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å¸Œæœ›é€éé€™äº›æ–°å‹çš„è˜¿è””ç¡«ç´ -ç³–è‹·çµåˆç‰©ä¾†å¢å¼·å…¶å°æŠ—ç‚ç—‡ç–¾ç—…çš„ç™‚æ•ˆã€‚é€™é …ç ”ç©¶ä¸åƒ…æ¢è¨äº†é€™äº›åŒ–åˆç‰©çš„æŠ—ç‚ç‰¹æ€§ï¼Œé‚„é—œå¿ƒå®ƒå€‘å¦‚ä½•å½±éŸ¿å…ç–«ç³»çµ±çš„èª¿ç¯€ï¼Œç‰¹åˆ¥æ˜¯åœ¨æ…¢æ€§ç‚ç—‡ç’°å¢ƒä¸­çš„ä½œç”¨ã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ä¾†è‡ªå¥åº·æè´ˆè€…çš„æ¨¹çªç´°èƒï¼Œä¸¦å°‡å…¶æš´éœ²æ–¼æ…¢æ€§LPSç’°å¢ƒä¸­ã€‚ç ”ç©¶è€…é–‹ç™¼äº†æ–°å‹çš„å–®åƒ¹è˜¿è””ç¡«ç´ -ç³–è‹·çµåˆç‰©ï¼Œä¸¦å°å…¶æŠ—ç‚å’Œå…ç–«èª¿ç¯€ç‰¹æ€§é€²è¡Œäº†æ¸¬è©¦ã€‚é€™äº›ç³–è‹·çµåˆç‰©çš„è¨­è¨ˆæ—¨åœ¨æé«˜è˜¿è””ç¡«ç´ çš„æº¶è§£åº¦å’Œç”Ÿç‰©åˆ©ç”¨åº¦ï¼Œä»¥å…‹æœå‚³çµ±å‚³éæ–¹æ³•çš„é™åˆ¶ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ -ç³–è‹·çµåˆç‰©åœ¨æŠ‘åˆ¶ç‚ç—‡æ–¹é¢çš„æ•ˆæœé¡¯è‘—ï¼Œç‰¹åˆ¥æ˜¯é€šéé‡å°p65 NF-ÎºBé€”å¾‘ä¾†å¯¦ç¾ï¼Œè€Œä¸å½±éŸ¿MAPKä¿¡è™Ÿå‚³å°ã€‚é€™äº›çµåˆç‰©èƒ½èª˜å°è€å—æ€§å…ç–«åæ‡‰ï¼Œå¢åŠ IL-10çš„ç”¢ç”Ÿï¼Œä¸¦ä¿ƒé€²èª¿ç¯€æ€§Tç´°èƒå’ŒBç´°èƒçš„å¢æ®–ã€‚é€™äº›æ•ˆæœè¶…éäº†å–®ç´”æŠ‘åˆ¶p65 NF-ÎºBçš„ä½œç”¨ï¼Œé¡¯ç¤ºå‡ºä¸€ç¨®ç¨ç‰¹ä¸”å¼·æ•ˆçš„èª¿ç¯€æ©Ÿåˆ¶ï¼Œé€™ç‚ºæœªä¾†åœ¨åŠŸèƒ½æ€§é£Ÿå“å’Œæ²»ç™‚æ–¹æ³•ä¸­çš„æ‡‰ç”¨æä¾›äº†æ–°çš„å¯èƒ½æ€§ã€‚",
    "fb_post": "æ ¹æ“šã€ŠBritish journal of pharmacologyã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿè˜¿è””è£¡é¢æœ‰ä¸€ç¨®ç¥å¥‡çš„æˆåˆ†å«è˜¿è””ç¡«ç´ ï¼Œå°å¥åº·æœ‰å¾ˆå¤šå¥½è™•ï¼ä½†æ˜¯ï¼Œé€™ç¨®æˆåˆ†ä¸å®¹æ˜“è¢«èº«é«”å¸æ”¶ï¼Œé€™è®“å®ƒçš„æ‡‰ç”¨è®Šå¾—æœ‰é»æ£˜æ‰‹ã€‚æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶å°ˆæ³¨æ–¼å¦‚ä½•æ”¹å–„é€™å€‹å•é¡Œï¼Œè®“æˆ‘å€‘èƒ½æ›´æœ‰æ•ˆåœ°åˆ©ç”¨è˜¿è””ç¡«ç´ ä¾†å°æŠ—ç‚ç—‡ç›¸é—œçš„ç–¾ç—…ã€‚\n\né€™é …ç ”ç©¶çš„åœ˜éšŠä¸»è¦é—œå¿ƒçš„æ˜¯ä¸€ç¨®æ–°å‹çš„è˜¿è””ç¡«ç´ -ç³–è‹·çµåˆç‰©ï¼Œçœ‹çœ‹å®ƒå°ç”±è„‚å¤šé†£ï¼ˆLPSï¼‰å¼•èµ·çš„ç‚ç—‡åæ‡‰æœ‰ä»€éº¼å½±éŸ¿ã€‚ç ”ç©¶è€…ä½¿ç”¨å¥åº·æè´ˆè€…çš„æ¨¹çªç´°èƒï¼Œä¸¦å°‡å…¶ç½®æ–¼æ…¢æ€§ç‚ç—‡çš„ç’°å¢ƒä¸­ï¼Œæ¸¬è©¦é€™äº›æ–°å‹çµåˆç‰©çš„æŠ—ç‚ç‰¹æ€§ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œé€™äº›è˜¿è””ç¡«ç´ -ç³–è‹·çµåˆç‰©åœ¨æŠ‘åˆ¶ç‚ç—‡æ–¹é¢æ•ˆæœé¡¯è‘—ï¼Œç‰¹åˆ¥æ˜¯é€éä¸€ç¨®å«åšp65 NF-ÎºBçš„è·¯å¾‘ä¾†ç™¼æ®ä½œç”¨ï¼Œä¸¦ä¸”ä¸æœƒå½±éŸ¿å…¶ä»–ä¿¡è™Ÿå‚³å°ã€‚é€™ä¸åƒ…èƒ½å¢åŠ å…ç–«ç³»çµ±ä¸­çš„æŸäº›æœ‰ç›Šç´°èƒï¼Œé‚„å¯èƒ½ç‚ºæœªä¾†çš„å¥åº·é£Ÿå“å’Œæ²»ç™‚æ–¹æ³•é–‹å•Ÿæ–°çš„å¤§é–€ã€‚\n\nğŸ” ä¸»è¦é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ æœ‰åŠ©æ–¼å°æŠ—ç‚ç—‡ï¼Œä½†å‚³éå›°é›£ã€‚\n2. æ–°å‹è˜¿è””ç¡«ç´ -ç³–è‹·çµåˆç‰©èƒ½æé«˜å…¶æ•ˆæœã€‚\n3. ç ”ç©¶çµæœç‚ºæœªä¾†å¥åº·ç”¢å“çš„é–‹ç™¼æä¾›äº†æ–°æ€è·¯ã€‚",
    "image_prompt": "Create an infographic that explains the experimental process and main results of a study on a compound called sulforaphane found in radishes. The design should be flat and simple, with a white or light-colored background and soft colors. Include symbols representing broccoli or radish to signify sulforaphane, simplified icons of experimental subjects like humans or cells, and arrows or flow lines to show the experimental steps. Add a section labeled 'Main Results' highlighting protective effects and changes observed in the study.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "ç‚ç—‡æ€§ç–¾ç—… Inflammatory Diseases",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40533430/"
  },
  {
    "id": "41171476",
    "title_en": "Online solid-phase extraction of glucoraphanin and sulforaphane from non-edible plants based on amino acid-functionalized covalent organic frameworks.",
    "pub_date": "2025 Oct",
    "journal": "Mikrochimica acta",
    "abstract_en": "Glucoraphanin (GR) and sulforaphane (SFN) are sulfur-containing compounds with diverse medicinal applications. However, cruciferous vegetables are a single source of GR and SFN, which limits development and utilization in natural resources. Herein, amino acid covalent organic framework (COF-Cys) was synthesized via click reactions and employed as an adsorbent in online solid-phase extraction (online SPE) to determine GR and SFN in non-edible plant samples. The adsorption mechanism was analyzed using density functional theory, revealing that adsorption occurred via electrostatic interaction and hydrogen bonding. Under the optimum conditions, good linearity (4-2500Â ng/mL; R<sup>2</sup>â€‰=â€‰0.9922 and 0.9968) and lower limits of detection (1.0Â ng/mL and 0.6Â ng/mL) were observed. GR and SFN were found in 18 non-edible plant samples, and recoveries of spiked samples were 89.1-109.3% with RSDâ€‰â‰¤â€‰6.9%. The COF-Cys-online SPE-UPLC-MS/MS approach displays great potential for application to detect GR and SFN in non-edible plants and provide valuable support for the development of functional products.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°è˜¿è””ç¡«ç´ å’Œå…¶å‰é«”ç‰©è³ªçš„æ½›åœ¨æ‡‰ç”¨ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å…·æœ‰å¤šç¨®è—¥ç”¨åƒ¹å€¼çš„åŒ–åˆç‰©ï¼Œä¸»è¦ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœï¼Œå¦‚é’èŠ±æ¤°èœã€‚é€™äº›åŒ–åˆç‰©åœ¨å¥åº·ä¿ƒé€²å’Œç–¾ç—…é é˜²æ–¹é¢å¯èƒ½å…·æœ‰é‡è¦ä½œç”¨ï¼Œå› æ­¤äº†è§£å¦‚ä½•æœ‰æ•ˆåœ°å¾éé£Ÿç”¨æ¤ç‰©ä¸­æå–å’Œæª¢æ¸¬é€™äº›æˆåˆ†ï¼Œå°æ–¼æœªä¾†çš„å¥åº·ç”¢å“é–‹ç™¼è‡³é—œé‡è¦ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨å¦‚ä½•å¾éé£Ÿç”¨æ¤ç‰©ä¸­æå–å’Œæª¢æ¸¬è˜¿è””ç¡«ç´ åŠå…¶å‰é«”ç‰©è³ªâ€”â€”è‘¡è„ç³–è˜¿è””ç¡«ç´ ã€‚ç”±æ–¼é€™äº›åŒ–åˆç‰©ä¸»è¦ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœï¼Œé€™é™åˆ¶äº†å®ƒå€‘åœ¨è‡ªç„¶è³‡æºä¸­çš„é–‹ç™¼å’Œåˆ©ç”¨ã€‚å› æ­¤ï¼Œç ”ç©¶è€…å¸Œæœ›æ‰¾åˆ°æ–°çš„æ–¹æ³•ä¾†æœ‰æ•ˆæå–é€™äº›æœ‰ç›Šæˆåˆ†ï¼Œä¸¦åˆ†æå…¶åœ¨éé£Ÿç”¨æ¤ç‰©ä¸­çš„å­˜åœ¨æƒ…æ³ã€‚",
    "para3": "ç ”ç©¶ä¸­ï¼Œç ”ç©¶äººå“¡åˆæˆäº†ä¸€ç¨®æ°¨åŸºé…¸å…±åƒ¹æœ‰æ©Ÿæ¡†æ¶ï¼ˆCOF-Cysï¼‰ï¼Œä¸¦å°‡å…¶ç”¨ä½œåœ¨ç·šå›ºç›¸èƒå–çš„å¸é™„åŠ‘ï¼Œä»¥æª¢æ¸¬éé£Ÿç”¨æ¤ç‰©æ¨£æœ¬ä¸­çš„è‘¡è„ç³–è˜¿è””ç¡«ç´ å’Œè˜¿è””ç¡«ç´ ã€‚ç ”ç©¶è€…åˆ©ç”¨å¯†åº¦æ³›å‡½ç†è«–åˆ†æäº†å¸é™„æ©Ÿåˆ¶ï¼Œç™¼ç¾å¸é™„ä¸»è¦æ˜¯é€šééœé›»ç›¸äº’ä½œç”¨å’Œæ°«éµé€²è¡Œçš„ã€‚é€™é …ç ”ç©¶çš„å¯¦é©—è¨­è¨ˆæ—¨åœ¨æé«˜æª¢æ¸¬çš„éˆæ•åº¦å’Œæº–ç¢ºæ€§ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œåœ¨æœ€ä½³æ¢ä»¶ä¸‹ï¼Œç ”ç©¶è€…æˆåŠŸæª¢æ¸¬åˆ°18ç¨®éé£Ÿç”¨æ¤ç‰©æ¨£æœ¬ä¸­çš„è‘¡è„ç³–è˜¿è””ç¡«ç´ å’Œè˜¿è””ç¡«ç´ ï¼Œä¸”æª¢æ¸¬çµæœçš„ç·šæ€§ç¯„åœè‰¯å¥½ï¼Œæª¢æ¸¬ä¸‹é™ä¹Ÿç›¸å°è¼ƒä½ã€‚æ¨£æœ¬çš„å›æ”¶ç‡åœ¨89.1%åˆ°109.3%ä¹‹é–“ï¼Œä¸”ç›¸å°æ¨™æº–åå·®ï¼ˆRSDï¼‰å°æ–¼6.9%ã€‚é€™è¡¨æ˜COF-Cysåœ¨ç·šå›ºç›¸èƒå–-è¶…é«˜æ•ˆæ¶²ç›¸è‰²è­œ-è³ªè­œè¯ç”¨çš„æ–¹æ³•åœ¨æª¢æ¸¬éé£Ÿç”¨æ¤ç‰©ä¸­çš„é€™äº›åŒ–åˆç‰©æ–¹é¢å…·æœ‰å¾ˆå¤§çš„æ½›åŠ›ï¼Œä¸¦ç‚ºåŠŸèƒ½æ€§ç”¢å“çš„é–‹ç™¼æä¾›äº†æœ‰åƒ¹å€¼çš„æ”¯æŒã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°è˜¿è””ç¡«ç´ å’Œå…¶å‰é«”ç‰©è³ªçš„æ½›åœ¨æ‡‰ç”¨ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å…·æœ‰å¤šç¨®è—¥ç”¨åƒ¹å€¼çš„åŒ–åˆç‰©ï¼Œä¸»è¦ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœï¼Œå¦‚é’èŠ±æ¤°èœã€‚é€™äº›åŒ–åˆç‰©åœ¨å¥åº·ä¿ƒé€²å’Œç–¾ç—…é é˜²æ–¹é¢å¯èƒ½å…·æœ‰é‡è¦ä½œç”¨ï¼Œå› æ­¤äº†è§£å¦‚ä½•æœ‰æ•ˆåœ°å¾éé£Ÿç”¨æ¤ç‰©ä¸­æå–å’Œæª¢æ¸¬é€™äº›æˆåˆ†ï¼Œå°æ–¼æœªä¾†çš„å¥åº·ç”¢å“é–‹ç™¼è‡³é—œé‡è¦ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨å¦‚ä½•å¾éé£Ÿç”¨æ¤ç‰©ä¸­æå–å’Œæª¢æ¸¬è˜¿è””ç¡«ç´ åŠå…¶å‰é«”ç‰©è³ªâ€”â€”è‘¡è„ç³–è˜¿è””ç¡«ç´ ã€‚ç”±æ–¼é€™äº›åŒ–åˆç‰©ä¸»è¦ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœï¼Œé€™é™åˆ¶äº†å®ƒå€‘åœ¨è‡ªç„¶è³‡æºä¸­çš„é–‹ç™¼å’Œåˆ©ç”¨ã€‚å› æ­¤ï¼Œç ”ç©¶è€…å¸Œæœ›æ‰¾åˆ°æ–°çš„æ–¹æ³•ä¾†æœ‰æ•ˆæå–é€™äº›æœ‰ç›Šæˆåˆ†ï¼Œä¸¦åˆ†æå…¶åœ¨éé£Ÿç”¨æ¤ç‰©ä¸­çš„å­˜åœ¨æƒ…æ³ã€‚\n\nç ”ç©¶ä¸­ï¼Œç ”ç©¶äººå“¡åˆæˆäº†ä¸€ç¨®æ°¨åŸºé…¸å…±åƒ¹æœ‰æ©Ÿæ¡†æ¶ï¼ˆCOF-Cysï¼‰ï¼Œä¸¦å°‡å…¶ç”¨ä½œåœ¨ç·šå›ºç›¸èƒå–çš„å¸é™„åŠ‘ï¼Œä»¥æª¢æ¸¬éé£Ÿç”¨æ¤ç‰©æ¨£æœ¬ä¸­çš„è‘¡è„ç³–è˜¿è””ç¡«ç´ å’Œè˜¿è””ç¡«ç´ ã€‚ç ”ç©¶è€…åˆ©ç”¨å¯†åº¦æ³›å‡½ç†è«–åˆ†æäº†å¸é™„æ©Ÿåˆ¶ï¼Œç™¼ç¾å¸é™„ä¸»è¦æ˜¯é€šééœé›»ç›¸äº’ä½œç”¨å’Œæ°«éµé€²è¡Œçš„ã€‚é€™é …ç ”ç©¶çš„å¯¦é©—è¨­è¨ˆæ—¨åœ¨æé«˜æª¢æ¸¬çš„éˆæ•åº¦å’Œæº–ç¢ºæ€§ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œåœ¨æœ€ä½³æ¢ä»¶ä¸‹ï¼Œç ”ç©¶è€…æˆåŠŸæª¢æ¸¬åˆ°18ç¨®éé£Ÿç”¨æ¤ç‰©æ¨£æœ¬ä¸­çš„è‘¡è„ç³–è˜¿è””ç¡«ç´ å’Œè˜¿è””ç¡«ç´ ï¼Œä¸”æª¢æ¸¬çµæœçš„ç·šæ€§ç¯„åœè‰¯å¥½ï¼Œæª¢æ¸¬ä¸‹é™ä¹Ÿç›¸å°è¼ƒä½ã€‚æ¨£æœ¬çš„å›æ”¶ç‡åœ¨89.1%åˆ°109.3%ä¹‹é–“ï¼Œä¸”ç›¸å°æ¨™æº–åå·®ï¼ˆRSDï¼‰å°æ–¼6.9%ã€‚é€™è¡¨æ˜COF-Cysåœ¨ç·šå›ºç›¸èƒå–-è¶…é«˜æ•ˆæ¶²ç›¸è‰²è­œ-è³ªè­œè¯ç”¨çš„æ–¹æ³•åœ¨æª¢æ¸¬éé£Ÿç”¨æ¤ç‰©ä¸­çš„é€™äº›åŒ–åˆç‰©æ–¹é¢å…·æœ‰å¾ˆå¤§çš„æ½›åŠ›ï¼Œä¸¦ç‚ºåŠŸèƒ½æ€§ç”¢å“çš„é–‹ç™¼æä¾›äº†æœ‰åƒ¹å€¼çš„æ”¯æŒã€‚",
    "fb_post": "æ ¹æ“šã€ŠMikrochimica actaã€‹æ–¼ 2025 å¹´ 10 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± ä½ çŸ¥é“è˜¿è””ç¡«ç´ å—ï¼Ÿå®ƒå¯æ˜¯ä¾†è‡ªé’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœçš„å¥åº·å°è‹±é›„ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶å°ˆæ³¨æ–¼å¦‚ä½•å¾éé£Ÿç”¨æ¤ç‰©ä¸­æå–é€™ç¨®æœ‰ç›Šçš„åŒ–åˆç‰©ï¼Œè®“æˆ‘å€‘ä¸€èµ·ä¾†çœ‹çœ‹å§ï¼\n\né€™é …ç ”ç©¶çš„é‡é»æ˜¯æ‰¾å‡ºå¾éé£Ÿç”¨æ¤ç‰©ä¸­èƒå–è˜¿è””ç¡«ç´ åŠå…¶å‰é«”ç‰©è³ªçš„æ–¹æ³•ã€‚ç”±æ–¼é€™äº›åŒ–åˆç‰©ä¸»è¦ä¾†è‡ªæˆ‘å€‘å¸¸åƒçš„è”¬èœï¼Œç ”ç©¶è€…å¸Œæœ›èƒ½æ‰¾åˆ°æ–°æ–¹æ³•ï¼Œè®“é€™äº›å¥åº·æˆåˆ†èƒ½è¢«æ›´å»£æ³›åœ°åˆ©ç”¨ã€‚\n\nç ”ç©¶åœ˜éšŠåˆæˆäº†ä¸€ç¨®å«åšæ°¨åŸºé…¸å…±åƒ¹æœ‰æ©Ÿæ¡†æ¶çš„ææ–™ï¼Œä¸¦ç”¨ä¾†æª¢æ¸¬éé£Ÿç”¨æ¤ç‰©ä¸­çš„è˜¿è””ç¡«ç´ ã€‚ä»–å€‘ç™¼ç¾ï¼Œé€™ç¨®ææ–™èƒ½æœ‰æ•ˆæé«˜æª¢æ¸¬çš„éˆæ•åº¦å’Œæº–ç¢ºæ€§ï¼Œè®“çµæœæ›´å¯é ã€‚\n\næœ€ä»¤äººèˆˆå¥®çš„æ˜¯ï¼Œç ”ç©¶è€…åœ¨æœ€ä½³æ¢ä»¶ä¸‹æˆåŠŸæª¢æ¸¬åˆ°18ç¨®éé£Ÿç”¨æ¤ç‰©ä¸­çš„è˜¿è””ç¡«ç´ ï¼Œä¸¦ä¸”æª¢æ¸¬çš„æº–ç¢ºåº¦ç›¸ç•¶é«˜ï¼é€™ç‚ºæœªä¾†é–‹ç™¼åŠŸèƒ½æ€§å¥åº·ç”¢å“æä¾›äº†å¾ˆå¥½çš„åŸºç¤ã€‚\n\nğŸ” ä¸»è¦é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ ä¾†è‡ªé’èŠ±æ¤°èœç­‰è”¬èœï¼Œå…·æœ‰æ½›åœ¨çš„å¥åº·ç›Šè™•ã€‚\n2. ç ”ç©¶è€…æ‰¾åˆ°æ–°æ–¹æ³•å¾éé£Ÿç”¨æ¤ç‰©æå–é€™äº›æœ‰ç›Šæˆåˆ†ã€‚\n3. æˆåŠŸæª¢æ¸¬åˆ°18ç¨®æ¤ç‰©ä¸­çš„è˜¿è””ç¡«ç´ ï¼Œç‚ºæœªä¾†å¥åº·ç”¢å“é–‹ç™¼é‹ªè·¯ï¼",
    "image_prompt": "Create a flat design infographic illustrating the extraction and detection method of sulforaphane from non-edible plants. Include symbols of broccoli and sulforaphane, simplified illustrations of experimental subjects like humans or cells, arrows or flow lines to show experimental steps, and a section highlighting the main results, such as detection accuracy and potential health benefits.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": false,
    "disease_name": "",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41171476/"
  },
  {
    "id": "41246347",
    "title_en": "Sulforaphane in cancer precision medicine: from biosynthetic origins to multiscale mechanisms and clinical translation.",
    "pub_date": "2025",
    "journal": "Frontiers in immunology",
    "abstract_en": "Sulforaphane (SFN), an isothiocyanate derived from glucoraphanin in cruciferous vegetables, has evolved from a dietary antioxidant to a sophisticated multi-target agent in oncology. While its roles in nuclear factor erythroid 2-related factor 2 (Nrf2) activation and histone deacetylase (HDAC) inhibition are well-established, this review provides a novel synthesis by integrating disparate research scales-a multiscale perspective that spans from the genetic and epigenetic regulation of glucoraphanin biosynthesis in plants to SFN's recently elucidated effects on ferroptosis, cancer stem cells (CSCs), and the tumor immune microenvironment in humans. We critically evaluate how key host factors, such as gut microbiota composition and glutathione S-transferase (GST) polymorphisms, dictate SFN bioavailability and efficacy, thereby framing a precision nutrition paradigm for its application. Furthermore, we move beyond generic claims of synergy to detail SFN's specific mechanisms in enhancing conventional therapies, including the modulation of drug transporters and immune checkpoints. By integrating advances from plant biochemistry to molecular oncology, this review establishes an updated and mechanism-oriented framework for realizing SFN's compelling potential in cancer prevention and therapy through a precision medicine approach.",
    "para1": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœçš„åŒ–åˆç‰©ï¼Œè¿‘å¹´ä¾†è¢«èªç‚ºåœ¨ç™Œç—‡é é˜²å’Œæ²»ç™‚ä¸­å…·æœ‰æ½›åœ¨çš„å¥½è™•ã€‚é€™é …ç ”ç©¶çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œé€éäº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ›´æœ‰æ•ˆçš„æ–¹å¼ä¾†é é˜²ç™Œç—‡æˆ–è¼”åŠ©æ²»ç™‚ã€‚ç ”ç©¶æŒ‡å‡ºï¼Œè˜¿è””ç¡«ç´ ä¸åƒ…èƒ½ä½œç‚ºæŠ—æ°§åŒ–åŠ‘ï¼Œé‚„èƒ½å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·å’Œå…ç–«ç’°å¢ƒï¼Œé€™å°æ–¼æœªä¾†çš„å¥åº·ä¿ƒé€²å’Œç–¾ç—…é é˜²ç­–ç•¥å…·æœ‰é‡è¦æ„ç¾©ã€‚",
    "para2": "é€™é …ç ”ç©¶ä¸»è¦é—œæ³¨è˜¿è””ç¡«ç´ çš„å¤šé‡ä½œç”¨ï¼Œç‰¹åˆ¥æ˜¯åœ¨ç™Œç—‡é ˜åŸŸçš„æ‡‰ç”¨ã€‚ç ”ç©¶è€…æ¢è¨äº†è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç—‡å¹¹ç´°èƒã€è…«ç˜¤å…ç–«å¾®ç’°å¢ƒä»¥åŠå…¶åœ¨ä¸åŒç”Ÿç‰©é«”å…§çš„ç”Ÿç‰©åˆ©ç”¨åº¦ã€‚é€éç¶œåˆä¸åŒç ”ç©¶çš„çµæœï¼Œé€™ç¯‡æ–‡ç»å›é¡§æä¾›äº†ä¸€å€‹å…¨æ–°çš„è¦–è§’ï¼Œè®“æˆ‘å€‘èƒ½æ›´æ·±å…¥äº†è§£è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡é é˜²å’Œæ²»ç™‚ä¸­çš„æ½›åŠ›ã€‚",
    "para3": "ç ”ç©¶æ–¹æ³•ä¸Šï¼Œé€™ç¯‡æ–‡ç»å›é¡§æ•´åˆäº†å¾æ¤ç‰©åŸºå› å’Œè¡¨è§€éºå‚³å­¸åˆ°äººé¡è‡¨åºŠç ”ç©¶çš„å¤šå±¤é¢è³‡æ–™ã€‚ç ”ç©¶è€…åˆ†æäº†å½±éŸ¿è˜¿è””ç¡«ç´ ç”Ÿç‰©åˆ©ç”¨åº¦çš„é—œéµå› ç´ ï¼Œä¾‹å¦‚è…¸é“å¾®ç”Ÿç‰©çµ„çš„çµ„æˆå’Œè°·èƒ±ç”˜è‚½S-è½‰ç§»é…¶çš„å¤šæ…‹æ€§ï¼Œä¸¦æ¢è¨äº†é€™äº›å› ç´ å¦‚ä½•å½±éŸ¿è˜¿è””ç¡«ç´ çš„ç™‚æ•ˆã€‚é€™æ¨£çš„å¤šå±¤æ¬¡åˆ†ææœ‰åŠ©æ–¼å»ºç«‹ç²¾æº–ç‡Ÿé¤Šçš„æ¦‚å¿µï¼Œä»¥ä¾¿æ›´å¥½åœ°æ‡‰ç”¨è˜¿è””ç¡«ç´ ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨å¢å¼·å‚³çµ±æ²»ç™‚æ–¹é¢å…·æœ‰æ½›åŠ›ï¼Œå°¤å…¶æ˜¯åœ¨èª¿ç¯€è—¥ç‰©é‹è¼¸å’Œå…ç–«æª¢æŸ¥é»æ–¹é¢ã€‚ç ”ç©¶è€…å¼·èª¿ï¼Œè˜¿è””ç¡«ç´ çš„å…·é«”ä½œç”¨æ©Ÿåˆ¶ä¸åƒ…é™æ–¼æŠ—æ°§åŒ–ï¼Œé‚„åŒ…æ‹¬å°ç™Œç´°èƒç”Ÿé•·çš„èª¿æ§ã€‚é€™äº›çµæœç‚ºæœªä¾†åœ¨ç™Œç—‡é é˜²å’Œæ²»ç™‚ä¸­æ‡‰ç”¨è˜¿è””ç¡«ç´ æä¾›äº†æ–°çš„æ€è·¯ï¼Œä½†ä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶å…·é«”æ•ˆæœã€‚",
    "explanation_zh": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœçš„åŒ–åˆç‰©ï¼Œè¿‘å¹´ä¾†è¢«èªç‚ºåœ¨ç™Œç—‡é é˜²å’Œæ²»ç™‚ä¸­å…·æœ‰æ½›åœ¨çš„å¥½è™•ã€‚é€™é …ç ”ç©¶çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œé€éäº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ›´æœ‰æ•ˆçš„æ–¹å¼ä¾†é é˜²ç™Œç—‡æˆ–è¼”åŠ©æ²»ç™‚ã€‚ç ”ç©¶æŒ‡å‡ºï¼Œè˜¿è””ç¡«ç´ ä¸åƒ…èƒ½ä½œç‚ºæŠ—æ°§åŒ–åŠ‘ï¼Œé‚„èƒ½å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·å’Œå…ç–«ç’°å¢ƒï¼Œé€™å°æ–¼æœªä¾†çš„å¥åº·ä¿ƒé€²å’Œç–¾ç—…é é˜²ç­–ç•¥å…·æœ‰é‡è¦æ„ç¾©ã€‚\n\né€™é …ç ”ç©¶ä¸»è¦é—œæ³¨è˜¿è””ç¡«ç´ çš„å¤šé‡ä½œç”¨ï¼Œç‰¹åˆ¥æ˜¯åœ¨ç™Œç—‡é ˜åŸŸçš„æ‡‰ç”¨ã€‚ç ”ç©¶è€…æ¢è¨äº†è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç—‡å¹¹ç´°èƒã€è…«ç˜¤å…ç–«å¾®ç’°å¢ƒä»¥åŠå…¶åœ¨ä¸åŒç”Ÿç‰©é«”å…§çš„ç”Ÿç‰©åˆ©ç”¨åº¦ã€‚é€éç¶œåˆä¸åŒç ”ç©¶çš„çµæœï¼Œé€™ç¯‡æ–‡ç»å›é¡§æä¾›äº†ä¸€å€‹å…¨æ–°çš„è¦–è§’ï¼Œè®“æˆ‘å€‘èƒ½æ›´æ·±å…¥äº†è§£è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡é é˜²å’Œæ²»ç™‚ä¸­çš„æ½›åŠ›ã€‚\n\nç ”ç©¶æ–¹æ³•ä¸Šï¼Œé€™ç¯‡æ–‡ç»å›é¡§æ•´åˆäº†å¾æ¤ç‰©åŸºå› å’Œè¡¨è§€éºå‚³å­¸åˆ°äººé¡è‡¨åºŠç ”ç©¶çš„å¤šå±¤é¢è³‡æ–™ã€‚ç ”ç©¶è€…åˆ†æäº†å½±éŸ¿è˜¿è””ç¡«ç´ ç”Ÿç‰©åˆ©ç”¨åº¦çš„é—œéµå› ç´ ï¼Œä¾‹å¦‚è…¸é“å¾®ç”Ÿç‰©çµ„çš„çµ„æˆå’Œè°·èƒ±ç”˜è‚½S-è½‰ç§»é…¶çš„å¤šæ…‹æ€§ï¼Œä¸¦æ¢è¨äº†é€™äº›å› ç´ å¦‚ä½•å½±éŸ¿è˜¿è””ç¡«ç´ çš„ç™‚æ•ˆã€‚é€™æ¨£çš„å¤šå±¤æ¬¡åˆ†ææœ‰åŠ©æ–¼å»ºç«‹ç²¾æº–ç‡Ÿé¤Šçš„æ¦‚å¿µï¼Œä»¥ä¾¿æ›´å¥½åœ°æ‡‰ç”¨è˜¿è””ç¡«ç´ ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨å¢å¼·å‚³çµ±æ²»ç™‚æ–¹é¢å…·æœ‰æ½›åŠ›ï¼Œå°¤å…¶æ˜¯åœ¨èª¿ç¯€è—¥ç‰©é‹è¼¸å’Œå…ç–«æª¢æŸ¥é»æ–¹é¢ã€‚ç ”ç©¶è€…å¼·èª¿ï¼Œè˜¿è””ç¡«ç´ çš„å…·é«”ä½œç”¨æ©Ÿåˆ¶ä¸åƒ…é™æ–¼æŠ—æ°§åŒ–ï¼Œé‚„åŒ…æ‹¬å°ç™Œç´°èƒç”Ÿé•·çš„èª¿æ§ã€‚é€™äº›çµæœç‚ºæœªä¾†åœ¨ç™Œç—‡é é˜²å’Œæ²»ç™‚ä¸­æ‡‰ç”¨è˜¿è””ç¡«ç´ æä¾›äº†æ–°çš„æ€è·¯ï¼Œä½†ä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶å…·é«”æ•ˆæœã€‚",
    "fb_post": "æ ¹æ“šã€ŠFrontiers in immunologyã€‹æ–¼ 2025 å¹´ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ€ä½ çŸ¥é“å—ï¼Ÿè˜¿è””ç¡«ç´ é€™å€‹ç¥å¥‡çš„æˆåˆ†ï¼Œä¾†è‡ªæˆ‘å€‘å¸¸è¦‹çš„åå­—èŠ±ç§‘è”¬èœï¼Œåƒæ˜¯é’èŠ±æ¤°èœå’Œè˜¿è””ï¼Œæœ€è¿‘åœ¨ç™Œç—‡é é˜²å’Œæ²»ç™‚æ–¹é¢å¼•èµ·äº†ä¸å°‘é—œæ³¨ï¼ğŸ¤”\n\nä¸€é …æœ€æ–°çš„ç ”ç©¶æ·±å…¥æ¢è¨äº†è˜¿è””ç¡«ç´ çš„å¤šé‡ä½œç”¨ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·å’Œå…ç–«ç³»çµ±ã€‚ç ”ç©¶è€…å€‘ä¸åƒ…åˆ†æäº†é€™äº›åŒ–åˆç‰©åœ¨ä¸åŒç”Ÿç‰©é«”å…§çš„è¡¨ç¾ï¼Œé‚„äº†è§£äº†è…¸é“å¾®ç”Ÿç‰©å’Œå…¶ä»–å› ç´ å¦‚ä½•å½±éŸ¿å®ƒçš„æ•ˆæœã€‚é€™æ¨£çš„ç ”ç©¶è®“æˆ‘å€‘å°æ–¼å¦‚ä½•åˆ©ç”¨è˜¿è””ç¡«ç´ ä¾†å¢å¼·å¥åº·æœ‰äº†æ–°çš„è¦‹è§£ï¼\n\né€™é …ç ”ç©¶çš„ä¸»è¦ç™¼ç¾åŒ…æ‹¬ï¼š\n1ï¸âƒ£ è˜¿è””ç¡«ç´ æœ‰åŠ©æ–¼å¢å¼·å‚³çµ±ç™Œç—‡æ²»ç™‚çš„æ•ˆæœã€‚\n2ï¸âƒ£ å®ƒä¸åƒ…æ˜¯æŠ—æ°§åŒ–åŠ‘ï¼Œé‚„èƒ½èª¿æ§ç™Œç´°èƒçš„ç”Ÿé•·ã€‚\n3ï¸âƒ£ äº†è§£è…¸é“å¾®ç”Ÿç‰©å’Œå…¶ä»–å› ç´ å°è˜¿è””ç¡«ç´ æ•ˆæœçš„å½±éŸ¿ï¼Œæœ‰åŠ©æ–¼æœªä¾†çš„ç²¾æº–ç‡Ÿé¤Šæ‡‰ç”¨ã€‚\n\né›–ç„¶é€™äº›ç™¼ç¾å¾ˆæœ‰å¸Œæœ›ï¼Œä½†ä»éœ€è¦æ›´å¤šçš„ç ”ç©¶ä¾†ç¢ºèªå…·é«”æ•ˆæœã€‚è®“æˆ‘å€‘ä¸€èµ·æœŸå¾…æœªä¾†çš„é€²å±•å§ï¼âœ¨",
    "image_prompt": "Create a flat design infographic illustrating the research on sulforaphane. Include symbols of broccoli and sulforaphane, simplified representations of experimental subjects like humans, animals, or cells. Use arrows or flow lines to show the experimental steps. Include a section labeled 'Main Findings' that highlights protective effects and changes observed in the study. Use a light-colored background with soft color tones in a scientific illustration style.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "ç™Œç—‡ Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41246347/"
  },
  {
    "id": "41056875",
    "title_en": "Sulforaphane inhibits gastric cancer progression by regulating the YY1/PSMB8-AS1/miR-888-5p/SLC4A7 axis.",
    "pub_date": "2025 Oct",
    "journal": "Biochemical and biophysical research communications",
    "abstract_en": "Sulforaphane (SFN) plays a vital role in many types of cancer as a natural extract from plants. However, whether SFN can inhibit gastric carcinogenesis by regulating the lncRNA-miRNA-mRNA axis is unclear. In the current work, the significantly differentially expressed lncRNA PSMB8AS1 was obtained by performing high-throughput sequencing of gastric cancer cells treated with SFN. The qRT-PCR assay results confirmed the inhibitory effect of SFN on PSM8AS1. Subsequently, using gastric cancer data from TCGA and 11 pairs of clinical samples from gastric and paracancerous tissues, we found that PSMB8-AS1 was upregulated in gastric cancer, and high expression of PSMB8-AS1 was associated with low survival of patients with gastric cancer. MTT, cell colony formation, scratch healing, flow cytometry, and qRT-PCR assays showed that the knockdown of PSMB8-AS1 significantly reduced the proliferation and migration of gastric cancer cells as well as promoted apoptosis. Dual luciferase reporter gene and RNA immunoprecipitation (RIP) assay confirmed that PSMB8-AS1 can function as the molecular sponge for miR-888-5p. Meanwhile, bioinformatics analysis and dual-luciferase reporter gene assay showed that miR-888-5p regulates SLC4A7. Overexpression of miR-888-5p or knockdown of SLC4A7 reduced the proliferation and migration of gastric cancer cells. In addition, rescue experiments confirmed that the inhibitory effects of the knockdown of PSMB8-AS1 or the knockdown of SLC4A7 on the proliferation and migration of gastric cancer cells could be reversed by miR-888-5p inhibitor treatment. Subcutaneous tumor formation experiments in nude mice demonstrated that the tumor volume of nude mice transplanted with PSMB8-AS1-knockdown gastric cancer cells was significantly reduced compared with that of the control group. Transcription factors can usually bind to the promoter regions of lncRNAs and regulate the transcription of lncRNAs. We demonstrated through website prediction and experiments that SFN can inhibit the level of PSMB8-AS1 by regulating the transcription factor YY1. These results suggest that SFN inhibits gastric cancer growth through the YY1/PSMB8-AS1/miR-888-5p/SLC4A7 axis. Therefore, SFN might be a promising therapeutical agent for GC prevention and therapy.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨èƒƒç™Œçš„é ˜åŸŸã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éèª¿æ§ç‰¹å®šçš„åˆ†å­è·¯å¾‘ä¾†æŠ‘åˆ¶èƒƒç™Œçš„ç™¼å±•ã€‚é€™æ„å‘³è‘—ï¼Œé€éé£²é£Ÿä¸­å¢åŠ é’èŠ±æ¤°èœç­‰å¯Œå«è˜¿è””ç¡«ç´ çš„é£Ÿç‰©ï¼Œå¯èƒ½å°æ–¼é™ä½èƒƒç™Œé¢¨éšªæœ‰å¹«åŠ©ï¼Œé›–ç„¶å…·é«”çš„æ•ˆæœé‚„éœ€è¦é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½å¤ é€éèª¿ç¯€é•·éˆéç·¨ç¢¼RNAï¼ˆlncRNAï¼‰èˆ‡å¾®å°RNAï¼ˆmiRNAï¼‰åŠä¿¡ä½¿RNAï¼ˆmRNAï¼‰ä¹‹é–“çš„ç›¸äº’ä½œç”¨ä¾†æŠ‘åˆ¶èƒƒç™Œçš„å½¢æˆã€‚ç ”ç©¶è€…é—œæ³¨çš„æ˜¯ä¸€ç¨®åç‚ºPSMB8-AS1çš„lncRNAï¼Œä¸¦è©¦åœ–äº†è§£å®ƒåœ¨èƒƒç™Œä¸­çš„è¡¨ç¾åŠå…¶å°ç™Œç´°èƒå¢æ®–å’Œé·ç§»çš„å½±éŸ¿ã€‚",
    "para3": "ç ”ç©¶ä¸­ï¼Œç§‘å­¸å®¶å€‘ä½¿ç”¨é«˜é€šé‡æ¸¬åºæŠ€è¡“åˆ†æäº†æ¥å—è˜¿è””ç¡«ç´ è™•ç†çš„èƒƒç™Œç´°èƒï¼Œç™¼ç¾PSMB8-AS1çš„è¡¨é”é¡¯è‘—ä¸åŒã€‚æ¥è‘—ï¼Œä»–å€‘åˆ©ç”¨TCGAçš„èƒƒç™Œæ•¸æ“šä»¥åŠ11å°è‡¨åºŠæ¨£æœ¬é€²è¡Œäº†é€²ä¸€æ­¥çš„åˆ†æï¼Œä¸¦æ¡ç”¨å¤šç¨®å¯¦é©—æ–¹æ³•ï¼ŒåŒ…æ‹¬ç´°èƒå¢æ®–ã€é·ç§»åŠå‡‹äº¡æ¸¬è©¦ï¼Œä¾†é©—è­‰PSMB8-AS1çš„åŠŸèƒ½åŠå…¶èˆ‡miR-888-5pçš„é—œä¿‚ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼ŒPSMB8-AS1åœ¨èƒƒç™Œä¸­è¡¨é”ä¸Šèª¿ï¼Œä¸”å…¶é«˜è¡¨é”èˆ‡æ‚£è€…çš„ä½ç”Ÿå­˜ç‡æœ‰é—œã€‚æŠ‘åˆ¶PSMB8-AS1çš„è¡¨é”èƒ½é¡¯è‘—æ¸›å°‘èƒƒç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»ï¼Œä¸¦ä¿ƒé€²ç´°èƒå‡‹äº¡ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„ç™¼ç¾è˜¿è””ç¡«ç´ èƒ½é€éèª¿æ§è½‰éŒ„å› å­YY1ä¾†æŠ‘åˆ¶PSMB8-AS1çš„è¡¨é”ï¼Œé€™äº›çµæœæš—ç¤ºè˜¿è””ç¡«ç´ å¯èƒ½é€éYY1/PSMB8-AS1/miR-888-5p/SLC4A7é€™ä¸€è·¯å¾‘ä¾†æŠ‘åˆ¶èƒƒç™Œçš„ç”Ÿé•·ï¼Œé¡¯ç¤ºå‡ºå…¶ä½œç‚ºæ½›åœ¨æ²»ç™‚åŠ‘çš„å¯èƒ½æ€§ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨èƒƒç™Œçš„é ˜åŸŸã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éèª¿æ§ç‰¹å®šçš„åˆ†å­è·¯å¾‘ä¾†æŠ‘åˆ¶èƒƒç™Œçš„ç™¼å±•ã€‚é€™æ„å‘³è‘—ï¼Œé€éé£²é£Ÿä¸­å¢åŠ é’èŠ±æ¤°èœç­‰å¯Œå«è˜¿è””ç¡«ç´ çš„é£Ÿç‰©ï¼Œå¯èƒ½å°æ–¼é™ä½èƒƒç™Œé¢¨éšªæœ‰å¹«åŠ©ï¼Œé›–ç„¶å…·é«”çš„æ•ˆæœé‚„éœ€è¦é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½å¤ é€éèª¿ç¯€é•·éˆéç·¨ç¢¼RNAï¼ˆlncRNAï¼‰èˆ‡å¾®å°RNAï¼ˆmiRNAï¼‰åŠä¿¡ä½¿RNAï¼ˆmRNAï¼‰ä¹‹é–“çš„ç›¸äº’ä½œç”¨ä¾†æŠ‘åˆ¶èƒƒç™Œçš„å½¢æˆã€‚ç ”ç©¶è€…é—œæ³¨çš„æ˜¯ä¸€ç¨®åç‚ºPSMB8-AS1çš„lncRNAï¼Œä¸¦è©¦åœ–äº†è§£å®ƒåœ¨èƒƒç™Œä¸­çš„è¡¨ç¾åŠå…¶å°ç™Œç´°èƒå¢æ®–å’Œé·ç§»çš„å½±éŸ¿ã€‚\n\nç ”ç©¶ä¸­ï¼Œç§‘å­¸å®¶å€‘ä½¿ç”¨é«˜é€šé‡æ¸¬åºæŠ€è¡“åˆ†æäº†æ¥å—è˜¿è””ç¡«ç´ è™•ç†çš„èƒƒç™Œç´°èƒï¼Œç™¼ç¾PSMB8-AS1çš„è¡¨é”é¡¯è‘—ä¸åŒã€‚æ¥è‘—ï¼Œä»–å€‘åˆ©ç”¨TCGAçš„èƒƒç™Œæ•¸æ“šä»¥åŠ11å°è‡¨åºŠæ¨£æœ¬é€²è¡Œäº†é€²ä¸€æ­¥çš„åˆ†æï¼Œä¸¦æ¡ç”¨å¤šç¨®å¯¦é©—æ–¹æ³•ï¼ŒåŒ…æ‹¬ç´°èƒå¢æ®–ã€é·ç§»åŠå‡‹äº¡æ¸¬è©¦ï¼Œä¾†é©—è­‰PSMB8-AS1çš„åŠŸèƒ½åŠå…¶èˆ‡miR-888-5pçš„é—œä¿‚ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼ŒPSMB8-AS1åœ¨èƒƒç™Œä¸­è¡¨é”ä¸Šèª¿ï¼Œä¸”å…¶é«˜è¡¨é”èˆ‡æ‚£è€…çš„ä½ç”Ÿå­˜ç‡æœ‰é—œã€‚æŠ‘åˆ¶PSMB8-AS1çš„è¡¨é”èƒ½é¡¯è‘—æ¸›å°‘èƒƒç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»ï¼Œä¸¦ä¿ƒé€²ç´°èƒå‡‹äº¡ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„ç™¼ç¾è˜¿è””ç¡«ç´ èƒ½é€éèª¿æ§è½‰éŒ„å› å­YY1ä¾†æŠ‘åˆ¶PSMB8-AS1çš„è¡¨é”ï¼Œé€™äº›çµæœæš—ç¤ºè˜¿è””ç¡«ç´ å¯èƒ½é€éYY1/PSMB8-AS1/miR-888-5p/SLC4A7é€™ä¸€è·¯å¾‘ä¾†æŠ‘åˆ¶èƒƒç™Œçš„ç”Ÿé•·ï¼Œé¡¯ç¤ºå‡ºå…¶ä½œç‚ºæ½›åœ¨æ²»ç™‚åŠ‘çš„å¯èƒ½æ€§ã€‚",
    "fb_post": "æ ¹æ“šã€ŠBiochemical and biophysical research communicationsã€‹æ–¼ 2025 å¹´ 10 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿå…¶å¯¦æˆ‘å€‘çš„é£²é£Ÿä¸­æœ‰äº›é£Ÿç‰©å¯èƒ½å°é é˜²ç™Œç—‡æœ‰å¹«åŠ©ï¼æœ€è¿‘ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ ï¼Œé€™ç¨®åœ¨é’èŠ±æ¤°èœç­‰è”¬èœä¸­æ‰¾åˆ°çš„æˆåˆ†ï¼Œå¯èƒ½å°èƒƒç™Œæœ‰æŠ‘åˆ¶ä½œç”¨ã€‚ç ”ç©¶è€…å€‘å°ˆæ³¨æ–¼ä¸€ç¨®åå«PSMB8-AS1çš„åˆ†å­ï¼Œé€™ç¨®åˆ†å­åœ¨èƒƒç™Œç´°èƒä¸­è¡¨ç¾å¾—ç‰¹åˆ¥æ´»èºï¼Œä¸¦ä¸”èˆ‡ç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»æœ‰é—œã€‚  \n  \né€™é …ç ”ç©¶ä½¿ç”¨äº†é«˜ç§‘æŠ€çš„åˆ†ææ–¹æ³•ï¼Œç™¼ç¾ç•¶èƒƒç™Œç´°èƒæ¥å—è˜¿è””ç¡«ç´ è™•ç†å¾Œï¼ŒPSMB8-AS1çš„è¡¨é”æ˜é¡¯è®ŠåŒ–ã€‚é€²ä¸€æ­¥çš„åˆ†æé¡¯ç¤ºï¼ŒPSMB8-AS1çš„é«˜è¡¨é”èˆ‡æ‚£è€…çš„ä½ç”Ÿå­˜ç‡æœ‰é—œï¼ŒæŠ‘åˆ¶é€™ç¨®åˆ†å­çš„è¡¨é”å¯ä»¥é¡¯è‘—æ¸›å°‘ç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»ï¼Œç”šè‡³ä¿ƒé€²ç´°èƒå‡‹äº¡ã€‚æ›´æœ‰è¶£çš„æ˜¯ï¼Œè˜¿è””ç¡«ç´ ä¼¼ä¹èƒ½é€éèª¿æ§ä¸€ç¨®åç‚ºYY1çš„è½‰éŒ„å› å­ä¾†å½±éŸ¿PSMB8-AS1çš„è¡¨é”ï¼Œé€™è®“æˆ‘å€‘çœ‹åˆ°äº†è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ½›åŠ›ã€‚  \n  \nç¸½çµä¸€ä¸‹ï¼š  \n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼é™ä½èƒƒç™Œé¢¨éšªï¼Œç‰¹åˆ¥æ˜¯é€éå¢åŠ é’èŠ±æ¤°èœç­‰é£Ÿç‰©çš„æ”å–ã€‚  \n2. PSMB8-AS1åœ¨èƒƒç™Œä¸­è¡¨é”ä¸Šèª¿ï¼Œèˆ‡æ‚£è€…ç”Ÿå­˜ç‡ç›¸é—œã€‚  \n3. æŠ‘åˆ¶PSMB8-AS1èƒ½æ¸›å°‘ç™Œç´°èƒå¢æ®–ï¼Œé¡¯ç¤ºè˜¿è””ç¡«ç´ çš„æ½›åœ¨æ²»ç™‚æ•ˆæœã€‚",
    "image_prompt": "Create a flat design infographic that explains the experimental methods and main results of a study on the effects of sulforaphane on gastric cancer. The image should have a light-colored background and soft color palette. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects like cells, and arrows or flow lines to indicate the experimental steps. There should also be a section clearly labeled 'Main Results' summarizing the protective effects observed.",
    "is_human_study": true,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "èƒƒç™Œ Gastric Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41056875/"
  }
]